<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>ê´€ì°° ì¦ê±°: RCTê°€ ë¶ˆê°€ëŠ¥í•œ ê²½ìš°</title>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:wght@400;600;700&amp;family=Source+Sans+Pro:wght@400;600&amp;display=swap" rel="stylesheet"/>
<script src="https://cdn.plot.ly/plotly-2.27.0.min.js"></script>
<script>
if (typeof Plotly === 'undefined') {
  document.addEventListener('DOMContentLoaded', function() {
    document.querySelectorAll('[id*="plot"], [id*="chart"], .plotly-graph-div, .js-plotly-plot').forEach(function(el) {
      el.innerHTML = '<div style="padding:2rem;text-align:center;background:#2a2a4a;border:1px dashed #D4AF37;border-radius:8px;color:#FAF8F5;margin:1rem 0;"><p style="font-size:1.1rem;margin-bottom:0.5rem;">Interactive chart unavailable offline</p><p style="font-size:0.85rem;opacity:0.7;">Connect to the internet to load interactive Plotly.js visualizations</p></div>';
    });
  });
}
</script>
<style>
:root {
  --navy: #1E2761;
  --deep-navy: #141B3D;
  --gold: #D4AF37;
  --cream: #FAF8F5;
  --red: #BF2D2D;
  --teal: #2D8B8B;
  --light-text: #718096;
  --green: #2D8B5F;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

body {
  font-family: 'Source Sans Pro', sans-serif;
  background: var(--cream);
  color: var(--navy);
  min-height: 100vh;
  display: flex;
}

/* Skip Link for Accessibility */
.skip-link {
  position: absolute;
  top: -40px;
  left: 0;
  background: var(--gold);
  color: var(--navy);
  padding: 8px 16px;
  z-index: 1000;
  font-weight: 600;
  text-decoration: none;
  border-radius: 0 0 8px 0;
}

.skip-link:focus {
  top: 0;
}

/* Hamburger Menu */
.hamburger {
  display: none;
  position: fixed;
  top: 1rem;
  left: 1rem;
  z-index: 1001;
  background: var(--navy);
  border: none;
  border-radius: 8px;
  padding: 12px;
  cursor: pointer;
  flex-direction: column;
  gap: 4px;
}

.hamburger span {
  display: block;
  width: 24px;
  height: 3px;
  background: var(--gold);
  border-radius: 2px;
  transition: transform 0.3s;
}

.sidebar-overlay {
  display: none;
  position: fixed;
  inset: 0;
  background: rgba(0,0,0,0.5);
  z-index: 999;
}

/* Sidebar */
.sidebar {
  width: 280px;
  background: var(--navy);
  padding: 2rem 1rem;
  display: flex;
  flex-direction: column;
  position: fixed;
  height: 100vh;
  overflow-y: auto;
  z-index: 1000;
}

.logo {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.3rem;
  color: var(--gold);
  margin-bottom: 0.5rem;
  text-align: center;
}

.tagline {
  font-size: 0.75rem;
  color: rgba(255,255,255,0.6);
  text-align: center;
  margin-bottom: 2rem;
  font-style: italic;
}

.nav-section {
  margin-bottom: 1.5rem;
}

.nav-label {
  font-size: 0.7rem;
  text-transform: uppercase;
  letter-spacing: 1px;
  color: rgba(255,255,255,0.4);
  margin-bottom: 0.75rem;
  padding-left: 0.5rem;
}

.module-item {
  display: flex;
  align-items: center;
  padding: 0.75rem;
  border-radius: 8px;
  cursor: pointer;
  transition: all 0.2s;
  margin-bottom: 0.25rem;
  border: none;
  background: transparent;
  width: 100%;
  text-align: left;
  font-family: inherit;
  font-size: inherit;
}

.module-item:hover {
  background: rgba(255,255,255,0.1);
}

.module-item.active {
  background: rgba(212, 175, 55, 0.2);
  border-left: 3px solid var(--gold);
}

.module-item.completed .module-number {
  background: var(--green);
}

.module-number {
  width: 28px;
  height: 28px;
  border-radius: 50%;
  background: rgba(255,255,255,0.2);
  display: flex;
  align-items: center;
  justify-content: center;
  font-size: 0.8rem;
  color: white;
  margin-right: 0.75rem;
  flex-shrink: 0;
}

.module-info {
  flex: 1;
  min-width: 0;
}

.module-title {
  font-size: 0.9rem;
  color: white;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
}

.module-subtitle {
  font-size: 0.7rem;
  color: rgba(255,255,255,0.5);
}

/* Main Content */
.main-content {
  flex: 1;
  margin-left: 280px;
  display: flex;
  flex-direction: column;
  min-height: 100vh;
}

.top-bar {
  display: flex;
  justify-content: space-between;
  align-items: center;
  padding: 1rem 2rem;
  background: white;
  border-bottom: 1px solid rgba(0,0,0,0.1);
  flex-wrap: wrap;
  gap: 1rem;
}

.progress-section {
  display: flex;
  align-items: center;
  gap: 1rem;
}

.progress-bar {
  width: 200px;
  height: 8px;
  background: rgba(0,0,0,0.1);
  border-radius: 4px;
  overflow: hidden;
}

.progress-fill {
  height: 100%;
  background: linear-gradient(90deg, var(--gold), var(--teal));
  border-radius: 4px;
  transition: width 0.3s;
}

.progress-text {
  font-size: 0.85rem;
  color: var(--light-text);
}

.points-display {
  display: flex;
  align-items: center;
  gap: 0.5rem;
  background: linear-gradient(135deg, var(--navy), #2a3a7d);
  color: var(--gold);
  padding: 0.5rem 1rem;
  border-radius: 20px;
  font-weight: 600;
}

.top-actions {
  display: flex;
  gap: 0.5rem;
}

.action-btn {
  padding: 0.5rem 1rem;
  border: 1px solid var(--navy);
  background: transparent;
  border-radius: 6px;
  cursor: pointer;
  font-size: 0.85rem;
  transition: all 0.2s;
}

.action-btn:hover {
  background: var(--navy);
  color: white;
}

/* Slide Container */
.slide-container {
  flex: 1;
  padding: 2rem;
  max-width: 900px;
  margin: 0 auto;
  width: 100%;
}

/* Slide Types */
.slide-title {
  text-align: center;
  padding: 4rem 2rem;
}

.slide-title h1 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 3rem;
  color: var(--navy);
  margin-bottom: 1rem;
}

.slide-title .subtitle {
  font-size: 1.5rem;
  color: var(--gold);
  margin-bottom: 1rem;
}

.slide-title .description {
  font-size: 1.1rem;
  color: var(--light-text);
  max-width: 600px;
  margin: 0 auto;
}

/* Principle Display */
.principle-box {
  background: linear-gradient(135deg, var(--navy), #2a3a7d);
  border-radius: 16px;
  padding: 3rem;
  text-align: center;
  margin: 2rem 0;
}

.principle-box .number {
  font-size: 4rem;
  color: var(--gold);
  font-family: 'Cormorant Garamond', serif;
  line-height: 1;
}

.principle-box .text {
  font-size: 1.8rem;
  color: white;
  font-family: 'Cormorant Garamond', serif;
  margin-top: 1rem;
  font-style: italic;
}

/* Story Deep */
.story-deep {
  background: linear-gradient(135deg, rgba(191,45,45,0.08), rgba(30,39,97,0.12));
  border-left: 4px solid var(--red);
  border-radius: 0 16px 16px 0;
  padding: 1.5rem;
  margin: 1.5rem 0;
}

.story-label {
  font-size: 0.75rem;
  text-transform: uppercase;
  letter-spacing: 2px;
  color: var(--red);
  margin-bottom: 0.5rem;
  font-weight: 600;
}

.story-source {
  font-size: 0.8rem;
  color: var(--light-text);
  margin-bottom: 1rem;
  font-style: italic;
}

.timeline {
  position: relative;
  padding-left: 2rem;
  margin: 1.5rem 0;
}

.timeline::before {
  content: '';
  position: absolute;
  left: 0.5rem;
  top: 0;
  bottom: 0;
  width: 2px;
  background: linear-gradient(to bottom, var(--gold), var(--red), var(--green));
}

.timeline-event {
  position: relative;
  margin-bottom: 1rem;
  padding-left: 1rem;
}

.timeline-event::before {
  content: '';
  position: absolute;
  left: -1.5rem;
  top: 0.5rem;
  width: 10px;
  height: 10px;
  border-radius: 50%;
  background: var(--gold);
}

.timeline-event.crisis::before {
  background: var(--red);
}

.timeline-event.revelation::before {
  background: var(--green);
}

.timeline-year {
  font-weight: 600;
  color: var(--gold);
  font-size: 0.9rem;
}

.timeline-text {
  color: var(--navy);
  font-size: 0.95rem;
  margin-top: 0.25rem;
}

.real-data-card {
  background: white;
  border: 2px solid var(--gold);
  border-radius: 12px;
  padding: 1rem;
  margin: 1rem 0;
}

.real-data-card h4 {
  color: var(--gold);
  font-size: 0.8rem;
  text-transform: uppercase;
  letter-spacing: 1px;
  margin-bottom: 0.75rem;
  display: flex;
  align-items: center;
  gap: 0.5rem;
}

.real-data-card h4::before {
  content: 'ğŸ“Š';
}

.data-grid {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
  gap: 0.75rem;
}

.data-item {
  text-align: center;
}

.data-value {
  font-size: 1.1rem;
  font-weight: 600;
  color: var(--navy);
}

.data-label {
  font-size: 0.75rem;
  color: var(--light-text);
}

.story-hook {
  background: rgba(212, 175, 55, 0.1);
  border-left: 3px solid var(--gold);
  padding: 1rem;
  margin-top: 1rem;
  font-style: italic;
  color: var(--navy);
}

/* Story Box - Real World Case Studies */
.story-box {
  background: linear-gradient(135deg, rgba(45,139,95,0.08), rgba(30,39,97,0.10));
  border-left: 4px solid var(--green);
  border-radius: 0 16px 16px 0;
  padding: 1.5rem;
  margin: 1.5rem 0;
  box-shadow: 0 2px 12px rgba(0,0,0,0.06);
}

.story-box-header {
  display: flex;
  align-items: center;
  gap: 0.75rem;
  margin-bottom: 1rem;
}

.story-box-icon {
  font-size: 1.5rem;
}

.story-box-title {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.3rem;
  color: var(--navy);
  font-weight: 600;
}

.story-box-source {
  font-size: 0.75rem;
  color: var(--light-text);
  font-style: italic;
  margin-bottom: 1rem;
  padding-bottom: 0.75rem;
  border-bottom: 1px solid rgba(0,0,0,0.08);
}

.story-box-content {
  color: var(--navy);
  line-height: 1.7;
  font-size: 0.95rem;
}

.story-box-content p {
  margin-bottom: 1rem;
}

.story-box-content p:last-child {
  margin-bottom: 0;
}

.story-box-lesson {
  background: rgba(212, 175, 55, 0.15);
  border-left: 3px solid var(--gold);
  padding: 1rem;
  margin-top: 1.25rem;
  border-radius: 0 8px 8px 0;
}

.story-box-lesson-label {
  font-size: 0.7rem;
  text-transform: uppercase;
  letter-spacing: 1.5px;
  color: var(--gold);
  font-weight: 700;
  margin-bottom: 0.5rem;
}

.story-box-lesson-text {
  color: var(--navy);
  font-weight: 500;
  font-size: 0.95rem;
  line-height: 1.5;
}

/* Content Box */
.content-box {
  background: white;
  border-radius: 12px;
  padding: 1.5rem;
  margin: 1rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.05);
}

.content-box h3 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.5rem;
  color: var(--navy);
  margin-bottom: 1rem;
}

.content-section {
  margin-bottom: 1.25rem;
}

.content-section h4 {
  color: var(--teal);
  font-size: 1rem;
  margin-bottom: 0.5rem;
}

.content-section p {
  color: var(--navy);
  line-height: 1.6;
}

.content-section ul {
  list-style: none;
  padding-left: 0;
}

.content-section li {
  padding: 0.4rem 0;
  padding-left: 1.5rem;
  position: relative;
  color: var(--navy);
}

.content-section li::before {
  content: 'â†’';
  position: absolute;
  left: 0;
  color: var(--gold);
}

/* Method Box */
.method-box {
  background: linear-gradient(135deg, rgba(45,139,139,0.08), rgba(30,39,97,0.08));
  border-left: 4px solid var(--teal);
  border-radius: 0 16px 16px 0;
  padding: 1.5rem;
  margin: 1.5rem 0;
}

.method-label {
  font-size: 0.75rem;
  text-transform: uppercase;
  letter-spacing: 2px;
  color: var(--teal);
  margin-bottom: 0.5rem;
  font-weight: 600;
}

.method-box h3 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.5rem;
  color: var(--navy);
  margin-bottom: 1rem;
}

/* Quiz */
.quiz-container {
  background: white;
  border-radius: 12px;
  padding: 1.5rem;
  margin: 1rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.05);
}

.quiz-question {
  font-size: 1.1rem;
  color: var(--navy);
  margin-bottom: 1.5rem;
  font-weight: 600;
}

.quiz-options {
  display: flex;
  flex-direction: column;
  gap: 0.75rem;
}

.quiz-option {
  padding: 1rem;
  border: 2px solid rgba(0,0,0,0.1);
  border-radius: 8px;
  cursor: pointer;
  transition: all 0.2s;
  background: white;
  text-align: left;
  font-size: 1rem;
  font-family: inherit;
  color: var(--navy);
}

.quiz-option:hover {
  border-color: var(--gold);
  background: rgba(212, 175, 55, 0.05);
}

.quiz-option.selected {
  border-color: var(--navy);
  background: rgba(30, 39, 97, 0.05);
}

.quiz-option.correct {
  border-color: var(--green);
  background: rgba(45, 139, 95, 0.1);
}

.quiz-option.incorrect {
  border-color: var(--red);
  background: rgba(191, 45, 45, 0.1);
}

.quiz-feedback {
  margin-top: 1rem;
  padding: 1rem;
  border-radius: 8px;
  display: none;
}

.quiz-feedback.show {
  display: block;
}

.quiz-feedback.correct {
  background: rgba(45, 139, 95, 0.1);
  border-left: 3px solid var(--green);
}

.quiz-feedback.incorrect {
  background: rgba(191, 45, 45, 0.1);
  border-left: 3px solid var(--red);
}

/* Decision Tree */
.decision-tree {
  background: white;
  border-radius: 12px;
  padding: 1.5rem;
  margin: 1rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.05);
}

.decision-tree h3 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.3rem;
  color: var(--navy);
  margin-bottom: 1rem;
}

.decision-scenario {
  background: rgba(212, 175, 55, 0.1);
  padding: 1rem;
  border-radius: 8px;
  margin-bottom: 1rem;
  font-style: italic;
}

.decision-situation {
  background: rgba(30, 39, 97, 0.05);
  padding: 1rem;
  border-radius: 8px;
  margin-bottom: 1rem;
}

.decision-question {
  font-weight: 600;
  color: var(--navy);
  margin-bottom: 1rem;
}

.decision-branches {
  display: flex;
  flex-direction: column;
  gap: 0.5rem;
}

.decision-branch {
  padding: 1rem;
  border: 2px solid rgba(0,0,0,0.1);
  border-radius: 8px;
  cursor: pointer;
  transition: all 0.2s;
  background: white;
  text-align: left;
  font-family: inherit;
  font-size: 0.95rem;
  color: var(--navy);
  min-height: 48px;
}

.decision-branch:hover {
  border-color: var(--gold);
  background: rgba(212, 175, 55, 0.05);
}

.decision-outcome {
  padding: 1.5rem;
  border-radius: 8px;
  margin-top: 1rem;
}

.decision-outcome.good {
  background: rgba(45, 139, 95, 0.1);
  border-left: 4px solid var(--green);
}

.decision-outcome.bad {
  background: rgba(191, 45, 45, 0.1);
  border-left: 4px solid var(--red);
}

.decision-outcome.neutral {
  background: rgba(212, 175, 55, 0.1);
  border-left: 4px solid var(--gold);
}

.decision-outcome h4 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.2rem;
  margin-bottom: 0.5rem;
}

.decision-lesson {
  margin-top: 1rem;
  padding-top: 1rem;
  border-top: 1px solid rgba(0,0,0,0.1);
  font-style: italic;
}

.decision-history {
  display: flex;
  flex-wrap: wrap;
  gap: 0.5rem;
  margin-bottom: 1rem;
}

.history-step {
  background: var(--navy);
  color: white;
  padding: 0.25rem 0.75rem;
  border-radius: 12px;
  font-size: 0.8rem;
}

.undo-btn {
  background: transparent;
  border: 1px solid var(--red);
  color: var(--red);
  padding: 0.5rem 1rem;
  border-radius: 6px;
  cursor: pointer;
  font-size: 0.85rem;
  margin-bottom: 1rem;
}

.undo-btn:hover {
  background: var(--red);
  color: white;
}

/* Tool Container */
.tool-container {
  background: white;
  border-radius: 12px;
  padding: 1.5rem;
  margin: 1rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.05);
  border: 2px solid var(--teal);
}

.tool-container h3 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.3rem;
  color: var(--teal);
  margin-bottom: 0.5rem;
}

.tool-description {
  color: var(--light-text);
  margin-bottom: 1rem;
}

.tool-inputs {
  display: grid;
  gap: 1rem;
  margin-bottom: 1rem;
}

.input-group {
  display: flex;
  flex-direction: column;
  gap: 0.25rem;
}

.input-group label {
  font-size: 0.85rem;
  font-weight: 600;
  color: var(--navy);
}

.input-group input, .input-group select, .input-group textarea {
  padding: 0.75rem;
  border: 1px solid rgba(0,0,0,0.2);
  border-radius: 6px;
  font-size: 1rem;
  font-family: inherit;
}

.input-group input:focus, .input-group select:focus, .input-group textarea:focus {
  outline: none;
  border-color: var(--teal);
}

.tool-btn {
  background: var(--teal);
  color: white;
  border: none;
  padding: 0.75rem 1.5rem;
  border-radius: 6px;
  cursor: pointer;
  font-size: 1rem;
  font-weight: 600;
  transition: background 0.2s;
}

.tool-btn:hover {
  background: #247070;
}

.tool-output {
  margin-top: 1rem;
  padding: 1rem;
  background: rgba(45, 139, 139, 0.05);
  border-radius: 8px;
  border: 1px solid rgba(45, 139, 139, 0.2);
}

.plot-area {
  min-height: 350px;
  background: white;
  border-radius: 8px;
  margin: 1rem 0;
}

/* Navigation */
.nav-buttons {
  display: flex;
  justify-content: space-between;
  padding: 1rem 2rem;
  background: white;
  border-top: 1px solid rgba(0,0,0,0.1);
}

.nav-btn {
  display: flex;
  align-items: center;
  gap: 0.5rem;
  padding: 0.75rem 1.5rem;
  border: none;
  border-radius: 8px;
  cursor: pointer;
  font-size: 1rem;
  font-weight: 600;
  transition: all 0.2s;
}

.nav-btn.prev {
  background: transparent;
  border: 2px solid var(--navy);
  color: var(--navy);
}

.nav-btn.prev:hover {
  background: var(--navy);
  color: white;
}

.nav-btn.next {
  background: var(--gold);
  color: var(--navy);
}

.nav-btn.next:hover {
  background: #c9a032;
}

.nav-btn:disabled {
  opacity: 0.5;
  cursor: not-allowed;
}

/* Focus States for Accessibility */
button:focus, .module-item:focus, .quiz-option:focus,
.decision-branch:focus, input:focus, select:focus, a:focus {
  outline: 3px solid var(--gold);
  outline-offset: 2px;
}

/* High Contrast Mode */
@media (prefers-contrast: high) {
  :root {
    --gold: #FFD700;
    --cream: #FFFFFF;
  }
}

/* Focus-visible styles for keyboard navigation */
:focus-visible {
  outline: 2px solid var(--gold, #D4AF37);
  outline-offset: 2px;
}

:focus:not(:focus-visible) {
  outline: none;
}

button:focus-visible,
a:focus-visible,
[role="button"]:focus-visible,
input:focus-visible,
select:focus-visible,
textarea:focus-visible {
  outline: 2px solid var(--gold, #D4AF37);
  outline-offset: 2px;
  box-shadow: 0 0 0 4px rgba(212, 175, 55, 0.3);
}

/* Reduced Motion */
@media (prefers-reduced-motion: reduce) {
  *, *::before, *::after {
    animation-duration: 0.01ms !important;
    transition-duration: 0.01ms !important;
  }
}

/* Screen Reader Only */
.sr-only {
  position: absolute;
  width: 1px;
  height: 1px;
  padding: 0;
  margin: -1px;
  overflow: hidden;
  clip: rect(0, 0, 0, 0);
  white-space: nowrap;
  border: 0;
}

/* Responsive Design */
@media (max-width: 768px) {
  .hamburger {
    display: flex;
  }

  .sidebar {
    transform: translateX(-100%);
    transition: transform 0.3s;
  }

  .sidebar.open {
    transform: translateX(0);
  }

  .sidebar-overlay.show {
    display: block;
  }

  .main-content {
    margin-left: 0;
  }

  .slide-title h1 {
    font-size: 2rem;
  }

  .principle-box .text {
    font-size: 1.4rem;
  }

  .top-bar {
    padding: 1rem;
  }

  .progress-bar {
    width: 120px;
  }

  .decision-branch {
    min-height: 48px;
  }

  .quiz-option {
    min-height: 48px;
  }
}

@media (max-width: 480px) {
  .sidebar {
    width: 100%;
  }

  .slide-container {
    padding: 1rem;
  }

  .story-deep, .method-box, .content-box {
    padding: 1rem;
  }

  .data-grid {
    grid-template-columns: 1fr 1fr;
  }

  .top-actions {
    width: 100%;
    justify-content: center;
  }
}

/* Time Estimates */
.time-estimate {
  color: var(--teal);
  font-weight: 600;
  font-size: 0.65rem;
}

.course-time {
  font-size: 0.8rem;
  color: var(--light-text);
  padding: 0.25rem 0.75rem;
  background: rgba(45, 139, 139, 0.1);
  border-radius: 12px;
}

/* Badge Notification */
.badge-notification {
  position: fixed;
  bottom: 2rem;
  right: 2rem;
  background: linear-gradient(135deg, var(--navy), #2a3a7d);
  border-radius: 16px;
  padding: 1rem 1.5rem;
  display: flex;
  align-items: center;
  gap: 1rem;
  box-shadow: 0 8px 32px rgba(0,0,0,0.3);
  z-index: 3000;
  transform: translateY(100px);
  opacity: 0;
  transition: all 0.5s cubic-bezier(0.34, 1.56, 0.64, 1);
}

.badge-notification.show {
  transform: translateY(0);
  opacity: 1;
}

.badge-icon {
  width: 48px;
  height: 48px;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-size: 1.5rem;
  box-shadow: 0 4px 12px rgba(0,0,0,0.2);
}

.badge-info {
  color: white;
}

.badge-earned {
  font-size: 0.7rem;
  text-transform: uppercase;
  letter-spacing: 1px;
  color: var(--gold);
  margin-bottom: 0.25rem;
}

.badge-name {
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.2rem;
  font-weight: 600;
}

/* Badge Grid in Modal */
.badge-grid {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(140px, 1fr));
  gap: 1rem;
  margin-top: 1rem;
}

.badge-card {
  background: white;
  border-radius: 12px;
  padding: 1rem;
  text-align: center;
  border: 2px solid transparent;
  transition: all 0.3s;
}

.badge-card.earned {
  border-color: var(--gold);
  box-shadow: 0 4px 12px rgba(212, 175, 55, 0.2);
}

.badge-card.locked {
  opacity: 0.5;
  filter: grayscale(1);
}

.badge-card .badge-icon {
  width: 56px;
  height: 56px;
  margin: 0 auto 0.75rem;
  font-size: 1.75rem;
}

.badge-card .badge-name {
  color: var(--navy);
  font-size: 0.9rem;
  font-weight: 600;
  margin-bottom: 0.25rem;
}

.badge-card .badge-requirement {
  font-size: 0.75rem;
  color: var(--light-text);
}

/* Mastery Checkpoint */
.mastery-checkpoint {
  background: linear-gradient(135deg, rgba(45, 139, 95, 0.15), rgba(45, 139, 139, 0.1));
  border: 2px solid var(--green);
  border-radius: 16px;
  padding: 1.5rem;
  margin: 2rem 0;
  text-align: center;
}

.mastery-checkpoint h3 {
  color: var(--green);
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.5rem;
  margin-bottom: 0.5rem;
}

.mastery-checkpoint .mastery-icon {
  font-size: 2.5rem;
  margin-bottom: 0.5rem;
}

.mastery-checkpoint p {
  color: var(--navy);
  font-size: 1rem;
  margin: 0;
}

.mastery-checkpoint .mastery-stats {
  display: flex;
  justify-content: center;
  gap: 2rem;
  margin-top: 1rem;
  padding-top: 1rem;
  border-top: 1px solid rgba(45, 139, 95, 0.3);
}

.mastery-stat {
  text-align: center;
}

.mastery-stat .stat-value {
  font-size: 1.5rem;
  font-weight: 700;
  color: var(--green);
}

.mastery-stat .stat-label {
  font-size: 0.75rem;
  color: var(--light-text);
  text-transform: uppercase;
  letter-spacing: 0.5px;
}

/* IPTW Deep Dive Box */
.iptw-deepdive {
  background: linear-gradient(135deg, rgba(212, 175, 55, 0.1), rgba(30, 39, 97, 0.08));
  border-left: 4px solid var(--gold);
  border-radius: 0 12px 12px 0;
  padding: 1.25rem;
  margin: 1rem 0;
}

.iptw-deepdive h4 {
  color: var(--gold);
  font-family: 'Cormorant Garamond', serif;
  font-size: 1.1rem;
  margin-bottom: 0.75rem;
}

.iptw-formula {
  font-family: monospace;
  background: rgba(30, 39, 97, 0.1);
  padding: 0.5rem 1rem;
  border-radius: 6px;
  margin: 0.5rem 0;
  color: var(--navy);
}
  </style>
</head>
<body>
<a class="skip-link" href="#main-content">Skip to main content</a>
<button aria-expanded="false" aria-label="Toggle navigation menu" class="hamburger">
<span></span>
<span></span>
<span></span>
</button>
<div class="sidebar-overlay"></div>
<nav aria-label="ê³¼ì • ëª¨ë“ˆ" class="sidebar" role="navigation">
<a href="index.html" onmouseout="this.style.color='rgba(212,175,55,0.7)'" onmouseover="this.style.color='#D4AF37'" style="display:block;font-size:0.7rem;color:rgba(212,175,55,0.7);text-decoration:none;margin-bottom:0.5rem;padding:0.5rem 1rem 0;">â† Course Library</a>
<div class="logo">Observational Evidence</div>
<div class="tagline">RCTê°€ ë¶ˆê°€ëŠ¥í•œ ê²½ìš°</div>
<div class="nav-section">
<div class="nav-label">Modules</div>
<div id="module-nav"></div>
</div>
</nav>
<main class="main-content" id="main-content">
<div class="top-bar">
<div class="progress-section">
<div class="progress-bar">
<div class="progress-fill" id="progress-fill" style="width: 0%"></div>
</div>
<span class="progress-text" id="progress-text">0% Complete</span>
</div>
<div class="points-display">
<span id="points-display">0</span> XP
      </div>
<div class="course-time">
<span id="total-time">5h 30m total</span>
</div>
<div class="top-actions">
<button class="action-btn" onclick="openBadges()">ğŸ† Badges</button>
<button class="action-btn" onclick="openGlossary()">Glossary</button>
<button class="action-btn" onclick="openToolLibrary()">Tools</button>
</div>
</div>
<div class="slide-container" id="slide-container"></div>
<div aria-live="polite" class="sr-only" id="slide-announce"></div>
<div class="nav-buttons">
<button class="nav-btn prev" id="prev-btn" onclick="prevSlide()">
<span>â†</span> Previous
      </button>
<button class="nav-btn next" id="next-btn" onclick="nextSlide()">
        Next <span>â†’</span>
</button>
</div>
</main>
<script>
// Course Data
const STORAGE_KEY = 'observational-evidence-course-progress';

let currentModule = 0;
let currentSlide = 0;
let gameState = {
  points: 0,
  earnedBadges: [],
  toolsUsed: [],
  modulesCompleted: [],
  scenariosCompleted: {},
  decisionTrees: {}
};

// Badge Definitions with visual designs
const BADGES = {
  'bias-detective': { name: 'Bias Detective', icon: 'ğŸ”', color: '#BF2D2D', requirement: 'ëª¨ë“  ë°”ì´ì–´ìŠ¤ ëª¨ë“ˆ ì™„ë£Œ' },
  'dag-master': { name: 'DAG Master', icon: 'ğŸ•¸ï¸', color: '#2D8B8B', requirement: 'Build 3 DAGs correctly' },
  'robins-ranger': { name: 'ROBINS Ranger', icon: 'ğŸ›¡ï¸', color: '#D4AF37', requirement: '5ê°œ ROBINS-I í‰ê°€ ì™„ë£Œ' },
  'story-scholar': { name: 'Story Scholar', icon: 'ğŸ“š', color: '#1e2761', requirement: '16ê°œ ì‚¬ë¡€ ì—°êµ¬ ëª¨ë‘ ì½ê¸°' },
  'decision-ace': { name: 'Decision Ace', icon: 'ğŸ¯', color: '#2D8B5F', requirement: '19ê°œ ì˜ì‚¬ê²°ì • íŠ¸ë¦¬ ëª¨ë‘ ì™„ë£Œ' },
  'quiz-champion': { name: 'Quiz Champion', icon: 'ğŸ†', color: '#9B59B6', requirement: 'Score 100% on all quizzes' },
  'methods-master': { name: 'Methods Master', icon: 'ğŸ“', color: '#E67E22', requirement: 'ì „ì²´ ì™„ë£Œ ê³¼ì •' },
  'capstone-conqueror': { name: 'Capstone Conqueror', icon: 'ğŸ‘‘', color: '#C0392B', requirement: '3ê°€ì§€ ìµœì¢… ì‹œë‚˜ë¦¬ì˜¤ ëª¨ë‘ ì™„ë£Œ' }
};

const modules = [
  {
    id: 0,
    title: "The Opening",
    subtitle: "ê´€ì°° ì¦ê±°ê°€ ì¤‘ìš”í•œ ì´ìœ ",
    principle: null,
    estimatedTime: "15 min",
    slides: [
      {
        type: 'title',
        content: {
          title: "Observational Evidence",
          subtitle: "RCTê°€ ë¶ˆê°€ëŠ¥í•œ ê²½ìš°",
          text: "ì†ì€ ì‚¬ëŒë“¤ê³¼ ë‹¨ í•œ ë²ˆë„ ë¬´ì‘ìœ„ë¡œ ìƒëª…ì„ êµ¬í•œ ì‚¬ëŒë“¤ì˜ ì´ì•¼ê¸°ë¥¼ í†µí•´ ì§€ì €ë¶„í•œ ì‹¤ì œ ë°ì´í„°ì—ì„œ ì§„ì‹¤ì„ ì¶”ì¶œí•˜ëŠ” ë°©ë²•ì„ ì•Œì•„ë³´ì„¸ìš”. ì¬íŒ."
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "THE SALVATION: THALIDOMIDE â€” WHEN OBSERVATION SAVED LIVES",
          source: "Lancet 1961; McBride | BMJ 1961; Lenz | No RCT existed",
          timeline: [
            { year: "1957", text: "Thalidomide marketed in Germany as 'completely safe' sedative. Sold over-the-counter. Pregnant women take it for morning sickness.", type: "normal" },
            { year: "1959-60", text: "Reports of peripheral neuropathy emerge. Company dismisses concerns. No systematic monitoring exists.", type: "normal" },
            { year: "Nov 1961", text: "Dr. William McBride in Australia notices pattern: mothers of babies with limb defects took thalidomide. He writes to Lancet.", type: "revelation" },
            { year: "Nov 1961", text: "Dr. Widukind Lenz in Germany independently identifies the same pattern through case-control reasoning.", type: "revelation" },
            { year: "Dec 1961", text: "Drug withdrawn worldwide. 10,000+ children affected. Two observant physicians saved countless more.", type: "crisis" },
            { year: "Legacy", text: "Modern pharmacovigilance born. FDA strengthened. The lesson: OBSERVATIONAL DATA can detect harms RCTs miss.", type: "revelation" }
          ],
          realData: {
            endpoint: "Phocomelia (limb defects)",
            drug: "Thalidomide exposure in first trimester",
            placebo: "No exposure",
            rr: "Case-control OR > 100",
            ci: "Unquestionable association",
            nnh: "~10,000 children affected"
          },
          hook: "THE HOOK: No RCT detected thalidomide's harm. Two physicians, using observational reasoning, saw a pattern and saved a generation. This course teaches you to see patterns â€” and to know when they're real."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ ì£¼ìš” í†µì°°ë ¥: íƒˆë¦¬ë„ë§ˆì´ë“œê°€ ê´€ì°° ì¦ê±°ë¡œ ìƒëª…ì„ êµ¬í•  ìˆ˜ ìˆìŒì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ HRTëŠ” ì†ì¼ ìˆ˜ë„ ìˆìŒì„ ì¦ëª…í•©ë‹ˆë‹¤. ë¬¸ì œëŠ” ê´€ì°° ë°ì´í„°ë¥¼ ì‚¬ìš©í• ì§€ ì—¬ë¶€ê°€ ì•„ë‹ˆë¼ ì´ë¥¼ í˜„ëª…í•˜ê²Œ ì‚¬ìš©í•˜ëŠ” ë°©ë²•ì…ë‹ˆë‹¤."
        }
      },
      {
        type: 'content',
        content: {
          title: "When RCTs Are Impossible or Insufficient",
          sections: [
            {
              heading: "RCTs Cannot Answer These Questions:",
              items: [
                "Rare harms (need millions of patients, decades of follow-up)",
                "Long-term outcomes (RCTs rarely last >5 years)",
                "Real-world effectiveness (RCTs select ideal patients)",
                "Unethical randomization (can't randomize smoking, poverty)",
                "Historical questions (what happened before RCTs existed?)"
              ]
            },
            {
              heading: "Observational Data Can:",
              items: [
                "Detect rare adverse events (thalidomide, Vioxx)",
                "Track lifetime outcomes (Framingham, Nurses' Health)",
                "ì‹¤ì œ ëª¨ì§‘ë‹¨ ì—°êµ¬(ì‹œí—˜ ëŒ€ìƒì´ ì•„ë‹Œ)",
                "Generate hypotheses for future RCTs",
                "Monitor post-marketing drug safety"
              ]
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "ê´€ì°° ì¦ê±°ì˜ 7ê°€ì§€ ì›ì¹™",
          sections: [
            {
              heading: "Your Guide Through This Course:",
              items: [
                "1. \"Association is not causation\" â€” Confounding deceives",
                "2. \"Time flows one direction\" â€” Temporality matters",
                "3. \\\"ì°¾ëŠ” ê²ƒì´ ë³´ì…ë‹ˆë‹¤\\\" â€” ì„ íƒ í¸í–¥ì´ ìˆ¨ê²¨ì§‘ë‹ˆë‹¤",
                "4. \"Measurement shapes reality\" â€” Information bias distorts",
                "5. \"Context determines meaning\" â€” Effect modification exists",
                "6. \"Adjustment is not magic\" â€” Residual confounding remains",
                "7. \"Replication builds confidence\" â€” One study is never enough"
              ]
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "ì´ ê°•ì¢Œì˜ ì§„í–‰ ë°©ì‹",
          sections: [
            {
              heading: "Each Module Contains:",
              items: [
                "ğŸ“– ì´ì•¼ê¸° â€” ê´€ì°° ì—°êµ¬ë¥¼ í†µí•œ ì‹¤ì œ ì¬ë‚œê³¼ ìŠ¹ë¦¬",
                "ğŸ”§ ë°©ë²• â€” ìˆ˜í–‰ ë°©ë²• ì˜¬ë°”ë¥´ê²Œ",
                "âš™ï¸ ë„êµ¬ â€” ëŒ€í™”í˜• ì—°ìŠµ",
                "ğŸ”€ ì‹œë‚˜ë¦¬ì˜¤ â€” íŒë‹¨ ì ìš©",
                "âœ… í€´ì¦ˆ â€” ì´í•´ë„ í…ŒìŠ¤íŠ¸"
              ]
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'rct-vs-obs-decision',
          title: "ê´€ì°° ë°ì´í„°ê°€ í•„ìš”í•œ ê²½ìš°",
          situation: "You're a researcher deciding how to study a clinical question. For each scenario, decide: RCT or observational?",
          nodes: {
            start: {
              question: "ì‹œë‚˜ë¦¬ì˜¤: í¡ì—°ì´ íì•”ì„ ìœ ë°œí•˜ëŠ”ì§€ ì—¬ë¶€ë¥¼ ì—°êµ¬í•˜ë ¤ê³  í•©ë‹ˆë‹¤. ì—°êµ¬ ì„¤ê³„ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "RCT â€” randomize people to smoke or not smoke", nextNode: "rct_smoking_wrong" },
                { text: "ê´€ì°° â€” ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ í¡ì—°ìì™€ ë¹„í¡ì—°ìë¥¼ ì¶”ì í•©ë‹ˆë‹¤.", nextNode: "obs_smoking_correct" }
              ]
            },
            rct_smoking_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Ethically impossible!",
              text: "ì‚¬ëŒë“¤ì„ ë¬´ì‘ìœ„ë¡œ í¡ì—°í•˜ë„ë¡ í•  ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤. í¡ì—°ì€ í•´ë¥¼ ë¼ì¹  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ í¡ì—° â†’ íì•”ì„ í™•ë¦½í•˜ëŠ” ë° ê´€ì°°ì  ì¦ê±°ê°€ í•„ìˆ˜ì ì¸ ì´ìœ ì…ë‹ˆë‹¤. Dollê³¼ Hillì€ RCTê°€ ë¹„ìœ¤ë¦¬ì ì´ê¸° ë•Œë¬¸ì— ì½”í˜¸íŠ¸ ì—°êµ¬ë¥¼ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤.",
              lesson: "ë…¸ì¶œì´ í•´ë¥¼ ì…í ê²½ìš° ë¬´ì‘ìœ„ ë°°ì •ì€ ë¹„ìœ¤ë¦¬ì ì…ë‹ˆë‹¤. ê´€ì°° ë°ì´í„°ê°€ ìœ ì¼í•œ ì˜µì…˜ì…ë‹ˆë‹¤."
            },
            obs_smoking_correct: {
              situation: "Correct! Smoking studies must be observational. NEXT SCENARIO:",
              question: "You want to know if a new diabetes drug reduces heart attacks. What design?",
              branches: [
                { text: "RCT â€” randomize patients to drug vs placebo", nextNode: "rct_drug_correct" },
                { text: "Observational â€” compare patients who chose the drug", nextNode: "obs_drug_partial" }
              ]
            },
            rct_drug_correct: {
              situation: "ì´ìƒì ì…ë‹ˆë‹¤! í•˜ì§€ë§Œ RCTì—ëŠ” 5ë…„, 10,000ëª…ì˜ í™˜ìê°€ ì†Œìš”ë©ë‹ˆë‹¤. ê²½ì˜ì§„ì€ ì²­êµ¬ ë°ì´í„°ë¥¼ ì‚¬ìš©í•˜ì—¬ 6ê°œì›” ì´ë‚´ì— ë‹µë³€ì„ ì›í•©ë‹ˆë‹¤. ì–´ë–»ê²Œ ë§í•˜ì‹œë‚˜ìš”?",
              question: "Your response:",
              branches: [
                { text: "ê´€ì°° ì—°êµ¬ë¥¼ ìˆ˜í–‰í•˜ì„¸ìš” - ì†ë„ê°€ ì¤‘ìš”í•©ë‹ˆë‹¤", nextNode: "speed_wrong" },
                { text: "ì´ ì§ˆë¬¸ì— ëŒ€í•œ ê´€ì°° ë°ì´í„°ê°€ í˜¼ë€ìŠ¤ëŸ¬ìš¸ ê²ƒì´ë¼ê³  ì„¤ëª…í•˜ì„¸ìš”", nextNode: "explain_correct" }
              ]
            },
            obs_drug_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Possible, but risky",
              text: "ì•½ë¬¼ íš¨ê³¼ì— ëŒ€í•œ ê´€ì°° ì—°êµ¬ëŠ” ì ì‘ì¦ì— ë”°ë¼ ì‹¬ê°í•œ í˜¼ë€ì„ ì•¼ê¸°í•©ë‹ˆë‹¤. ì•„í”ˆ í™˜ìëŠ” ì•½ì„ ë³µìš©í•©ë‹ˆë‹¤. ì‹¬ì¥ë§ˆë¹„ì— ê±¸ë¦¬ê¸° ì‰¬ìš´ í™˜ìë“¤ì´ ì´ ì•½ì„ ì²˜ë°©ë°›ì•˜ë‹¤ëŠ” ì´ìœ ë§Œìœ¼ë¡œ ê·¸ ì•½ì´ ì‹¬ì¥ë§ˆë¹„ë¥¼ ì¼ìœ¼í‚¤ëŠ” ê²ƒì„ ë°œê²¬í•  ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ HRTì˜ êµí›ˆì…ë‹ˆë‹¤.",
              lesson: "ì¹˜ë£Œ ê°€ëŠ¥í•œ ì§ˆí™˜ì˜ ê²½ìš° ê°€ëŠ¥í•˜ë‹¤ë©´ RCTê°€ ì„ í˜¸ë©ë‹ˆë‹¤. ê´€ì°° ì•½ë¬¼ ì—°êµ¬ì—ëŠ” ë§¤ìš° ì‹ ì¤‘í•œ ì„¤ê³„(í™œì„± ë¹„êµì, ì‹ ê·œ ì‚¬ìš©ì, í‘œì  ì‹œí—˜ ì—ë®¬ë ˆì´ì…˜)ê°€ í•„ìš”í•©ë‹ˆë‹¤."
            },
            speed_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì´ HRTê°€ ë°œìƒí•œ ë°©ì‹ì…ë‹ˆë‹¤!",
              text: "HRTì— ëŒ€í•œ ê´€ì°° ì—°êµ¬ëŠ” RCTë³´ë‹¤ ë¹ ë¥´ê³  ì‰¬ì› ê¸° ë•Œë¬¸ì— ìˆ˜í–‰ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ 20ë…„ ë™ì•ˆ ì˜ëª»ëœ ëŒ€ë‹µì„ í–ˆìŠµë‹ˆë‹¤. íƒ€ë‹¹ì„±ì´ ì—†ëŠ” ì†ë„ëŠ” ê¸°ë‹¤ë¦¬ëŠ” ê²ƒë³´ë‹¤ ë‚˜ì©ë‹ˆë‹¤.",
              lesson: "ë¹ ë¥¸ ì˜¤ë‹µì€ í™˜ìì—ê²Œ í•´ë¥¼ ë¼ì¹©ë‹ˆë‹¤. ê´€ì°° ì¦ê±°ê°€ ë„ˆë¬´ í¸í–¥ëœ ê²½ìš° RCTë¥¼ ê¸°ë‹¤ë¦¬ëŠ” ê²ƒì´ ë” ì¢‹ìŠµë‹ˆë‹¤."
            },
            explain_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Excellent scientific judgment!",
              text: "ì´ ì§ˆë¬¸(ì•½ë¬¼ â†’ ì‹¬í˜ˆê´€ ê²°ê³¼)ì´ ì ì‘ì¦ì— ì˜í•œ í˜¼ë€ì— ë§¤ìš° ì·¨ì•½í•˜ë‹¤ëŠ” ì ì„ ì˜¬ë°”ë¥´ê²Œ ì‹ë³„í•˜ì…¨ìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œì˜ ê´€ì°° ì¦ê±°ëŠ” ì‹ ë¢°í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. RCTëŠ” ê¸°ë‹¤ë¦´ ê°€ì¹˜ê°€ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ê´€ì¸¡ ë°ì´í„°ê°€ ì§ˆë¬¸ì— ë‹µë³€í•  ìˆ˜ ìˆëŠ” ê²½ìš°ì™€ ì—†ëŠ” ê²½ìš°ë¥¼ ì•Œì•„ë³´ì„¸ìš”. ì ì‘ì¦ì— ë”°ë¥¸ í˜¼ë€ìŠ¤ëŸ¬ìš´ ì•½ë¬¼ íš¨ëŠ¥ì€ ìœ„í—˜í•œ ì˜ì—­ì…ë‹ˆë‹¤."
            }
          }
        }
      },
      {
        type: 'principle',
        content: {
          text: "âš ï¸ THE WARNING: As you learn observational methods, remember both faces of the coin. Thalidomide shows observation SAVES lives. But this course will also show how it COSTS lives when done carelessly. Stay humble. Stay skeptical. Stay curious."
        }
      }
    ]
  },
  {
    id: 1,
    title: "The Trap",
    subtitle: "Confounding",
    principle: 0,
    story: "HRT",
    estimatedTime: "25 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "ì—°ê´€ì„±ì€ ì¸ê³¼ê´€ê³„ê°€ ì•„ë‹™ë‹ˆë‹¤"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ê¸°ë§Œ: HRT â€” 30ê°œ ì—°êµ¬ê°€ ê±°ì§“ë§ì„ í•œ ê²½ìš°",
          source: "JAMA 2002; 288:321-333 | WHI Writing Group | PubMed: 12117397",
          timeline: [
            { year: "1960s-80s", text: "Observational studies consistently show HRT reduces CHD by 40-50%. Biological rationale compelling: estrogen improves lipids.", type: "normal" },
            { year: "1985", text: "Framingham: Women on HRT have 50% lower CHD risk. Millions of prescriptions written for 'cardioprotection.'", type: "normal" },
            { year: "1991", text: "ê°„í˜¸ì‚¬ì˜ ê±´ê°• ì—°êµ¬: RR 0.56(95% CI CHDì˜ ê²½ìš° 0.40-0.80). 'í™•ì‹¤í•œ' ì¦ê±°. HRTê°€ ì¹˜ë£Œì˜ í‘œì¤€ì´ ë©ë‹ˆë‹¤.", type: "normal" },
            { year: "1998", text: "HERS trial (first large RCT): HR 0.99 (0.81-1.22). NO BENEFIT. Dismissed as 'wrong population.'", type: "crisis" },
            { year: "Jul 2002", text: "HARMìœ¼ë¡œ ì¸í•´ WHIê°€ ì¤‘ë‹¨ë˜ì—ˆìŠµë‹ˆë‹¤. CHD HR 1.29(1.02-1.63). ìœ ë°©ì•”ì´ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. 30ê°œ ì´ìƒì˜ ì—°êµ¬ëŠ” ëª¨ë‘ í‹€ë ¸ìŠµë‹ˆë‹¤.", type: "crisis" },
            { year: "The Truth", text: "Healthy user bias: Women who chose HRT were healthier, richer, more educated, exercised more. The 'benefit' was confounding.", type: "revelation" }
          ],
          realData: {
            endpoint: "Coronary heart disease",
            drug: "Observational: RR 0.56 (0.40-0.80)",
            placebo: "RCT (WHI): HR 1.29 (1.02-1.63)",
            rr: "OPPOSITE DIRECTIONS",
            ci: "Confounding flipped benefit to harm",
            nnh: "Millions of women misled for decades"
          },
          hook: "THE QUESTION: How can 30 observational studies, 40+ meta-analyses, and 'compelling' biological rationale all be wrong? Because they measured WHO TAKES HRT, not WHAT HRT DOES. The women who chose HRT were already healthier. Confounding is invisible â€” until an RCT exposes it."
        }
      },
      {
        type: 'story-box',
        content: {
          icon: 'ğŸ’”',
          title: "The HRT Reversal: 20 Years of Wrong Answers",
          source: "Women's Health Initiative, JAMA 2002",
          paragraphs: [
            "For decades, observational studies showed women on hormone replacement therapy had 50% fewer heart attacks. The biological rationale was compelling: estrogen improves lipid profiles. Millions of women were prescribed HRT specifically for 'cardioprotection.'",
            "ê·¸ëŸ° ë‹¤ìŒ Women's Health Initiative RCT(2002)ëŠ” ì¶©ê²©ì„ ì£¼ì—ˆìŠµë‹ˆë‹¤. HRTëŠ” ì‹¤ì œë¡œ ì‹¬ì¥ë§ˆë¹„ë¥¼ 29% ì¦ê°€ì‹œì¼°ìŠµë‹ˆë‹¤. í”¼í•´ë¡œ ì¸í•´ ì¬íŒì´ ì¡°ê¸° ì¤‘ë‹¨ë˜ì—ˆìŠµë‹ˆë‹¤.",
            "What went wrong? The observational studies suffered from 'healthy user bias.' Women who chose HRT were wealthier, more educated, more health-conscious, and more likely to exercise. They would have had fewer heart attacks regardless of HRT. The studies were measuring the TYPE of woman who took HRT, not what HRT actually did."
          ],
          lesson: "Confounding created a false signal that lasted 20 years and influenced millions of prescriptions. When you observe that users of something have better outcomes, always ask: are they better off BECAUSE of the treatment, or were they already different?"
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ KEY TAKEAWAY: HRT's 'benefit' wasn't from the drug â€” it was from the type of woman who chose to take it. Confounders are variables that affect BOTH the exposure and the outcome. Unless you account for them, you're measuring the confounder, not the treatment."
        }
      },
      {
        type: 'content',
        content: {
          title: "What is Confounding?",
          sections: [
            {
              heading: "The Three Conditions for Confounding:",
              items: [
                "1. í˜¼ë€ìëŠ” EXPOSURE",
                "2ì™€ ì—°ê´€ë˜ì–´ ìˆìŠµë‹ˆë‹¤. í˜¼ë€ìëŠ” OUTCOME",
                "3ê³¼ ì—°ê´€ë˜ì–´ ìˆìŠµë‹ˆë‹¤. êµë€ìëŠ” ì¸ê³¼ ê²½ë¡œì— ìˆì§€ ì•ŠìŠµë‹ˆë‹¤"
              ]
            },
            {
              heading: "HRT Example:",
              items: [
                "Confounder: Socioeconomic status / health consciousness",
                "Associated with exposure: Wealthy, educated women more likely to seek HRT",
                "Associated with outcome: Wealthy, educated women have lower CHD risk anyway",
                "Not on causal pathway: SES doesn't mediate HRT's biological effect",
                "ê²°ê³¼: HRT ì‚¬ìš©ìëŠ” ì²˜ìŒë¶€í„° ë” ê±´ê°•í–ˆê¸° ë•Œë¬¸ì— HRTê°€ ìœ ìµí•œ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤."
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: í˜¼ë€ ìš”ì¸ ì‹ë³„",
          title: "Thinking Causally",
          sections: [
            {
              heading: "Step 1: Draw a DAG (Directed Acyclic Graph)",
              text: "ë…¸ì¶œ, ê²°ê³¼ ë° ì ì¬ì  í˜¼ë€ ìš”ì¸ ê°„ì˜ ì¸ê³¼ ê´€ê³„ë¥¼ ì‹œê°í™”í•©ë‹ˆë‹¤. í™”ì‚´í‘œëŠ” ì›ì¸ ë°©í–¥ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤."
            },
            {
              heading: "Step 2: Identify Backdoor Paths",
              text: "ë…¸ì¶œì—ì„œ ê³µí†µ ì›ì¸ì„ í†µí•´ ë’¤ë¡œ ê°€ëŠ” ê²°ê³¼ê¹Œì§€ì˜ ëª¨ë“  ê²½ë¡œëŠ” ì°¨ë‹¨ë˜ì–´ì•¼ í•˜ëŠ” êµë€ ê²½ë¡œì…ë‹ˆë‹¤."
            },
            {
              heading: "Step 3: Decide What to Adjust For",
              text: "êµë€ ìš”ì†Œ(ê³µí†µ ì›ì¸)ì— ë§ê²Œ ì¡°ì •í•©ë‹ˆë‹¤. ì¤‘ì¬ì¸(ì¸ê³¼ ê²½ë¡œ)ì´ë‚˜ ì¶©ëŒ ìš”ì¸(ê³µí†µ íš¨ê³¼)ì„ ì¡°ì •í•˜ì§€ ë§ˆì‹­ì‹œì˜¤."
            },
            {
              heading: "Step 4: Assess Residual Confounding",
              text: "Even after adjustment, unmeasured confounders remain. Sensitivity analysis can estimate their potential impact."
            }
          ]
        }
      },
      {
        type: 'tool',
        content: {
          id: 'dag-builder',
          title: "DAG Builder",
          description: "Build a Directed Acyclic Graph to visualize causal relationships and identify confounders"
        }
      },
      {
        type: 'story-box',
        content: {
          icon: 'â˜•',
          title: "ê°„í˜¸ì‚¬ì˜ ê±´ê°• ì—°êµ¬ ì»¤í”¼ ì—­ì„¤",
          source: "Nurses' Health Study, Multiple Publications 1980s-2000s",
          paragraphs: [
            "ê°„í˜¸ì‚¬ ê±´ê°• ì—°êµ¬ì˜ ì´ˆê¸° ë¶„ì„ì—ì„œëŠ” ë¬¸ì œê°€ ë˜ëŠ” ì—°ê´€ì„±ì„ ë°œê²¬í–ˆìŠµë‹ˆë‹¤. ì¦‰, ì»¤í”¼ë¥¼ ë§ˆì‹œëŠ” ì‚¬ëŒì€ ì‹¬ì¥ë³‘ ë°œë³‘ë¥ ì´ ë” ë†’ì•˜ìŠµë‹ˆë‹¤. ì˜ë£Œ ì§€ì¹¨ì—ì„œëŠ” ì»¤í”¼ ì†Œë¹„ì— ëŒ€í•´ ê²½ê³ í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ë°ì´í„°ì—ì„œëŠ” ì—°ê´€ì„±ì´ ëª…í™•í•´ ë³´ì˜€ìŠµë‹ˆë‹¤.",
            "Then researchers noticed something: coffee drinkers smoked more. In that era, coffee and cigarettes went together. When smoking was properly adjusted for, the coffee-heart disease link vanished entirely.",
            "ê·¸ëŸ¬ë‚˜ ì´ì•¼ê¸°ëŠ” ì—¬ê¸°ì„œ ëë‚˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë” ë‚˜ì€ ë°©ë²•ê³¼ ì¥ê¸°ê°„ì˜ í›„ì† ì—°êµ¬ë¥¼ í†µí•´ ì»¤í”¼ê°€ ì‹¤ì œë¡œ ì‹¬ì¥ë³‘, ì œ2í˜• ë‹¹ë‡¨ë³‘ ë° íŠ¹ì • ì•”ì„ ì˜ˆë°©í•  ìˆ˜ ìˆë‹¤ëŠ” ì‚¬ì‹¤ì´ ë°í˜€ì¡ŒìŠµë‹ˆë‹¤. ë™ì¼í•œ ë°ì´í„° ì„¸íŠ¸ë¥¼ ë” ë‚˜ì€ êµë€ ì œì–´ë¡œ ë¶„ì„í•œ ê²°ê³¼ ì •ë°˜ëŒ€ì˜ ê²°ë¡ ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤."
          ],
          lesson: "êµë€ ì œì–´ëŠ” ì¤‘ìš”í•  ë¿ë§Œ ì•„ë‹ˆë¼ ê²°ë¡ ì„ ì™„ì „íˆ ë’¤ì§‘ì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ì»¤í”¼ ì´ì•¼ê¸°ëŠ” ì ì§„ì ìœ¼ë¡œ ë” ë‚˜ì€ ë°©ë²•ìœ¼ë¡œ ë¶„ì„í•  ë•Œ ë™ì¼í•œ ê¸°ë³¸ ë°ì´í„°ë¥¼ ì‚¬ìš©í•˜ì—¬ ìœ í•´í•œ ì—°ê´€ì„±ì´ ì–´ë–»ê²Œ ë¬´íš¨í™”ë˜ê³  ë³´í˜¸ë  ìˆ˜ ìˆëŠ”ì§€ ë³´ì—¬ì¤ë‹ˆë‹¤."
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'confounding_decision_tree',
          title: "ì»¤í”¼ ìˆ˜ìˆ˜ê»˜ë¼",
          situation: "You're analyzing observational data on coffee consumption and mortality. Your crude analysis shows coffee drinkers have 15% higher mortality (RR 1.15, p<0.01). A colleague suggests this proves coffee is harmful.",
          nodes: {
            start: {
              id: 'start',
              situation: "'COFFEE KILLS'ë¥¼ ê²Œì‹œí•˜ê¸° ì „ì— ì ì¬ì ì¸ í˜¼ë€ ìš”ì¸ì„ ê³ ë ¤í•©ë‹ˆë‹¤. ê°€ì¥ ë¨¼ì € ìƒê°ë‚˜ëŠ” ê²ƒì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              question: "ê°€ì¥ ìš°ë ¤ë˜ëŠ” í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì¸ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { id: 'smoking', text: "Smoking â€” coffee drinkers smoke more", nextNode: 'smoking_path' },
                { id: 'age', text: "Age â€” older people drink more coffee", nextNode: 'age_path' },
                { id: 'no_confounder', text: "ì—°ê´€ì€ ì‹¤ì œì…ë‹ˆë‹¤. ìˆëŠ” ê·¸ëŒ€ë¡œ ê²Œì‹œ", nextNode: 'publish_crude' }
              ]
            },
            smoking_path: {
              id: 'smoking_path',
              situation: "í¡ì—° ìƒíƒœì— ë”°ë¼ ê³„ì¸µí™”í•©ë‹ˆë‹¤. ë¹„í¡ì—°ì ì¤‘: RR 0.92(0.85-0.99). í¡ì—°ì ì¤‘: RR 1.35(1.20-1.52). 1.15ì˜ ì¡°ì¡í•œ RRì€ í¡ì—°ìœ¼ë¡œ ì¸í•´ í˜¼ë€ìŠ¤ëŸ¬ì›Œì¡ŒìŠµë‹ˆë‹¤.",
              question: "ì–´ë–¤ ê²°ë¡ ì„ ë‚´ë¦½ë‹ˆê¹Œ?",
              branches: [
                { id: 'coffee_protective', text: "Coffee is actually protective (in non-smokers)", nextNode: 'protective_finding' },
                { id: 'more_analysis', text: "Need to adjust for more confounders before concluding", nextNode: 'multivariate' },
                { id: 'effect_modification', text: "ì´ê²ƒì€ ë‹¨ìˆœí•œ í˜¼ë€ì´ ì•„ë‹Œ íš¨ê³¼ ìˆ˜ì •ì²˜ëŸ¼ ë³´ì…ë‹ˆë‹¤.", nextNode: 'effect_mod_insight' }
              ]
            },
            age_path: {
              id: 'age_path',
              situation: "You check age distribution. Mean age: coffee drinkers 58 years, non-drinkers 52 years. Older people drink more coffee AND have higher mortality. Classic confounding.",
              question: "ì§„í–‰ ë°©ë²•ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { id: 'age_adjust', text: "ì—°ë ¹ì„ ì¡°ì •í•˜ê³  ë‹¤ì‹œ ë¶„ì„í•©ë‹ˆë‹¤", nextNode: 'age_adjusted' },
                { id: 'age_stratify', text: "Stratify by age groups", nextNode: 'age_stratified' }
              ]
            },
            publish_crude: {
              id: 'publish_crude',
              type: 'outcome',
              consequence: 'bad',
              title: "ì»¤í”¼ íŒ¨ë‹‰",
              text: "Your paper is published. Headlines: 'COFFEE INCREASES DEATH RISK BY 15%'. Three months later, another team adjusts for smoking â€” finding coffee is protective. Your paper is criticized as a textbook example of confounding. Your credibility suffers.",
              lesson: "ê²°ê³¼: ëª¨ë“  ê´€ì°° í˜‘íšŒì—ëŠ” ì ì¬ì ì¸ í˜¼ë€ì´ ìˆìŠµë‹ˆë‹¤. í˜¼ë€ì„ ê³ ë ¤í•˜ì§€ ì•Šê³  ì¡°ì¡í•œ ì—°ê´€ì„±ì„ ì¶œíŒí•˜ëŠ” ê²ƒì€ ê³¼í•™ì´ ì•„ë‹™ë‹ˆë‹¤. ê·¸ê²ƒì€ ì¶”ì¸¡ì…ë‹ˆë‹¤. HRT ì´ì•¼ê¸°ë¥¼ í†µí•´ ì´ ì‚¬ì‹¤ì„ ì•Œ ìˆ˜ ìˆì—ˆì„ ê²ƒì…ë‹ˆë‹¤."
            },
            protective_finding: {
              id: 'protective_finding',
              type: 'outcome',
              consequence: 'neutral',
              title: "Partial Credit",
              text: "Adjusting for smoking reveals coffee's apparent protective effect. But other confounders remain: socioeconomic status, diet, exercise. The non-smokers who drink coffee may still differ from non-smokers who don't.",
              lesson: "THE GRADUAL REVEAL: Adjusting for one confounder is better than none, but rarely sufficient. Multiple confounders usually exist. Each adjustment can reveal new associations â€” or new biases."
            },
            multivariate: {
              id: 'multivariate',
              situation: "You build a multivariate model adjusting for: smoking, age, BMI, alcohol, income, education, exercise. Adjusted RR: 0.88 (0.82-0.95). Coffee appears protective after accounting for measured confounders.",
              question: "Can you now conclude coffee prevents death?",
              branches: [
                { id: 'conclude_protective', text: "ì˜ˆ â€” ì¡°ì •ëœ ë¶„ì„ì€ ì¸ê³¼ì ì…ë‹ˆë‹¤", nextNode: 'overclaiming' },
                { id: 'residual_confounding', text: "No â€” unmeasured confounders may remain", nextNode: 'wise_conclusion' }
              ]
            },
            effect_mod_insight: {
              id: 'effect_mod_insight',
              type: 'outcome',
              consequence: 'good',
              title: "Sharp Thinking",
              text: "í¡ì—° ìƒíƒœ(í¡ì—°ìì—ê²ŒëŠ” í•´ë¡œì›€, ë¹„í¡ì—°ìì—ê²ŒëŠ” ë³´í˜¸)ì— ë”°ë¼ íš¨ê³¼ê°€ ë‹¤ë¥´ë‹¤ëŠ” ê²ƒì„ í™•ì¸í•˜ì…¨ìŠµë‹ˆë‹¤. ì´ê²ƒì´ íš¨ê³¼ ìˆ˜ì •ì…ë‹ˆë‹¤. ì»¤í”¼ì˜ íš¨ê³¼ëŠ” í•˜ìœ„ ê·¸ë£¹ë§ˆë‹¤ ë‹¤ë¦…ë‹ˆë‹¤. ë‹¨ì¼ í‰ê·  íš¨ê³¼ë¥¼ ë³´ê³ í•˜ëŠ” ê²ƒì€ ì˜¤í•´ì˜ ì†Œì§€ê°€ ìˆìŠµë‹ˆë‹¤.",
              lesson: "THE PROTECTION: Confounding distorts the overall effect. Effect modification means the effect truly varies. In your paper, report stratum-specific effects: 'Coffee was associated with lower mortality in non-smokers (RR 0.92) but higher mortality in smokers (RR 1.35).'"
            },
            age_adjusted: {
              id: 'age_adjusted',
              situation: "ì—°ë ¹ ì¡°ì • í›„: RR 1.02(0.95-1.10). í˜‘íšŒê°€ ì‚¬ë¼ì¡Œì–´ìš”! ë‚˜ì´ëŠ” ê°•ë ¥í•œ í˜¼ë€ ìš”ì¸ì´ì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì ê¹ë§Œìš”. í¡ì—°ì— ëŒ€í•´ì„œë„ ì¡°ì •í•´ì•¼ í• ê¹Œìš”?",
              isEnding: true,
              outcome: 'neutral',
              lesson: "THE REPETITION: One confounder down, potentially many to go. Age adjustment removed most of the crude association. But comprehensive analysis requires considering ALL major confounders. The job isn't done."
            },
            age_stratified: {
              id: 'age_stratified',
              situation: "Age-stratified results: <50 years: RR 0.95. 50-65 years: RR 1.01. >65 years: RR 0.98. No age group shows significant association. The crude RR 1.15 was entirely due to age confounding.",
              isEnding: true,
              outcome: 'good',
              lesson: "THE REVELATION: Stratification lets you SEE the confounding. In every age stratum, coffee shows no association with mortality. The crude association was an artifact of age differences between coffee drinkers and non-drinkers."
            },
            overclaiming: {
              id: 'overclaiming',
              type: 'outcome',
              consequence: 'bad',
              title: "ê³¼ì‹ í•œ ê²°ë¡ ",
              text: "You conclude 'coffee prevents death.' But unmeasured confounders remain: genetics, personality type, sleep quality, stress levels. The HRT studies also 'adjusted for everything' â€” and were still wrong. Observational data, no matter how adjusted, cannot prove causation.",
              lesson: "ê²½ê³ : ì¡°ì •ì€ í˜¼ë€ì„ ì¤„ì—¬ì£¼ì§€ë§Œ ì œê±°í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì¸¡ì •ë˜ì§€ ì•Šì€ í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì¸ì€ í•­ìƒ ì¡´ì¬í•©ë‹ˆë‹¤. 'ì›ì¸'ì´ ì•„ë‹Œ '~ê³¼ ì—°ê´€ë¨'ì´ë¼ê³  ë§í•˜ì„¸ìš”. 'ì¦ëª…'ì´ ì•„ë‹ˆë¼ 'ì œì•ˆ'ì´ë¼ê³  ë§í•˜ì„¸ìš”. ê²¸ì†ì€ ì•½ì ì´ ì•„ë‹ˆë¼ ì •ì§ì…ë‹ˆë‹¤."
            },
            wise_conclusion: {
              id: 'wise_conclusion',
              type: 'outcome',
              consequence: 'good',
              title: "ì •ì§í•œ ê²°ë¡ ",
              text: "Your paper states: 'After adjustment for measured confounders, coffee consumption was associated with lower mortality (RR 0.88, 0.82-0.95). However, residual confounding cannot be excluded. These findings are hypothesis-generating and require confirmation in randomized trials.'",
              lesson: "THE PROTECTION: This is honest science. You report the finding, acknowledge limitations, and don't overclaim. If coffee truly is protective, future studies will confirm it. If it's residual confounding, you haven't misled anyone."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "ê°„í˜¸ì‚¬ ê±´ê°• ì—°êµ¬ì— ë”°ë¥´ë©´ HRT ì‚¬ìš©ìëŠ” CHD ìœ„í—˜ì´ 44% ë” ë‚®ì€ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤(RR 0.56). WHI RCTì—ì„œëŠ” HRTê°€ CHD ìœ„í—˜ì„ 29%(HR 1.29) ì¦ê°€ì‹œí‚¤ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¶ˆì¼ì¹˜ë¥¼ ê°€ì¥ ì˜ ì„¤ëª…í•˜ëŠ” ê²ƒì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
          options: [
            { id: 'a', text: "ë‹¤ë¥¸ HRT ê³µì‹ì„ ì‚¬ìš©í–ˆê¸° ë•Œë¬¸ì— RCTê°€ í‹€ë ¸ìŠµë‹ˆë‹¤", correct: false },
            { id: 'b', text: "ê´€ì°° ì—°êµ¬ì—ì„œ ê±´ê°•í•œ ì‚¬ìš©ì íŠ¹ì„±ìœ¼ë¡œ ì¸í•œ í˜¼ë€", correct: true },
            { id: 'c', text: "ê´€ì°° ì—°êµ¬ì˜ í†µê³„ì  ê²€ì •ë ¥ì´ ë” ë†’ì•˜ìŠµë‹ˆë‹¤", correct: false },
            { id: 'd', text: "Effect modification by age of participants", correct: false }
          ],
          explanation: "Healthy user bias (confounding): Women who chose HRT were systematically healthier, more educated, and had better healthcare access. These factors independently reduce CHD risk. When an RCT randomized women regardless of these characteristics, the 'benefit' disappeared and harm emerged. This is the canonical example of confounding in epidemiology."
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "THE REVERSAL: BETA-CAROTENE â€” WHEN MECHANISM MET REALITY",
          source: "NEJM 1994 ATBC | NEJM 1996 CARET | Observational promise, RCT destruction",
          timeline: [
            { year: "1980s", text: "ê´€ì°° ì—°êµ¬ì—ì„œëŠ” ì‚¬ëŒë“¤ì´ ì§€ì†ì ìœ¼ë¡œ ë†’ì€ ë² íƒ€ì¹´ë¡œí‹´ ìˆ˜ì¹˜ëŠ” ì•” ë°œìƒë¥ ì„ ë‚®ì¶¥ë‹ˆë‹¤. í•­ì‚°í™” ê°€ì„¤: ë² íƒ€ì¹´ë¡œí‹´ì€ ì•”ì„ ìœ ë°œí•˜ëŠ” ììœ  ë¼ë””ì¹¼ì„ ì¤‘í™”í•©ë‹ˆë‹¤.", type: "normal" },
            { year: "Mechanism", text: "Compelling biology: oxidative stress â†’ DNA damage â†’ cancer. Antioxidants should prevent this. Prospective cohorts show 30-40% lower lung cancer in high beta-carotene consumers.", type: "normal" },
            { year: "1994 ATBC", text: "Finnish RCT of beta-carotene in smokers: INCREASED lung cancer by 18% (RR 1.18, 95% CI 1.03-1.36). 8% higher total mortality. Trial stopped for harm.", type: "crisis" },
            { year: "1996 CARET", text: "US RCT stopped 21 months early: 28% INCREASE in lung cancer (RR 1.28, 95% CI 1.04-1.57). 17% higher death rate. Two RCTs showed same harm.", type: "crisis" },
            { year: "The Explanation", text: "Confounding: People who eat vegetables are healthier overall. Beta-carotene was a MARKER of healthy diet, not the CAUSE of protection. Supplementing the chemical didn't help â€” it may have hurt.", type: "revelation" },
            { year: "Lesson", text: "ìƒë¬¼í•™ì  íƒ€ë‹¹ì„±ì€ ì¦ê±°ê°€ ì•„ë‹™ë‹ˆë‹¤. ë¬´ì‘ìœ„í™”ê°€ ì—†ëŠ” ë©”ì»¤ë‹ˆì¦˜ì€ ìŠ¤í† ë¦¬í…”ë§ì…ë‹ˆë‹¤. ì‹ ì²´ëŠ” ë³µì¡í•©ë‹ˆë‹¤. ë¶„ë¦¬ëœ ë³´ì¶©ì œëŠ” ì „ì²´ ì‹í’ˆì˜ ì´ì ì„ ì¬í˜„í•˜ì§€ ëª»í•©ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "Lung cancer incidence",
            drug: "Beta-carotene supplements",
            placebo: "Placebo",
            rr: "Observational: RR ~0.70 | RCT ATBC: RR 1.18 | RCT CARET: RR 1.28",
            ci: "Observational WRONG direction",
            nnh: "Supplements INCREASED cancer, opposite of observational prediction"
          },
          hook: "THE HOOK: Beta-carotene was the 'perfect' hypothesis â€” strong observational association, compelling mechanism, clear dose-response. And it was COMPLETELY WRONG. This is why we need RCTs, and why observational data showing protective effects of interventions must be treated with deep skepticism."
        }
      },
      {
        type: 'principle',
        content: {
          text: "âš ï¸ THE WARNING: Every observational finding of benefit should be treated as provisional until an RCT confirms it. HRT, beta-carotene, vitamin E, hormone replacement â€” all showed 'benefit' observationally, all showed harm or null in RCTs. The pattern is clear: CONFOUNDING MAKES THINGS LOOK HELPFUL THAT AREN'T."
        }
      }
    ]
  },
  {
    id: 2,
    title: "The Designs",
    subtitle: "Study Architecture",
    principle: 1,
    story: "Framingham",
    estimatedTime: "20 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "Time flows one direction"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "THE FOUNDATION: FRAMINGHAM â€” 75 YEARS OF WATCHING",
          source: "Framingham Heart Study | Est. 1948 | 15,000+ participants across 3 generations",
          timeline: [
            { year: "1948", text: "NIH recruits 5,209 residents of Framingham, Massachusetts. Goal: understand cardiovascular disease. No one knows what 'risk factors' are yet.", type: "normal" },
            { year: "1960s", text: "First major findings: smoking, high cholesterol, high blood pressure linked to heart disease. The term 'risk factor' is coined.", type: "revelation" },
            { year: "1971", text: "Offspring Study begins: 5,124 children of original participants enrolled. Multigenerational follow-up starts.", type: "normal" },
            { year: "1988", text: "Landmark finding: HDL cholesterol is protective. Distinguishing 'good' from 'bad' cholesterol transforms cardiology.", type: "revelation" },
            { year: "2002", text: "Third Generation Study enrolls grandchildren. 75 years of continuous observation.", type: "normal" },
            { year: "Legacy", text: "3,000í¸ ì´ìƒì˜ ë…¼ë¬¸ì´ ì¶œíŒë˜ì—ˆìŠµë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ ì‚¬ìš©ë˜ëŠ” ìœ„í—˜ ì˜ˆì¸¡ ëª¨ë¸. ì½”í˜¸íŠ¸ ì—°êµ¬ê°€ ì˜í•™ì„ ë³€í™”ì‹œí‚¬ ìˆ˜ ìˆë‹¤ëŠ” ì¦ê±°.", type: "revelation" }
          ],
          realData: {
            endpoint: "Cardiovascular disease incidence and mortality",
            drug: "Prospective cohort design",
            placebo: "75+ years of follow-up",
            rr: "Identified smoking, cholesterol, BP, diabetes as risk factors",
            ci: "Risk prediction equations used globally",
            nnh: "Transformed preventive cardiology"
          },
          hook: "THE HOOK: Framingham didn't randomize anyone. It just watched â€” carefully, systematically, for 75 years. It discovered that smoking causes heart disease, that cholesterol matters, that prevention is possible. Sometimes the most powerful studies are the most patient."
        }
      },
      {
        type: 'story-box',
        content: {
          icon: 'â¤ï¸',
          title: "The Framingham Heart Study's 70-Year Legacy",
          source: "í”„ë ˆì´ë°í–„ ì‹¬ì¥ ì—°êµ¬ | NIH êµ­ë¦½ ì‹¬ì¥, í ë° í˜ˆì•¡ ì—°êµ¬ì†Œ | 1948-Present",
          paragraphs: [
            "In 1948, 5,209 residents of Framingham, Massachusetts enrolled in a study with no clear hypothesis. ì—°êµ¬ìë“¤ì€ ìì‹ ë“¤ì´ ë¬´ì—‡ì„ ì°¾ê³  ìˆëŠ”ì§€ ëª°ëìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ ë‹¨ì§€ ì‹¬ì¥ë³‘ì´ ë¯¸êµ­ì¸ë“¤ì„ ì£½ì´ê³  ìˆë‹¤ëŠ” ê²ƒë§Œ ì•Œê³  ìˆì—ˆì§€ë§Œ ì•„ë¬´ë„ ê·¸ ì´ìœ ë¥¼ ì´í•´í•˜ì§€ ëª»í–ˆìŠµë‹ˆë‹¤.",
            "75ë…„ í›„, Framinghamers 3ì„¸ëŒ€ëŠ” ìš°ë¦¬ê°€ ì‹¬í˜ˆê´€ ìœ„í—˜ì— ëŒ€í•´ ì•Œê³  ìˆëŠ” ëŒ€ë¶€ë¶„ì˜ ì •ë³´ë¥¼ ê°€ë¥´ì³ ì£¼ì—ˆìŠµë‹ˆë‹¤. LDL ì½œë ˆìŠ¤í…Œë¡¤. í¡ì—°. ê³ í˜ˆì••. ë‹¹ë‡¨ë³‘. ë¹„ë§Œ. í”„ë ˆì´ë°í–„ ìœ„í—˜ ì ìˆ˜. ì—¬ê¸°ì„œ 'ìœ„í—˜ ìš”ì†Œ'ë¼ëŠ” ê°œë…ì´ íƒ„ìƒí–ˆìŠµë‹ˆë‹¤.",
            "ì•„ë¬´ë„ ë¬´ì‘ìœ„ë¡œ ë°°ì •ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ê°œì…ì€ í…ŒìŠ¤íŠ¸ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì—°êµ¬ìë“¤ì€ ê°€ëŠ¥í•œ ëª¨ë“  ê²ƒì„ ì¸¡ì •í•œ ë‹¤ìŒ ìˆ˜ì‹­ ë…„ ë™ì•ˆ ê¸°ë‹¤ë ¸ë‹¤ê°€ ì§€ì¼œë³´ì•˜ìŠµë‹ˆë‹¤. í˜„ëŒ€ ì‹¬í˜ˆê´€ ì—­í•™ì„ ì°½ì•ˆí•œ ì—°êµ¬ëŠ” ì¸ë‚´ì‹¬ì„ ê°–ê³  ê¼¼ê¼¼í•œ ê´€ì°°ì„ í†µí•´ ì´ë¥¼ ì‹¤í˜„í–ˆìŠµë‹ˆë‹¤."
          ],
          lesson: "ì¼ë¶€ ì§ˆë¬¸ì€ ì˜¤ë«ë™ì•ˆ ì£¼ì˜ ê¹Šê²Œ ê´€ì°°í•´ì•¼ë§Œ ë‹µì„ ì–»ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. Framinghamì€ ì¶©ë¶„í•œ ì‹œê°„ì— ê±¸ì³ ì—„ê²©í•˜ê²Œ ìˆ˜í–‰ëœ ê´€ì°° ì½”í˜¸íŠ¸ ì—°êµ¬ê°€ ë¬´ì‘ìœ„ ë°°ì • ì—†ì´ë„ ì˜í•™ì„ ë³€í™”ì‹œí‚¬ ìˆ˜ ìˆìŒì„ ì¦ëª…í–ˆìŠµë‹ˆë‹¤."
        }
      },
      {
        type: 'content',
        content: {
          title: "The Three Major Observational Designs",
          sections: [
            {
              heading: "1. ì½”í˜¸íŠ¸ ì—°êµ¬ â€” ì•ìœ¼ë¡œ ë‚˜ì•„ê°€ê¸°",
              items: [
                "ê²°ê³¼ê°€ ì—†ëŠ” ì‚¬ëŒë“¤ë¶€í„° ì‹œì‘í•˜ì„¸ìš”",
                "Measure exposures at baseline",
                "Follow over time, count who develops outcome",
                "Calculate INCIDENCE rates and RISK ratios",
                "Strength: Temporal sequence clear (exposure before outcome)",
                "Weakness: Expensive, time-consuming, rare outcomes difficult"
              ]
            },
            {
              heading: "2. ì‚¬ë¡€ ê´€ë¦¬ ì—°êµ¬ â€” ê³¼ê±°ë¥¼ ëŒì•„ë³´ì„¸ìš”",
              items: [
                "ê²°ê³¼ê°€ ìˆëŠ” ì‚¬ëŒë“¤ë¶€í„° ì‹œì‘í•˜ì„¸ìš”(ì‚¬ë¡€)",
                "Match to people WITHOUT the outcome (controls)",
                "Look backward: what exposures did they have?",
                "Calculate ODDS ratios (cannot calculate RR directly)",
                "Strength: Efficient for rare outcomes",
                "Weakness: Recall bias, selection bias in choosing controls"
              ]
            },
            {
              heading: "3. ë‹¨ë©´ì  ì—°êµ¬ â€” ìŠ¤ëƒ…ìƒ·",
              items: [
                "Measure exposure and outcome at SAME TIME",
                "Cannot determine temporal sequence",
                "Calculate PREVALENCE ratios or odds ratios",
                "Strength: Quick, cheap, good for prevalence estimation",
                "Weakness: Cannot establish causation (chicken vs egg)"
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ë””ìì¸ ì„ íƒ",
          title: "ì§ˆë¬¸ì— ë””ìì¸ ì—°ê²°",
          sections: [
            {
              heading: "Use COHORT When:",
              text: "â€¢ Exposure is common, outcome is common\nâ€¢ You can wait for outcomes to occur\nâ€¢ You want to calculate incidence/risk\nâ€¢ You need clear temporal sequence\nâ€¢ Example: Framingham (CVD risk factors)"
            },
            {
              heading: "Use CASE-CONTROL When:",
              text: "â€¢ ê²°ê³¼ê°€ ë“œë¬¼ë‹¤ â€¢ ì‹ ì†í•˜ê²Œ ë‹µë³€ì´ í•„ìš”í•¨ â€¢ ë¦¬ì†ŒìŠ¤ê°€ ì œí•œë˜ì–´ ìˆìŒ â€¢ ì˜ˆ: íƒˆë¦¬ë„ë§ˆì´ë“œ(í¬ê·€ ì¶œìƒ) ê²°í•¨)"
            },
            {
              heading: "Use CROSS-SECTIONAL When:",
              text: "â€¢ You need prevalence, not incidence\nâ€¢ Resources are very limited\nâ€¢ Temporal sequence doesn't matter\nâ€¢ Example: Disease burden surveys"
            },
            {
              heading: "The Nested Designs:",
              text: "â€¢ ì¤‘ì²© ì‚¬ë¡€ ê´€ë¦¬: ì½”í˜¸íŠ¸ ë‚´ ì‚¬ë¡€ ë° í†µì œ â€¢ ì‚¬ë¡€ ì½”í˜¸íŠ¸: ë¬´ì‘ìœ„ í•˜ìœ„ ì½”í˜¸íŠ¸ + ëª¨ë“  ì‚¬ë¡€ â€¢ ì´ëŠ” ì‚¬ë¡€ ê´€ë¦¬ì˜ íš¨ìœ¨ì„±ê³¼ ì½”í˜¸íŠ¸ì˜ ìœ íš¨ì„±ì„ ê²°í•©í•©ë‹ˆë‹¤."
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "Why Temporal Sequence Matters",
          sections: [
            {
              heading: "The Reverse Causation Trap:",
              items: [
                "Cross-sectional: Low BMI associated with cancer",
                "Interpretation A: Being thin causes cancer",
                "Interpretation B: Cancer causes weight loss (the truth)",
                "ì‹œê°„ ë°ì´í„°ê°€ ì—†ìœ¼ë©´ ì–´ëŠ ê²ƒì´ ë¨¼ì € ë°œìƒí–ˆëŠ”ì§€ ì•Œ ìˆ˜ ì—†ìŠµë‹ˆë‹¤."
              ]
            },
            {
              heading: "Cohort Advantage:",
              items: [
                "Measure BMI in healthy people",
                "10ê°œë¥¼ ë”°ë¦…ë‹ˆë‹¤. ë…„",
                "See who develops cancer",
                "Now temporal sequence is clear: BMI preceded cancer",
                "But still can't prove causation (confounding possible)"
              ]
            }
          ]
        }
      },
      {
        type: 'quiz',
        content: {
          question: "Dr. McBrideëŠ” ì‚¬ì§€ ê²°í•¨ì´ ìˆëŠ” ì•„ê¸°ì˜ ì–´ë¨¸ë‹ˆê°€ íƒˆë¦¬ë„ë§ˆì´ë“œë¥¼ ë³µìš©í–ˆë‹¤ëŠ” ì‚¬ì‹¤ì„ ì•Œì•„ëƒˆìŠµë‹ˆë‹¤. ê·¸ëŠ” ê·¸ë“¤ì„ ê±´ê°•í•œ ì•„ê¸°ì˜ ì–´ë¨¸ë‹ˆì— ë¹„ìœ í–ˆìŠµë‹ˆë‹¤. ê·¸ëŠ” ì•”ì‹œì ìœ¼ë¡œ ì–´ë–¤ ì—°êµ¬ ì„¤ê³„ë¥¼ ì‚¬ìš©í–ˆìŠµë‹ˆê¹Œ?",
          options: [
            { id: 'a', text: "Cohort study â€” following pregnant women forward", correct: false },
            { id: 'b', text: "ì‚¬ë¡€ ëŒ€ì¡° ì—°êµ¬ â€” ì˜í–¥ì„ ë°›ì€ ì•„ê¸°ë¶€í„° ì‹œì‘(ì‚¬ë¡€)", correct: true },
            { id: 'c', text: "ë‹¨ë©´ ì—°êµ¬ â€” ë…¸ì¶œê³¼ ê²°ê³¼ë¥¼ ë™ì‹œì— ì¸¡ì •", correct: false },
            { id: 'd', text: "Randomized trial â€” assigning thalidomide exposure", correct: false }
          ],
          explanation: "McBride started with the outcome (babies with phocomelia = cases), compared to babies without defects (controls), and looked backward at maternal exposures. This is the essence of case-control design â€” efficient for rare outcomes, which is why it detected thalidomide so quickly."
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ì§€ì—°ëœ ê³µí¬: DES â€” ë”¸ë“¤ì´ ì–´ë¨¸ë‹ˆë¥¼ ìœ„í•´ ëˆì„ ì§€ë¶ˆí•  ë•Œ ì˜ì•½í’ˆ",
          source: "NEJM 1971; Herbst et al | Cancer 1977 | Delayed harm 20+ years",
          timeline: [
            { year: "1940s-70s", text: "ìœ ì‚° ì˜ˆë°©ì„ ìœ„í•´ ìˆ˜ë°±ë§Œ ëª…ì˜ ì„ì‚°ë¶€ì—ê²Œ ì œê³µë˜ëŠ” ë””ì—í‹¸ìŠ¤í‹¸ë² ìŠ¤íŠ¸ë¡¤(DES). ê´€ì°°ëœ 'ì¦ê±°'ì™€ ìƒë¬¼í•™ì  íƒ€ë‹¹ì„±ì— ê·¼ê±°í•©ë‹ˆë‹¤.", type: "normal" },
            { year: "1953", text: "RCT shows DES doesn't prevent miscarriage. Drug continues to be prescribed anyway â€” 'it might help, can't hurt.'", type: "crisis" },
            { year: "1971", text: "Herbst notices cluster of vaginal clear cell adenocarcinoma in young women. EXTREMELY RARE cancer. Case-control study: 7/8 cases had DES-exposed mothers.", type: "revelation" },
            { year: "The Horror", text: "ë…¸ì¶œ í›„ 15~25ë…„ í›„ì— ìœ í•´ì„±ì´ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì•”ì€ ì–´ë¨¸ë‹ˆê°€ ì•„ë‹ˆë¼ ë”¸ë“¤ì—ê²Œ ê±¸ë ¸ìŠµë‹ˆë‹¤. ì–´ë–¤ RCTë„ ì´ë¥¼ ê°ì§€í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤.", type: "crisis" },
            { year: "Observational Power", text: "Only case-control design could link rare cancer to decades-old exposure. Cohort would have taken 30 years. RCT would have ended long before cancers appeared.", type: "revelation" },
            { year: "Lesson", text: "ì¼ë¶€ í”¼í•´ëŠ” ìˆ˜ì‹­ ë…„ê¹Œì§€ ì§€ì—°ë©ë‹ˆë‹¤. ì¼ë¶€ëŠ” ì°¨ì„¸ëŒ€ì— ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. ê´€ì°° ì—­í•™ë§Œì´ ì´ë¥¼ íƒì§€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì•½ë¬¼ ê°ì‹œê°€ ì¡´ì¬í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "Clear cell adenocarcinoma of vagina/cervix",
            drug: "DES exposure in utero",
            placebo: "No DES exposure",
            rr: "OR = 40+ (case-control)",
            ci: "Extremely rare cancer in young women",
            nnh: "~1 in 1000 exposed daughters developed cancer"
          },
          hook: "THE HOOK: DESëŠ” í”¼í•´ê°€ í•œ ì„¸ëŒ€ë¥¼ ê±´ë„ˆë›°ê³  ìˆ˜ì‹­ ë…„ í›„ì— ë‚˜íƒ€ë‚  ìˆ˜ ìˆìŒì„ ì¦ëª…í•©ë‹ˆë‹¤. ì–´ë–¤ RCTë„ ì„¸ëŒ€ì— ê±¸ì³ 25ë…„ê°„ì˜ ê²°ê³¼ë¥¼ ì¶”ì í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì¼€ì´ìŠ¤ ì œì–´ ì„¤ê³„ëŠ” ì´ ë§í¬ë¥¼ ê°ì§€í•  ìˆ˜ ìˆëŠ” ìœ ì¼í•œ ë°©ë²•ì´ì—ˆìŠµë‹ˆë‹¤. ê´€ì°°ì€ ë„ì›€ì´ ë  ë¿ë§Œ ì•„ë‹ˆë¼ ìœ ì¼í•œ ì„ íƒì´ì—ˆìŠµë‹ˆë‹¤."
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'study-design-choice',
          title: "ì˜¬ë°”ë¥¸ ì—°êµ¬ ì„¤ê³„ ì„ íƒ",
          situation: "ë‹¹ì‹ ì€ ë‹¤ì–‘í•œ ì—°êµ¬ ì§ˆë¬¸ì— ì§ë©´í•œ ì—­í•™ìì…ë‹ˆë‹¤. ê°ê°ì— ëŒ€í•´ ê°€ì¥ ì ì ˆí•œ ê´€ì°° ì„¤ê³„ë¥¼ ì„ íƒí•˜ì„¸ìš”.",
          nodes: {
            start: {
              question: "QUESTION 1: A rare childhood leukemia (1 in 100,000) may be linked to living near power lines. Resources are limited. Which design?",
              branches: [
                { text: "Cohort study â€” follow children near power lines", nextNode: "cohort_leukemia_wrong" },
                { text: "ì‚¬ë¡€ ê´€ë¦¬ ì—°êµ¬ â€” ë°±í˜ˆë³‘ ì‚¬ë¡€ë¶€í„° ì‹œì‘í•˜ì—¬ ê±°ì£¼ì§€ í™•ì¸", nextNode: "casecontrol_leukemia_correct" },
                { text: "Cross-sectional â€” survey current residence and disease", nextNode: "cross_leukemia_wrong" }
              ]
            },
            cohort_leukemia_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "í¬ê·€í•œ ê²°ê³¼ì—ëŠ” ë¹„í˜„ì‹¤ì ì…ë‹ˆë‹¤!",
              text: "100,000ëª… ì¤‘ 1ëª…ì˜ ë¹„ìœ¨ë¡œ 100ë§Œ ëª…ì˜ ì–´ë¦°ì´ë¥¼ ì¶”ì í•´ì•¼ 10ëª…ì˜ ì‚¬ë¡€ë§Œ ì˜ˆìƒí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì½”í˜¸íŠ¸ ì—°êµ¬ëŠ” ë“œë¬¸ ê²°ê³¼ì— ëŒ€í•´ ë”ì°í•©ë‹ˆë‹¤. ì´ë¥¼ ìœ„í•´ì„œëŠ” ìˆ˜ì‹­ ë…„ì´ ê±¸ë¦¬ê³  ë§‰ëŒ€í•œ ìì›ì´ í•„ìš”í•©ë‹ˆë‹¤.",
              lesson: "ë“œë¬¸ ê²°ê³¼ â†’ ì‚¬ê±´ í†µì œ. ê¸°ì¡´ ì¼€ì´ìŠ¤ë¶€í„° ì‹œì‘í•˜ë©´ íš¨ìœ¨ì ì…ë‹ˆë‹¤."
            },
            cross_leukemia_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ë°œë³‘ë¥  ì§ˆë¬¸ì´ ì˜ëª»ë˜ì—ˆìŠµë‹ˆë‹¤!",
              text: "ë°œìƒë¥ (ì§ˆë³‘ì„ ë°œë³‘í•œ ì‚¬ëŒ)ì´ ì•„ë‹Œ íš¡ë‹¨ë©´ì—ì„œ ìœ ë³‘ë¥ (í˜„ì¬ ì§ˆë³‘ì´ ìˆëŠ” ì‚¬ëŒ)ì„ ì¸¡ì •í•©ë‹ˆë‹¤. ì•”ì˜ ê²½ìš° ìƒˆë¡œìš´ ì‚¬ë¡€ì— ëŒ€í•´ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. ë‹¨ë©´ ë˜í•œ ì‹œê°„ì„±ì„ ì„¤ì •í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì•”ì´ ë°œìƒí•˜ê¸° ì „ì— ì „ë ¥ì„  ê·¼ì²˜ì— ì‚´ì•˜ìŠµë‹ˆê¹Œ?",
              lesson: "Cross-sectional can't establish temporal sequence. Useless for cancer etiology."
            },
            casecontrol_leukemia_correct: {
              situation: "í›Œë¥­í•©ë‹ˆë‹¤! ì‚¬ë¡€ ê´€ë¦¬ëŠ” ë“œë¬¸ ê²°ê³¼ì— íš¨ìœ¨ì ì…ë‹ˆë‹¤. ì§ˆë¬¸ 2: ê·€í•˜ëŠ” 30ë…„ ë™ì•ˆ ì‹¬í˜ˆê´€ ì§ˆí™˜ì— ëŒ€í•œ ëª¨ë“  ìœ„í—˜ ìš”ì†Œë¥¼ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì–´ë–¤ ì„¤ê³„ì¸ê°€ìš”?",
              question: "Choose:",
              branches: [
                { text: "ì½”í˜¸íŠ¸ ì—°êµ¬ â€” ê¸°ì¤€ì„ ì—ì„œ ëª¨ë“  ê²ƒì„ ì¸¡ì •í•˜ê³  CVD ì¶”ì ", nextNode: "cohort_cvd_correct" },
                { text: "ì‚¬ë¡€ ëŒ€ì¡° ì—°êµ¬ â€” CVD ì‚¬ë¡€ ì°¾ê¸°, ê³¼ê±° ë…¸ì¶œì— ëŒ€í•´ ì§ˆë¬¸", nextNode: "casecontrol_cvd_partial" }
              ]
            },
            cohort_cvd_correct: {
              situation: "ì™„ë²½í•©ë‹ˆë‹¤! ì´ê²ƒì´ ë°”ë¡œ Framinghamì´ í•œ ì¼ì…ë‹ˆë‹¤. ì§ˆë¬¸ 3: ì§€ë‚œ ë‹¬ì— ìƒˆë¡œìš´ ë°±ì‹ ì´ ì¶œì‹œë˜ì—ˆìŠµë‹ˆë‹¤. ë³´ê³ ì— ë”°ë¥´ë©´ ë°±ì‹  ì ‘ì¢… í›„ 2ì£¼ ì´ë‚´ì— ë“œë¬¼ê²Œ ìê°€ë©´ì—­ ë°˜ì‘ì„ ì¼ìœ¼í‚¬ ìˆ˜ ìˆë‹¤ê³  í•©ë‹ˆë‹¤. ìµœì„ ì˜ ì„¤ê³„?",
              question: "Choose:",
              branches: [
                { text: "Case-control â€” find autoimmune cases, check vaccination status", nextNode: "casecontrol_vaccine_partial" },
                { text: "Self-controlled case series â€” compare each person's risk during exposed vs unexposed time", nextNode: "sccs_vaccine_correct" }
              ]
            },
            casecontrol_cvd_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Possible, but limited",
              text: "ì‚¬ë¡€ í†µì œëŠ” CVD ìœ„í—˜ ìš”ì¸ì„ ì—°êµ¬í•  ìˆ˜ ìˆì§€ë§Œ íšŒìƒ í¸í–¥(ì‚¬ë¡€ëŠ” ë…¸ì¶œì„ ë‹¤ë¥´ê²Œ ê¸°ì–µí•¨)ìœ¼ë¡œ ì¸í•´ ì–´ë ¤ì›€ì„ ê²ªìœ¼ë©° í•œ ë²ˆì— í•˜ë‚˜ì˜ ê²°ê³¼ë§Œ ì—°êµ¬í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì½”í˜¸íŠ¸ë¥¼ ì‚¬ìš©í•˜ë©´ ì—¬ëŸ¬ ê²°ê³¼ë¥¼ ì—°êµ¬í•˜ê³  ê¸°ì¤€ì„ ì—ì„œ ì •í™•í•œ ë…¸ì¶œ ì¸¡ì •ì„ ì–»ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ì •í™•í•œ ë…¸ì¶œ ì¸¡ì •ìœ¼ë¡œ í¬ê´„ì ì¸ ìœ„í—˜ ìš”ì¸ì„ ì‹ë³„í•˜ë ¤ë©´ ì½”í˜¸íŠ¸ê°€ ì„ í˜¸ë©ë‹ˆë‹¤."
            },
            casecontrol_vaccine_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Works, but there's a better option",
              text: "ì‚¬ë¡€ í†µì œê°€ íš¨ê³¼ì ì´ì§€ë§Œ ê±´ê°•í•œ ë°±ì‹ ì ‘ì¢…ì í¸ê²¬(ê±´ê°•í•œ ì‚¬ëŒì´ ì˜ˆë°©ì ‘ì¢…ì„ ë°›ìŒ)ì— ì·¨ì•½í•©ë‹ˆë‹¤. ìœ„í—˜ ì°½ì´ ì •ì˜ëœ ë°±ì‹ ì— ëŒ€í•œ ê¸‰ì„± ë°˜ì‘ì˜ ê²½ìš° ìê°€ ì œì–´ ì„¤ê³„ëŠ” ì‚¬ëŒ ê°„ í˜¼ë™ì„ ì œê±°í•©ë‹ˆë‹¤.",
              lesson: "ìê¸° ì œì–´ ì„¤ê³„ëŠ” ëª…í™•í•œ ì„ì‹œ ì°½ì´ ìˆëŠ” ê¸‰ì„± ë°˜ì‘ì— ê°•ë ¥í•©ë‹ˆë‹¤."
            },
            sccs_vaccine_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Excellent choice!",
              text: "ìê¸° ì œì–´ ì‚¬ë¡€ ì‹œë¦¬ì¦ˆëŠ” ë°±ì‹  ì ‘ì¢… í›„ 2ì£¼ ê¸°ê°„ ë™ì•ˆì˜ ê° ê°œì¸ì˜ ìœ„í—˜ì„ ê¸°ì¤€ ê¸°ê°„ê³¼ ë¹„êµí•©ë‹ˆë‹¤. ì‚¬ëŒ ê°„ ëª¨ë“  í˜¼ë€ ìš”ì†Œ(ë‚˜ì´, ê±´ê°• ìƒíƒœ, ìœ ì „ì  íŠ¹ì„±)ëŠ” ê° ì‚¬ëŒì´ ìŠ¤ìŠ¤ë¡œ í†µì œí•  ìˆ˜ ìˆê¸° ë•Œë¬¸ì— ìë™ìœ¼ë¡œ í†µì œë©ë‹ˆë‹¤.",
              lesson: "SCCSëŠ” MMR-ìíì¦ ì‹ í™”ë¥¼ í­ë¡œí•˜ëŠ” ë“± ë°±ì‹  ì•ˆì „ì„± ì—°êµ¬ì—ì„œ ë§¤ìš° ì¤‘ìš”í–ˆìŠµë‹ˆë‹¤. ìœ„í—˜ ê¸°ê°„ì´ ì˜ ì •ì˜ë˜ì–´ ìˆìœ¼ë©´ ê°•ë ¥í•©ë‹ˆë‹¤."
            }
          }
        }
      },
      {
        type: 'principle',
        content: {
          text: "âš ï¸ ê²½ê³ : ì™„ë²½í•œ ì—°êµ¬ ì„¤ê³„ëŠ” ì—†ìŠµë‹ˆë‹¤. ì½”í˜¸íŠ¸ ì—°êµ¬ì—ëŠ” ì‹œê°„ê³¼ ìì›ì´ í•„ìš”í•©ë‹ˆë‹¤. ì‚¬ë¡€ ê´€ë¦¬ ì—°êµ¬ëŠ” íšŒìƒ í¸í–¥ì„ ê²ªìŠµë‹ˆë‹¤. ë‹¨ë©´ì€ ì‹œê°„ì„±ì„ í™•ë¦½í•  ìˆ˜ ì—†ë‹¤. ìì²´ ì œì–´ ì„¤ê³„ëŠ” ì‹œê°„ì— ë”°ë¼ ë³€í•˜ëŠ” í˜¼ë€ ìš”ì¸ì„ ì²˜ë¦¬í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ê²°ê³¼ë¥¼ ì‹ ë¢°í•˜ê¸° ì „ì— ë””ìì¸ì˜ ì•½ì ì„ íŒŒì•…í•˜ì‹­ì‹œì˜¤."
        }
      },
      {
        type: 'principle',
        content: {
          text: "ğŸ¯ PROGRESS CHECK: You've completed the foundations. You understand WHY observational evidence matters (Module 0), HOW confounding deceives (Module 1), and WHICH study designs exist (Module 2). Now we go deeper: DAGs for causal reasoning, specific biases, and the tools to handle them."
        }
      }
    ]
  },
  // MODULE 3: THE CONFOUNDERS (DAGs and Causal Diagrams)
  {
    id: 3,
    title: "The Confounders",
    subtitle: "DAGs & Causal Thinking",
    principle: 5,
    estimatedTime: "25 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "ì¡°ì •ì€ ë§ˆìˆ ì´ ì•„ë‹™ë‹ˆë‹¤"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ì—­ì„¤: ë¹„ë§Œê³¼ ì‚¬ë§ë¥  â€” ì¡°ì •ì´ ì¤‘ë‹¨ë  ë•Œ",
          source: "JAMA 2005; Flegal et al | Epidemiology wars | Multiple analyses",
          timeline: [
            { year: "2005", text: "CDC ì—°êµ¬: ê³¼ì²´ì¤‘(BMI 25-30) ì •ìƒ ì²´ì¤‘ë³´ë‹¤ ì‚¬ë§ë¥ ì´ ë‚®ìŠµë‹ˆë‹¤. í—¤ë“œë¼ì¸ì—ì„œëŠ” 'ì§€ë°©ì´ ê±´ê°•í•˜ë‹¤'ê³  ì„ ì–¸í•©ë‹ˆë‹¤.", type: "normal" },
            { year: "2005-10", text: "Scientists divided: Some see 'obesity paradox,' others see confounding and collider bias. Adjustment strategies differ dramatically.", type: "crisis" },
            { year: "Key Issue", text: "í¡ì—°ì— ì ì‘í•´ì•¼ í• ê¹Œìš”? í¡ì—°ìëŠ” ë‚ ì”¬í•˜ê³  ì¼ì° ì£½ìŠµë‹ˆë‹¤. í¡ì—°ì— ì ì‘í•˜ë©´ ê³¼ì²´ì¤‘ì´ ë” ì•…í™”ëœ ê²ƒì²˜ëŸ¼ ë³´ì…ë‹ˆë‹¤(ì˜¬ë°”ë¥¸). ì¡°ì •í•˜ì§€ ì•Šìœ¼ë©´ ë³´í˜¸ì ì¸ ê²ƒì²˜ëŸ¼ ë³´ì…ë‹ˆë‹¤(ì˜ëª»ë¨).", type: "revelation" },
            { year: "Another Issue", text: "ë¹„ë§Œìœ¼ë¡œ ì¸í•œ ì§ˆë³‘ì„ ì¡°ì •í•´ì•¼ í•©ë‹ˆê¹Œ? ë‹¹ë‡¨ë³‘, ì‹¬ì¥ë³‘ì€ ì¤‘ì¬ìì…ë‹ˆë‹¤. ì¡°ì •í•˜ë©´ ì¶”ì •í•˜ë ¤ëŠ” ì¸ê³¼ ê²½ë¡œê°€ ì°¨ë‹¨ë©ë‹ˆë‹¤.", type: "revelation" },
            { year: "Resolution", text: "ë‹¤ë¥¸ DAG ê°€ì • â†’ ë‹¤ë¥¸ ì¡°ì • ì „ëµ â†’ ë‹¤ë¥¸ ê²°ë¡ . DAGëŠ” ì„ íƒ ì‚¬í•­ì´ ì•„ë‹ˆë©° ë‹µì„ ê²°ì •í•©ë‹ˆë‹¤.", type: "revelation" },
            { year: "Lesson", text: "ì¸ê³¼ ê´€ê³„ ê°€ì •ì„ ëª…ì‹œì ìœ¼ë¡œ ê·¸ë ¤ì•¼ í•©ë‹ˆë‹¤. ê·¸ë ‡ì§€ ì•Šìœ¼ë©´ ë§¹ëª©ì ìœ¼ë¡œ ì¡°ì •í•˜ëŠ” ê²ƒì´ë©°, (ì–¸ê¸‰ë˜ì§€ ì•Šì€) ê°€ì •ì´ ì§€ì‹œí•˜ëŠ” ëŒ€ë¡œ ë¬´ì—‡ì´ë“  ë‹µì„ ì–»ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "All-cause mortality",
            drug: "Overweight (BMI 25-30)",
            placebo: "Normal weight (BMI 18.5-25)",
            rr: "HR 0.88 (unadjusted) to 1.20+ (smoking-adjusted)",
            ci: "Conclusion flips based on adjustment",
            nnh: "Public health messaging chaos"
          },
          hook: "THE HOOK: The same data, analyzed by competent scientists, gave opposite answers. Not because anyone cheated â€” but because they had different causal models in their heads. DAGs make those models explicit."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ ì£¼ìš” í†µì°°ë ¥: ì¡°ì •ì€ ë‹¨ìˆœí•œ 'ë³€ìˆ˜ ì œì–´'ê°€ ì•„ë‹™ë‹ˆë‹¤. ì¡°ì •í•˜ëŠ” ê° ë³€ìˆ˜ëŠ” ì¸ê³¼ì ì¸ ì£¼ì¥ì„ ë§Œë“­ë‹ˆë‹¤. í˜¼ë€ìë¥¼ ì¡°ì •í•˜ê³  â†’ í¸í–¥ì„ ì°¨ë‹¨í•©ë‹ˆë‹¤. ì¤‘ì¬ìë¥¼ ì¡°ì • â†’ ì›í•˜ëŠ” íš¨ê³¼ë¥¼ ì°¨ë‹¨í•©ë‹ˆë‹¤. ì¶©ëŒì²´ì— ë§ê²Œ ì¡°ì • â†’ ë°”ì´ì–´ìŠ¤ë¥¼ ìƒì„±í•©ë‹ˆë‹¤. DAGëŠ” ì£¼ì¥ì„ ëª…ì‹œì ìœ¼ë¡œ ì§„ìˆ í•˜ë„ë¡ ê°•ì œí•©ë‹ˆë‹¤."
        }
      },
      {
        type: 'content',
        content: {
          title: "What Is a DAG?",
          sections: [
            {
              heading: "Directed Acyclic Graph",
              items: [
                "DIRECTED: Arrows show causal direction (cause â†’ effect)",
                "ACYCLIC: ë£¨í”„ ì—†ìŒ â€” ìì²´ ì›ì¸ì„ ìœ ë°œí•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤.",
                "GRAPH: Visual network of variables and relationships",
                "Purpose: Makes causal assumptions EXPLICIT and testable"
              ]
            },
            {
              heading: "Three Types of Variables:",
              items: [
                "CONFOUNDER: ë…¸ì¶œ ë° ê²°ê³¼ì˜ ì¼ë°˜ì ì¸ ì›ì¸(ì¡°ì •)",
                "MEDIATOR: ë…¸ì¶œì—ì„œ ê²°ê³¼ê¹Œì§€ì˜ ì¸ê³¼ ê²½ë¡œ(í•˜ì§€ ë§ˆì„¸ìš”) ì¡°ì •)",
                "COLLIDER: Common effect of two variables (DON'T adjust â€” creates bias)"
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: DAG ì½ê¸°",
          title: "ë°±ë„ì–´ ê²½ë¡œ ë° ì¡°ì •",
          sections: [
            {
              heading: "1ë‹¨ê³„: ì§ˆë¬¸ ì‹ë³„",
              text: "EXPOSUREê°€ ê²°ê³¼ì— ë¯¸ì¹˜ëŠ” ì¸ê³¼ íš¨ê³¼ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ? ë…¸ì¶œ â†’ ê²°ê³¼ì—ì„œ ì§ì ‘ í™”ì‚´í‘œë¥¼ ê·¸ë¦½ë‹ˆë‹¤. ì´ê²ƒì´ ë‹¹ì‹ ì´ ì¶”ì •í•˜ê³  ì‹¶ì€ ê²ƒì…ë‹ˆë‹¤."
            },
            {
              heading: "Step 2: Find Backdoor Paths",
              text: "ë°±ë„ì–´ ê²½ë¡œëŠ” ê²°ê³¼ì— ì´ë¥´ëŠ” ëª¨ë“  ê²½ë¡œë¥¼ í†µí•´ (í™”ì‚´í‘œ ë°˜ëŒ€) ë…¸ì¶œì—ì„œ ë’¤ë¡œ ì´ë™í•©ë‹ˆë‹¤. ì˜ˆ: ë…¸ì¶œ â† í˜¼ë€ ìš”ì¸ â†’ ê²°ê³¼. ì´ë¡œ ì¸í•´ ê°€ì§œ ì—°ê²°ì´ ìƒì„±ë©ë‹ˆë‹¤."
            },
            {
              heading: "Step 3: Block Backdoor Paths",
              text: "ëª¨ë“  ë°±ë„ì–´ ê²½ë¡œë¥¼ ì°¨ë‹¨í•˜ëŠ” ë³€ìˆ˜ë¥¼ ì¡°ì •í•©ë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ ì´ëŠ” í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì¸ì„ ì¡°ì •í•˜ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì ˆëŒ€ë¡œ ì¶©ëŒì²´ë¥¼ ì¡°ì •í•˜ì§€ ë§ˆì‹­ì‹œì˜¤. ì´ê²ƒì€ ê²½ë¡œë¥¼ ì—½ë‹ˆë‹¤."
            },
            {
              heading: "Step 4: Check for Collider Bias",
              text: "ì¶©ëŒì²´ëŠ” ì¼ë°˜ì ì¸ íš¨ê³¼ì…ë‹ˆë‹¤: A â†’ ì¶©ëŒì²´ â† B. ì¶©ëŒì²´ì— ëŒ€í•œ ì¡°ê±´ì€ ì¡´ì¬í•˜ì§€ ì•ŠëŠ” ê²½ìš°ì—ë„ Aì™€ B ì‚¬ì´ì˜ ì—°ê´€ì„ ìƒì„±í•©ë‹ˆë‹¤. í´ë˜ì‹ íŠ¸ë©: ë³‘ì› ê¸°ë°˜ ì—°êµ¬ì—ì„œ 'ì…ì›' ì¡°ì •."
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "The Collider Trap: Berkson's Paradox",
          sections: [
            {
              heading: "The Classic Example:",
              items: [
                "Question: Does diabetes cause respiratory disease?",
                "Hospital-based study: Among hospitalized patients, diabetes is NEGATIVELY associated with respiratory disease",
                "ì¸êµ¬ ê¸°ë°˜ ì—°êµ¬: ì—°ê´€ì„± ì—†ìŒ",
                "Why? Hospitalization is a COLLIDER â€” both diabetes and respiratory disease cause hospitalization"
              ]
            },
            {
              heading: "The Mechanism:",
              items: [
                "Among hospitalized patients, if someone DOESN'T have diabetes, they must have respiratory disease (otherwise why hospitalized?)",
                "This creates artificial negative association",
                "ì…ì› ì¡°ì •(ì¶©ëŒê¸° ì¡°ê±´) ëª¨ì§‘ë‹¨ì— ì¡´ì¬í•˜ì§€ ì•Šì•˜ë˜ INDUCED í¸ê²¬"
              ]
            },
            {
              heading: "Modern Examples:",
              items: [
                "COVID severity paradox: Smokers seemed protected because hospitalized non-smokers had other severe conditions",
                "Obesity paradox in heart failure: Sicker thin patients, healthier obese patients selected into studies",
                "If it seems paradoxical, look for a collider"
              ]
            }
          ]
        }
      },
      {
        type: 'story-box',
        content: {
          icon: 'ğŸ§¬',
          title: "ì˜êµ­ ë°”ì´ì˜¤ë±…í¬ ì¶©ëŒê¸° ë¬¸ì œ",
          source: "UK Biobank | Nature Communications 2020 | COVID-19 Studies",
          paragraphs: [
            "UK Biobank is a treasureâ€”500,000 participants with genetic and health data. But participants are systematically different from the UK average: healthier, wealthier, and more educated. This is selection into a study.",
            "In 2020, researchers using UK Biobank found something strange: obesity appeared to be PROTECTIVE against COVID-19 death. This contradicted everything known about COVID risk factors. How could obesity protect against a disease where obesity is a major risk factor?",
            "The answer was a collider effect. The same factors that led to UK Biobank participation (health consciousness, education, access) also reduced COVID risk. Among UK Biobank participants, those who were obese but still healthy enough to participate were a selected, healthier group. Selection into the study created a spurious protective association."
          ],
          lesson: "Even the best datasets can produce wrong answers if you don't account for how people got into the study. Selection is a collider. When your study population is selected (and it always is, somehow), ask: could that selection distort the relationship I'm studying?"
        }
      },
      {
        type: 'tool',
        content: {
          type: 'dag-builder',
          title: "DAG ë¹Œë” ë„êµ¬",
          description: "Build a causal diagram to identify confounders, mediators, and colliders."
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'dag-adjustment',
          title: "ì¡°ì • ê²°ì •",
          situation: "You're studying whether a new diabetes drug reduces cardiovascular events. You have data on: the drug, CV events, age, prior CV disease, and HbA1c (blood sugar control). HbA1c improves with the drug. What should you adjust for?",
          nodes: {
            start: {
              question: "ë‚˜ì´ëŠ” ì•½ë¬¼ ì²˜ë°©(ë‚˜ì´ê°€ ë§ì€ í™˜ìê°€ ë” ë§ì€ ì•½ì„ ë°›ìŒ) ë° CV ì‚¬ê±´ ëª¨ë‘ì™€ ì—°ê´€ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì—°ë ¹ì€ ì–´ë–¤ ìœ í˜•ì˜ ë³€ìˆ˜ì¸ê°€ìš”?",
              branches: [
                { text: "í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì¸ â€” ì´ì— ë§ê²Œ ì¡°ì •", nextNode: "age_correct" },
                { text: "Mediator â€” don't adjust", nextNode: "age_wrong" },
                { text: "Collider â€” adjusting would create bias", nextNode: "age_wrong" }
              ]
            },
            age_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤! ë‚˜ì´ëŠ” í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œì…ë‹ˆë‹¤(ê³µí†µ ì›ì¸). í˜„ì¬: ì•½ë¬¼ì„ ì‚¬ìš©í•˜ë©´ HbA1c(í˜ˆë‹¹)ê°€ ê°œì„ ë˜ê³  CV ì¦ìƒì—ë„ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. HbA1cëŠ” ì–´ë–¤ ìœ í˜•ì˜ ë³€ìˆ˜ì…ë‹ˆê¹Œ?",
              question: "HbA1cì— ë§ê²Œ ì¡°ì •í•´ì•¼ í•©ë‹ˆê¹Œ?",
              branches: [
                { text: "Yes â€” it's a confounder", nextNode: "hba1c_wrong" },
                { text: "No â€” it's a mediator on the causal pathway", nextNode: "hba1c_correct" },
                { text: "ì—°êµ¬ ì§ˆë¬¸ì— ë”°ë¼ ë‹¤ë¦…ë‹ˆë‹¤.", nextNode: "hba1c_nuanced" }
              ]
            },
            age_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ë³„ë¡œ ë§ì§€ ì•ŠìŠµë‹ˆë‹¤",
              text: "ë‚˜ì´ëŠ” í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œì…ë‹ˆë‹¤. ì•½ë¬¼) ë° ê²°ê³¼(ë‚˜ì´ê°€ ë§ì€ í™˜ìì˜ ê²½ìš° CV ì‚¬ê±´ì´ ë” ë§ì´ ë°œìƒí•¨). ì´ ë°±ë„ì–´ ê²½ë¡œë¥¼ ì°¨ë‹¨í•˜ë ¤ë©´ ì—°ë ¹ì„ ì¡°ì •í•´ì•¼ í•©ë‹ˆë‹¤.",
              lesson: "í˜¼ë€ ìš”ì¸ì´ ì¼ë°˜ì ì¸ ì›ì¸ì…ë‹ˆë‹¤. ë‚˜ì´ëŠ” ì¹˜ë£Œ ê²°ì •ì„ ë‚´ë¦¬ê³  CV ì‚¬ê±´ì„ ìœ ë°œí•©ë‹ˆë‹¤. ì•½ë¬¼ â†’ CV ì‚¬ê±´ì˜ ì¸ê³¼ ê²½ë¡œì— ìˆì§€ ì•ŠìŠµë‹ˆë‹¤."
            },
            hba1c_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Careful!",
              text: "HbA1c is on the CAUSAL PATHWAY: Drug â†’ HbA1c â†’ CV events. If the drug works by improving blood sugar, adjusting for HbA1c blocks the very effect you're trying to measure!",
              lesson: "ì¤‘ì¬ìë¥¼ ì¡°ì •í•˜ì§€ ë§ˆì„¸ìš”. í•´ë‹¹ ê²½ë¡œë¥¼ í†µí•´ ë§¤ê°œë˜ì§€ ì•ŠëŠ” 'ì§ì ‘ íš¨ê³¼'ë§Œ ì¶”ì •í•˜ê²Œ ë©ë‹ˆë‹¤. ì´ëŠ” ì•½ë¬¼ì´ ì‹¤ì œë¡œ íš¨ê³¼ê°€ ìˆë”ë¼ë„ 0ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤."
            },
            hba1c_correct: {
              situation: "Excellent! Now the final question: Prior CV disease predicts both drug prescribing (doctors give the drug to high-risk patients) AND CV events. What is it?",
              question: "ì´ì „ ì‹¬í˜ˆê´€ ì§ˆí™˜ì— ë§ì¶° ì¡°ì •í•´ì•¼ í•©ë‹ˆê¹Œ?",
              branches: [
                { text: "Yes â€” it's a confounder (confounding by indication)", nextNode: "final_success" },
                { text: "No â€” it might be a collider", nextNode: "final_partial" }
              ]
            },
            hba1c_nuanced: {
              type: 'outcome',
              outcome: 'partial',
              title: "ì •êµí•œ ë‹µë³€ì…ë‹ˆë‹¤",
              text: "ìƒí™©ì— ë”°ë¼ ë‹¤ë¥´ë‹¤ëŠ” ë§ì´ ë§ìŠµë‹ˆë‹¤! ì•½ë¬¼ì˜ ì „ì²´ íš¨ê³¼ë¥¼ ì›í•œë‹¤ë©´ HbA1cë¥¼ ì¡°ì •í•˜ì§€ ë§ˆì‹­ì‹œì˜¤(ì¤‘ì¬ìì…ë‹ˆë‹¤). ì•½ë¬¼ì´ í˜ˆë‹¹ ì¡°ì ˆ ì´ìƒì˜ íš¨ê³¼ê°€ ìˆëŠ”ì§€ ì•Œê³  ì‹¶ë‹¤ë©´ ì¡°ì •í•  ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ë‹¤ë¥¸ ì§ˆë¬¸ì…ë‹ˆë‹¤.",
              lesson: "DAGëŠ” íŠ¹ì • ì¸ê³¼ ê´€ê³„ ì§ˆë¬¸ì„ ë°˜ì˜í•´ì•¼ í•©ë‹ˆë‹¤. ë‹¤ë¥¸ ì§ˆë¬¸ â†’ ë‹¤ë¥¸ ì¡°ì • ì„¸íŠ¸."
            },
            final_success: {
              type: 'outcome',
              outcome: 'success',
              title: "Perfect DAG reasoning!",
              text: "You correctly identified: Age = confounder (adjust), HbA1c = mediator (don't adjust), Prior CV disease = confounder by indication (adjust). Your analysis will estimate the causal effect of the drug.",
              lesson: "ì´ë¥¼ 'í‘œì‹œì— ë”°ë¥¸ êµë€'ì´ë¼ê³  í•˜ë©°, ì´ëŠ” ì•½ë¬¼ ì—°êµ¬ì—ì„œ ê°€ì¥ í”í•œ í¸í–¥ì…ë‹ˆë‹¤. ì•„í”ˆ í™˜ìëŠ” ì¹˜ë£Œë¥¼ ë°›ê¸° ë•Œë¬¸ì— ì¹˜ë£Œê°€ í•´ë¡œì›Œ ë³´ì…ë‹ˆë‹¤. ê¸°ë³¸ ì‹¬ê°ë„ë¥¼ ì¡°ì •í•´ì•¼ í•©ë‹ˆë‹¤."
            },
            final_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Almost!",
              text: "ì´ì „ CV ì§ˆí™˜ì€ ì—¬ê¸°ì„œ í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œì…ë‹ˆë‹¤. ì´ëŠ” ì¹˜ë£Œ ê²°ì •ê³¼ ê²°ê³¼ ëª¨ë‘ë¥¼ ìœ ë°œí•©ë‹ˆë‹¤. ë‹¹ì‹ ì€ ê·¸ê²ƒì„ ì¡°ì •í•´ì•¼í•©ë‹ˆë‹¤. CV ì´ë²¤íŠ¸(ê²°ê³¼)ëŠ” ì´ì „ CV ì§ˆë³‘(ì¼ì‹œì ìœ¼ë¡œ ë¶ˆê°€ëŠ¥)ì„ ìœ ë°œí•˜ì§€ ì•Šê¸° ë•Œë¬¸ì— ì¶©ëŒì²´ê°€ ì•„ë‹™ë‹ˆë‹¤.",
              lesson: "ì¶©ëŒì²´ì—ëŠ” ë³€ìˆ˜ ë‚´ë¶€ë¥¼ ê°€ë¦¬í‚¤ëŠ” ë‘ ê°œì˜ í™”ì‚´í‘œê°€ í•„ìš”í•©ë‹ˆë‹¤. ì´ì „ CV ì§ˆí™˜ì—ëŠ” OUT(ì•½ë¬¼, ê²°ê³¼)ì„ ê°€ë¦¬í‚¤ëŠ” í™”ì‚´í‘œê°€ ìˆìŠµë‹ˆë‹¤. í˜¼ë€ìŠ¤ëŸ½ìŠµë‹ˆë‹¤."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "ì»¤í”¼ì™€ íì•”ì— ëŒ€í•œ ì—°êµ¬ì—ì„œ í¡ì—°ì€ ì»¤í”¼ ë§ˆì‹œëŠ” ê²ƒê³¼ íì•” ëª¨ë‘ì™€ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. í¡ì—°ì— ì ì‘í•œ í›„ì—ëŠ” ì»¤í”¼ì™€ ì•”ì˜ ì—°ê´€ì„±ì´ ì‚¬ë¼ì§‘ë‹ˆë‹¤. ë¬´ìŠ¨ ì¼ì´ ì¼ì–´ë‚¬ë‚˜ìš”?",
          options: [
            { id: 'a', text: "Smoking was a mediator â€” coffee causes smoking which causes cancer", correct: false },
            { id: 'b', text: "Smoking was a confounder â€” adjusting removed spurious association", correct: true },
            { id: 'c', text: "Smoking was a collider â€” adjusting induced bias", correct: false },
            { id: 'd', text: "Coffee protects against cancer but smoking cancels the benefit", correct: false }
          ],
          explanation: "Smoking is a classic confounder: Coffee â† Smoking â†’ Cancer. Smokers drink more coffee AND get more cancer. The coffee-cancer association was spurious, created by the common cause (smoking). Adjusting for the confounder blocked the backdoor path and revealed no true effect."
        }
      }
    ]
  },
  // MODULE 4: THE BIAS (Selection, Information, Time-Related Biases)
  {
    id: 4,
    title: "The Bias",
    subtitle: "Selection & Information Bias",
    principle: 2,
    estimatedTime: "30 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "Time flows one direction"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ë¶ˆë©¸ì˜ í™˜ìƒ: ìŠ¤íƒ€í‹´ê³¼ ì‚¬ë§ ì‹œê°„",
          source: "Am J Epidemiol 2003; Suissa | Drug Safety 2007 | 'Immortal Time Bias'",
          timeline: [
            { year: "2001-04", text: "Multiple observational studies find statins reduce cancer mortality by 30-50%. Biologically plausible: anti-inflammatory effects, cell cycle regulation.", type: "normal" },
            { year: "The Design", text: "ì½”í˜¸íŠ¸ ì—°êµ¬: ìŠ¤íƒ€í‹´ ì²˜ë°©ì „ì„ ë°›ì€ ì ì´ ìˆëŠ” í™˜ìëŠ” 'ìŠ¤íƒ€í‹´ ì‚¬ìš©ì'ë¡œ ë¶„ë¥˜ë˜ì—ˆìŠµë‹ˆë‹¤. í•œë²ˆë„ ì‚¬ìš©í•˜ì§€ ì•Šì€ ì‚¬ìš©ìì™€ ë¹„êµ. ì§„ë‹¨ë¶€í„° ì‚¬ë§ê¹Œì§€ ì¶”ì .", type: "normal" },
            { year: "The Flaw", text: "'ìŠ¤íƒ€í‹´ ì‚¬ìš©ì'ë¡œ ë¶„ë¥˜ë˜ê¸° ìœ„í•´ì„œëŠ” ì²˜ë°©ì „ì„ ë°›ì„ ìˆ˜ ìˆì„ ë§Œí¼ ìƒì¡´í•´ì•¼ í•©ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì²˜ë°©ì „ê¹Œì§€ì˜ ì‹œê°„ì€ 'ë¶ˆë©¸'ì…ë‹ˆë‹¤. ì •ì˜ì— ë”°ë¥´ë©´, ê·¸ ê¸°ê°„ ë™ì•ˆì—ëŠ” ì£½ì„ ìˆ˜ ì—†ìŠµë‹ˆë‹¤.", type: "revelation" },
            { year: "The Math", text: "ë¶ˆë©¸ì˜ ì‹œê°„ì€ 'ë…¸ì¶œëœ' ê²ƒìœ¼ë¡œ ì˜ëª» ë¶„ë¥˜ëœë‹¤. ì´ëŠ” ë…¸ì¶œëœ ê·¸ë£¹ì˜ ìƒì¡´ì„ ì¸ìœ„ì ìœ¼ë¡œ ë¶€í’€ë¦½ë‹ˆë‹¤. 'ì´ì 'ì€ ìˆ˜í•™ì  ì¸ê³µë¬¼ì…ë‹ˆë‹¤.", type: "crisis" },
            { year: "Correction", text: "When immortal time is properly handled (time-varying exposure), statin's cancer mortality benefit disappears: HR 0.99 (0.89-1.10)", type: "revelation" },
            { year: "Lesson", text: "ë…¸ì¶œ íƒ€ì´ë°ì´ ì¤‘ìš”í•œ ê²½ìš° 'ì „í˜€ vs ì „í˜€'ë¥¼ ë¹„êµí•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì‹œê°„ì€ ì˜¬ë°”ë¥´ê²Œ ë¶„ë¥˜ë˜ì–´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë ‡ì§€ ì•Šìœ¼ë©´ ë¶ˆë©¸ì´ë¼ëŠ” í™˜ìƒì´ ìƒê¹ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "Cancer mortality",
            drug: "Statins (immortal time bias)",
            placebo: "No statins",
            rr: "HR 0.52 (biased) â†’ HR 0.99 (corrected)",
            ci: "Artifact â†’ null",
            nnh: "False hope for cancer patients"
          },
          hook: "THE HOOK: Immortal time bias is everywhere. Any study comparing 'ever vs never' users is at risk. The bias direction is ALWAYS toward benefit for the exposure. If your observational study shows a drug prevents cancer/death/etc, check for immortal time first."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ KEY TAKEAWAY: Immortal time bias occurs when the definition of 'exposed' requires surviving to a certain point, but that survival time is misclassified as 'exposed' time. The bias ALWAYS makes the exposure look beneficial. Landmark analysis or time-varying covariates can fix it."
        }
      },
      {
        type: 'story-box',
        content: {
          icon: 'ğŸ’Š',
          title: "ìŠ¤íƒ€í‹´ ì•” ì—°êµ¬ì˜ ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥",
          source: "Am J Epidemiol 2003; Suissa S. | Drug Safety 2007",
          paragraphs: [
            "In the early 2000s, several observational studies reported exciting findings: statins appeared to reduce cancer risk by 20-30%. The biological mechanism seemed plausibleâ€”statins have anti-inflammatory properties and might inhibit cancer cell growth.",
            "ê·¸ëŸ¬ë‚˜ ì—­í•™ì Samy SuissaëŠ” ì¹˜ëª…ì ì¸ ê²°í•¨ì„ ë°œê²¬í–ˆìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ì—ì„œëŠ” ì§„ë‹¨ ë‚ ì§œ ë˜ëŠ” ì½”í˜¸íŠ¸ ë“±ë¡ ë‚ ì§œì¸ 0ì‹œì ë¶€í„° 'ìŠ¤íƒ€í‹´ ì‚¬ìš©ì'ì™€ 'ë¹„ì‚¬ìš©ì'ë¥¼ ë¹„êµí–ˆìŠµë‹ˆë‹¤. ë¬¸ì œ: ì¼ë¶€ 'ì‚¬ìš©ì'ëŠ” 0ì‹œì— ì•„ì§ ìŠ¤íƒ€í‹´ì„ ì‹œì‘í•˜ì§€ë„ ì•Šì•˜ìŠµë‹ˆë‹¤.",
            "The time between cohort entry and first statin prescription was 'immortal time'â€”by definition, patients couldn't die during this period (they had to survive to become statin users). This immortal time was misclassified as 'exposed' time, artificially inflating survival in the statin group. When properly analyzed with time-varying exposure, the cancer benefit disappeared completely."
          ],
          lesson: "Whenever you see an observational study showing a drug 'prevents' cancer or death, ask: How was exposure defined? Did patients need to survive to become 'exposed'? If the answer is yes, immortal time bias is likely inflating the benefit."
        }
      },
      {
        type: 'content',
        content: {
          title: "The Three Major Bias Families",
          sections: [
            {
              heading: "1. SELECTION BIAS",
              items: [
                "ëˆ„ê°€ ì—°êµ¬ì— ì°¸ì—¬í•©ë‹ˆê¹Œ? ëˆ„ê°€ ë‚¨ì•„ ìˆìŠµë‹ˆê¹Œ?",
                "Healthy user bias: HRT users were healthier to start",
                "Sick quitter bias: People quit smoking because they're ill, making quitters look worse",
                "Loss to follow-up: Sicker patients drop out, making survivors look better",
                "Berkson's bias: Hospital-based selection distorts associations"
              ]
            },
            {
              heading: "2. INFORMATION BIAS",
              items: [
                "How accurately is exposure/outcome measured?",
                "Recall bias: Cases remember exposures better than controls",
                "Interviewer bias: Interviewers probe harder when they know disease status",
                "Misclassification: Errors in exposure or outcome measurement",
                "Differential misclassification can bias in either direction"
              ]
            },
            {
              heading: "3. TIME-RELATED BIAS",
              items: [
                "Immortal time bias: Survival required to become 'exposed'",
                "Time-lag bias: Comparing prevalent vs incident users",
                "Depletion of susceptibles: Early deaths remove high-risk from 'current user' category",
                "Lead time bias: Screening advances diagnosis without extending life"
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ ê°ì§€",
          title: "ìœ„í—˜ ì‹ í˜¸ ë° í•´ê²° ë°©ë²•",
          sections: [
            {
              heading: "Red Flags (Study Design):",
              text: "â€¢ Exposure defined as 'ever vs never' with no time component\nâ€¢ Exposure requires multiple prescriptions/visits\nâ€¢ Time zero differs between groups\nâ€¢ Exposure definition is based on future events"
            },
            {
              heading: "Red Flags (Results):",
              text: "â€¢ Unexpectedly large protective effect (HR < 0.70)\nâ€¢ Exposure 'protects' against multiple unrelated outcomes\nâ€¢ Biologically implausible benefit for plausible exposure\nâ€¢ Dose-response goes the 'wrong' direction"
            },
            {
              heading: "Solutions:",
              text: "1. LANDMARK ANALYSIS: Start follow-up at a fixed time point (e.g., 6 months post-diagnosis). Classify exposure based on that time.\n\n2. TIME-VARYING EXPOSURE: Change exposure status on the day it occurs. Before first statin = unexposed time. After = exposed time.\n\n3. CLONING METHODS: Create copies of patients, assign to exposure groups, censor appropriately."
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "ì„ íƒ í¸í–¥: ê±´ê°•í•œ ì‚¬ìš©ìì™€ ë³‘ì— ê±¸ë¦° ì‚¬ìš©ì",
          sections: [
            {
              heading: "Healthy User Bias:",
              items: [
                "People who choose treatment are systematically different",
                "HRT: Women who chose HRT were wealthier, more health-conscious",
                "Vaccines: Parents who vaccinate also do other healthy behaviors",
                "Supplements: Users have healthier lifestyles overall",
                "ì¹˜ë£Œ 'í˜œíƒ'ì€ ì‹¤ì œë¡œ ì„ íƒì…ë‹ˆë‹¤. íš¨ê³¼"
              ]
            },
            {
              heading: "Sick Quitter Bias:",
              items: [
                "People stop behaviors when they feel ill",
                "Alcohol: Former drinkers have higher mortality than current drinkers",
                "But former drinkers quit because they were sick",
                "Smoking: Recent quitters have higher cancer rates (cancer caused quitting)",
                "Creates the appearance of 'J-shaped' curves or protective effects"
              ]
            },
            {
              heading: "Detection and Correction:",
              items: [
                "Compare to 'never users,' not 'former users'",
                "Look at TIME of quitting relative to outcome",
                "Use active comparators (another drug) not non-users",
                "Consider intentions (prescriptions filled vs filled and taken)"
              ]
            }
          ]
        }
      },
      {
        type: 'story-box',
        content: {
          icon: 'ğŸ¥',
          title: "The Hospitalized Patient Paradox: Berkson's Bias",
          source: "Berkson J, Biometrics 1946 | Classic Selection Bias",
          paragraphs: [
            "In hospital-based studies, researchers noticed something strange: diabetes appeared to be PROTECTIVE against infections. Diabetic patients seemed less likely to have infectious diseases. This was paradoxicalâ€”diabetes impairs immune function.",
            "ì„ íƒ í¸í–¥ì˜ ì¼ì¢…ì¸ ë²„í¬ìŠ¨ í¸í–¥ìœ¼ë¡œ ì„¤ëª…ë˜ì—ˆìŠµë‹ˆë‹¤. ì…ì›í•œ ë‹¹ë‡¨ë³‘ í™˜ìëŠ” ì£¼ë¡œ ê°ì—¼ì´ ì•„ë‹Œ ë‹¹ë‡¨ë³‘ ê´€ë¦¬ë¥¼ ìœ„í•´ ì¡´ì¬í–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì…ì›í•œ ë¹„ë‹¹ë‡¨ë³‘ í™˜ìëŠ” ê°ì—¼(ë‹¤ë¥¸ ê¸‰ì„± ì§ˆí™˜ ì¤‘ì—ì„œ)ì— ìˆì„ ê°€ëŠ¥ì„±ì´ ë” ë†’ì•˜ìŠµë‹ˆë‹¤.",
            "ì—°êµ¬ì›ë“¤ì€ ì…ì›í•œ í™˜ìë§Œì„ ì—°êµ¬í•˜ì—¬ í—ˆìœ„ ë¶€ì •ì  ì—°ê´€ì„±ì„ ë§Œë“¤ì—ˆìŠµë‹ˆë‹¤. ì¼ë°˜ ì¸êµ¬ë¥¼ ëŒ€ìƒìœ¼ë¡œ ì—°êµ¬ëœ ë™ì¼í•œ ë‹¹ë‡¨ë³‘-ê°ì—¼ ê´€ê³„ëŠ” ì˜ˆìƒë˜ëŠ” ê¸ì •ì ì¸ ì—°ê´€ì„±ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì¦‰, ë‹¹ë‡¨ë³‘ì€ ê°ì—¼ ìœ„í—˜ì„ ì¦ê°€ì‹œí‚µë‹ˆë‹¤."
          ],
          lesson: "Studying only hospitalized (or otherwise selected) populations can create, eliminate, or reverse associations that exist in the general population. Always ask: how did patients get INTO this study, and could that selection process distort the exposure-outcome relationship?"
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'bias-detection',
          title: "í¸í–¥ íƒì§€ê¸°",
          situation: "í•œ ì—°êµ¬ì—ì„œëŠ” ë©”íŠ¸í¬ë¥´ë¯¼ì´ ë‹¹ë‡¨ë³‘ í™˜ìì˜ ì•” ìœ„í—˜ì„ ê°ì†Œì‹œí‚¨ë‹¤ê³  ì£¼ì¥í•©ë‹ˆë‹¤(HR 0.63, 95% CI 0.58-0.68). ì´ ì—°êµ¬ëŠ” ë©”íŠ¸í¬ë¥´ë¯¼ ì‚¬ìš©ìì™€ ë¹„ì‚¬ìš©ìë¥¼ ë¹„êµí–ˆìŠµë‹ˆë‹¤. 2ê°œ ì´ìƒì˜ ì²˜ë°©ì„ ë°›ì€ í™˜ìëŠ” ë©”íŠ¸í¬ë¥´ë¯¼ ì‚¬ìš©ìë¡œ ë¶„ë¥˜ë˜ì—ˆìŠµë‹ˆë‹¤. ë‹¹ë‡¨ë³‘ ì§„ë‹¨ë¶€í„° í›„ì† ì¡°ì¹˜ê°€ ì‹œì‘ë˜ì—ˆìŠµë‹ˆë‹¤.",
          nodes: {
            start: {
              question: "ì´ ì—°êµ¬ì—ì„œ ê°€ì¥ ê°€ëŠ¥ì„±ì´ ë†’ì€ í¸í–¥ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "Confounding by indication â€” metformin given to healthier patients", nextNode: "confounding" },
                { text: "Immortal time bias â€” must survive to fill 2 prescriptions", nextNode: "immortal_correct" },
                { text: "Healthy user bias â€” metformin users are health-conscious", nextNode: "healthy_user" },
                { text: "No bias â€” the confidence interval is narrow", nextNode: "no_bias_wrong" }
              ]
            },
            immortal_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤! 2ê°œì˜ ì²˜ë°©ì „ì„ ì¡°ì œí•˜ë ¤ë©´ í™˜ìëŠ” ìµœì†Œí•œ ê·¸ ì‚¬ì´ì˜ ì‹œê°„ ë™ì•ˆ ìƒì¡´í•´ì•¼ í•©ë‹ˆë‹¤. ì´ ìƒì¡´ ì‹œê°„ì€ 'ë…¸ì¶œë˜ì§€ ì•ŠìŒ'ì´ì–´ì•¼ í•˜ëŠ”ë° 'ë…¸ì¶œë¨'ìœ¼ë¡œ ì˜ëª» ë¶„ë¥˜ë˜ì—ˆìŠµë‹ˆë‹¤.",
              question: "ì´ ì—°êµ¬ë¥¼ ì–´ë–»ê²Œ ìˆ˜ì •í•˜ì‹œê² ìŠµë‹ˆê¹Œ?",
              branches: [
                { text: "Use landmark analysis â€” start follow-up after a fixed period", nextNode: "fix_correct" },
                { text: "ë™ë°˜ ì§ˆí™˜ì— ëŒ€í•œ ì¡°ì •", nextNode: "fix_wrong" },
                { text: "Exclude patients who died early", nextNode: "fix_wrong2" }
              ]
            },
            confounding: {
              type: 'outcome',
              outcome: 'partial',
              title: "ê°€ëŠ¥í•˜ì§€ë§Œ ì£¼ìš” ë¬¸ì œëŠ” ì•„ë‹˜",
              text: "í‘œì‹œì— ë”°ë¥¸ í˜¼ë€ì´ ìš°ë ¤ë©ë‹ˆë‹¤. ('ë” ê±´ê°•í•œ' ë‹¹ë‡¨ë³‘ í™˜ìì—ê²Œ íˆ¬ì—¬ë˜ëŠ” ë©”íŠ¸í¬ë¥´ë¯¼). ê·¸ëŸ¬ë‚˜ ì—°êµ¬ ì„¤ê³„ëŠ” ëª…ì‹œì ìœ¼ë¡œ IMMORTAL TIMEì„ ìƒì„±í•©ë‹ˆë‹¤. ì¦‰, 2ê°€ì§€ ì²˜ë°©ì´ í•„ìš”í•˜ë‹¤ëŠ” ê²ƒì€ ìƒì¡´ì´ ë…¸ì¶œëœ ê²ƒìœ¼ë¡œ ë¶„ë¥˜ë˜ì–´ì•¼ í•¨ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì´ê²ƒì´ ì§€ë°°ì ì¸ í¸í–¥ì…ë‹ˆë‹¤.",
              lesson: "When a study requires multiple events (prescriptions, visits, tests) to define exposure, immortal time bias is almost always present."
            },
            healthy_user: {
              type: 'outcome',
              outcome: 'partial',
              title: "ê´€ë ¨ì´ ìˆì§€ë§Œ ë©”ì»¤ë‹ˆì¦˜ì€ ì•„ë‹™ë‹ˆë‹¤",
              text: "Healthy user bias is a form of confounding â€” metformin users may be more health-conscious. But the study design creates a STRONGER bias: immortal time. Even if users and non-users were identical at baseline, requiring 2 prescriptions creates artificial immortality.",
              lesson: "ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ì€ í˜¼ë™ì„ ì¼ìœ¼í‚¤ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ëŠ” ì‹œê°„ì„ ì˜ëª» ë¶„ë¥˜í•˜ì—¬ ë°œìƒí•˜ëŠ” êµ¬ì¡°ì  í¸í–¥ì…ë‹ˆë‹¤. ê·¸ë£¹ ê°„ ì°¨ì´ê°€ ì—†ì–´ë„ ì¡´ì¬í•©ë‹ˆë‹¤."
            },
            no_bias_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Narrow CI doesn't mean no bias!",
              text: "ì‹ ë¢° êµ¬ê°„ì´ ì¢ë‹¤ëŠ” ê²ƒì€ ì¶”ì •ì¹˜ê°€ ì •í™•í•˜ë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•˜ì§€ë§Œ í¸í–¥ë˜ì§€ ì•Šì•˜ë‹¤ëŠ” ì˜ë¯¸ëŠ” ì•„ë‹™ë‹ˆë‹¤. ì´ ì—°êµ¬ì—ëŠ” ì—„ì²­ë‚œ ì²´ê³„ì  ì˜¤ë¥˜ê°€ ìˆìŠµë‹ˆë‹¤. 0.63 ì •ë„ì˜ ì—„ê²©í•œ CIì—ë„ ë¶ˆêµ¬í•˜ê³  'ì°¸' íš¨ê³¼ëŠ” null(HR 1.0)ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ì •ë°€ë„ â‰  ì •í™•ë„. í¸í–¥ì€ ì²´ê³„ì ì¸ ì˜¤ë¥˜ì…ë‹ˆë‹¤. í‘œë³¸ í¬ê¸°ì™€ ì •ë°€ë„ëŠ” í¸í–¥ì„ ìˆ˜ì •í•˜ì§€ ì•Šìœ¼ë©° ë‹¨ì§€ ë” ì •í™•í•˜ê²Œ í‹€ë¦¬ê²Œ ë§Œë“¤ ë¿ì…ë‹ˆë‹¤."
            },
            fix_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Excellent solution!",
              text: "ëœë“œë§ˆí¬ ë¶„ì„ì€ ì§„ë‹¨ í›„ 6ê°œì›” í›„ì— í›„ì† ì¡°ì¹˜ë¥¼ ì‹œì‘í•˜ë„ë¡ ì„¤ì •í•©ë‹ˆë‹¤. 6ê°œì›”ê¹Œì§€ ìƒì¡´í•œ ëª¨ë“  ì‚¬ëŒì´ í¬í•¨ë©ë‹ˆë‹¤. ë…¸ì¶œ ìƒíƒœëŠ” í•´ë‹¹ ì‹œì ì—ì„œ ì •ì˜ë©ë‹ˆë‹¤. ë¶ˆë©¸ì˜ ì‹œê°„ì€ ì˜ëª» ë¶„ë¥˜ë  ìˆ˜ ì—†ìŠµë‹ˆë‹¤.",
              lesson: "ëœë“œë§ˆí¬ ë¶„ì„ì€ ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ì„ í•´ê²°í•˜ëŠ” ê°€ì¥ ê°„ë‹¨í•œ ë°©ë²•ì…ë‹ˆë‹¤. 'ëœë“œë§ˆí¬'ëŠ” ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ê°€ ìˆì–´ì•¼ í•˜ë©° ëª¨ë“  í™˜ìì—ê²Œ ë™ì¼í•˜ê²Œ ì ìš©ë˜ì–´ì•¼ í•©ë‹ˆë‹¤."
            },
            fix_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Adjustment doesn't fix immortal time",
              text: "Immortal time bias is NOT confounding â€” you can't adjust it away. No matter how many comorbidities you control for, the structural problem remains: time before first prescription is misclassified.",
              lesson: "Immortal time bias requires DESIGN fixes (landmark, time-varying exposure), not statistical adjustment."
            },
            fix_wrong2: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ë ‡ê²Œ í•˜ë©´ ìƒí™©ì´ ë”ìš± ì•…í™”ë©ë‹ˆë‹¤!",
              text: "ì¡°ê¸° ì‚¬ë§ì„ ì œì™¸í•˜ë©´ í¸ê²¬ì„ ë³´ì´ëŠ” ë°”ë¡œ ê·¸ í™˜ìê°€ ì œê±°ë©ë‹ˆë‹¤! ìƒì¡´ìë§Œ ë‚¨ê²¨ë‘ë©´ ë¶ˆë©¸ì˜ ì‹œê°„ ë¬¸ì œê°€ ë”ìš± ì‹¬ê°í•´ì§‘ë‹ˆë‹¤. ì´ëŠ” ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ì— ë”í•´ ìƒì¡´ í¸í–¥ì…ë‹ˆë‹¤.",
              lesson: "ë°ì´í„°ë¥¼ ì œê±°í•˜ì—¬ í¸í–¥ì„ 'ìˆ˜ì •'í•˜ì§€ ë§ˆì„¸ìš”. ì²˜ìŒë¶€í„° ì‹œê°„ì„ ì˜¬ë°”ë¥´ê²Œ ë¶„ë¥˜í•˜ì—¬ ìˆ˜ì •í•˜ì„¸ìš”."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "í•œ ì—°êµ¬ì— ë”°ë¥´ë©´ ì•” ì§„ë‹¨ í›„ 5ë…„ ì´ìƒ ìƒì¡´í•œ í›„ ëª…ìƒì„ ì‹œì‘í•œ í™˜ìëŠ” ëª…ìƒì„ í•˜ì§€ ì•Šì€ ì‚¬ëŒë³´ë‹¤ ì‚¬ë§ë¥ ì´ 60% ë” ë‚®ìŠµë‹ˆë‹¤. ê°€ì¥ ì‹¬ê°í•œ ê²°ì ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
          options: [
            { id: 'a', text: "Confounding â€” meditators are healthier overall", correct: false },
            { id: 'b', text: "Immortal time bias â€” must survive 5 years to become a meditator", correct: true },
            { id: 'c', text: "Recall bias â€” survivors remember meditation better", correct: false },
            { id: 'd', text: "Selection bias â€” only motivated patients meditate", correct: false }
          ],
          explanation: "The study defines 'meditators' as those who survive 5+ years AND THEN start meditation. All 5 years of survival are 'immortal' â€” by definition, you can't die during time required to become exposed. This immortal time is then misclassified as 'exposed' time, artificially inflating survival in meditators."
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ê¸°ì–µì˜ í•¨ì •: í¸ê²¬ íšŒìƒê³¼ í™˜ìƒ ë…¸ì¶œ",
          source: "Case-control studies of birth defects | Multiple examples | Information bias",
          timeline: [
            { year: "Classic Setup", text: "ì„ ì²œì  ê²°í•¨ì´ ìˆëŠ” ì•„ê¸°ì˜ ì—„ë§ˆëŠ” 'ì„ì‹  ì¤‘ì— ì•½ì„ ë³µìš©í•˜ì…¨ë‚˜ìš”?'ë¼ê³  ì§ˆë¬¸í•©ë‹ˆë‹¤. ê·¸ë…€ëŠ” ìë…€ì˜ ìƒíƒœë¥¼ ì„¤ëª…í•  ìˆ˜ ìˆëŠ” ëª¨ë“  ê²ƒì„ í•„ì‚¬ì ìœ¼ë¡œ ê¸°ì–µì„ ê²€ìƒ‰í•©ë‹ˆë‹¤.", type: "normal" },
            { year: "The Comparison", text: "Mother of healthy baby is asked same question. She shrugs: 'Maybe some Tylenol? I don't really remember.' No motivation to dig through memory.", type: "normal" },
            { year: "The Bias", text: "ì‚¬ë¡€ ì–´ë¨¸ë‹ˆëŠ” ëŒ€ì¡° ì–´ë¨¸ë‹ˆë³´ë‹¤ ë” ë§ì€ ë…¸ì¶œì„ ê¸°ì–µí•©ë‹ˆë‹¤. ë” ë§ì´ ê²€ìƒ‰í–ˆê¸° ë•Œë¬¸ì´ ì•„ë‹ˆë¼ ë” ì—´ì‹¬íˆ ê²€ìƒ‰í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ê²ƒì´ ì°¨ë“± íšŒìƒì…ë‹ˆë‹¤.", type: "crisis" },
            { year: "Real Example", text: "ì‚¬ë¡€ ëŒ€ì¡° ì—°êµ¬ì—ì„œëŠ” ë§ì€ ì•½ë¬¼ê³¼ ì„ ì²œì  ê²°í•¨ ì‚¬ì´ì˜ ì—°ê´€ì„±ì„ ë°œê²¬í–ˆìŠµë‹ˆë‹¤. ë¦¬ì½œ ëŒ€ì‹  ì²˜ë°©ê¸°ë¡(ê°ê´€ì  ë°ì´í„°)ì„ í™œìš©í•˜ì ëŒ€ë¶€ë¶„ì˜ ì—°ê´€ì„±ì´ ì‚¬ë¼ì¡Œë‹¤.", type: "revelation" },
            { year: "Bendectin Disaster", text: "ì…ë§ì œ ë²¤ë±í‹´ì€ ì‚¬ë¡€ê´€ë¦¬ ë¦¬ì½œ ì—°êµ¬ì— ëŒ€í•œ ì†Œì†¡ ì••ë ¥ìœ¼ë¡œ ì¸í•´ ì² íšŒëë‹¤. ë‚˜ì¤‘ì— ì—°êµ¬ì— ë”°ë¥´ë©´ ì•ˆì „í•˜ë‹¤ëŠ” ê²ƒì´ ë°í˜€ì¡ŒìŠµë‹ˆë‹¤. ì„ì‚°ë¶€ëŠ” íšŒìƒ í¸í–¥ìœ¼ë¡œ ì¸í•´ íš¨ê³¼ì ì¸ ì¹˜ë£Œë¥¼ ë°›ì„ ìˆ˜ ì—†ì—ˆìŠµë‹ˆë‹¤.", type: "crisis" },
            { year: "Lesson", text: "When outcomes prompt memory searches, recall is biased. Use OBJECTIVE exposure data (records, biomarkers) when possible. When using recall, make interviewers BLIND to case/control status.", type: "revelation" }
          ],
          realData: {
            endpoint: "Various birth defects",
            drug: "Multiple medications (recall-based)",
            placebo: "No medication (recall-based)",
            rr: "OR 2-4x higher in recall studies vs objective records",
            ci: "Recall-based associations often spurious",
            nnh: "Bendectin withdrawn despite being safe"
          },
          hook: "THE HOOK: Recall bias is insidious because it feels like valid data. Mothers genuinely believe they're reporting accurately â€” but grief and guilt drive memory searches that control mothers don't perform. The cure? Objective data sources, or blinded interviewers."
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'recall-bias-detection',
          title: "ì´ íšŒìƒ í¸í–¥ì¸ê°€ìš”?",
          situation: "You're reviewing case-control studies. Identify whether recall bias is a major threat.",
          nodes: {
            start: {
              question: "ì—°êµ¬ A: íì•” í™˜ìì˜ ê²½ìš° í¡ì—° ì´ë ¥ê³¼ ì•”ì´ ì—†ëŠ” ëŒ€ì¡°êµ°ì— ëŒ€í•´ ì§ˆë¬¸í–ˆìŠµë‹ˆë‹¤. ë‘ ê·¸ë£¹ ëª¨ë‘ ê°™ì€ ë©´ì ‘ê´€ì—ê²Œ ê°™ì€ ì§ˆë¬¸ì„ í–ˆìŠµë‹ˆë‹¤. íšŒìƒ í¸í–¥ì´ ë¬¸ì œì¸ê°€ìš”?",
              branches: [
                { text: "Yes â€” lung cancer patients remember smoking differently", nextNode: "lung_cancer_wrong" },
                { text: "Minimal â€” smoking is a salient, memorable behavior", nextNode: "lung_cancer_correct" }
              ]
            },
            lung_cancer_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤! í¡ì—°ì€ ê¸°ì–µì— ë‚¨ê³  ê²€ì¦ ê°€ëŠ¥í•©ë‹ˆë‹¤. íšŒìƒ í¸í–¥ì€ MAJOR SALIENT ë…¸ì¶œì— ëŒ€í•´ ëœ ë¬¸ì œê°€ ë©ë‹ˆë‹¤. ì—°êµ¬ B: ì†Œì•„ ë°±í˜ˆë³‘ ì‚¬ë¡€ì™€ ëŒ€ì¡°êµ° ë¹„êµ. ë¶€ëª¨ë‹˜ë“¤ì€ 5ë…„ ì „ì— ê°€ì •ìš© ì‚´ì¶©ì œ ì‚¬ìš©ì— ëŒ€í•´ ë¬¸ì˜í•˜ì…¨ìŠµë‹ˆë‹¤.",
              question: "Is recall bias a concern?",
              branches: [
                { text: "Major concern â€” parents of sick children search memory harder", nextNode: "leukemia_correct" },
                { text: "Minor concern â€” pesticide use is memorable", nextNode: "leukemia_wrong" }
              ]
            },
            lung_cancer_wrong: {
              type: 'outcome',
              outcome: 'partial',
              title: "Some concern, but limited",
              text: "ê¸°ì–µ í¸í–¥ì€ ê¸°ì–µ ê²€ìƒ‰ì´ í•„ìš”í•œ SUBTLE, MINOR ë…¸ì¶œì—ì„œ ê°€ì¥ ë¬¸ì œê°€ ë©ë‹ˆë‹¤. í¡ì—°ì€ ë‘ë“œëŸ¬ì§‘ë‹ˆë‹¤. ì‚¬ëŒë“¤ì€ í¡ì—° ì—¬ë¶€ë¥¼ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë°”ì´ì˜¤ë§ˆì»¤ë¥¼ í†µí•´ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. íì•” ì—°êµ¬ì— ëŒ€í•œ ë” í° ìš°ë ¤ëŠ” í˜¼ë€ìŠ¤ëŸ½ìŠµë‹ˆë‹¤(í¡ì—°ìëŠ” ë‹¤ë¥¸ ìœ„í—˜ í–‰ë™ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤).",
              lesson: "Recall bias is exposure-specific. Major behaviors (smoking, alcohol) are less affected than minor ones (dietary supplements, brief exposures)."
            },
            leukemia_correct: {
              situation: "ì •í™•í•©ë‹ˆë‹¤! 5ë…„ ì „ ê°€ì •ìš© ë†ì•½ ì‚¬ìš© ë‚´ì—­ì€ ëª¨í˜¸í•˜ê³  ê²€ìƒ‰ ê°€ëŠ¥í•©ë‹ˆë‹¤. ì—°êµ¬ C: ì‹¬ê·¼ê²½ìƒ‰ì¦ ì‚¬ë¡€. MIê°€ ë°œìƒí•˜ê¸° ì „ì— ì•½êµ­ ì²˜ë°© ê¸°ë¡ì—ì„œ ì¶”ì¶œëœ ë…¸ì¶œ ë°ì´í„°.",
              question: "Is recall bias a concern?",
              branches: [
                { text: "Yes â€” patients still might misreport", nextNode: "mi_wrong" },
                { text: "ì•„ë‹ˆì˜¤ â€” ë°ì´í„°ëŠ” ê²°ê³¼ ì „ì— ê¸°ë¡ë˜ì—ˆìœ¼ë¯€ë¡œ ì˜í–¥ì„ ë°›ì„ ìˆ˜ ì—†ìŠµë‹ˆë‹¤.", nextNode: "mi_correct" }
              ]
            },
            leukemia_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "High recall bias risk!",
              text: "Pesticide use 5 years ago is exactly the type of exposure prone to recall bias: (1) vague definition, (2) long ago, (3) guilt-inducing for parents of sick children. Parents of leukemia cases will search memory for ANY chemical exposure. Controls won't.",
              lesson: "Red flags for recall bias: vague exposures, long recall periods, emotionally-charged outcomes (especially children), differential motivation to remember."
            },
            mi_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "No recall bias possible!",
              text: "ê²°ê³¼ê°€ ë°œìƒí•˜ê¸° ì „ì— ë…¸ì¶œ ë°ì´í„°ê°€ ê¸°ë¡ë˜ë©´(ì „í–¥ì  í™•ì¸) íšŒìƒ í¸í–¥ì´ ë¶ˆê°€ëŠ¥í•©ë‹ˆë‹¤. ë°ì´í„°ëŠ” ê²°ê³¼ ìƒíƒœì— ë”°ë¼ ë³€ê²½ë  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì½”í˜¸íŠ¸ ì—°êµ¬ì™€ ì˜ë£Œ ê¸°ë¡ì„ ì‚¬ìš©í•œ ì—°êµ¬ê°€ íšŒìƒ í¸í–¥ì— ëœ ì·¨ì•½í•œ ì´ìœ ì…ë‹ˆë‹¤.",
              lesson: "The cure for recall bias: prospective data collection, medical/pharmacy records, biomarkers â€” anything recorded before the outcome is known."
            },
            mi_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ê°ê´€ì  ê¸°ë¡ì´ ì—†ìŠµë‹ˆë‹¤!",
              text: "ì•½êµ­ ê¸°ë¡ì€ MI ì „ì— ì‘ì„±ë˜ì—ˆìŠµë‹ˆë‹¤. í™˜ìëŠ” ëŒì•„ê°€ì„œ ìì‹ ì´ ì±„ìš´ ì²˜ë°©ì „ì„ ë³€ê²½í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì´ëŠ” íšŒìƒ í¸í–¥ì— ì˜í–¥ì„ ë°›ì§€ ì•ŠëŠ” ê°ê´€ì ì´ê³  ì „í–¥ì ìœ¼ë¡œ ê¸°ë¡ëœ ë°ì´í„°ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì—°êµ¬ìë“¤ì´ ì „ì ê±´ê°• ê¸°ë¡ì„ ì‚¬ìš©í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤.",
              lesson: "Objective records > memory. Prospective > retrospective. When you have records, use them instead of asking patients to remember."
            }
          }
        }
      },
      {
        type: 'principle',
        content: {
          text: "âš ï¸ THE WARNING: Selection bias, information bias, and time-related bias all make associations appear where none exist (or disappear when real). They are NOT fixed by larger sample sizes. They are NOT fixed by narrow confidence intervals. They are ONLY fixed by proper study design. A precise biased estimate is just precise bias."
        }
      },
      {
        type: 'principle',
        content: {
          text: "ğŸ¯ PROGRESS CHECK: You've mastered the bias zoo. Immortal time (survival to exposure), healthy user (who chooses treatment), sick quitter (who stops), recall bias (differential memory), Berkson's (hospital selection). Now you'll learn ROBINS-I â€” the systematic framework to assess all these biases together."
        }
      }
    ]
  },
  // MODULE 5: THE ASSESSMENT (ROBINS-I)
  {
    id: 5,
    title: "The Assessment",
    subtitle: "í¸í–¥ì„ ìœ„í•œ ROBINS-I",
    principle: 4,
    estimatedTime: "25 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "Measurement shapes reality"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "íŒ¬ë°ë¯¹ í•¨ì •: í•˜ì´ë“œë¡œì˜¥ì‹œí´ë¡œë¡œí€¸ê³¼ ê´€ì¸¡ í˜¼ë€",
          source: "Lancet 2020 (retracted) | Multiple observational studies | COVID-19 pandemic",
          timeline: [
            { year: "Mar 2020", text: "French study (Gautret): HCQ + azithromycin shows viral clearance. 'Cure found!' Small, non-randomized, methodologically flawed.", type: "normal" },
            { year: "Apr 2020", text: "Observational studies flood preprint servers. Some show benefit (confounding by indication, immortal time). Some show harm (sicker patients got HCQ).", type: "crisis" },
            { year: "May 2020", text: "Lancetì€ ê´€ì°° ì—°êµ¬ë¥¼ ë°œí‘œí•©ë‹ˆë‹¤. HCQëŠ” ì‚¬ë§ë¥ ì„ ì¦ê°€ì‹œí‚µë‹ˆë‹¤(HR 1.35). ì„¸ê³„ëŠ” ì¬íŒì„ ì¼ì‹œ ì¤‘ì§€í•©ë‹ˆë‹¤. ë‚˜ì¤‘ì— ì—°êµ¬ ì² íšŒë¨ â€” ë°ì´í„°ê°€ ì¡°ì‘ë˜ì—ˆìŠµë‹ˆë‹¤.", type: "crisis" },
            { year: "Jun 2020", text: "WHO SOLIDARITY, RECOVERY ì‹œí—˜(RCT)ì— ë”°ë¥´ë©´ HCQê°€ ì‘ë™í•˜ì§€ ì•ŠëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê´€ì°° ì—°êµ¬ëŠ” ëª‡ ë‹¬ ë™ì•ˆ ëª¨ìˆœëœ ë‹µë³€ì„ ì œì‹œí–ˆìŠµë‹ˆë‹¤.", type: "revelation" },
            { year: "The Problem", text: "ìœ„ê¸° ê¸°ê°„ ë™ì•ˆì˜ ê´€ì°° ì—°êµ¬ì—ëŠ” ì‹¬ê°í•œ í˜¼ë€(ì•„í”ˆ í™˜ìê°€ HCQë¥¼ ë°›ìŒ), ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥(ì•½ë¬¼ì„ ë°›ê¸° ìœ„í•´ ìƒì¡´ì´ í•„ìš”í•¨) ë° í‘œì‹œ í¸í–¥ì´ ìˆì—ˆìŠµë‹ˆë‹¤.", type: "revelation" },
            { year: "The Lesson", text: "ì²´ê³„ì  í¸í–¥ í‰ê°€(ROBINS-I)ëŠ” ì •ì±…ì´ ìˆ˜ë¦½ë˜ê¸° ì „ì— ê°€ì¥ ì‹ ë¢°í•  ìˆ˜ ì—†ëŠ” ì—°êµ¬ë¥¼ í‘œì‹œí•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. í’ˆì§ˆì´ ë–¨ì–´ì§€ì§€ ì•ŠëŠ” ì†ë„ëŠ” ìƒëª…ì„ ì•—ì•„ê°‘ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "COVID-19 mortality",
            drug: "Hydroxychloroquine observational",
            placebo: "No HCQ",
            rr: "Ranged from HR 0.50 to HR 2.60",
            ci: "Completely contradictory",
            nnh: "Months of confusion, RCTs delayed"
          },
          hook: "í›…: HCQì˜ ëŒ€ì‹¤íŒ¨ëŠ” ì—„ê²©í•œ í¸ê²¬ í‰ê°€ ì—†ì´ ê´€ì°° ì—°êµ¬ê°€ ìˆ˜í–‰ë  ë•Œ ì–´ë–¤ ì¼ì´ ì¼ì–´ë‚˜ëŠ”ì§€ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ROBINS-IëŠ” ê²°ê³¼ë¥¼ ì‹ ë¢°í•˜ê¸° ì „ì— ë¹„ë¬´ì‘ìœ„ ì—°êµ¬ì˜ í¸í–¥ â€‹â€‹ìœ„í—˜ì„ í‰ê°€í•  ìˆ˜ ìˆëŠ” ì²´ê³„ì ì¸ í”„ë ˆì„ì›Œí¬ë¥¼ ì œê³µí•©ë‹ˆë‹¤."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ ì£¼ìš” í†µì°°ë ¥: ROBINS-IëŠ” ë‹¤ìŒê³¼ ê°™ì´ ë¬»ìŠµë‹ˆë‹¤. 'ì´ ì—°êµ¬ëŠ” RCTë¡œì„œ ì–´ë–¤ ëª¨ìŠµì¼ê¹Œìš”?' ê·¸ëŸ° ë‹¤ìŒ ì–´ë””ì—ì„œ ë²—ì–´ë‚˜ëŠ”ì§€ ì²´ê³„ì ìœ¼ë¡œ í™•ì¸í•©ë‹ˆë‹¤. ê´€ì°° ì—°êµ¬ê°€ 'ë‚˜ìœ'ì§€ ì—¬ë¶€ê°€ ì•„ë‹ˆë¼ ê·¸ í•œê³„ë¥¼ ì†”ì§í•˜ê²Œ í‰ê°€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤."
        }
      },
      {
        type: 'content',
        content: {
          title: "ROBINS-I: Risk of Bias In Non-randomized Studies of Interventions",
          sections: [
            {
              heading: "What Is ROBINS-I?",
              items: [
                "Developed by Cochrane for systematic reviews",
                "Structured assessment of 7 bias domains",
                "'í‘œì  ì‹œí—˜'ì— ê³ ì • â€” ì¡´ì¬í•˜ê¸°ë¥¼ ë°”ë¼ëŠ” ì´ìƒì ì¸ RCT",
                "Produces domain-level and overall risk of bias judgments",
                "Required by many journals and guideline bodies"
              ]
            },
            {
              heading: "The Target Trial Concept:",
              items: [
                "ìœ¤ë¦¬ì™€ ì‹¤í–‰ì´ í—ˆìš©ëœë‹¤ë©´ ì–´ë–¤ RCTë¥¼ í•˜ì‹œê² ìŠµë‹ˆê¹Œ?",
                "Define: eligibility, interventions, outcomes, follow-up, analysis",
                "ê´€ì°° ì—°êµ¬ëŠ” ì´ë¥¼ ëª¨ë°©í•©ë‹ˆë‹¤. í‰ê°€íŒ",
                "Bias = deviation from the target trial"
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ROBINS-I ë„ë©”ì¸",
          title: "Seven Sources of Bias",
          sections: [
            {
              heading: "Pre-Intervention Domains:",
              text: "1. í˜¼ë€ìŠ¤ëŸ¬ìš´ ì : ê¸°ì¤€ì„ ì—ì„œ ê·¸ë£¹ì„ ë¹„êµí•  ìˆ˜ ìˆì—ˆìŠµë‹ˆê¹Œ? - ì¸¡ì •ë˜ì§€ ì•Šì€ í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œ? ì‹œê°„ì— ë”°ë¼ ë³€í•˜ëŠ” í˜¼ë€? - ìƒê°í•´ ë³´ì„¸ìš”: HRT ì‚¬ìš©ì ëŒ€ ë¹„ì‚¬ìš©ì 2. ì„ íƒ: ì—°êµ¬ ì„ íƒì´ ê°œì… ë° ê²°ê³¼ì™€ ê´€ë ¨ì´ ìˆì—ˆìŠµë‹ˆê¹Œ? - ë§Œì—°í•œ ì‚¬ìš©ì í¸ê²¬? ë³‘ì› ê¸°ë°˜ ì„ íƒ? - ìƒê°í•´ ë³´ì„¸ìš”: ìƒì¡´ìë§Œ ì„ íƒ"
            },
            {
              heading: "At-Intervention Domain:",
              text: "3. ì¤‘ì¬ ë¶„ë¥˜: ì¤‘ì¬ ìƒíƒœê°€ ì˜ ì •ì˜ë˜ê³  í™•ì¸ë˜ì—ˆìŠµë‹ˆê¹Œ? - ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥? ë…¸ì¶œì„ ì˜ëª» ë¶„ë¥˜í–ˆë‚˜ìš”? - ìƒê°í•´ ë³´ì„¸ìš”: 'í•œ ë²ˆë„ ì—†ì—ˆë‹¤' ì •ì˜"
            },
            {
              heading: "Post-Intervention Domains:",
              text: "4. DEVIATIONS: Were there deviations from intended interventions?\n   - Non-adherence? Co-interventions?\n   - Think: Patients stopping treatment\n\n5. MISSING DATA: Were outcomes measured for all participants?\n   - Differential loss to follow-up?\n   - Think: Sicker patients dropping out\n\n6. MEASUREMENT: Could outcome measurement be affected by intervention status?\n   - Blinding? Detection bias?\n   - Think: Knowing treatment affects diagnosis\n\n7. SELECTION OF RESULTS: Were results selected from multiple analyses?\n   - Outcome switching? Subgroup fishing?\n   - Think: Reporting only favorable analyses"
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "ROBINS-I Judgment Levels",
          sections: [
            {
              heading: "Low Risk of Bias:",
              text: "ì´ ì—°êµ¬ëŠ” ì´ ì˜ì—­ê³¼ ê´€ë ¨í•˜ì—¬ ì˜ ìˆ˜í–‰ëœ RCTì™€ ë¹„ìŠ·í•©ë‹ˆë‹¤. í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì¸ì„ ì‹ë³„í•˜ê³  ì¡°ì •í–ˆìŠµë‹ˆë‹¤. ë¶ˆë©¸ì˜ ì‹œê°„ì€ ì—†ìŠµë‹ˆë‹¤. ì™„ì „í•œ í›„ì† ì¡°ì¹˜."
            },
            {
              heading: "Moderate Risk of Bias:",
              text: "ë¹„ë¬´ì‘ìœ„ ì—°êµ¬ì— ì í•©í•˜ì§€ë§Œ RCTì™€ ë¹„êµí•  ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤. ì¼ë¶€ í˜¼ë€ìŠ¤ëŸ¬ìš´ ë¶€ë¶„ì´ ë‚¨ì•„ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë°©ë²•ì— ëŒ€í•œ ì‚¬ì†Œí•œ ìš°ë ¤."
            },
            {
              heading: "Serious Risk of Bias:",
              text: "ì—°êµ¬ì—ëŠ” ì¤‘ìš”í•œ ë¬¸ì œê°€ ìˆìŠµë‹ˆë‹¤. ìƒë‹¹íˆ í˜¼ë€ìŠ¤ëŸ¬ìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë””ìì¸ ê²°í•¨(ë¶ˆë©¸ì˜ ì‹œê°„, ì„ íƒ). ê²°ê³¼ëŠ” ë§¤ìš° ì£¼ì˜ ê¹Šê²Œ í•´ì„ë˜ì–´ì•¼ í•©ë‹ˆë‹¤."
            },
            {
              heading: "Critical Risk of Bias:",
              text: "ì´ ì—°êµ¬ëŠ” ìœ ìš©í•œ ì¦ê±°ë¥¼ ì œê³µí•˜ê¸°ì—ëŠ” ë¬¸ì œê°€ ë„ˆë¬´ ë§ìŠµë‹ˆë‹¤. í•´ê²°ë  ìˆ˜ ì—†ëŠ” ê·¼ë³¸ì ì¸ ê²°í•¨. ì¼ë°˜ì ìœ¼ë¡œ í•©ì„±ì—ëŠ” í¬í•¨ë˜ì§€ ì•Šì•„ì•¼ í•©ë‹ˆë‹¤."
            },
            {
              heading: "Overall Judgment:",
              text: "The overall risk of bias is the MOST SEVERE judgment across domains. One critical domain = critical overall. This is intentionally conservative."
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'robins-assessment',
          title: "ROBINS-I Assessment Practice",
          situation: "ê´€ì°° ì—°êµ¬ì—ì„œëŠ” ë ˜ë°ì‹œë¹„ë¥´ì™€ í‘œì¤€ ì¹˜ë£Œë¥¼ ë°›ì€ í™˜ìì˜ ì½”ë¡œë‚˜19 ê²°ê³¼ë¥¼ ë¹„êµí•©ë‹ˆë‹¤. ë ˜ë°ì‹œë¹„ë¥´ëŠ” ì˜ì‚¬ì˜ íŒë‹¨ì— ë”°ë¼ íˆ¬ì—¬ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ëŠ” ì—°ë ¹, ì„±ë³„, ë™ë°˜ì§ˆí™˜ì„ ì¡°ì •í–ˆìŠµë‹ˆë‹¤. ì¹˜ë£Œ ì‹œì‘ ì‹œ ì§ˆë³‘ ì‹¬ê°ë„ì— ëŒ€í•œ ë°ì´í„°ê°€ ì—†ìŠµë‹ˆë‹¤.",
          nodes: {
            start: {
              question: "CONFOUNDING ì˜ì—­ì— ëŒ€í•´ ê·€í•˜ì˜ íŒë‹¨ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "Low risk â€” they adjusted for key confounders", nextNode: "confound_low" },
                { text: "Serious risk â€” disease severity unmeasured", nextNode: "confound_correct" },
                { text: "ì¤‘ìš”í•œ ìœ„í—˜ - ì—°êµ¬ì— ê·¼ë³¸ì ìœ¼ë¡œ ê²°í•¨ì´ ìˆìŠµë‹ˆë‹¤", nextNode: "confound_critical" }
              ]
            },
            confound_correct: {
              situation: "Good judgment! Physicians gave remdesivir to sicker patients. Without adjusting for baseline severity, the study is biased AGAINST remdesivir (confounding by indication). Now assess CLASSIFICATION OF INTERVENTIONS:",
              question: "Patients were classified as 'remdesivir users' if they received at least one dose during hospitalization.",
              branches: [
                { text: "Low risk â€” clear definition", nextNode: "class_low" },
                { text: "Serious risk â€” immortal time bias possible", nextNode: "class_correct" }
              ]
            },
            confound_low: {
              type: 'outcome',
              outcome: 'danger',
              title: "Too optimistic!",
              text: "Adjusting for age, sex, and comorbidities doesn't capture the most important confounder: DISEASE SEVERITY at treatment initiation. Physicians gave remdesivir to sicker patients. This creates confounding by indication â€” the treatment appears harmful because treated patients were sicker.",
              lesson: "Always ask: 'What determined who got treatment?' If it's disease severity and you can't measure that, confounding is serious."
            },
            confound_critical: {
              type: 'outcome',
              outcome: 'partial',
              title: "Possibly too harsh",
              text: "êµë€ì´ ì‹¬ê°í•œ ë°˜ë©´, 'ì¤‘ìš”'ëŠ” ì›ì¹™ì ìœ¼ë¡œë„ ìˆ˜ì •í•  ìˆ˜ ì—†ëŠ” í¸í–¥ ë˜ëŠ” ë°©í–¥ê³¼ í¬ê¸°ê°€ ê²°ê³¼ë¥¼ ì™„ì „íˆ ë§Œë“œëŠ” ê²½ìš°ì— ì‚¬ìš©ë©ë‹ˆë‹¤. ìœ ìµí•˜ì§€ ì•Šì€. ë¹„êµì— ëŒ€í•œ ì¼ë¶€ ì •ë³´ëŠ” ì—¬ì „íˆ ì£¼ì˜í•´ì„œ ì¶”ì¶œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ë¹„ëš¤ë¦¼ì˜ ì‹¬ê°í•œ ìœ„í—˜ì€ ì—°êµ¬ê°€ ì¼ë°˜ì ìœ¼ë¡œ ì¢…í•©ì—ì„œ ì œì™¸ë˜ì–´ì•¼ í•¨ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì •ë§ ì¹˜ëª…ì ì¸ ê²°ì ì„ ëŒ€ë¹„í•´ì„œ ì˜ˆì•½í•˜ì„¸ìš”."
            },
            class_low: {
              type: 'outcome',
              outcome: 'danger',
              title: "ë¶ˆë©¸ì˜ ì‹œê°„ì„ í™•ì¸í•˜ì„¸ìš”!",
              text: "ì…ì› ì¤‘ì— ë ˜ë°ì‹œë¹„ë¥´ë¥¼ íˆ¬ì—¬ë°›ìœ¼ë ¤ë©´ í™˜ìëŠ” ì¹˜ë£Œ ì „ê¹Œì§€ ìƒì¡´í•´ì•¼ í•©ë‹ˆë‹¤. ì…ì›ë¶€í„° ì²« ë²ˆì§¸ íˆ¬ì—¬ê¹Œì§€ì˜ ì‹œê°„ì€ 'ë¶ˆë©¸'ì…ë‹ˆë‹¤. í™˜ìëŠ” ì´ ê¸°ê°„ ë™ì•ˆ ì‚¬ë§í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì´ ì‹œê°„ì„ 'ì¹˜ë£Œ' ì‹œê°„ìœ¼ë¡œ ë¶„ë¥˜í•˜ë©´ ë ˜ë°ì‹œë¹„ë¥´ë¥¼ ì„ í˜¸í•˜ëŠ” ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ì´ ìƒê¸°ê²Œ ë©ë‹ˆë‹¤.",
              lesson: "Any time-to-treatment or requirement to survive to receive treatment creates potential immortal time bias."
            },
            class_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤! ë ˜ë°ì‹œë¹„ë¥´ì— ì…ì›í•œ í›„ë¶€í„° ì‹œê°„ì´ 'ë…¸ì¶œ'ë¡œ ë¶„ë¥˜ëœë‹¤ë©´ ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ì´ ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ì œ ì „ë°˜ì ì¸ í¸í–¥ íŒë‹¨ ìœ„í—˜ì€ ì–¼ë§ˆë‚˜ ë©ë‹ˆê¹Œ?",
              question: "Overall judgment:",
              branches: [
                { text: "ë³´í†µ â€” ìš°ë ¤ê°€ ìˆì§€ë§Œ ì—°êµ¬ê°€ ìœ ìš©í•¨", nextNode: "overall_moderate" },
                { text: "Serious â€” multiple domains have important problems", nextNode: "overall_correct" },
                { text: "ì¤‘ìš” â€” ì—°êµ¬ê°€ ìœ ìš©í•œ ì¦ê±°ë¥¼ ì œê³µí•˜ì§€ ì•ŠìŒ", nextNode: "overall_critical" }
              ]
            },
            overall_moderate: {
              type: 'outcome',
              outcome: 'partial',
              title: "Likely too generous",
              text: "ì‹¬ê°í•œ í˜¼ë€ê³¼ ì‹¬ê°í•œ ë¶„ë¥˜ í¸í–¥(ë¶ˆë©¸ì˜ ì‹œê°„)ì´ ìˆëŠ” ê²½ìš° ì „ë°˜ì ì¸ íŒë‹¨ì€ ìµœì†Œí•œ ì‹¬ê°í•´ì•¼ í•©ë‹ˆë‹¤. ì „ì²´ëŠ” ìµœì•…ì˜ ì˜ì—­ì— ì˜í•´ ê²°ì •ë©ë‹ˆë‹¤. ì‹¬ê°í•œ ìš°ë ¤ë¥¼ í‰ê· ìœ¼ë¡œ ì—†ì•¨ ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤.",
              lesson: "Overall ROBINS-I judgment = worst single domain judgment. One serious domain = serious overall."
            },
            overall_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Appropriate judgment!",
              text: "ì‹¬ê°í•œ êµë€(ì¸¡ì •ë˜ì§€ ì•Šì€ ì‹¬ê°ë„) ë° ì‹¬ê°í•œ ë¶„ë¥˜ í¸í–¥(ì ì¬ì  ë¶ˆë©¸ ì‹œê°„)ì´ ìˆëŠ” ê²½ìš° í¸í–¥ì˜ ì „ë°˜ì ì¸ ìœ„í—˜ì€ ì‹¬ê°í•©ë‹ˆë‹¤. ì—°êµ¬ ê²°ê³¼ëŠ” ë§¤ìš° ì£¼ì˜ ê¹Šê²Œ í•´ì„ë˜ì–´ì•¼ í•˜ë©° ì •ëŸ‰ì  í•©ì„±ì—ëŠ” ì í•©í•˜ì§€ ì•Šì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ROBINS-IëŠ” ì˜ë„ì ìœ¼ë¡œ ë³´ìˆ˜ì ì…ë‹ˆë‹¤. ì‹¤ì œ ê´€ì°° ì•½ë¬¼ ì—°êµ¬ì—ëŠ” ì¢…ì¢… ì‹¬ê°í•œ ë¹„ëš¤ë¦¼ ìœ„í—˜ì´ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì„ ì†”ì§í•˜ê²Œ ì¸ì •í•˜ëŠ” ê²ƒì´ ê·¸ë ‡ì§€ ì•Šì€ ì²™í•˜ëŠ” ê²ƒë³´ë‹¤ ë‚«ìŠµë‹ˆë‹¤."
            },
            overall_critical: {
              type: 'outcome',
              outcome: 'partial',
              title: "Possibly warranted, but justify carefully",
              text: "ì¤‘ëŒ€í•œ ìœ„í—˜ì—ëŠ” ìµœì†Œí•œ í•˜ë‚˜ì˜ ì¤‘ìš” ë„ë©”ì¸ì´ í•„ìš”í•˜ê±°ë‚˜ í•¨ê»˜ ê²°ê³¼ë¥¼ ìœ ìµí•˜ì§€ ì•Šê²Œ ë§Œë“œëŠ” ì—¬ëŸ¬ ì‹¬ê°í•œ ë„ë©”ì¸ì´ í•„ìš”í•©ë‹ˆë‹¤. ìœ ìš©í•œ ì •ë³´ë¥¼ ì¶”ì¶œí•  ìˆ˜ ì—†ëŠ” ì´ìœ ë¥¼ ì„¤ëª…í•  ìˆ˜ ìˆë‹¤ë©´ ë¹„íŒì ì´ë¼ëŠ” í‘œí˜„ì´ ì ì ˆí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ë¹„íŒì  íŒë‹¨ì€ 'ì´ ì—°êµ¬ëŠ” ì„ìƒì  ê²°ì •ì„ ì•Œë ¤ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤.'ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. ë“œë¬¼ê²Œ ì‚¬ìš©í•˜ë˜ ì‹¤ì œë¡œ ë³´ì¦ë˜ëŠ” ê²½ìš°ì—ëŠ” í”¼í•˜ì§€ ë§ˆì‹­ì‹œì˜¤."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "ì—°êµ¬ëŠ” 6ê°œì˜ ROBINS-I ë„ë©”ì¸ì— ëŒ€í•´ 'ë‚®ì€' ìœ„í—˜ì„ ê°–ì§€ë§Œ êµë€ì— ëŒ€í•œ 'ì‹¬ê°í•œ' ìœ„í—˜ì„ ê°–ìŠµë‹ˆë‹¤. í¸í–¥ì˜ ì „ë°˜ì ì¸ ìœ„í—˜ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
          options: [
            { id: 'a', text: "Low â€” most domains are fine", correct: false },
            { id: 'b', text: "Moderate â€” one serious domain warrants caution", correct: false },
            { id: 'c', text: "Serious â€” overall is the worst single domain", correct: true },
            { id: 'd', text: "Cannot determine â€” need to average the domains", correct: false }
          ],
          explanation: "ROBINS-Iì—ì„œ í¸í–¥ íŒë‹¨ì˜ ì „ë°˜ì ì¸ ìœ„í—˜ì€ ëª¨ë“  ì˜ì—­ì—ì„œ ê°€ì¥ ì‹¬ê°í•œ íŒë‹¨ê³¼ ë™ì¼í•©ë‹ˆë‹¤. ì´ëŠ” í‰ê· ì´ ì•„ë‹™ë‹ˆë‹¤. í•˜ë‚˜ì˜ ì¹˜ëª…ì ì¸ ê²°í•¨ì€ ì—¬ì „íˆ â€‹â€‹â€‹â€‹ì¹˜ëª…ì ì…ë‹ˆë‹¤. êµë€ì´ ì‹¬ê°í•œ ê²½ìš°, ë‹¤ë¥¸ ì˜ì—­ì´ ì–¼ë§ˆë‚˜ ì˜ ì²˜ë¦¬ë˜ëŠ”ì§€ì— ê´€ê³„ì—†ì´ ì—°êµ¬ëŠ” ì „ë°˜ì ìœ¼ë¡œ 'ë‚®ìŒ' ë˜ëŠ” 'ë³´í†µ' ìœ„í—˜ìœ¼ë¡œ ê°„ì£¼ë  ìˆ˜ ì—†ìŠµë‹ˆë‹¤."
        }
      }
    ]
  },
  // MODULE 6: THE ADJUSTMENT (Propensity Scores)
  {
    id: 6,
    title: "The Adjustment",
    subtitle: "Propensity Scores",
    principle: 5,
    estimatedTime: "30 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "ì¡°ì •ì€ ë§ˆìˆ ì´ ì•„ë‹™ë‹ˆë‹¤"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ê· í˜• í™˜ìƒ: ì„±í–¥ ì ìˆ˜ ë° ì¸¡ì •ë˜ì§€ ì•Šì€",
          source: "King & Nielsen 2019 | Epidemiology debates | Propensity score wars",
          timeline: [
            { year: "1983", text: "Rosenbaum ë° Rubinì€ ì„±í–¥ ì ìˆ˜: ê³µë³€ëŸ‰ì´ ì£¼ì–´ì§„ ì¹˜ë£Œ í™•ë¥ ì„ ì†Œê°œí•©ë‹ˆë‹¤. ê´€ì°° ë°ì´í„°ì˜ ì¸ê³¼ ì¶”ë¡ ì— í˜ëª…ì„ ì¼ìœ¼ì¼°ìŠµë‹ˆë‹¤.", type: "normal" },
            { year: "2000s", text: "ì„±í–¥ ì ìˆ˜ ë§¤ì¹­ì€ ê´€ì°° ì—°êµ¬ì˜ 'ìµœì  í‘œì¤€'ì´ ë©ë‹ˆë‹¤. 'RCTì™€ ìœ ì‚¬í•œ' ê· í˜•ì„ ì£¼ì¥í•˜ëŠ” ë…¼ë¬¸ì´ ëŠ˜ì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤.", type: "normal" },
            { year: "2010s", text: "Problems emerge: matching discards data, pruning can increase bias. IPTW and overlap weighting gain favor.", type: "crisis" },
            { year: "Key Issue", text: "Propensity scores balance MEASURED confounders only. If the key confounder is UNMEASURED, propensity scores give false confidence.", type: "revelation" },
            { year: "Example", text: "COX-2 inhibitors vs NSAIDs: propensity-matched studies showed safety. But unmeasured factors (channeling to lower-risk patients) weren't captured. RCTs revealed CV harm.", type: "crisis" },
            { year: "Lesson", text: "ì„±í–¥ ì ìˆ˜ëŠ” ì¹˜ë£Œë²•ì´ ì•„ë‹ˆë¼ ë„êµ¬ì…ë‹ˆë‹¤. ì¸¡ì •í•œ ë‚´ìš©ì˜ ê· í˜•ì„ ë§ì¶¥ë‹ˆë‹¤. ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ ìš”ì¸ì´ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤. ë¯¼ê°ë„ ë¶„ì„ì€ í•„ìˆ˜ì ì…ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "Cardiovascular events",
            drug: "COX-2 inhibitors (propensity-adjusted)",
            placebo: "Traditional NSAIDs",
            rr: "Observational: HR ~0.80 | RCT: HR 1.50+",
            ci: "Unmeasured channeling bias",
            nnh: "Vioxx withdrawn after 88,000+ cardiac events"
          },
          hook: "ê³ ë ¤ì : ì„±í–¥ ì ìˆ˜ë¡œ ì¸í•´ ê´€ì°° ì—°êµ¬ëŠ” 'ê· í˜• ì¡íŒ' ê²ƒì²˜ëŸ¼ ë³´ì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì¸¡ì •ëœ ìš”ì†Œì˜ ê· í˜•ì´ ëª¨ë“  ìš”ì†Œì˜ ê· í˜•ì„ ì˜ë¯¸í•˜ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. COX-2/Vioxx ì¬í•´ëŠ” ì •êµí•œ í†µê³„ë¡œëŠ” ëˆ„ë½ëœ ë°ì´í„°ë¥¼ ìˆ˜ì •í•  ìˆ˜ ì—†ìŒì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ KEY INSIGHT: Propensity scores control for confounding by MEASURED variables. They create a pseudo-population where treatment is unrelated to those variables. But UNMEASURED confounders remain â€” and propensity scores can create false confidence by making studies look 'rigorous' when key confounders are missing."
        }
      },
      {
        type: 'content',
        content: {
          title: "What Is a Propensity Score?",
          sections: [
            {
              heading: "Definition:",
              items: [
                "Probability of receiving treatment given observed covariates",
                "PS = P(Treatment=1 | Xâ‚, Xâ‚‚, ..., Xâ‚–)",
                "Estimated using logistic regression (or machine learning)",
                "Summarizes many confounders into a single number"
              ]
            },
            {
              heading: "Why It Works (When It Works):",
              items: [
                "Balancing property: At each PS value, treatment is 'random' with respect to covariates",
                "Creates pseudo-randomization: mimics what an RCT would do",
                "Enables comparison of 'like with like'",
                "Reduces dimensionality: many confounders â†’ one score"
              ]
            },
            {
              heading: "The Limitation:",
              items: [
                "Only balances what's IN the model",
                "Unmeasured confounders remain unbalanced",
                "Can't balance what you don't know",
                "The 'strong ignorability' assumption is UNTESTABLE"
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ì„±í–¥ ì ìˆ˜ ì ‘ê·¼ ë°©ì‹",
          title: "Four Ways to Use Propensity Scores",
          sections: [
            {
              heading: "1. MATCHING",
              text: "ìœ ì‚¬í•œ PS ê°’ì„ ê°€ì§„ ì¹˜ë£Œë°›ì€ í™˜ìì™€ ì¹˜ë£Œë°›ì§€ ì•Šì€ í™˜ìë¥¼ ì—°ê²°í•©ë‹ˆë‹¤. + ì§ê´€ì ì´ê³  íˆ¬ëª…í•˜ë©° ì¼ì¹˜í•˜ì§€ ì•ŠëŠ” í™˜ìë¥¼ íê¸°í•©ë‹ˆë‹¤. âˆ’ ì œëŒ€ë¡œ ìˆ˜í–‰ë˜ì§€ ì•Šìœ¼ë©´ í¸í–¥ì´ ì¦ê°€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤(King & Nielsen)"
            },
            {
              heading: "2. STRATIFICATION",
              text: "Divide population into strata (e.g., quintiles) by PS.\n+ Simple, uses all data\nâˆ’ Residual confounding within strata\nâˆ’ Fewer strata = more bias; more = sparse data"
            },
            {
              heading: "3. INVERSE PROBABILITY WEIGHTING (IPTW)",
              text: "Weight patients by inverse of their PS.\n+ Uses all data, estimates population effect\nâˆ’ Extreme weights cause instability\nâˆ’ Sensitive to model misspecification"
            },
            {
              heading: "4. COVARIATE ADJUSTMENT",
              text: "Include PS as covariate in outcome model.\n+ Simple to implement\nâˆ’ Less efficient than other methods\nâˆ’ Doesn't check balance directly"
            },
            {
              heading: "Modern Preference:",
              text: "ì•ˆì •í™”ëœ ê°€ì¤‘ì¹˜ ë˜ëŠ” ì¤‘ì²© ê°€ì¤‘ì¹˜ê°€ ì„ í˜¸ë˜ëŠ” IPTW. ë§¤ì¹­ì´ ì ì  ë¹„íŒì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ëª¨ë“  ë°©ë²•ì—ëŠ” ì¢‹ì€ ê³µë³€ëŸ‰ ì„ íƒê³¼ ë¯¼ê°ë„ ë¶„ì„ì´ í•„ìš”í•©ë‹ˆë‹¤."
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "Checking Balance: The Key Diagnostic",
          sections: [
            {
              heading: "Standardized Mean Difference (SMD):",
              items: [
                "SMD = (mean_treated - mean_control) / pooled_SD",
                "Before PS adjustment: expect large SMDs (confounding)",
                "After PS adjustment: SMDs should be <0.1 (balanced)",
                "If SMDs remain large, PS failed to balance"
              ]
            },
            {
              heading: "What to Check:",
              items: [
                "Balance on ALL measured confounders (not just PS)",
                "Balance on important interactions and non-linearities",
                "Overlap: both groups should have similar PS distributions",
                "ê²¹ì¹¨ì´ ì—†ìœ¼ë©´ íš¨ê³¼ë¥¼ ì¶”ì •í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤."
              ]
            },
            {
              heading: "Red Flags:",
              items: [
                "SMD >0.1 after adjustment = residual imbalance",
                "Non-overlapping PS distributions = positivity violation",
                "Extreme weights (>10 or <0.1) = instability",
                "Results sensitive to PS model specification = fragile"
              ]
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "IPTW Deep Dive: Modern Weighting Methods",
          sections: [
            {
              heading: "Standard IPTW (Inverse Probability of Treatment Weighting)",
              items: [
                "Weight for treated: w = 1/PS",
                "Weight for untreated: w = 1/(1-PS)",
                "Creates pseudo-population where treatment is independent of covariates",
                "Estimates AVERAGE TREATMENT EFFECT (ATE) in full population",
                "Problem: extreme weights when PS near 0 or 1"
              ]
            },
            {
              heading: "Stabilized Weights (sw-IPTW)",
              items: [
                "Treated: sw = P(T=1)/PS",
                "Untreated: sw = P(T=0)/(1-PS)",
                "Numerator stabilizes by multiplying by marginal probability",
                "Reduces variance, preserves sample size interpretation",
                "Preferred over standard IPTW in modern practice"
              ]
            },
            {
              heading: "Overlap Weights (OW) â€” Modern Favorite",
              items: [
                "Treated: w = 1-PS",
                "Untreated: w = PS",
                "Targets patients with clinical equipoise (PS near 0.5)",
                "Automatically handles extreme PS â€” no trimming needed",
                "Estimates effect in population where treatment decision is uncertain",
                "Best balance properties; increasingly recommended"
              ]
            },
            {
              heading: "Weight Diagnostics:",
              items: [
                "Check weight distribution (mean, max, SD)",
                "Mean of weights should â‰ˆ 1 for stabilized",
                "Truncate at 99th percentile if extreme (but acknowledge sensitivity)",
                "Plot weighted SMDs â€” all should be <0.1",
                "Effective sample size: ESS = (Î£w)Â²/Î£wÂ² â€” watch for low ESS"
              ]
            },
            {
              heading: "When to Use Which:",
              text: "IPTW/stabilized: want population-average effect, have good overlap. Overlap weights: extreme PS values, want robust estimates, uncertain treatment decisions. Matching: want intuitive comparison, can afford data loss. Avoid matching if sample is small or effect heterogeneity matters."
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'propensity-decision',
          title: "ì„±í–¥ ì ìˆ˜ ê²°ì •",
          situation: "You're analyzing whether a new anticoagulant (vs warfarin) reduces stroke in atrial fibrillation. You have data on age, sex, comorbidities, and CHAâ‚‚DSâ‚‚-VASc score. You DON'T have data on: renal function, patient frailty, or reason for drug choice.",
          nodes: {
            start: {
              question: "ì„±í–¥ ì ìˆ˜ ë§¤ì¹­ì„ ì‚¬ìš©í•  ê³„íšì…ë‹ˆë‹¤. ê°€ì¥ ë¨¼ì € í™•ì¸í•´ì•¼ í•  ê²ƒì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "Whether the propensity score model is statistically significant", nextNode: "sig_wrong" },
                { text: "Whether covariates are balanced after matching (SMDs <0.1)", nextNode: "balance_correct" },
                { text: "Whether the treatment effect is statistically significant", nextNode: "effect_wrong" }
              ]
            },
            balance_correct: {
              situation: "Correct! After matching, your SMDs are all <0.1. But you're worried about unmeasured confounding (renal function, frailty). What should you do?",
              question: "How do you address unmeasured confounding?",
              branches: [
                { text: "Add more measured variables to the PS model", nextNode: "more_vars" },
                { text: "ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ì— ëŒ€í•œ ë¯¼ê°ë„ ë¶„ì„ ìˆ˜í–‰", nextNode: "sensitivity_correct" },
                { text: "ì¼ì¹˜ëœ ê²°ê³¼ë¥¼ 'êµë€ì— ëŒ€í•´ ì¡°ì •ë¨'ìœ¼ë¡œ ë³´ê³ ", nextNode: "report_wrong" }
              ]
            },
            sig_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Wrong focus!",
              text: "PS ëª¨ë¸ì˜ í†µê³„ì  ìœ ì˜ì„±ì€ ë¶€ì í•©í•©ë‹ˆë‹¤. ì¹˜ë£Œê°€ 'ì˜ˆì¸¡ ê°€ëŠ¥í•œì§€' ì—¬ë¶€ëŠ” ì¤‘ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê³µë³€ëŸ‰ì´ ê· í˜•ì„ ì´ë£¨ê³  ìˆëŠ”ì§€ ì—¬ë¶€ëŠ” ì¤‘ìš”í•©ë‹ˆë‹¤. ë§¤ìš° ì¤‘ìš”í•œ PS ëª¨ë¸ì€ ì—¬ì „íˆ â€‹â€‹ì£¼ìš” í˜¼ë€ ìš”ì†Œì˜ ê· í˜•ì„ ë§ì¶”ì§€ ëª»í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ì„±í–¥ ì ìˆ˜ ëª¨ë¸ì€ p-ê°’ì´ë‚˜ c-í†µê³„ê°€ ì•„ë‹Œ ë‹¬ì„±ëœ ê· í˜•ìœ¼ë¡œ íŒë‹¨ë©ë‹ˆë‹¤. ëª¨ë¸ ì í•©ì„±ì´ ì•„ë‹Œ SMDë¥¼ í™•ì¸í•˜ì‹­ì‹œì˜¤."
            },
            effect_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Wrong order!",
              text: "ê· í˜•ì„ í™•ì¸í•˜ê¸° ì „ì—ëŠ” ì¹˜ë£Œ íš¨ê³¼ë¥¼ ì‚´í´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ê³µë³€ëŸ‰ì´ ê· í˜•ì„ ì´ë£¨ì§€ ì•Šìœ¼ë©´ íš¨ê³¼ ì¶”ì •ì¹˜ê°€ í¸í–¥ë©ë‹ˆë‹¤. íš¨ê³¼ë¥¼ ë¨¼ì € ì‚´í´ë³´ë©´ ì›í•˜ëŠ” ë‹µì„ ì–»ì„ ë•Œê¹Œì§€ ê³„ì† ì¡°ì •í•˜ê³  ì‹¶ì€ ìœ í˜¹ì„ ëŠë‚„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ì¹˜ë£Œ íš¨ê³¼ë¥¼ ê²€í† í•˜ê¸° ì „ì— í•­ìƒ ê· í˜•ì„ í™•ì¸í•˜ì„¸ìš”. PS ì ‘ê·¼ ë°©ì‹ê³¼ ê· í˜• ê¸°ì¤€ì„ ë¯¸ë¦¬ ì§€ì •í•˜ì„¸ìš”."
            },
            more_vars: {
              type: 'outcome',
              outcome: 'partial',
              title: "Helpful but insufficient",
              text: "ì¸¡ì • ë³€ìˆ˜ë¥¼ ì¶”ê°€í•˜ë©´ ë„ì›€ì´ ë  ìˆ˜ ìˆì§€ë§Œ ì‹ ì¥ ê¸°ëŠ¥ê³¼ ë…¸ì‡ ê°€ ì¸¡ì •ë˜ì§€ ì•ŠëŠ”ë‹¤ê³  ë§ì”€í•˜ì…¨ìŠµë‹ˆë‹¤. ê°€ì§€ê³  ìˆì§€ ì•Šì€ ê²ƒì„ ì¶”ê°€í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ê²°ë¡ ì„ ë³€ê²½í•˜ëŠ” ë° ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ì´ ì–¼ë§ˆë‚˜ í•„ìš”í•œì§€ í‰ê°€í•˜ë ¤ë©´ ë¯¼ê°ë„ ë¶„ì„ì´ í•„ìš”í•©ë‹ˆë‹¤.",
              lesson: "ì¸¡ì •í•˜ì§€ ì•Šì€ í•­ëª©ì€ ì¡°ì •í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ë¯¼ê°ë„ ë¶„ì„ì€ ëˆ„ë½ëœ í•­ëª©ì˜ ì ì¬ì  ì˜í–¥ì„ ì •ëŸ‰í™”í•©ë‹ˆë‹¤."
            },
            sensitivity_correct: {
              situation: "í›Œë¥­í•©ë‹ˆë‹¤! E-ê°’ì„ ì‚¬ìš©í•˜ì—¬ ë¯¼ê°ë„ ë¶„ì„ì„ ì‹¤í–‰í•©ë‹ˆë‹¤. ê²°ê³¼ëŠ” HR 0.75(0.65-0.87)ì…ë‹ˆë‹¤. E-ê°’ì€ 1.82ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë¬´ì—‡ì„ ì˜ë¯¸í•©ë‹ˆê¹Œ?",
              question: "Interpretation:",
              branches: [
                { text: "ì¹˜ë£Œì™€ ê²°ê³¼ ëª¨ë‘ì—ì„œ RR â‰¥1.82ì¸ ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ë³€ìˆ˜ëŠ” íš¨ê³¼ë¥¼ ì„¤ëª…í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤.", nextNode: "evalue_correct" },
                { text: "The result is robust because 1.82 is a large number", nextNode: "evalue_partial" }
              ]
            },
            report_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Misleading claim!",
              text: "'í˜¼ë€ì— ëŒ€í•´ ì¡°ì •ë¨'ìœ¼ë¡œ ë³´ê³ í•˜ëŠ” ê²ƒì€ ëª¨ë“  í˜¼ë€ì´ í•´ê²°ë˜ì—ˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì„±í–¥ ì ìˆ˜ëŠ” ì¸¡ì •ëœ ë³€ìˆ˜ë§Œ ê· í˜•ì„ ì´ë£¹ë‹ˆë‹¤. ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ë³€ìˆ˜(ì‹ ì¥ ê¸°ëŠ¥, ë…¸ì‡ , ì±„ë„ë§)ë¥¼ ì‚¬ìš©í•˜ë©´ ì¶”ì •ì¹˜ê°€ ì—¬ì „íˆ ì‹¬ê°í•˜ê²Œ í¸í–¥ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "Always state: 'Adjusted for MEASURED confounders.' Acknowledge what's missing. Never claim full adjustment."
            },
            evalue_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Perfect interpretation!",
              text: "E-ê°’ì€ ê²¬ê³ ì„±ì„ ì •ëŸ‰í™”í•©ë‹ˆë‹¤. ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ë³€ìˆ˜ëŠ” ê²°ê³¼ë¥¼ ì™„ì „íˆ ì„¤ëª…í•˜ê¸° ìœ„í•´ ë…¸ì¶œê³¼ ê²°ê³¼ê°€ ëª¨ë‘ í¬í•¨ëœ RR â‰¥1.82ê°€ í•„ìš”í•©ë‹ˆë‹¤. ì´ì œ ë‹¤ìŒê³¼ ê°™ì´ ì§ˆë¬¸í•´ì•¼ í•©ë‹ˆë‹¤. 'RR 1.82ì˜ í˜¼ë€ ìš”ì¸ì´ íƒ€ë‹¹í•œê°€?' í•­ì‘ê³ ì œ ì„ íƒê³¼ ë‡Œì¡¸ì¤‘ ëª¨ë‘ì— ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ì‹ ì¥ ê¸°ëŠ¥ì˜ ê²½ìš° â€” ê·¸ëŸ´ ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤.",
              lesson: "E-values don't prove causation. They help you assess: 'How strong would hidden bias need to be?' Compare to known confounder strengths."
            },
            evalue_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Needs context!",
              text: "1.82ê°€ 'í°'ì§€ ì—¬ë¶€ëŠ” ìƒí™©ì— ë”°ë¼ ë‹¤ë¦…ë‹ˆë‹¤. í¡ì—°ì€ íì•”ì˜ ê²½ìš° RR ~20, ì‹¬ì¥ë³‘ì˜ ê²½ìš° ~2-3ì…ë‹ˆë‹¤. ì‹ ì¥ ê¸°ëŠ¥ì˜ ë‡Œì¡¸ì¤‘ì— ëŒ€í•œ RR 1.5-2ê°€ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì„ì˜ì˜ ì„ê³„ê°’ì´ ì•„ë‹Œ ê·¸ëŸ´ë“¯í•œ í˜¼ë€ ìš”ì¸ ê°•ë„ì™€ ë¹„êµí•´ì•¼ í•©ë‹ˆë‹¤.",
              lesson: "E-ê°’ì—ëŠ” ì„ìƒì  íŒë‹¨ì´ í•„ìš”í•©ë‹ˆë‹¤. 1.82ëŠ” ë³¸ì§ˆì ìœ¼ë¡œ ê²¬ê³ í•˜ê±°ë‚˜ ì·¨ì•½í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ëŠ” ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ ìš”ì¸ì´ ë¬´ì—‡ì¸ì§€, ê·¸ê²ƒì´ ì–¼ë§ˆë‚˜ ê°•í•œì§€ì— ë”°ë¼ ë‹¤ë¦…ë‹ˆë‹¤."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "After propensity score matching, you achieve perfect balance (all SMDs <0.1) on 15 measured covariates. You can now conclude:",
          options: [
            { id: 'a', text: "ì¹˜ë£Œ íš¨ê³¼ëŠ” êµë€ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤.", correct: false },
            { id: 'b', text: "ì¹˜ë£Œ íš¨ê³¼ëŠ” 15ê°œì˜ ì¸¡ì •ëœ ê³µë³€ëŸ‰ì— ì˜í•´ êµë€ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤.", correct: true },
            { id: 'c', text: "ì´ ì—°êµ¬ëŠ” RCT", correct: false },
            { id: 'd', text: "Unmeasured confounding has been addressed", correct: false }
          ],
          explanation: "ì„±í–¥ ì ìˆ˜ëŠ” ëª¨ë¸ì— ìˆëŠ” ë‚´ìš©ì˜ ê· í˜•ë§Œ ìœ ì§€í•©ë‹ˆë‹¤. 15ê°œ ê³µë³€ëŸ‰ì˜ ì™„ë²½í•œ ê· í˜•ì€ í•´ë‹¹ 15ê°œê°€ ë” ì´ìƒ í˜¼ë€ìŠ¤ëŸ¬ìš´ ë³€ìˆ˜ê°€ ì•„ë‹ˆë¼ëŠ” ê²ƒì„ ì˜ë¯¸í•˜ì§€ë§Œ ì¸¡ì •ë˜ì§€ ì•Šì€ ë³€ìˆ˜ì— ëŒ€í•´ì„œëŠ” ì•„ë¬´ ì˜ë¯¸ë„ ì—†ìŠµë‹ˆë‹¤. ë¬´ì‘ìœ„ ë°°ì •ì€ ì¸¡ì •ëœ ê²ƒê³¼ ì¸¡ì •ë˜ì§€ ì•Šì€ ëª¨ë“  í˜¼ë€ ìš”ì¸ì˜ ê· í˜•ì„ ë§ì¶”ê¸° ë•Œë¬¸ì— RCTì™€ ë™ë“±í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤."
        }
      },
      {
        type: 'content',
        content: {
          title: "Negative Control Outcomes: Testing Your Adjustment",
          sections: [
            {
              heading: "The Brilliant Idea:",
              items: [
                "ë…¸ì¶œì´ ê·¸ëŸ´ë“¯í•˜ê²Œ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ì—†ëŠ” ê²°ê³¼ë¥¼ ì„ íƒí•˜ì„¸ìš”",
                "ë¶„ì„ì´ ì´ ìŒì„± ëŒ€ì¡°êµ°ì— 'íš¨ê³¼'ë¥¼ ë‚˜íƒ€ë‚´ëŠ” ê²½ìš° â†’ ì”ë¥˜ í˜¼ë€ì´ ìˆëŠ” ê²ƒì…ë‹ˆë‹¤",
                "ì˜ˆ: ìŠ¤íƒ€í‹´ ìë™ì°¨ ì‚¬ê³ ì— ì˜í–¥ì„ ì£¼ì–´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ìŠ¤íƒ€í‹´ ì—°êµ¬ì—ì„œ ìŠ¤íƒ€í‹´ ì‚¬ìš©ìì˜ ìë™ì°¨ ì‚¬ê³ ê°€ ë” ì ì€ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚˜ë©´ â†’ í˜¼ë€ìŠ¤ëŸ½ìŠµë‹ˆë‹¤(ê±´ê°•í•œ ì‚¬ëŒë“¤ì´ ìŠ¤íƒ€í‹´ì„ ë³µìš©í•˜ê³  ì•ˆì „í•˜ê²Œ ìš´ì „í•¨)"
              ]
            },
            {
              heading: "How It Works:",
              items: [
                "Same exposure, same adjustment, different outcome",
                "Negative control outcome should share confounders with primary outcome",
                "But exposure has no biological pathway to negative control",
                "Association with negative control = confounding signal"
              ]
            },
            {
              heading: "Real Example:",
              items: [
                "Study: Do ACE inhibitors reduce COVID mortality?",
                "Primary outcome: COVID death",
                "Negative control: Injuries/accidents",
                "If ACE inhibitors 'reduce' injuries too â†’ healthy user confounding",
                "Used in major COVID-19 pharmacoepidemiology studies"
              ]
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'negative-control-design',
          title: "Design a Negative Control Test",
          situation: "ë…ê° ë°±ì‹  ì ‘ì¢…ì´ ì‹¬í˜ˆê´€ ì‚¬ê±´ì„ ê°ì†Œì‹œí‚¤ëŠ”ì§€ ì—¬ë¶€ë¥¼ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìŒì„± ëŒ€ì¡°êµ°ì„ ì‚¬ìš©í•˜ì—¬ ê±´ê°•í•œ ë°±ì‹ ì ‘ì¢…ì êµë€ì„ í…ŒìŠ¤íŠ¸í•˜ë ¤ê³  í•©ë‹ˆë‹¤.",
          nodes: {
            start: {
              question: "Which outcome would be a good NEGATIVE CONTROL for flu vaccine â†’ cardiovascular events?",
              branches: [
                { text: "Pneumonia hospitalization", nextNode: "pneumonia_wrong" },
                { text: "Hip fracture", nextNode: "hip_correct" },
                { text: "Diabetes diagnosis", nextNode: "diabetes_wrong" }
              ]
            },
            pneumonia_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì¢‹ì€ ìŒì„± ëŒ€ì¡°êµ°ì´ ì•„ë‹™ë‹ˆë‹¤!",
              text: "Flu vaccine MIGHT actually prevent pneumonia (flu can lead to secondary bacterial pneumonia). A negative control must be an outcome the exposure CANNOT plausibly affect. Pneumonia is biologically related to flu.",
              lesson: "ìŒì„± ëŒ€ì¡°êµ°ì—ëŠ” ë…¸ì¶œë¡œ ì¸í•œ ìƒë¬¼í•™ì  ê²½ë¡œê°€ ì—†ì–´ì•¼ í•©ë‹ˆë‹¤. ê·¸ëŸ´ë“¯í•œ ë©”ì»¤ë‹ˆì¦˜ì´ ìˆë‹¤ë©´ ê·¸ê²ƒì€ ìœ íš¨í•œ ì œì–´ê°€ ì•„ë‹™ë‹ˆë‹¤."
            },
            hip_correct: {
              situation: "í›Œë¥­í•œ ì„ íƒì…ë‹ˆë‹¤! ë…ê° ë°±ì‹ ì—ëŠ” ê³ ê´€ì ˆ ê³¨ì ˆì— ëŒ€í•œ ìƒë¬¼í•™ì  ê²½ë¡œê°€ ì—†ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ê³ ê´€ì ˆ ê³¨ì ˆì€ ì‹¬í˜ˆê´€ ì‚¬ê±´(ë‚˜ì´, í—ˆì•½í•¨, ê±´ê°• ì¶”êµ¬ í–‰ë™)ê³¼ í˜¼ë™ë˜ëŠ” ìš”ì†Œë¥¼ ê³µìœ í•©ë‹ˆë‹¤. ì´ì œ ë…ê° ì˜ˆë°©ì ‘ì¢…ì´ ê³ ê´€ì ˆ ê³¨ì ˆì„ 20% ê°ì†Œì‹œí‚¤ëŠ” ê²ƒê³¼ ê´€ë ¨ì´ ìˆë‹¤ëŠ” ì‚¬ì‹¤ì„ ì•Œê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤(RR 0.80).",
              question: "ì´ê²ƒì´ ì‹¬í˜ˆê´€ ê²€ì‚¬ ê²°ê³¼ì— ëŒ€í•´ ë¬´ì—‡ì„ ë§í•´ì£¼ëŠ”ê°€?",
              branches: [
                { text: "Flu vaccine might actually prevent fractures too â€” it's beneficial!", nextNode: "beneficial_wrong" },
                { text: "You have unmeasured confounding â€” healthy vaccinees have better outcomes generally", nextNode: "confounding_correct" }
              ]
            },
            diabetes_wrong: {
              type: 'outcome',
              outcome: 'partial',
              title: "ê°€ëŠ¥í•˜ì§€ë§Œ ì´ìƒì ì´ì§€ ì•ŠìŒ",
              text: "ë‹¹ë‡¨ë³‘ ì§„ë‹¨ì€ ë§Œì„±ì ì´ë©° í˜¼ë€ìŠ¤ëŸ¬ìš´ ìš”ì†Œë¥¼ ê³µìœ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹œê¸°ê°€ ê¹Œë‹¤ë¡­ìŠµë‹ˆë‹¤. ì˜ˆë°©ì ‘ì¢… í›„ ìƒˆë¡œìš´ ê²°ê³¼ê°€ í•„ìš”í•©ë‹ˆë‹¤. ë§Œì„± ì§ˆí™˜ì€ ì •í™•í•œ ì‹œê¸°ë¥¼ íŒŒì•…í•˜ê¸°ê°€ ë” ì–´ë µìŠµë‹ˆë‹¤. ê³ ê´€ì ˆ ê³¨ì ˆì´ë‚˜ ì‚¬ê³ ëŠ” ê¸‰ì„± ì‚¬ê±´ì´ê¸° ë•Œë¬¸ì— ë” ì¢‹ìŠµë‹ˆë‹¤.",
              lesson: "Good negative controls are: (1) acute (clear timing), (2) share confounders with primary outcome, (3) have no biological link to exposure."
            },
            beneficial_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì´ í˜¼ë€ìŠ¤ëŸ¬ìš´ í•¨ì •ì…ë‹ˆë‹¤!",
              text: "There is NO biological mechanism by which flu vaccine prevents hip fractures. The 'benefit' is confounding: people who get vaccinated are healthier, more mobile, less frail, and less likely to fall. This SAME confounding affects your cardiovascular finding.",
              lesson: "ìŒì„± ëŒ€ì¡°êµ°ì— 'íš¨ê³¼'ê°€ í‘œì‹œë˜ë©´ ì£¼ìš” ë¶„ì„ì´ í˜¼ë€ìŠ¤ëŸ¬ìš´ ê²ƒì…ë‹ˆë‹¤. ìŒì„± ëŒ€ì¡° íš¨ê³¼ì˜ í¬ê¸°ëŠ” í¸í–¥ì˜ í¬ê¸°ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤."
            },
            confounding_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Exactly right!",
              text: "ì¸í”Œë£¨ì—”ì ë°±ì‹ ì´ ê³ ê´€ì ˆ ê³¨ì ˆì„ 'ì˜ˆë°©'í•˜ê³ (RR 0.80) ìƒë¬¼í•™ì  ë©”ì»¤ë‹ˆì¦˜ì´ ì—†ë‹¤ë©´ ê´€ì°°ëœ íš¨ê³¼ì˜ ~20%ëŠ” ê±´ê°•í•œ ë°±ì‹ ì ‘ì¢…ì êµë€ìœ¼ë¡œ ì¸í•œ ê²ƒì…ë‹ˆë‹¤. 0.70ì˜ ì‹¬í˜ˆê´€ RRì€ ì‹¤ì œë¡œ 0.88(RR/0.80)ì— ê°€ê¹Œìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìŒì„± ëŒ€ì¡°êµ°ì€ í¸ê²¬ì„ ì •ëŸ‰í™”í•©ë‹ˆë‹¤.",
              lesson: "Negative controls are diagnostic. Use them to: (1) detect confounding, (2) estimate its magnitude, (3) potentially calibrate your main estimate. This is essential for credible observational research."
            }
          }
        }
      },
      {
        type: 'principle',
        content: {
          text: "âš ï¸ THE WARNING: Propensity scores are TOOLS, not magic wands. They balance what you measure. They create false confidence when you haven't measured the key confounders. Always ask: 'What would a negative control show?' If your exposure 'prevents' outcomes it biologically cannot affect, your adjustment has failed."
        }
      }
    ]
  },
  // MODULE 7: THE TARGET TRIAL (Target Trial Emulation)
  {
    id: 7,
    title: "í‘œì  ì‹œí—˜",
    subtitle: "Emulating RCTs",
    principle: 1,
    estimatedTime: "25 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "ì—°ê´€ì„±ì€ ì¸ê³¼ê´€ê³„ê°€ ì•„ë‹™ë‹ˆë‹¤"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ëª…í™•: ì•„ìŠ¤í”¼ë¦°ê³¼ ì•” â€” í”„ë ˆì´ë°ì´ ëª¨ë“  ê²ƒì„ ë³€í™”ì‹œì¼°ì„ ë•Œ",
          source: "HernÃ¡n & Robins | Am J Epidemiol 2016 | Target trial framework",
          timeline: [
            { year: "1990s-2000s", text: "ì•„ìŠ¤í”¼ë¦°ê³¼ ì•”ì— ëŒ€í•œ ê´€ì°° ì—°êµ¬ëŠ” ì¼ê´€ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì¼ë¶€ëŠ” ë³´í˜¸ë¥¼ í‘œì‹œí•˜ê³  ì¼ë¶€ëŠ” í‘œì‹œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê¸°ê°„, ì¸êµ¬, ì •ì˜ê°€ ë‹¤ë¦…ë‹ˆë‹¤.", type: "normal" },
            { year: "The Problem", text: "ê° ì—°êµ¬ì—ì„œ ì•½ê°„ ë‹¤ë¥¸ ì§ˆë¬¸ì„ í–ˆìŠµë‹ˆë‹¤. 'ì•„ìŠ¤í”¼ë¦°ì´ ì•”ì„ ì˜ˆë°©í•˜ë‚˜ìš”?' ëª¨í˜¸í•˜ë‹¤. ì–´ë–¤ ì•„ìŠ¤í”¼ë¦° ì²˜ë°©ì„ í•˜ë‚˜ìš”? ëˆ„êµ¬ì—ê²Œ? ì–¸ì œ ì‹œì‘ë˜ì—ˆë‚˜ìš”? ë¬´ì—‡ê³¼ ë¹„êµí•˜ë©´?", type: "crisis" },
            { year: "Target Trial", text: "Specify the RCT you WISH you could do: eligibility (healthy adults 50-70), intervention (aspirin 75mg daily), comparator (no aspirin), outcomes (cancer incidence at 10 years), time zero.", type: "revelation" },
            { year: "Emulation", text: "ì´ì œ ì´ê²ƒì´ ì´ ì‹¤í—˜ì¸ ê²ƒì²˜ëŸ¼ ê´€ì°° ë°ì´í„°ë¥¼ ë¶„ì„í•˜ì‹­ì‹œì˜¤. 0ì‹œì— í™˜ìë¥¼ ë³µì œí•©ë‹ˆë‹¤. ìê²© ê¸°ì¤€ì„ ì ìš©í•©ë‹ˆë‹¤. ë™ì¼í•œ ì‹œì‘ì ì—ì„œ ì¶”ì í•©ë‹ˆë‹¤. ë™ì¼í•œ ê²°ê³¼ë¥¼ ë¹„êµí•˜ì„¸ìš”.", type: "revelation" },
            { year: "Resolution", text: "SAME ëŒ€ìƒ ì„ìƒì‹œí—˜ì„ ì—ë®¬ë ˆì´ì…˜í•œ ì—°êµ¬ì—ì„œ ê²°ê³¼ëŠ” ì¼ê´€ë˜ì—ˆìŠµë‹ˆë‹¤. ë¶ˆì¼ì¹˜ëŠ” ì„œë¡œ ë‹¤ë¥¸(ì¢…ì¢… ì•”ì‹œì ì¸) ì—°êµ¬ ì§ˆë¬¸ìœ¼ë¡œ ì¸í•´ ë°œìƒí–ˆìŠµë‹ˆë‹¤.", type: "revelation" },
            { year: "Lesson", text: "ê´€ì°° ë°ì´í„°ë¥¼ ë¶„ì„í•˜ê¸° ì „ì— ëŒ€ìƒ ì„ìƒì‹œí—˜ì„ ì§€ì •í•˜ì„¸ìš”. ì´ë¥¼ í†µí•´ ê°€ì •ì´ ëª…í™•í•´ì§€ê³  ì¼ë°˜ì ì¸ í¸ê²¬ì´ ë°©ì§€ë˜ë©° ì—°êµ¬ ê°„ ë¹„êµê°€ ê°€ëŠ¥í•´ì§‘ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "Cancer incidence/mortality",
            drug: "Aspirin (various regimens)",
            placebo: "No aspirin (various comparators)",
            rr: "Ranged HR 0.70 to 1.20 depending on implicit trial",
            ci: "Clarified once target trial specified",
            nnh: "Decades of confusion from ambiguous questions"
          },
          hook: "THE HOOK: 'Does aspirin prevent cancer?' isn't a research question â€” it's a family of questions. Target trial emulation forces you to be precise: WHICH intervention, in WHOM, compared to WHAT, measured HOW. Precision enables causal inference."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ KEY INSIGHT: Every observational analysis implicitly emulates SOME randomized trial. The target trial framework makes this explicit. By specifying eligibility, interventions, outcomes, and time zero BEFORE analysis, you prevent biases like immortal time, prevalent user bias, and confounding by indication."
        }
      },
      {
        type: 'story-box',
        content: {
          icon: 'ğŸ¯',
          title: "The Target Trial Emulation Revolution",
          source: "Hernan & Robins, Am J Epidemiol 2016 | Causal Inference Framework",
          paragraphs: [
            "In 2016, Miguel Hernan and James Robins formalized a methodological revolution: 'target trial emulation.' The idea was deceptively simpleâ€”design your observational analysis as if it were the RCT you wish you could do.",
            "They applied this to a contentious question: do statins prevent death in primary prevention? Traditional observational methods showed a 25% mortality reduction. But when analyzed using target trial emulationâ€”proper time zero, new-user design, clear eligibilityâ€”the benefit dropped to 15%.",
            "The 10-percentage-point difference wasn't noiseâ€”it was bias that traditional methods had missed. Immortal time, prevalent user bias, and unclear time zero had all inflated the apparent benefit. Target trial emulation didn't just give a different answer; it gave a more honest one."
          ],
          lesson: "Target trial emulation is reshaping observational research. By forcing explicit specification of eligibility, interventions, time zero, and outcomes BEFORE analysis, it prevents the biases that have historically made observational studies unreliable. It's not a statistical trickâ€”it's a framework for honest causal thinking."
        }
      },
      {
        type: 'content',
        content: {
          title: "íƒ€ê²Ÿ ì‹œí—˜ í”„ë ˆì„ì›Œí¬",
          sections: [
            {
              heading: "Step 1: Specify the Protocol (7 Components):",
              items: [
                "1. ELIGIBILITY: Who would be enrolled?",
                "2. INTERVENTIONS: What treatments, at what doses?",
                "3. ASSIGNMENT: How would randomization work?",
                "4. TIME ZERO: When does follow-up start?",
                "5. OUTCOMES: What do you measure, and when?",
                "6. FOLLOW-UP: How long do you track patients?",
                "7. ë¶„ì„: ì¹˜ë£Œ ì˜ë„? í”„ë¡œí† ì½œë³„?"
              ]
            },
            {
              heading: "Step 2: Emulate with Observational Data:",
              items: [
                "Apply eligibility criteria to your database",
                "Define time zero (same for all patients!)",
                "Classify exposure at time zero (not after)",
                "Use methods to handle confounding (PS, IPW)",
                "RCTì™€ ë§ˆì°¬ê°€ì§€ë¡œ ë¶„ì„"
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ëª©í‘œ ì‹œí—˜ì„ í†µí•œ í¸í–¥ ë°©ì§€",
          title: "How Specification Prevents Bias",
          sections: [
            {
              heading: "Prevents IMMORTAL TIME BIAS:",
              text: "ì‹œê°„ 0ì„ ì •ì˜í•˜ë©´ ìƒì¡´ ì‹œê°„ì„ ë…¸ì¶œ ì‹œê°„ìœ¼ë¡œ ì˜ëª» ë¶„ë¥˜í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ëª¨ë“  ì‚¬ëŒì˜ ì‹œê³„ëŠ” ì¹˜ë£Œë¥¼ ë°›ì€ ë•Œê°€ ì•„ë‹ˆë¼ ë™ì¼í•œ ì‹œì (ìê²© + ì¹˜ë£Œ í• ë‹¹)ì— ì‹œì‘ë©ë‹ˆë‹¤."
            },
            {
              heading: "Prevents PREVALENT USER BIAS:",
              text: "í‘œì  ì„ìƒì‹œí—˜ì€ RCTì™€ ë§ˆì°¬ê°€ì§€ë¡œ ì‹ ê·œ ì‚¬ìš©ìë¥¼ ì§€ì •í•©ë‹ˆë‹¤. ë°©ê¸ˆ ì‹œì‘í•œ(ì‚¬ê±´) ì‚¬ëŒê³¼ ìˆ˜ë…„ê°„ ì¹˜ë£Œë¥¼ ë°›ì€ ì‚¬ëŒ(ë³´í†µ)ì„ ì„ì§€ ë§ˆì‹­ì‹œì˜¤. í‰ê°€íŒì—ëŠ” ì¼ë°˜ ì‚¬ìš©ìê°€ ë“±ë¡ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤."
            },
            {
              heading: "Prevents CONFOUNDING BY INDICATION:",
              text: "Eligibility criteria define who could receive either treatment. Propensity scores or IPW handle remaining confounding. You're comparing 'like with like' at time zero."
            },
            {
              heading: "Ensures CLEAR OUTCOMES:",
              text: "ê²°ê³¼ í‰ê°€ëŠ” ì„ í—˜ì ìœ¼ë¡œ ì •ì˜ë©ë‹ˆë‹¤. ë°ì´í„°ë¥¼ ë³¸ í›„ì—ëŠ” ì—”ë“œí¬ì¸íŠ¸ë¥¼ ë³€ê²½í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ë¶„ì„ ê³„íšì—ëŠ” í‘œì  ì„ìƒì‹œí—˜ í”„ë¡œí† ì½œì´ ê³ ì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤."
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "Time Zero: The Critical Concept",
          sections: [
            {
              heading: "What Is Time Zero?",
              items: [
                "ê°€ì„¤ ì„ìƒì‹œí—˜ì´ ë¬´ì‘ìœ„í™”ë˜ëŠ” ìˆœê°„",
                "ë¶„ì„ì˜ ëª¨ë“  í™˜ìì— ëŒ€í•´ ë™ì¼í•´ì•¼ í•©ë‹ˆë‹¤",
                "MUST be when exposure status is assigned",
                "Follow-up starts AT time zero, not before"
              ]
            },
            {
              heading: "Common Mistakes:",
              items: [
                "Using 'ever vs never' exposure (no time zero)",
                "Starting follow-up at diagnosis but assigning exposure later",
                "Mixing incident and prevalent users",
                "Different time zeros for different groups"
              ]
            },
            {
              heading: "Example: Statins After MI",
              items: [
                "Target trial: Randomize at hospital discharge",
                "Emulation: Time zero = discharge date",
                "Assign statin status AT DISCHARGE (not later prescriptions)",
                "í‡´ì›ë¶€í„° ê²°ê³¼ê¹Œì§€ ë”°ë¥´ì„¸ìš”",
                "This prevents immortal time bias"
              ]
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'target-trial-design',
          title: "ëª©í‘œ ì„¤ê³„ ì‹œí—˜",
          situation: "ì‹¬ì¥ë§ˆë¹„ í›„ ì§€ì¤‘í•´ì‹ ì‹ë‹¨ì„ ì‹œì‘í•˜ë©´ ì¼ë°˜ ì‹ë‹¨ì— ë¹„í•´ ì‚¬ë§ë¥ ì´ ê°ì†Œí•˜ëŠ”ì§€ ì—¬ë¶€ë¥¼ ì—°êµ¬í•˜ë ¤ê³  í•©ë‹ˆë‹¤. ë‹¤ì–‘í•œ ì‹œì ì˜ ì‹ì´ í‰ê°€ê°€ í¬í•¨ëœ ì „ì ê±´ê°• ê¸°ë¡ì´ ìˆìŠµë‹ˆë‹¤.",
          nodes: {
            start: {
              question: "What should be your time zero?",
              branches: [
                { text: "Date of first Mediterranean diet assessment", nextNode: "diet_date_wrong" },
                { text: "Hospital discharge after MI", nextNode: "discharge_correct" },
                { text: "Date of MI diagnosis", nextNode: "mi_date_partial" }
              ]
            },
            discharge_correct: {
              situation: "Good choice! Discharge is when a dietary intervention could plausibly start. Now, how do you define 'Mediterranean diet' exposure?",
              question: "Exposure definition:",
              branches: [
                { text: "Any Mediterranean diet assessment scored 'high' during follow-up", nextNode: "any_high_wrong" },
                { text: "Mediterranean diet score at the first post-discharge assessment", nextNode: "first_assessment_correct" },
                { text: "Sustained high Mediterranean diet score for 6+ months", nextNode: "sustained_partial" }
              ]
            },
            diet_date_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "This creates immortal time bias!",
              text: "í™˜ìëŠ” ì²« ë²ˆì§¸ ì‹ì´ í‰ê°€ê°€ 'ì§€ì¤‘í•´ ì‹ë‹¨'ìœ¼ë¡œ ë¶„ë¥˜ë  ë•Œê¹Œì§€ ìƒì¡´í•´ì•¼ í•©ë‹ˆë‹¤. MIì™€ í‰ê°€ ì‚¬ì´ì˜ ì‹œê°„ì€ ë¶ˆë©¸ì˜ ì‹œê°„ì…ë‹ˆë‹¤. ì˜ëª» ë¶„ë¥˜ë˜ë©´ ë‹¤ì´ì–´íŠ¸ ê·¸ë£¹ì˜ ìƒì¡´ìœ¨ì´ ì¸ìœ„ì ìœ¼ë¡œ ë¶€í’€ë ¤ì§‘ë‹ˆë‹¤.",
              lesson: "ì‹œê°„ 0ì€ ê°œì…ì´ ì¸¡ì •ëœ ì‹œì ì´ ì•„ë‹ˆë¼ ê°œì…ì´ ì‹œì‘ë  ìˆ˜ ìˆëŠ” ì‹œì ì´ì–´ì•¼ í•©ë‹ˆë‹¤. ì‹ì´ í‰ê°€ ë‚ ì§œëŠ” ë‹¤ì–‘í•©ë‹ˆë‹¤. ì´ë¡œ ì¸í•´ ì°¨ë“± ì‹œê°„ 0ì´ ìƒì„±ë©ë‹ˆë‹¤."
            },
            mi_date_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Reasonable but challenging",
              text: "MI ë‚ ì§œëŠ” ì‹œê°„ 0ì— ì í•©í•˜ì§€ë§Œ ì‹ì´ ìš”ë²• ì¤‘ì¬ëŠ” í™˜ìê°€ ì•ˆì •ë  ë•Œê¹Œì§€(ë³´í†µ í‡´ì›) ì‹œì‘í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. MIì—ì„œ ì‹œì‘í•˜ë©´ ì‹ì´ ë…¸ì¶œì´ ì •ì˜ë˜ì§€ ì•Šì€ ì§§ì€ 'ê¸‰ì„± ì¹˜ë£Œ' ê¸°ê°„ì„ ê°–ê²Œ ë©ë‹ˆë‹¤.",
              lesson: "ê°œì…ì´ ê°€ëŠ¥í•œ ì‹œì ì€ 0ì´ ë˜ì–´ì•¼ í•©ë‹ˆë‹¤. MI ì´í›„ ìƒí™œ ë°©ì‹ ì¤‘ì¬ì˜ ê²½ìš°, MI ìì²´ë³´ë‹¤ í‡´ì›ì´ ë” ì‹¤ìš©ì ì¸ ê²½ìš°ê°€ ë§ìŠµë‹ˆë‹¤."
            },
            any_high_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "This is immortal time bias again!",
              text: "ì¶”ì  ì¡°ì‚¬ ì¤‘ ëª¨ë“  í‰ê°€ë¡œ ë…¸ì¶œì„ ì •ì˜í•œë‹¤ëŠ” ê²ƒì€ í™˜ìê°€ í•´ë‹¹ í‰ê°€ì—ì„œ ìƒì¡´í•´ì•¼ í•¨ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. 'ìµœê³ ' ì ìˆ˜ ì´ì „ì˜ ì‹œê°„ì€ ë¶ˆë©¸ì˜ ì‹œê°„ì…ë‹ˆë‹¤. ì´ëŠ” ìŠ¤íƒ€í‹´-ì•” ì—°êµ¬ì™€ ë™ì¼í•œ í¸í–¥ì…ë‹ˆë‹¤.",
              lesson: "ë…¸ì¶œì€ ë¯¸ë˜ ì‚¬ê±´ì„ ê¸°ì¤€ìœ¼ë¡œ í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ 0ì‹œì— í• ë‹¹ë˜ì–´ì•¼ í•©ë‹ˆë‹¤. ëŒ€ìƒ ì‹œí—˜ í”„ë ˆì„ì›Œí¬ì—ì„œëŠ” í›„ì† ì¡°ì¹˜ ì¤‘ì— 'ë…¸ì¶œ'ë  ìˆ˜ ì—†ìŠµë‹ˆë‹¤."
            },
            first_assessment_correct: {
              situation: "í›Œë¥­í•´ìš”! 0ì‹œê°„ ì´í›„ ì²« ë²ˆì§¸ í‰ê°€ì—ì„œ ë…¸ì¶œì´ í• ë‹¹ë˜ì—ˆìŠµë‹ˆë‹¤. ì, ì‹ì´ í‰ê°€ê°€ ì—†ëŠ” í™˜ìëŠ” ì–´ë–»ê²Œ ë˜ë‚˜ìš”?",
              question: "ëˆ„ë½ëœ ì‹ì´ ë°ì´í„°ëŠ” ì–´ë–»ê²Œ ì²˜ë¦¬í•˜ë‚˜ìš”?",
              branches: [
                { text: "Exclude them â€” they don't have the key variable", nextNode: "exclude_wrong" },
                { text: "'í‰ì†Œ ì‹ì´'(ë¹„êµì)ë¡œ ë¶„ë¥˜í•˜ê³  ë¯¼ê°ë„ ë¶„ì„ì„ ì‹¤ì‹œí•©ë‹ˆë‹¤", nextNode: "classify_correct" }
              ]
            },
            sustained_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "ë‹¤ë¥¸ ì§ˆë¬¸ì…ë‹ˆë‹¤",
              text: "'Sustained' exposure over 6 months is a valid question, but it's a DIFFERENT target trial: one studying adherent patients (per-protocol effect). The primary analysis should be intention-to-treat: initial assignment regardless of subsequent adherence.",
              lesson: "Target trial can be ITT or per-protocol. ITT compares initial strategies. Per-protocol compares sustained adherence. State which you're emulating."
            },
            exclude_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ë ‡ê²Œ í•˜ë©´ ì„ íƒì´ ìƒì„±ë©ë‹ˆë‹¤. í¸ê²¬!",
              text: "ì‹ì´ ë°ì´í„°ê°€ ì—†ëŠ” í™˜ìë¥¼ ì œì™¸í•œë‹¤ëŠ” ê²ƒì€ ë¬´ì‘ìœ„ê°€ ì•„ë‹Œ í•˜ìœ„ ì§‘í•©ì„ ì„ íƒí•œë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ì•„í”ˆ í™˜ìê°€ ì‹ì´ í‰ê°€ë¥¼ ì™„ë£Œí•  ê°€ëŠ¥ì„±ì´ ë‚®ì€ ê²½ìš° ì´ì œ ë” ê±´ê°•í•œ í™˜ìë§Œ ë¹„êµí•©ë‹ˆë‹¤(ì„ íƒ í¸í–¥).",
              lesson: "ëˆ„ë½ëœ ë°ì´í„°ëŠ” ì œì™¸ìš©ìœ¼ë¡œ ì‚¬ìš©í•˜ì§€ ì•Šê³  ì²˜ë¦¬í•´ì•¼ í•©ë‹ˆë‹¤. ëŒ€ìƒ ì„ìƒì‹œí—˜ì—ì„œëŠ” ì„¤ë¬¸ì§€ë¥¼ ë†“ì¹œ í™˜ìë¥¼ ì œì™¸í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤."
            },
            classify_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Thoughtful approach!",
              text: "ì‹¤ì¢…ì„ 'í‰ì†Œ ì‹ë‹¨'ìœ¼ë¡œ ì²˜ë¦¬í•˜ë©´ ì½”í˜¸íŠ¸ê°€ ìœ ì§€ë©ë‹ˆë‹¤. ë¯¼ê°ë„ ë¶„ì„ì„ í†µí•´ ëŒ€ì•ˆì„ íƒìƒ‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” RCTê°€ ìˆ˜í–‰í•˜ëŠ” ì‘ì—…ì„ ëª¨ë°©í•©ë‹ˆë‹¤. ì‹ì´ìš”ë²• í”„ë¡œí† ì½œì„ ë”°ë¥´ì§€ ì•ŠëŠ” í™˜ìëŠ” ì—¬ì „íˆ í• ë‹¹ëœ ê·¸ë£¹(ITT)ì—ì„œ ë¶„ì„ë©ë‹ˆë‹¤.",
              lesson: "ì›ì¹™ì ì¸ ë°©ë²•(ë‹¤ì¤‘ ëŒ€ì¹˜, ì—­í™•ë¥  ê°€ì¤‘ì¹˜)ìœ¼ë¡œ ëˆ„ë½ëœ ë°ì´í„°ë¥¼ ì²˜ë¦¬í•©ë‹ˆë‹¤. íƒ€ì„ ì œë¡œ ì´í›„ì˜ ë°ì´í„° ê°€ìš©ì„±ì„ ê¸°ì¤€ìœ¼ë¡œ ì œì™¸í•˜ì§€ ë§ˆì‹­ì‹œì˜¤."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "A study compares 'metformin initiators' to 'sulfonylurea initiators' among patients with newly diagnosed diabetes. Time zero is defined as the date of first drug prescription. This study design:",
          options: [
            { id: 'a', text: "Has immortal time bias because patients must survive to get a prescription", correct: false },
            { id: 'b', text: "Appropriately emulates a target trial comparing these two treatments", correct: true },
            { id: 'c', text: "Has prevalent user bias because some patients are on long-term therapy", correct: false },
            { id: 'd', text: "Cannot estimate causal effects because it's observational", correct: false }
          ],
          explanation: "This is an ACTIVE COMPARATOR NEW USER (ACNU) design â€” the gold standard for drug safety studies. Time zero is first prescription (new users). Both groups start at the same point. There's no immortal time because patients are classified at the moment of first prescription, and no prevalent user bias because only new users are included."
        }
      }
    ]
  },
  // MODULE 8: THE SYNTHESIS (Meta-analysis of Observational Studies)
  {
    id: 8,
    title: "The Synthesis",
    subtitle: "ê´€ì°° ì¦ê±° í’€ë§",
    principle: 6,
    estimatedTime: "30 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "í‰ê· ì€ ê±°ì§“ë§ì„ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "í’€ë§ ë¬¸ì œ: ë¹„íƒ€ë¯¼ Dì™€ ì‚¬ë§ â€” ë©”íƒ€ ë¶„ì„ì´ í¸í–¥ì„ í™•ëŒ€í•  ë•Œ",
          source: "Multiple vitamin D meta-analyses | Autier 2014 | Mendelian randomization studies",
          timeline: [
            { year: "2007-2012", text: "ê´€ì°° ì—°êµ¬ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ë¹„íƒ€ë¯¼ Dê°€ ë‚®ì€ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ë” ë†’ì€ ì‚¬ë§ë¥ ì„ ì˜ˆì¸¡í•©ë‹ˆë‹¤. ê·¸ëŸ´ë“¯í•œ ìƒë¬¼í•™. ì½”í˜¸íŠ¸ì˜ ë©”íƒ€ ë¶„ì„: ë‚®ì€ ë¹„íƒ€ë¯¼ Dì™€ ë†’ì€ ë¹„íƒ€ë¯¼ Dì— ëŒ€í•´ í’€ë§ëœ RR ~1.5-2.0.", type: "normal" },
            { year: "The MA Problem", text: "ë©”íƒ€ ë¶„ì„ ê´€ì°° ì—°êµ¬ëŠ” ë‹¨ìˆœí•œ ì‹ í˜¸ê°€ ì•„ë‹Œ BIASë¥¼ í’€ë§í•©ë‹ˆë‹¤. ê° ì—°êµ¬ì— ê±´ì „í•œ ì‚¬ìš©ì í¸í–¥ì´ ìˆëŠ” ê²½ìš° í†µí•© ì¶”ì •ì¹˜ëŠ” í¸í–¥ íš¨ê³¼ì— ëŒ€í•œ ì •í™•í•œ ì¶”ì •ì¹˜ì…ë‹ˆë‹¤.", type: "crisis" },
            { year: "RCTs Arrive", text: "VITAL, ViDA, D-Health: large RCTs of vitamin D supplementation. Results: null effects on mortality, cardiovascular disease, cancer. RR ~1.00.", type: "revelation" },
            { year: "Mendelian Randomization", text: "MR ì—°êµ¬(ìœ ì „ì  ë³€ì´ë¥¼ ë„êµ¬ë¡œ ì‚¬ìš©): ë¹„íƒ€ë¯¼ Dê°€ ì‚¬ë§ë¥ ì— ë¯¸ì¹˜ëŠ” ì¸ê³¼ íš¨ê³¼ëŠ” ì—†ìŠµë‹ˆë‹¤. ê´€ì°° ì—°ê´€ì„±ì€ í˜¼ë€ìŠ¤ëŸ¬ì› ìŠµë‹ˆë‹¤.", type: "revelation" },
            { year: "The Explanation", text: "Reverse causation: illness lowers vitamin D levels. Confounding: outdoor activity, exercise, healthy lifestyle all correlate with vitamin D AND longevity.", type: "revelation" },
            { year: "Lesson", text: "í¸í–¥ëœ ì—°êµ¬ì— ëŒ€í•œ ë©”íƒ€ ë¶„ì„ì€ ì •í™•í•œ í¸í–¥ëœ ë‹µë³€ì„ ì œê³µí•©ë‹ˆë‹¤. ê·œëª¨ì— ë”°ë¥¸ 'ì“°ë ˆê¸° ìœ ì…, ì“°ë ˆê¸° ë°°ì¶œ'. íš¨ê³¼ë¿ë§Œ ì•„ë‹ˆë¼ í¸í–¥ì˜ ì´ì§ˆì„±ì´ ì¤‘ìš”í•©ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "All-cause mortality",
            drug: "Vitamin D (observational low vs high)",
            placebo: "RCT supplementation vs placebo",
            rr: "Observational: RR 1.57 | RCT: RR 0.97 (0.93-1.02)",
            ci: "Confounding created false association",
            nnh: "Billions spent on vitamin D supplements"
          },
          hook: "THE HOOK: Meta-analysis of 50 biased studies doesn't give you the truth â€” it gives you a very precise biased estimate. Before pooling observational studies, assess each one's ROBINS-I risk of bias. Consider whether you're pooling signal or noise."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ KEY INSIGHT: Heterogeneity in observational meta-analyses isn't just about effect size variation â€” it's about BIAS variation. Different studies have different confounding structures, selection mechanisms, and measurement approaches. Pooling doesn't solve this; it obscures it."
        }
      },
      {
        type: 'content',
        content: {
          title: "ê´€ì°° ì—°êµ¬ë¥¼ ë©”íƒ€ ë¶„ì„í•´ì•¼ í•˜ëŠ” ê²½ìš°",
          sections: [
            {
              heading: "Appropriate Situations:",
              items: [
                "RCTs are impossible (rare harms, long-term outcomes)",
                "Exposure cannot be randomized (smoking, environmental)",
                "Complementing RCT evidence (generalizability, subgroups)",
                "ì—°êµ¬ëŠ” ìœ ì‚¬í•œ ì„¤ê³„ë¥¼ ì‚¬ìš©í•˜ê³  ìœ ì‚¬í•œ í¸í–¥ì„ í•´ê²°í•©ë‹ˆë‹¤.",
                "ì§ˆë¬¸ì€ ì—°ê´€ì„±ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤(ë°˜ë“œì‹œ ê·¸ëŸ° ê²ƒì€ ì•„ë‹˜). ì¸ê³¼ê´€ê³„)"
              ]
            },
            {
              heading: "Problematic Situations:",
              items: [
                "Studies have incompatible confounding structures",
                "Major unmeasured confounders likely differ across studies",
                "Studies use different exposure/outcome definitions",
                "Pooling to achieve 'statistical significance'",
                "Ignoring within-study bias to focus on between-study variance"
              ]
            },
            {
              heading: "The Fundamental Question:",
              text: "STUDIESë¥¼ í’€ë§í•˜ì‹œë‚˜ìš”, ì•„ë‹ˆë©´ BIASë¥¼ í’€ë§í•˜ì‹œë‚˜ìš”? ê° ì—°êµ¬ê°€ ë™ì¼í•œ ë°©í–¥ìœ¼ë¡œ í˜¼ë€ìŠ¤ëŸ¬ìš´ ê²½ìš° ë©”íƒ€ ë¶„ì„ì€ ì§„ì‹¤ì´ ì•„ë‹Œ ë” ì •í™•í•œ í˜¼ë€ìŠ¤ëŸ¬ìš´ ì¶”ì •ì¹˜ë¥¼ ì œê³µí•©ë‹ˆë‹¤."
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ê´€ì°° ë©”íƒ€ ë¶„ì„",
          title: "Best Practices",
          sections: [
            {
              heading: "1. Use ROBINS-I for Each Study:",
              text: "ì˜ì—­ë³„ë¡œ í¸í–¥ ìœ„í—˜ì„ í‰ê°€í•©ë‹ˆë‹¤. ì¤‘ëŒ€í•œ ìœ„í—˜ ì—°êµ¬ëŠ” ì¼ë°˜ì ìœ¼ë¡œ ì œì™¸ë˜ê±°ë‚˜ ë³„ë„ë¡œ ë¶„ì„ë˜ì–´ì•¼ í•©ë‹ˆë‹¤. ì‹¬ê°í•œ ìœ„í—˜ ì—°êµ¬ì—ëŠ” ë¯¼ê°ë„ ë¶„ì„ì´ í•„ìš”í•©ë‹ˆë‹¤."
            },
            {
              heading: "2. Don't Mix RCTs and Observational:",
              text: "í¸í–¥ êµ¬ì¡°ê°€ ë‹¤ë¥´ê¸° ë•Œë¬¸ì— ê²°í•©ì´ ë¬¸ì œê°€ ë©ë‹ˆë‹¤. ë³„ë„ë¡œ ì œì‹œí•˜ì„¸ìš”. ê²°í•©ëœ ê²½ìš° ë¶„ì‚°ë¿ë§Œ ì•„ë‹ˆë¼ ì—°êµ¬ ì„¤ê³„ í’ˆì§ˆë³„ë¡œ ê°€ì¤‘ì¹˜ë¥¼ ë¶€ì—¬í•©ë‹ˆë‹¤."
            },
            {
              heading: "3. Explore Heterogeneity by Bias:",
              text: "Subgroup by ROBINS-I risk level. If low-risk studies give different answers than high-risk studies, that's informative: bias explains heterogeneity."
            },
            {
              heading: "4. Consider Adjusted vs Crude:",
              text: "Meta-analyze adjusted estimates (not crude). But different adjustment sets = different estimands. Document what each study adjusted for."
            },
            {
              heading: "5. Use GRADE for Observational:",
              text: "'ë‚®ì€' í™•ì‹¤ì„±ì—ì„œ ì‹œì‘í•©ë‹ˆë‹¤(RCTì²˜ëŸ¼ 'ë†’ìŒ'ì´ ì•„ë‹˜). ì¶”ê°€ì ì¸ í¸ê²¬, ë¶ˆì¼ì¹˜, ë¶€ì •í™•ì„±, ê°„ì ‘ì ì¸ ì ì— ëŒ€í•´ì„œëŠ” í‰ê°€ë¥¼ ë‚®ì¶”ì‹­ì‹œì˜¤. ì£¼ì˜í•´ì„œ í‰ê°€í•˜ì„¸ìš”."
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "Heterogeneity: Different Sources in Observational Data",
          sections: [
            {
              heading: "Clinical Heterogeneity:",
              text: "Different populations, interventions, outcomes, timing â€” same as in RCT meta-analyses."
            },
            {
              heading: "Methodological Heterogeneity:",
              text: "ë‹¤ì–‘í•œ ì—°êµ¬ ì„¤ê³„(ì½”í˜¸íŠ¸ ëŒ€ ì‚¬ë¡€ ëŒ€ì¡°), ë‹¤ì–‘í•œ ì¡°ì • ì „ëµ, ë‹¤ì–‘í•œ ë…¸ì¶œ ì •ì˜. ì´ëŠ” ê´€ì°° MAì—ì„œ ë”ìš± ì¤‘ìš”í•©ë‹ˆë‹¤."
            },
            {
              heading: "Bias Heterogeneity:",
              text: "Different confounding structures, different amounts of unmeasured confounding, different selection mechanisms. This is UNIQUE to observational MA."
            },
            {
              heading: "What High IÂ² Means:",
              items: [
                "In RCT MA: treatment effects truly differ across populations",
                "In observational MA: could be effect heterogeneity OR bias heterogeneity",
                "ì—°êµ¬ë¥¼ ê²€í† í•˜ì§€ ì•Šê³ ëŠ” êµ¬ë³„í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤",
                "Meta-regression by study quality can help, but is often underpowered"
              ]
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'obs-ma-decision',
          title: "ì´ëŸ¬í•œ ì—°êµ¬ë¥¼ í†µí•©í•´ì•¼ í•©ë‹ˆê¹Œ?",
          situation: "You're conducting a systematic review on coffee and cardiovascular disease. You found 15 cohort studies, 3 case-control studies, and 2 RCTs. ROBINS-I assessment: 5 cohorts at moderate risk, 8 at serious risk, 2 at critical risk. The case-controls are all serious risk. RCTs are low risk but underpowered.",
          nodes: {
            start: {
              question: "í•©ì„±ì— ëŒ€í•œ ì ‘ê·¼ ë°©ì‹ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "Pool all 20 studies to maximize power", nextNode: "pool_all_wrong" },
                { text: "Pool only low/moderate risk studies, exclude high risk", nextNode: "exclude_high" },
                { text: "Present stratified analyses by risk of bias level", nextNode: "stratified_correct" }
              ]
            },
            pool_all_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì€ í™•ëŒ€ë©ë‹ˆë‹¤. í¸í–¥!",
              text: "10ê°œ ì´ìƒì˜ ì—°êµ¬ì— ì‹¬ê°í•œ/ì¤‘ìš”í•œ í¸í–¥ì´ ìˆì„ ë•Œ 20ê°œì˜ ì—°êµ¬ë¥¼ í•©ì¹œë‹¤ëŠ” ê²ƒì€ í•©ë™ ì¶”ì •ì¹˜ê°€ í¸í–¥ëœ ë°ì´í„°ì— ì˜í•´ ì§€ë°°ëœë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì—°êµ¬ ì „ë°˜ì— ê±¸ì³ í‰ê·  í¸í–¥ì— ëŒ€í•œ ë§¤ìš° ì •í™•í•œ ì¶”ì •ì¹˜ë¥¼ ì–»ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "ë” ë§ì€ ì—°êµ¬ â‰  ë” ë‚˜ì€ ë©”íƒ€ ë¶„ì„. ì–‘ë³´ë‹¤ ì§ˆì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ì£¼ìš” ìœ„í—˜ ì—°êµ¬ë¥¼ ì£¼ìš” ë¶„ì„ì— í†µí•©í•˜ì§€ ë§ˆì‹­ì‹œì˜¤."
            },
            exclude_high: {
              situation: "ë” ì¢‹ìŠµë‹ˆë‹¤! í•˜ì§€ë§Œ ì´ì œ 5ê°œì˜ ì½”í˜¸íŠ¸(ì¤‘ê°„)ì™€ 2ê°œì˜ RCT(ë‚®ìŒ)ë§Œ ìˆìœ¼ë¯€ë¡œ ë°ì´í„°ê°€ ì œí•œë©ë‹ˆë‹¤. ë‹¤ìŒì—ëŠ” ë¬´ì—‡ì„ í•˜ì‹œê² ìŠµë‹ˆê¹Œ?",
              question: "Synthesis approach:",
              branches: [
                { text: "5ê°œ ì½”í˜¸íŠ¸ì™€ 2ê°œ RCTë¥¼ í•¨ê»˜ í†µí•©", nextNode: "pool_mixed_wrong" },
                { text: "ë¯¼ê°ë„ ë¶„ì„ì„ í†µí•´ RCTë¥¼ ë³„ë„ë¡œ ì œì‹œí•˜ê³  ì½”í˜¸íŠ¸ë¥¼ ë³„ë„ë¡œ ì œì‹œ", nextNode: "separate_correct" }
              ]
            },
            stratified_correct: {
              situation: "Excellent! You plan to show: (1) RCTs alone, (2) Low/moderate risk cohorts, (3) All studies. This is transparent.",
              question: "ê·€í•˜ì˜ RCTëŠ” RR 0.95(0.60-1.50)ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì¤‘ê°„ ìœ„í—˜ ì§‘ë‹¨ì€ RR 0.75(0.70-0.80)ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ê³ ìœ„í—˜ ì—°êµ¬ì—ì„œëŠ” RR 0.65(0.60-0.70)ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì–´ë–¤ ê²°ë¡ ì„ ë‚´ë¦¬ì‹œë‚˜ìš”?",
              branches: [
                { text: "Coffee protects â€” all estimates show benefit", nextNode: "conclude_benefit_wrong" },
                { text: "Lower quality studies show stronger effects â€” suggests bias", nextNode: "conclude_bias_correct" }
              ]
            },
            pool_mixed_wrong: {
              type: 'outcome',
              outcome: 'partial',
              title: "í˜¼í•© ì‹œ ì£¼ì˜í•˜ì„¸ìš”!",
              text: "RCTì™€ ê´€ì°° ì—°êµ¬ëŠ” ê·¼ë³¸ì ìœ¼ë¡œ í¸í–¥ êµ¬ì¡°ê°€ ë‹¤ë¦…ë‹ˆë‹¤. ê·¸ê²ƒë“¤ì„ í•©ì¹˜ë©´ ìˆ«ìê°€ ë‚˜ì˜¤ì§€ë§Œ ê·¸ ìˆ«ìê°€ ë¬´ì—‡ì„ ì¶”ì •í•˜ëŠ”ì§€ ëª…í™•í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë³„ë„ë¡œ ì œì‹œí•˜ê³  ì¼ì¹˜/ë¶€ì¡°ì— ëŒ€í•´ ë…¼ì˜í•˜ëŠ” ê²ƒì´ ë” ì¢‹ìŠµë‹ˆë‹¤.",
              lesson: "RCTì™€ ê´€ì°° ì—°êµ¬ê°€ ë™ì˜í•˜ë©´ ì‹ ë¢°ë„ê°€ ë†’ì•„ì§‘ë‹ˆë‹¤. ë™ì˜í•˜ì§€ ì•ŠëŠ” ê²½ìš° ì´ìœ ë¥¼ ì‚´í´ë³´ì„¸ìš”(í˜¼ë€ìŠ¤ëŸ¬ìš´ê°€ìš”? íš¨ê³¼ ìˆ˜ì •ì¸ê°€ìš”?). ì˜ê²¬ì„ ëª¨ì•„ ì˜ê²¬ ì°¨ì´ë¥¼ ìˆ¨ê¸°ì§€ ë§ˆì‹­ì‹œì˜¤."
            },
            separate_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Rigorous approach!",
              text: "RCTì™€ ê´€ì°° ì—°êµ¬ë¥¼ ë³„ë„ë¡œ ì œì‹œí•˜ë©´ ë…ìê°€ ì¼ì¹˜/ë¶ˆì¼ì¹˜ë¥¼ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë¯¼ê°ë„ ë¶„ì„ì€ ë‹¤ì–‘í•œ ê°€ì •ì— ë”°ë¼ ê²°ê³¼ê°€ ì–´ë–»ê²Œ ë³€í•˜ëŠ”ì§€ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ëŠ” íˆ¬ëª…í•˜ê³  ìœ ìµí•©ë‹ˆë‹¤.",
              lesson: "ë©”íƒ€ ë¶„ì„ì˜ ëª©í‘œëŠ” ì¦ê±°ë¥¼ ìš”ì•½í•˜ëŠ” ê²ƒì´ì§€ ë‹¨ì¼ ìˆ«ìë¥¼ ë§Œë“œëŠ” ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì—°êµ¬ í’ˆì§ˆì— ë”°ë¥¸ ê³„ì¸µí™”ëŠ” ëª¨ë“  ê²ƒì„ í•©ì¹˜ëŠ” ê²ƒë³´ë‹¤ ë” ì •ì§í•©ë‹ˆë‹¤."
            },
            conclude_benefit_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "íŒ¨í„´ì„ ì‚´í´ë³´ì„¸ìš”!",
              text: "RCT(ìµœì € í¸í–¥)ëŠ” ë„ íš¨ê³¼(0.95, CI êµì°¨ 1)ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ë¹„ëš¤ë¦¼ ìœ„í—˜ì´ ì¦ê°€í•˜ë©´ ëª…ë°±í•œ ì´ì ë„ ì¦ê°€í•©ë‹ˆë‹¤(0.75 â†’ 0.65). ì´ëŠ” ì»¤í”¼ê°€ ì•„ë‹Œ CONFOUNDINGì´ 'ì´ì 'ì„ ì„¤ëª…í•œë‹¤ëŠ” ê³ ì „ì ì¸ ì‹ í˜¸ì…ë‹ˆë‹¤.",
              lesson: "í¸í–¥ ìœ„í—˜ê³¼ í•¨ê»˜ íš¨ê³¼ í¬ê¸°ê°€ ì¦ê°€í•˜ë©´ ì¸ê³¼ê´€ê³„ê°€ ì•„ë‹Œ í¸í–¥ì„ ì˜ì‹¬í•´ ë³´ì„¸ìš”. RCTê°€ í•µì‹¬ì…ë‹ˆë‹¤. ê´€ì°° ì¶”ì •ì¹˜ëŠ” ì´ë¥¼ ê¸°ì¤€ìœ¼ë¡œ í•´ì„ë˜ì–´ì•¼ í•©ë‹ˆë‹¤."
            },
            conclude_bias_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Astute interpretation!",
              text: "'í¸í–¥ ìœ„í—˜ ëŒ€ íš¨ê³¼ í¬ê¸°' íŒ¨í„´ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. í’ˆì§ˆì´ ë‚®ì€ ì—°êµ¬ì—ì„œëŠ” ë” í° íš¨ê³¼ê°€ ë‚˜íƒ€ë‚©ë‹ˆë‹¤. ì´ëŠ” êµë€ì— ëŒ€í•œ ê°•ë ¥í•œ ì¦ê±°ì…ë‹ˆë‹¤(ê±´ê°•í•œ ì‚¬ìš©ì í¸ê²¬: ì»¤í”¼ë¥¼ ë§ˆì‹œëŠ” ì‚¬ëŒì´ ë” ê±´ê°•í•©ë‹ˆë‹¤). RCTì˜ null ê²°ê³¼ëŠ” ì§„ì‹¤ì— ë” ê°€ê¹Œìš¸ ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤.",
              lesson: "í¸í–¥ ìœ„í—˜ì„ ê¸°ì¤€ìœ¼ë¡œ ê³„ì¸µí™”í•˜ëŠ” ê²ƒì´ ì§„ë‹¨ì…ë‹ˆë‹¤. í’ˆì§ˆì´ ë†’ì€ ì—°êµ¬ì™€ í’ˆì§ˆì´ ë‚®ì€ ì—°êµ¬ì—ì„œ ì„œë¡œ ë‹¤ë¥¸ ë‹µì„ ì œê³µí•˜ëŠ” ê²½ìš° í’ˆì§ˆì´ ë†’ì€ ì—°êµ¬ë¥¼ ì‹ ë¢°í•˜ê³  í’ˆì§ˆì´ ë‚®ì€ ì—°êµ¬ì— í¸í–¥ì„ ì£¼ëŠ” ìš”ì†Œê°€ ë¬´ì—‡ì¸ì§€ ì¡°ì‚¬í•˜ì„¸ìš”."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "A meta-analysis of 30 observational studies shows a pooled OR of 0.72 (0.68-0.76) with IÂ² = 5%. What can you conclude?",
          options: [
            { id: 'a', text: "íš¨ê³¼ëŠ” ì‹¤ì œì ì…ë‹ˆë‹¤. ì—°êµ¬ ì „ë°˜ì— ê±¸ì³ ë†’ì€ ì •ë°€ë„ë¡œ ì¼ê´€ë©ë‹ˆë‹¤.", correct: false },
            { id: 'b', text: "ì—°êµ¬ëŠ” ë™ì§ˆì ì´ë¯€ë¡œ ì¶”ì •ì— ëŒ€í•œ ì‹ ë¢°ë„ê°€ ë†’ì•„ì§‘ë‹ˆë‹¤.", correct: false },
            { id: 'c', text: "ë‚®ì€ IÂ²ëŠ” ì—°êµ¬ê°€ ë™ì˜í•˜ì§€ë§Œ ëª¨ë‘ í¸í–¥ë  ìˆ˜ ìˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ê°™ì€ ë°©í–¥ìœ¼ë¡œ", correct: true },
            { id: 'd', text: "ì´ê²ƒì€ ì¸ê³¼ì  ë³´í˜¸ íš¨ê³¼ì— ëŒ€í•œ ê°•ë ¥í•œ ì¦ê±°ì…ë‹ˆë‹¤", correct: false }
          ],
          explanation: "Low IÂ² means studies are consistent â€” but they could be consistently BIASED. If all 30 studies have healthy user bias, they'll all show a protective effect, and IÂ² will be low. Homogeneity is reassuring only if studies aren't all biased the same way. Without ROBINS-I assessment, you can't distinguish consistency of effect from consistency of bias."
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "THE TIME ILLUSION: LEAD TIME BIAS â€” WHEN SCREENING LOOKED MIRACULOUS",
          source: "Welch 2010 | Overdiagnosed | Neuroblastoma screening | PSA debates",
          timeline: [
            { year: "The Promise", text: "Cancer screening finds disease early. 'Early detection saves lives.' 5-year survival with screening: 95%. Without screening: 60%. Screening works... right?", type: "normal" },
            { year: "The Illusion", text: "A patient diagnosed at age 60 (no screening) dies at 65. 5-year survival = 0%. The SAME patient diagnosed at 55 (screening) dies at 65. 5-year survival = 100%. NOTHING CHANGED except diagnosis date.", type: "revelation" },
            { year: "Neuroblastoma", text: "ì¼ë³¸ì€ ëª¨ë“  ì˜ìœ ì•„ì—ê²Œ ì‹ ê²½ì•„ì„¸í¬ì¢…(ì†Œì•„ì•”) ê²€ì‚¬ë¥¼ ì‹¤ì‹œí–ˆìŠµë‹ˆë‹¤. 3ë°° ë” ë§ì€ ì‚¬ë¡€ë¥¼ ë°œê²¬í–ˆìŠµë‹ˆë‹¤. 5ë…„ ìƒì¡´ìœ¨ì´ ê¸‰ì¦í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ: ì‚¬ë§ë¥ ì€ ë³€í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ ì €ì ˆë¡œ í‡´í–‰ë  ìˆ˜ ìˆëŠ” ì•”ì„ ë°œê²¬í–ˆìŠµë‹ˆë‹¤.", type: "crisis" },
            { year: "PSA Screening", text: "ì „ë¦½ì„  ê²€ì§„ì€ 5ë…„ ìƒì¡´ìœ¨ì„ ê·¹ì ìœ¼ë¡œ ì¦ê°€ì‹œí‚µë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ë§ì€ ì„ìƒì‹œí—˜ì—ì„œ ì‚¬ë§ë¥  í˜œíƒì€ ì•„ì£¼ ì‘ê±°ë‚˜ ì „í˜€ ì—†ìŠµë‹ˆë‹¤. ë§ì€ ë‚¨ì„±ë“¤ì´ ê²°ì½” ëª©ìˆ¨ì„ ìƒì„ ìˆ˜ ì—†ëŠ” ì•” ì¹˜ë£Œë¥¼ ë°›ìŠµë‹ˆë‹¤.", type: "crisis" },
            { year: "The Math", text: "Lead time = time between screen detection and when symptoms would appear. If lead time is 5 years, 5-year survival improves by 100% even with ZERO mortality benefit.", type: "revelation" },
            { year: "Lesson", text: "ì ˆëŒ€ ìƒì¡´ í†µê³„ë¥¼ ì‚¬ìš©í•˜ì—¬ ì„ ë³„ê²€ì‚¬ë¥¼ í‰ê°€í•˜ì§€ ë§ˆì„¸ìš”. ì˜¤ì§ ì‚¬ë§ë¥ (ì¸êµ¬ë‹¹ ì‚¬ë§ì ìˆ˜)ë§Œì´ ì§„ì‹¤ì„ ë§í•´ì¤ë‹ˆë‹¤. ë¦¬ë“œ íƒ€ì„ê³¼ ê³¼ì‰ ì§„ë‹¨ìœ¼ë¡œ ì¸í•´ ìƒì¡´ì´ ì˜¤ì—¼ë˜ì—ˆìŠµë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "5-year survival vs population mortality",
            drug: "Cancer screening programs",
            placebo: "No screening",
            rr: "Survival: dramatic improvement | Mortality: often minimal",
            ci: "Lead time creates illusion of benefit",
            nnh: "ìˆ˜ë°±ë§Œ ëª…ì´ ê²°ì½” í•´ë¥¼ ë¼ì¹˜ì§€ ì•Šì•˜ì„ 'ì•”'ìœ¼ë¡œ ê³¼ì‰ ì§„ë‹¨ì„ ë°›ì•˜ìŠµë‹ˆë‹¤"
          },
          hook: "THE HOOK: '5-year survival improved 50%' sounds like screening works. But it might just mean you moved the starting line. Survival measures time from DIAGNOSIS. If diagnosis is earlier but death is the same, survival 'improves' without anyone living longer. This is lead time bias â€” and it has fooled millions."
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'screening-evaluation',
          title: "ì´ ì„ ë³„ ê²€ì‚¬ ì£¼ì¥ì„ í‰ê°€í•˜ì‹­ì‹œì˜¤",
          situation: "ì·Œì¥ì•”ì— ëŒ€í•œ ìƒˆë¡œìš´ ì„ ë³„ ê²€ì‚¬ê°€ ì¥ë ¤ë©ë‹ˆë‹¤. ë§ˆì¼€íŒ… ìë£Œì— ë”°ë¥´ë©´ '5ë…„ ìƒì¡´ìœ¨ì€ ê²€ì§„ì„ ë°›ì€ ê²½ìš° 25%, ê²€ì§„ì„ ë°›ì§€ ì•Šì€ ê²½ìš° 5%ì…ë‹ˆë‹¤.' í…ŒìŠ¤íŠ¸ ë¹„ìš©ì€ $500ì´ê³  ì¹¨ìŠµì  í›„ì† ì¡°ì¹˜ê°€ í•„ìš”í•œ ìœ„ì–‘ì„± ë¹„ìœ¨ì€ 3%ì…ë‹ˆë‹¤.",
          nodes: {
            start: {
              question: "'25% ëŒ€ 5%' ìƒì¡´ ì£¼ì¥ì— ëŒ€í•´ ê°€ì¥ ë¨¼ì € ìš°ë ¤ë˜ëŠ” ì ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "It's impressive â€” 5x better survival!", nextNode: "impressed_wrong" },
                { text: "Survival doesn't prove mortality benefit â€” could be lead time", nextNode: "lead_time_correct" },
                { text: "ì—°êµ¬ëŠ” ë¬´ì‘ìœ„ ë°°ì •ë˜ì§€ ì•Šì•˜ì„ ê²ƒì…ë‹ˆë‹¤.", nextNode: "randomization_partial" }
              ]
            },
            impressed_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "You've been fooled by lead time!",
              text: "ì·Œì¥ì•”ì€ ê±°ì˜ ë³´í¸ì ìœ¼ë¡œ ì¹˜ëª…ì ì…ë‹ˆë‹¤. ì„ ë³„ê²€ì‚¬ë¥¼ í†µí•´ ì§„ë‹¨ì´ 1ë…„ ì •ë„ ì§„í–‰ë˜ì§€ë§Œ í™˜ìê°€ ì—¬ì „íˆ ê°™ì€ ë‚˜ì´ì— ì‚¬ë§í•˜ëŠ” ê²½ìš° 1ë…„ ìƒì¡´ìœ¨ì€ ~20%ì—ì„œ ~40%ë¡œ ì¦ê°€í•˜ë©° ìƒëª…ì„ êµ¬í•œ ì‚¬ëŒì€ 0ëª…ì…ë‹ˆë‹¤. ìƒì¡´ í†µê³„ëŠ” ê²€ì§„ í‰ê°€ì— ì˜ë¯¸ê°€ ì—†ìŠµë‹ˆë‹¤.",
              lesson: "ì ˆëŒ€ ìƒì¡´ì„ ê²€ì§„ í˜œíƒì˜ ì¦ê±°ë¡œ ë°›ì•„ë“¤ì´ì§€ ë§ˆì„¸ìš”. ë¬´ì‘ìœ„ ì‹œí—˜ì—ì„œ ì‚¬ë§ë¥  ë°ì´í„°ë¥¼ ìš”êµ¬í•©ë‹ˆë‹¤."
            },
            lead_time_correct: {
              situation: "Excellent skepticism! You ask for mortality data. They provide: 'In a cohort study, screened patients had 30% lower pancreatic cancer mortality.'",
              question: "Is this convincing?",
              branches: [
                { text: "Yes â€” mortality is the right endpoint", nextNode: "cohort_wrong" },
                { text: "No â€” cohort studies of screening have healthy screener bias", nextNode: "healthy_screener_correct" }
              ]
            },
            randomization_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Good instinct, but the specific bias matters",
              text: "ì˜ˆ, ì´ ì—°êµ¬ëŠ” ê´€ì°°ì¼ ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ íŠ¹ì • í¸í–¥ì€ ë¦¬ë“œ íƒ€ì„ì…ë‹ˆë‹¤. ì‚¬ë§ ë‚ ì§œê°€ ë³€í•˜ì§€ ì•Šë”ë¼ë„ ì¡°ê¸° ì§„ë‹¨ì„ í•˜ë©´ ìƒì¡´ìœ¨ì´ í–¥ìƒë©ë‹ˆë‹¤. ë¬´ì‘ìœ„ ë°°ì •ì´ ë„ì›€ì´ ë˜ì§€ë§Œ, ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ì¢…ë£Œì ìœ¼ë¡œ ìƒì¡´ì´ ì•„ë‹Œ ì‚¬ë§ì´ í•„ìš”í•©ë‹ˆë‹¤.",
              lesson: "For screening evaluation: (1) Must be mortality, not survival, (2) Must be randomized or very carefully designed to avoid healthy screener bias."
            },
            cohort_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Healthy screener bias!",
              text: "ì„ ë³„ê²€ì‚¬ë¥¼ ì„ íƒí•˜ëŠ” ì‚¬ëŒë“¤ì€ ì²´ê³„ì ìœ¼ë¡œ ë” ê±´ê°•í•©ë‹ˆë‹¤. ê·¸ë“¤ì€ ë” ë§ì´ ìš´ë™í•˜ê³ , ë” ì˜ ë¨¹ê³ , ê±´ê°• ê´€ë¦¬ì— ë” ì˜ ì ‘ê·¼í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê²€ì§„ì´ íš¨ê³¼ê°€ ì—†ë”ë¼ë„ ì·Œì¥ì•”ì„ í¬í•¨í•œ ëª¨ë“  ê²ƒì—ì„œ ì‚¬ë§ë¥ ì´ ë‚®ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë‹¤ì‹œ HRTì…ë‹ˆë‹¤.",
              lesson: "ê±´ì „í•œ ìŠ¤í¬ë¦¬ë„ˆ í¸ê²¬ì€ ìŠ¤í¬ë¦¬ë‹ì— ì ìš©ë˜ëŠ” ê±´ì „í•œ ì‚¬ìš©ì í¸ê²¬ì…ë‹ˆë‹¤. RCTë§Œì´ ì´ë¥¼ ì œê±°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì„ ë³„ê²€ì‚¬ë¥¼ ìœ„í•œ ê´€ì°° ì‚¬ë§ë¥  ë¹„êµëŠ” ì‹ ë¢°í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤."
            },
            healthy_screener_correct: {
              situation: "Perfect! You demand RCT evidence. The company says: 'An RCT is ongoing but won't report for 10 years. In the meantime, shouldn't we offer screening?'",
              question: "Your response:",
              branches: [
                { text: "Yes â€” some benefit is likely, and screening is harmless", nextNode: "harmless_wrong" },
                { text: "No â€” unproven screening causes harm through false positives, overdiagnosis, and anxiety", nextNode: "wait_correct" }
              ]
            },
            harmless_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ê²€ì‚¬ëŠ” ë¬´í•´í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤!",
              text: "3% false positive rate Ã— millions screened = tens of thousands of invasive biopsies. Pancreas biopsies can cause pancreatitis, bleeding, death. Plus anxiety from false alarms. Plus overdiagnosis of indolent tumors treated unnecessarily. Screening without proven benefit is NET HARM.",
              lesson: "Screening has COSTS: false positives, overdiagnosis, anxiety, procedures. These are CERTAIN. Benefit is UNCERTAIN until RCT-proven. Uncertain benefit + certain harm = wait for evidence."
            },
            wait_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Evidence-based patience!",
              text: "You correctly identified: (1) survival claims mean nothing (lead time), (2) observational mortality claims have healthy screener bias, (3) screening has real harms. Until an RCT shows MORTALITY benefit outweighs harms, screening should not be implemented.",
              lesson: "Screening is INTERVENTION. It requires the same evidence standard as drugs: RCT showing benefits > harms. 'Early detection' sounds good but isn't automatically beneficial."
            }
          }
        }
      },
      {
        type: 'principle',
        content: {
          text: "âš ï¸ THE WARNING: Screening programs are among the most bias-prone topics in medicine. Lead time bias makes survival look better than reality. Length bias makes screening find slow-growing (less lethal) cancers. Healthy screener bias makes screened populations look healthier. Overdiagnosis turns healthy people into patients. DEMAND RCT mortality evidence before accepting screening claims."
        }
      },
      {
        type: 'principle',
        content: {
          text: "ğŸ¯ PROGRESS CHECK: You've learned to pool observational evidence carefully. You understand that meta-analysis can magnify bias as easily as signal. You can identify lead time bias in screening studies. You know when to trust pooled estimates and when to be skeptical. Next: pharmacovigilance â€” detecting drug safety signals."
        }
      }
    ]
  },
  // MODULE 9: THE PHARMACOVIGILANCE (Signal Detection)
  {
    id: 9,
    title: "The Pharmacovigilance",
    subtitle: "Signal Detection",
    principle: 2,
    estimatedTime: "25 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "Time flows one direction"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "THE SIGNAL IGNORED: VIOXX â€” WHEN 88,000 HEARTS STOPPED",
          source: "NEJM 2005 | FDA | Merck internal documents | VIGOR, APPROVe trials",
          timeline: [
            { year: "1999", text: "Vioxx (rofecoxib) approved. COX-2 inhibitor for arthritis. Marketed as 'safer on stomach' than older NSAIDs. Billions in sales projected.", type: "normal" },
            { year: "2000", text: "VIGOR trial: 4x higher cardiovascular events vs naproxen. Merck interprets as 'naproxen is cardioprotective,' not 'Vioxx is cardiotoxic.' FDA concerned.", type: "crisis" },
            { year: "2001-04", text: "Observational studies show signal: cardiovascular events in Vioxx users. David Graham (FDA) estimates 88,000-140,000 excess cardiac events. Internal Merck data shows risk.", type: "crisis" },
            { year: "2004", text: "APPROVe trial (colon polyps): Stopped early for cardiovascular harm. RR 1.92 (95% CI 1.19-3.11). Merck withdraws Vioxx worldwide.", type: "revelation" },
            { year: "The Failure", text: "ìë°œì ì¸ ë³´ê³ , ê´€ì°° ì‹ í˜¸, ì‹¬ì§€ì–´ ë‚´ë¶€ ë°ì´í„°ë„ ë¬´ì‹œë˜ì—ˆìŠµë‹ˆë‹¤. RCTì—ì„œ ìœ í•´ì„±ì´ í™•ì¸ë  ë•Œê¹Œì§€ ê²½ê³  ì‹ í˜¸ë¥¼ ë¬´ì‹œí•˜ëŠ” ë° ì¦ê±° ê³„ì¸µ êµ¬ì¡°ê°€ ì‚¬ìš©ë˜ì—ˆìŠµë‹ˆë‹¤.", type: "revelation" },
            { year: "Lesson", text: "HARMSì— ëŒ€í•œ ê´€ì°° ì¦ê±°ëŠ” ì´ì ì— ëŒ€í•œ ì¦ê±°ì™€ ë™ì¼í•œ ì„ê³„ê°’ì„ ìš”êµ¬í•´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ì‹ í˜¸ê°€ ì¤‘ìš”í•©ë‹ˆë‹¤. 88,000ëª…ì˜ ì‚¬ë§ìëŠ” 'ì™„ë²½í•œ' ì¦ê±°ë¥¼ ê¸°ë‹¤ë¦¬ëŠ” ëŒ€ê°€ì…ë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "Myocardial infarction / sudden cardiac death",
            drug: "Rofecoxib (Vioxx)",
            placebo: "Naproxen / placebo",
            rr: "RR 1.92 (1.19-3.11) in APPROVe",
            ci: "Signal present for 4 years before withdrawal",
            nnh: "88,000-140,000 excess cardiac events estimated"
          },
          hook: "THE HOOK: Pharmacovigilance failed because signals were dismissed as 'only observational.' The evidence hierarchy that protects against false positives for benefits should not be used to dismiss warnings of harm. When lives are at stake, false negatives kill."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ KEY INSIGHT: For HARMS, the evidence threshold should be LOWER than for benefits. Why? False positive (thinking something harmful is safe) has worse consequences than false negative (thinking something safe is harmful). Observational signals for harm deserve urgent attention, not dismissal."
        }
      },
      {
        type: 'content',
        content: {
          title: "Pharmacovigilance: The Science of Safety Signals",
          sections: [
            {
              heading: "Why Observational Data Is Essential for Safety:",
              items: [
                "RCTëŠ” ë“œë¬¸ í”¼í•´ê°€ ì•„ë‹Œ ì´ìµì„ ìœ„í•´ êµ¬ë™ë©ë‹ˆë‹¤.",
                "100-patient RCT: can detect 3% event rate, NOT 0.1% rate",
                "Rare harms need millions of patient-years of exposure",
                "Post-marketing surveillance is the only way to detect them",
                "Thalidomide, Vioxx, DES â€” all detected observationally"
              ]
            },
            {
              heading: "Signal Detection Methods:",
              items: [
                "Spontaneous reporting (FAERS, Yellow Card) â€” passive surveillance",
                "Disproportionality analysis â€” observed vs expected reports",
                "Case series â€” temporal clustering of events",
                "Cohort studies â€” active surveillance in databases",
                "Self-controlled designs â€” within-person comparisons"
              ]
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ì•ˆì „ ì‹ í˜¸ í‰ê°€",
          title: "ì‹ í˜¸ì—ì„œ ë‹¤ìŒìœ¼ë¡œ ì¡°ì¹˜",
          sections: [
            {
              heading: "Signal Detection (Is there something there?):",
              text: "â€¢ Spontaneous reports: PRR, ROR, IC (information component)\nâ€¢ Database studies: compare exposed vs unexposed rates\nâ€¢ Case series: temporal pattern, dose-response\nâ€¢ Biological plausibility: is there a mechanism?"
            },
            {
              heading: "Signal Validation (Is it real?):",
              text: "â€¢ ì‹ í˜¸ë¥¼ ë‹¤ë¥¸ ë°ì´í„°ë² ì´ìŠ¤ì— ë³µì œí•  ìˆ˜ ìˆìŠµë‹ˆê¹Œ? â€¢ ì§•í›„ì— ë”°ë¥¸ í˜¼ë™ì´ ìˆìŠµë‹ˆê¹Œ? â€¢ íƒì§€/ì•…ëª… í¸í–¥ì´ ìˆìŠµë‹ˆê¹Œ? â€¢ ë…ë¦½ì ì¸ ë°©ë²•ì´ ì¼ê´€ëœ ê²°ê³¼ë¥¼ ì œê³µí•©ë‹ˆê¹Œ?"
            },
            {
              heading: "Signal Assessment (Is it clinically important?):",
              text: "â€¢ Absolute risk: how many excess events per 1,000 users?\nâ€¢ Comparison to alternatives: are other drugs safer?\nâ€¢ Severity: death/disability vs transient symptoms?\nâ€¢ Population at risk: vulnerable subgroups?"
            },
            {
              heading: "Action:",
              text: "â€¢ Communicate risk (label changes, dear doctor letters)\nâ€¢ Restrict use (contraindications, REMS)\nâ€¢ Withdraw (if risk outweighs all benefit)\nâ€¢ Request confirmatory studies (if uncertainty remains)"
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "Self-Controlled Designs: Eliminating Between-Person Confounding",
          sections: [
            {
              heading: "The Idea:",
              items: [
                "Use each person as their own control",
                "Compare risk during 'exposed' periods to 'unexposed' periods",
                "All time-invariant confounders automatically controlled",
                "No healthy user bias from comparing different people"
              ]
            },
            {
              heading: "Case-Crossover Design:",
              items: [
                "ì‚¬ë¡€ë¶€í„° ì‹œì‘(ì‚¬ê±´ì„ ê²ªì€ ì‚¬ëŒ)",
                "Compare their exposure in the hazard period (just before event)",
                "To their exposure in control periods (earlier times)",
                "If exposure is higher in hazard periods â†’ association"
              ]
            },
            {
              heading: "Self-Controlled Case Series (SCCS):",
              items: [
                "Uses only people who had BOTH exposure and outcome",
                "Compares rate during exposed periods to unexposed periods",
                "Requires that exposure doesn't affect future outcome probability",
                "ë°±ì‹  ì•ˆì „ì„±ì„ ìœ„í•´ ê´‘ë²”ìœ„í•˜ê²Œ ì‚¬ìš©ë¨(MMR-ìíì¦ì€ ì´ëŸ° ì‹ìœ¼ë¡œ ë°í˜€ì¡ŒìŠµë‹ˆë‹¤)"
              ]
            },
            {
              heading: "Limitations:",
              items: [
                "Can't control for TIME-VARYING confounders",
                "Assumes event doesn't change future exposure probability",
                "Needs intermittent exposure (not continuous use)",
                "Can be affected by exposure trends over time"
              ]
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'signal-assessment',
          title: "ì´ ì•ˆì „ ì‹ í˜¸ í‰ê°€",
          situation: "ìƒˆë¡œìš´ í•­ìš°ìš¸ì œê°€ ê°œë°œë˜ì—ˆìŠµë‹ˆë‹¤. 2ë…„ ë™ì•ˆ ì‹œì¥ì— ì¶œì‹œë˜ì—ˆìŠµë‹ˆë‹¤. FAERSì— ëŒ€í•œ ìë°œì ì¸ ë³´ê³ ëŠ” ê¸‰ì„± ì‹¬ì¥ì‚¬ì™€ì˜ ì—°ê´€ ê°€ëŠ¥ì„±ì„ ì‹œì‚¬í•©ë‹ˆë‹¤. ë³´ê³ ìœ¨ì€ ë‹¤ë¥¸ í•­ìš°ìš¸ì œë³´ë‹¤ 3ë°° ë” ë†’ìŠµë‹ˆë‹¤. ì´ ì•½ë¬¼ì€ ì„ìƒì‹œí—˜ì—ì„œ QT ì—°ì¥ì— ëŒ€í•´ ì•Œë ¤ì§„ ë°”ê°€ ì—†ìŠµë‹ˆë‹¤. 500,000ëª…ì˜ í™˜ìê°€ ì´ ì œí’ˆì„ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤.",
          nodes: {
            start: {
              question: "First step: Is this signal reliable?",
              branches: [
                { text: "No â€” spontaneous reports are unreliable, need RCT confirmation", nextNode: "dismiss_wrong" },
                { text: "ì•„ë§ˆë„ â€” ë³´ê³  í¸ê²¬ê³¼ ì§•í›„ì— ë”°ë¥¸ í˜¼ë€ì„ í™•ì¸í•˜ì„¸ìš”", nextNode: "check_bias_correct" },
                { text: "Yes â€” 3x higher is definitely a signal, withdraw the drug", nextNode: "overreact_wrong" }
              ]
            },
            check_bias_correct: {
              situation: "Good. You investigate. The drug is preferentially prescribed to older, sicker patients (confounding by indication). But the disproportionality persists after adjusting for age and comorbidity in database studies. Rate ratio: 2.1 (95% CI 1.4-3.2) vs comparator antidepressants.",
              question: "Next step:",
              branches: [
                { text: "Validate in an independent database using different methods", nextNode: "validate_correct" },
                { text: "Issue immediate drug withdrawal â€” 2.1 RR is alarming", nextNode: "withdraw_early" },
                { text: "í•´ì œ â€” ë°ì´í„°ë² ì´ìŠ¤ ì—°êµ¬ëŠ” ê´€ì°°ì´ë¯€ë¡œ RCTë¥¼ ê¸°ë‹¤ë¦¬ì„¸ìš”", nextNode: "dismiss_again_wrong" }
              ]
            },
            dismiss_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Dangerous dismissal!",
              text: "ìë°œì ì¸ ë³´ê³ ì„œëŠ” ì‹ ë¢°í•  ìˆ˜ ì—†ì§€ë§Œ ì•ˆì „ ê°ì‹œì˜ ìµœì „ì„ ì…ë‹ˆë‹¤. 3ë°° ë” ë†’ì€ ì‹ ê³ ìœ¨ì€ í•´ê³ ê°€ ì•„ë‹Œ ì¡°ì‚¬ë¥¼ ë³´ì¥í•©ë‹ˆë‹¤. Vioxxì˜ ì‹¬ì¥ ì‹ í˜¸ëŠ” ì¡°ì¹˜ê°€ ì·¨í•´ì§€ê¸° ëª‡ ë…„ ì „ë¶€í„° ìë°œì ìœ¼ë¡œ ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹¤.",
              lesson: "ì‹ í˜¸ëŠ” ì¡°ì‚¬ê°€ í•„ìš”í•©ë‹ˆë‹¤. 'ì‹ ë¢°í•  ìˆ˜ ì—†ë‹¤'ëŠ” ê²ƒì´ 'ë¬´ì‹œí•˜ë‹¤'ëŠ” ëœ»ì€ ì•„ë‹™ë‹ˆë‹¤. ì´ëŠ” 'ë” ë‚˜ì€ ë°©ë²•ìœ¼ë¡œ ì¶”ê°€ ì¡°ì‚¬'ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤."
            },
            overreact_wrong: {
              type: 'outcome',
              outcome: 'partial',
              title: "Premature action!",
              text: "Spontaneous reporting has many biases: notoriety bias (more reports after media coverage), channeling (drug given to sicker patients), stimulated reporting. A 3x disproportionality needs confirmation before withdrawing a drug that may help millions.",
              lesson: "ê³¼ê²©í•œ ì¡°ì¹˜ë¥¼ ì·¨í•˜ê¸° ì „ì— ì‹ í˜¸ë¥¼ ê²€ì¦í•´ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ê²€ì¦ì€ ë¹¨ë¼ì•¼ í•©ë‹ˆë‹¤. Vioxxì˜ ê²½ìš° 4ë…„ì´ ê±¸ë¦¬ì§€ ì•ŠìŠµë‹ˆë‹¤."
            },
            validate_correct: {
              situation: "ë‘ ë²ˆì§¸ ë°ì´í„°ë² ì´ìŠ¤ì— ë³µì œí•˜ê³  ë¹„ìŠ·í•œ ê²°ê³¼ë¥¼ ì°¾ìŠµë‹ˆë‹¤: RR 1.9(1.3-2.8). ìì²´ í†µì œ ì‚¬ë¡€ ì‹œë¦¬ì¦ˆëŠ” ë˜í•œ ë…¸ì¶œëœ ê¸°ê°„ì— ìœ„í—˜ì´ ì¦ê°€í•œ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤: IRR 2.5(1.6-3.9). ì´ì œ ì–´ë–»ê²Œ í•˜ì‹œê² ìŠµë‹ˆê¹Œ?",
              question: "Decision time:",
              branches: [
                { text: "ê°•ë ¥í•œ ì¦ê±° â€” ìœ„í—˜ì„ ì•Œë¦¬ê³  ì œí•œ ì‚¬í•­ì„ ê³ ë ¤í•˜ì„¸ìš”", nextNode: "action_correct" },
                { text: "Still observational â€” request an RCT before acting", nextNode: "request_rct_wrong" }
              ]
            },
            withdraw_early: {
              type: 'outcome',
              outcome: 'partial',
              title: "Maybe appropriate, but validate first",
              text: "ì‹¬ì¥ ëŒì—°ì‚¬ì— ëŒ€í•œ ë¹„ìœ¨ ë¹„ìœ¨ 2.1ì€ ì‹¬ê°í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ë…ë¦½ì ì¸ ë°ì´í„°ì˜ ë³µì œëŠ” ì‹ ë¢°ë„ë¥¼ ê°•í™”í•  ê²ƒì…ë‹ˆë‹¤. ì‹ í˜¸ê°€ ì‹¤ì œë¼ë©´ ì¡°ì¹˜ê°€ í•„ìš”í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì¸ìœ„ì ì¸ ê²½ìš°, ì•½ë¬¼ ì¤‘ë‹¨ì€ ì•½ë¬¼ì˜ í˜œíƒì„ ë°›ëŠ” í™˜ìì—ê²Œ í•´ë¥¼ ë¼ì¹©ë‹ˆë‹¤.",
              lesson: "ì‹¬ê°í•œ í•´ë¥¼ ë¼ì¹˜ëŠ” ê²½ìš°ì—ëŠ” ì¡°ì¹˜ë¥¼ ì·¨í•˜ëŠ” ê²ƒì´ ì¢‹ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹ ì†í•œ ê²€ì¦(ëª‡ ë…„ì´ ì•„ë‹Œ ë©°ì¹ ì—ì„œ ëª‡ ì£¼ê¹Œì§€)ì„ í†µí•´ ë¶ˆí•„ìš”í•œ ì² íšŒì™€ ì¡°ì¹˜ ì§€ì—°ì„ ëª¨ë‘ ë°©ì§€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤."
            },
            dismiss_again_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì€ Vioxxì˜ ì‹¤íŒ¨ì…ë‹ˆë‹¤!",
              text: "í•´ë¡œì›€ì— ëŒ€í•œ RCT ì¦ê±°ë¥¼ ê¸°ë‹¤ë¦¬ëŠ” ê²ƒì€ ì‹¤ìˆ˜ì…ë‹ˆë‹¤. í¬ê·€í•œ í”¼í•´ì— ëŒ€í•œ RCTì—ëŠ” ì—„ì²­ë‚œ ì–‘ì˜ í‘œë³¸ì´ í•„ìš”í•©ë‹ˆë‹¤. ë°©ë²•(ì½”í˜¸íŠ¸, SCCS) ë° ëª¨ì§‘ë‹¨ ì „ë°˜ì— ê±¸ì³ ì¼ê´€ëœ ê²°ê³¼ë¥¼ ì œê³µí•˜ëŠ” ë°ì´í„°ë² ì´ìŠ¤ ì—°êµ¬ëŠ” ê°•ë ¥í•œ ì¦ê±°ë¥¼ ì œê³µí•©ë‹ˆë‹¤. 'ê´€ì°°'ì€ 'ë¬´ì‹œ'ë¥¼ ì˜ë¯¸í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.",
              lesson: "í•´ë¡œì›€ì˜ ê²½ìš° ì—¬ëŸ¬ ê°œì˜ ì¼ê´€ëœ ê´€ì°° ì—°êµ¬ê°€ (ì¢…ì¢… ë¶ˆê°€ëŠ¥í•œ) RCTë¥¼ ê¸°ë‹¤ë¦¬ëŠ” ê²ƒë³´ë‹¤ ë” ê°•ë ¥í•œ ì¦ê±°ë¥¼ ì œê³µí•˜ëŠ” ê²½ìš°ê°€ ë§ìŠµë‹ˆë‹¤. ì´ìš© ê°€ëŠ¥í•œ ìµœì„ ì˜ ì¦ê±°ì— ë”°ë¼ ì¡°ì¹˜ë¥¼ ì·¨í•˜ì„¸ìš”."
            },
            request_rct_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "An RCT for sudden cardiac death?",
              text: "ì‹¬ì¥ ëŒì—°ì‚¬ì˜ ë‘ ë°° ì¦ê°€(ê¸°ì¤€ ë¹„ìœ¨ ~0.1%)ë¥¼ íƒì§€í•˜ë ¤ë©´ ìˆ˜ë…„ê°„ 50,000ëª… ì´ìƒì˜ í™˜ìë¥¼ ì¶”ì í•´ì•¼ í•©ë‹ˆë‹¤. ì´ê²ƒì€ ë¹„ì‹¤ìš©ì ì…ë‹ˆë‹¤. RCTê°€ ì™„ë£Œë  ë•Œê¹Œì§€ ìˆ˜ì²œ ëª…ì´ ë” ì‚¬ë§í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê´€ì°° ì¦ê±°ëŠ” ë“œë¬¼ì§€ë§Œ ì‹¬ê°í•œ í”¼í•´ì— ëŒ€í•´ ì–»ì„ ìˆ˜ ìˆëŠ” ìµœê³ ì˜ ì¦ê±°ì…ë‹ˆë‹¤.",
              lesson: "ì¦ê±° ê¸°ë°˜ ì˜í•™ì€ 'RCT ì—¬ë¶€'ê°€ ì•„ë‹™ë‹ˆë‹¤. 'ê°€ëŠ¥í•œ ìµœì„ ì˜ ì¦ê±°ë¥¼ ì‚¬ìš©'í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë“œë¬¸ í”¼í•´ì˜ ê²½ìš° ì´ëŠ” ì˜ ìˆ˜í–‰ëœ ê´€ì°° ì—°êµ¬ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤."
            },
            action_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Appropriate response!",
              text: "With replicated observational evidence using multiple methods, action is warranted. Options: label warnings, contraindications for high-risk patients, REMS program, or (if alternatives exist and harm is severe) withdrawal. The exact action depends on benefit-harm balance.",
              lesson: "ì‹ í˜¸ â†’ ê²€ì¦ â†’ í‰ê°€ â†’ ì¡°ì¹˜. Vioxx ì°¸ì‚¬ëŠ” ì¡°ì¹˜ê°€ ì§€ì—°ë˜ì—ˆê¸° ë•Œë¬¸ì— ë°œìƒí–ˆìŠµë‹ˆë‹¤. ë‹¤ìˆ˜ì˜ ì¼ê´€ëœ ê´€ì°° ì‹ í˜¸ ìˆ˜ìš” ë°˜ì‘"
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "ì™œ ì•½ë¬¼ HARMSì— ëŒ€í•œ ì¦ê±° ì„ê³„ê°’ì´ ì¼ë°˜ì ìœ¼ë¡œ ì•½ë¬¼ ì´ìµì— ëŒ€í•œ ì¦ê±° ì„ê³„ê°’ë³´ë‹¤ ë‚®ìŠµë‹ˆê¹Œ?",
          options: [
            { id: 'a', text: "Harms are easier to measure than benefits", correct: false },
            { id: 'b', text: "ìœ„ìŒì„±(í•´ë¡œì›€ ëˆ„ë½)ì˜ ë¹„ìš©ì´ ìœ„ì–‘ì„±(í˜œíƒ ëˆ„ë½) ë¹„ìš©ì„ ì´ˆê³¼í•©ë‹ˆë‹¤.", correct: true },
            { id: 'c', text: "ê´€ì°° ì—°êµ¬ëŠ” ì´ì ë³´ë‹¤ í•´ë¡œì›€ì— ëŒ€í•´ ë” ì‹ ë¢°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.", correct: false },
            { id: 'd', text: "RCTs cannot detect harms, only benefits", correct: false }
          ],
          explanation: "í˜œíƒì˜ ê²½ìš° ìœ„ì–‘ì„±(ë¹„íš¨ê³¼ì ì¸ ì¹˜ë£Œ ìŠ¹ì¸)ì€ ìì›ì„ ë‚­ë¹„í•©ë‹ˆë‹¤. í•´ë¡œì›€ì˜ ê²½ìš° ê±°ì§“ ìŒì„±(ìœ í•´í•œ íš¨ê³¼ ëˆ„ë½)ì´ ì‚¬ëŒì„ ì£½ì…ë‹ˆë‹¤. ê²°ê³¼ì˜ ë¹„ëŒ€ì¹­ì„±ì€ ë¹„ëŒ€ì¹­ ì¦ê±° ì„ê³„ê°’ì„ ì •ë‹¹í™”í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë“ì„ ë¯¿ëŠ” ê²ƒë³´ë‹¤ í•´ë¥¼ ì˜ì‹¬í•˜ëŠ” ë°ì— ëœ í™•ì‹¤ì„±ì„ ìš”êµ¬í•´ì•¼ í•©ë‹ˆë‹¤."
        }
      }
    ]
  },
  // MODULE 10: THE INTEGRATION (When to Trust Observational Evidence)
  {
    id: 10,
    title: "The Integration",
    subtitle: "When to Trust",
    principle: 6,
    estimatedTime: "35 min",
    slides: [
      {
        type: 'principle-display',
        content: {
          principle: "Replication builds confidence"
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "ìˆ˜ë ´: í¡ì—°ê³¼ íì•” â€” ê´€ì°°ì´ ì¶©ë¶„í–ˆì„ ë•Œ",
          source: "Doll & Hill 1950-2004 | Bradford Hill Criteria | Never randomized",
          timeline: [
            { year: "1950", text: "Doll & Hill case-control study: smokers 9x more likely to have lung cancer. Tobacco industry demands RCT proof. (Unethical to randomize smoking)", type: "normal" },
            { year: "1954", text: "British Doctors cohort begins. Prospective design addresses reverse causation. Shows dose-response: more cigarettes â†’ more cancer.", type: "normal" },
            { year: "1964", text: "US Surgeon General declares smoking causes lung cancer. Based entirely on observational evidence. No RCT ever conducted.", type: "revelation" },
            { year: "2004", text: "50-year follow-up: smokers lose 10 years of life expectancy. Quitting at any age helps. Observational evidence now indisputable.", type: "revelation" },
            { year: "How We Knew", text: "Strength (RR = 10-30), consistency (every study), temporality (smoking preceded cancer), dose-response, biological plausibility, coherence, specificity, analogy, experiment (cessation reduces risk).", type: "revelation" },
            { year: "Lesson", text: "Bradford Hill ê¸°ì¤€ì€ RCTê°€ ë¶ˆê°€ëŠ¥í–ˆì„ ë•Œ ê´€ì°° ë°ì´í„°ë¡œë¶€í„° ì¸ê³¼ê´€ê³„ ì¶”ë¡ ì„ ê°€ëŠ¥í•˜ê²Œ í–ˆìŠµë‹ˆë‹¤. ê°•ë ¥í•˜ê³  ì¼ê´€ë˜ë©° ìƒë¬¼í•™ì ìœ¼ë¡œ ê·¸ëŸ´ë“¯í•œ ì—°ê´€ì„±ì€ ë¬´ì‘ìœ„ ë°°ì • ì—†ì´ ì¸ê³¼ ê´€ê³„ë¥¼ í™•ë¦½í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "Lung cancer mortality",
            drug: "Heavy smoking (20+ cigarettes/day)",
            placebo: "Never smokers",
            rr: "RR 10-30 (study dependent)",
            ci: "Unmistakable association",
            nnh: "Millions of deaths attributable to smoking"
          },
          hook: "ë¬¸ì œ: ìš°ë¦¬ëŠ” í¡ì—°ì„ ë¬´ì‘ìœ„ë¡œ ë°°ì •í•œ ì ì´ ì—†ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ í¡ì—°ì´ íì•”ì„ ìœ ë°œí•œë‹¤ëŠ” ì‚¬ì‹¤ì„ ì˜ì‹¬í•˜ëŠ” ì‚¬ëŒì€ ì•„ë¬´ë„ ì—†ìŠµë‹ˆë‹¤. ê´€ì°° ì¦ê±°ë§Œìœ¼ë¡œ ì„¸ìƒì´ ì–´ë–»ê²Œ í™•ì‹ ì„ ê°–ê²Œ ë˜ì—ˆìŠµë‹ˆê¹Œ? Bradford Hill ê¸°ì¤€ì€ RCTê°€ ë¶ˆê°€ëŠ¥í•˜ê±°ë‚˜ ë¹„ìœ¤ë¦¬ì ì¸ ê²½ìš° ì¸ê³¼ê´€ê³„ ì¶”ë¡ ì„ ìœ„í•œ í”„ë ˆì„ì›Œí¬ì…ë‹ˆë‹¤."
        }
      },
      {
        type: 'principle',
        content: {
          text: "â¸ï¸ KEY INSIGHT: Observational evidence CAN establish causation when: (1) associations are STRONG, (2) results REPLICATE across studies/populations/methods, (3) temporality is clear, (4) dose-response exists, (5) biological mechanism is plausible, (6) findings are COHERENT with existing knowledge. No single criterion is required; it's the totality of evidence."
        }
      },
      {
        type: 'content',
        content: {
          title: "The Bradford Hill Criteria (Updated)",
          sections: [
            {
              heading: "1. Strength of Association:",
              text: "Larger effect sizes are less likely to be entirely due to confounding. RR = 10 is hard to explain by bias alone; RR = 1.2 might be entirely confounded."
            },
            {
              heading: "2. Consistency:",
              text: "Same finding across different populations, settings, methods, times. If it replicates everywhere, less likely to be artifact."
            },
            {
              heading: "3. Specificity:",
              text: "ë…¸ì¶œì€ íŠ¹ì • ê²°ê³¼(ëª¨ë“  ê²ƒì´ ì•„ë‹˜)ë¡œ ì´ì–´ì§‘ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ë‹¤ì¤‘ ì›ì¸ ì§ˆë³‘ì€ ì´ë¥¼ ìœ„ë°˜í•©ë‹ˆë‹¤. í¡ì—°ì€ ë§ì€ ì§ˆë³‘ì„ ìœ ë°œí•©ë‹ˆë‹¤. ê°€ì¥ ëœ ì¤‘ìš”í•œ ê¸°ì¤€."
            },
            {
              heading: "4. Temporality:",
              text: "Cause MUST precede effect. This is essential. Cohort studies establish temporality; cross-sectional cannot."
            },
            {
              heading: "5. Biological Gradient (Dose-Response):",
              text: "More exposure â†’ more outcome. Supports causation. But non-linear relationships can be causal too."
            },
            {
              heading: "6. Plausibility:",
              text: "ê´€ê³„ë¥¼ ì„¤ëª…í•  ìˆ˜ ìˆëŠ” ìƒë¬¼í•™ì  ë©”ì»¤ë‹ˆì¦˜ì´ ì¡´ì¬í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì‹¤ì œ ì›ì¸ì— ëŒ€í•œ ë©”ì»¤ë‹ˆì¦˜ì´ í•­ìƒ ì•Œë ¤ì§„ ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤."
            },
            {
              heading: "7. Coherence:",
              text: "Association doesn't conflict with known biology, natural history, epidemiology. Should 'fit' existing knowledge."
            },
            {
              heading: "8. Experiment:",
              text: "ë…¸ì¶œì„ ì œê±°í•˜ë©´ ê²°ê³¼ê°€ ì¤„ì–´ë“­ë‹ˆë‹¤(ì¤‘ë‹¨ ì—°êµ¬). ë˜ëŠ” ìì—° ì‹¤í—˜ì´ íš¨ê³¼ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤."
            },
            {
              heading: "9. Analogy:",
              text: "Similar exposures cause similar outcomes. If A causes X, then similar B might cause similar Y."
            }
          ]
        }
      },
      {
        type: 'method',
        content: {
          label: "ë°©ë²•: ì‚¼ê°ì¸¡ëŸ‰",
          title: "Modern Approach to Causal Inference",
          sections: [
            {
              heading: "What Is Triangulation?",
              text: "ê°ê° ì„œë¡œ ë‹¤ë¥¸ í¸í–¥ ì†ŒìŠ¤ê°€ ìˆëŠ” ì—¬ëŸ¬ ì—°êµ¬ ì„¤ê³„ë¥¼ ì‚¬ìš©í•˜ì—¬ ë™ì¼í•œ ë‹µì— ìˆ˜ë ´ë˜ëŠ”ì§€ í™•ì¸í•©ë‹ˆë‹¤. í¸í–¥ì€ ë‹¤ë¥´ì§€ë§Œ ê²°ê³¼ëŠ” ì¼ì¹˜í•˜ëŠ” ê²½ìš° ì¸ê³¼ê´€ê³„ê°€ ìˆì„ ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤."
            },
            {
              heading: "Example: Alcohol and Heart Disease",
              text: "â€¢ Cohort studies: moderate drinking appears protective (confounded by healthy user?)\nâ€¢ Mendelian randomization: genetic variants for alcohol metabolism show NO protection\nâ€¢ Sibling comparisons: within-family, no protective effect\n\nTriangulation: cohort studies were confounded. Observational 'benefit' is not causal."
            },
            {
              heading: "Key Insight:",
              text: "Different methods have different biases:\nâ€¢ Cohort studies: confounding, selection\nâ€¢ Case-control: recall bias\nâ€¢ Mendelian randomization: pleiotropy, weak instruments\nâ€¢ Within-family: shared family environment\n\nIf ALL methods agree despite DIFFERENT biases, confidence in causality increases."
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "ê´€ì°° ì¦ê±°ë¥¼ ì‹ ë¢°í•´ì•¼ í•˜ëŠ” ê²½ìš°",
          sections: [
            {
              heading: "HIGH Confidence When:",
              items: [
                "Large effect size (RR > 2-3) â€” hard to explain by bias alone",
                "í¸í–¥ì´ ì„œë¡œ ë‹¤ë¥¸ ì—¬ëŸ¬ ë°©ë²•ì—ì„œ ì¼ê´€ë¨",
                "Clear temporality (prospective cohort, not cross-sectional)",
                "Dose-response present",
                "Biologically plausible mechanism known",
                "Low risk of bias by ROBINS-I criteria",
                "Mendelian randomization agrees with observational"
              ]
            },
            {
              heading: "LOW Confidence When:",
              items: [
                "Small effect size (RR 1.0-1.5) â€” easily confounded",
                "ê²°ê³¼ëŠ” ë°©ë²•ì— ë”°ë¼ ë‹¤ì–‘í•¨(ì½”í˜¸íŠ¸ ëŒ€ ì‚¬ë¡€ ëŒ€ì¡° ë¶ˆì¼ì¹˜)",
                "Cross-sectional design (reverse causation possible)",
                "No dose-response or paradoxical patterns",
                "Mechanism unknown or contradicts biology",
                "High risk of bias across studies",
                "Mendelian randomization contradicts observational"
              ]
            },
            {
              heading: "The 'Smoking Test':",
              text: "ê°€ëŠ¥ ì¸¡ì •ë˜ì§€ ì•Šì€ í˜¼ë€ì€ í¡ì—° â†’ íì•”(RR 10-30)ë§Œí¼ ê°•ë ¥í•©ë‹ˆê¹Œ? íš¨ê³¼ê°€ RR 1.3ì¸ ê²½ìš° ë…¸ì¶œê³¼ ê²°ê³¼ ëª¨ë‘ì— ëŒ€í•œ RR 2ì˜ í˜¼ë€ ìš”ì¸ì´ ì´ë¥¼ ì™„ì „íˆ ì„¤ëª…í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. íš¨ê³¼ê°€ RR 10ì´ë©´ ì„¤ëª…í•˜ê¸°ê°€ í›¨ì”¬ ë” ì–´ë µìŠµë‹ˆë‹¤."
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'trust-decision',
          title: "ì´ ê´€ì°° ê²°ê³¼ë¥¼ ì‹ ë¢°í•´ì•¼ í•©ë‹ˆê¹Œ?",
          situation: "You've read that red meat consumption is associated with colorectal cancer. Cohort studies show RR ~1.2 (1.1-1.4) for high vs low consumption. This is consistent across multiple cohorts. Biological plausibility exists (heme iron, heterocyclic amines). No RCT is possible (can't randomize diet for decades).",
          nodes: {
            start: {
              question: "First consideration: What do you think of RR = 1.2?",
              branches: [
                { text: "Moderate effect â€” warrants public health attention", nextNode: "moderate_wrong" },
                { text: "Small effect â€” could easily be explained by confounding", nextNode: "small_correct" },
                { text: "Negligible â€” ignore it", nextNode: "ignore_wrong" }
              ]
            },
            small_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤. RR 1.2ëŠ” í¬ê¸°ê°€ ì‘ì•„ í˜¼ë€ìŠ¤ëŸ¬ìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì´ëŠ” ì§‘ë‹¨ ì „ë°˜ì— ê±¸ì³ ì¼ê´€ì„±ì´ ìˆìŠµë‹ˆë‹¤. ìƒí™©ì´ ë°”ë€Œë‚˜ìš”?",
              question: "Consistency across cohorts means:",
              branches: [
                { text: "It's probably causal â€” too consistent to be chance", nextNode: "consistent_overinterpret" },
                { text: "ì—°êµ¬ëŠ” ë™ì¼í•œ í¸í–¥ì„ ê³µìœ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤(ê±´ê°•í•œ ì‚¬ìš©ì, ì”ì—¬ í˜¼ë€)", nextNode: "shared_bias_correct" }
              ]
            },
            moderate_wrong: {
              type: 'outcome',
              outcome: 'partial',
              title: "Be more skeptical",
              text: "RR 1.2ëŠ” ì „ì—¼ë³‘í•™ì—ì„œ ì‘ì€ íš¨ê³¼ì…ë‹ˆë‹¤. ë¹„êµë¥¼ ìœ„í•´ í¡ì—°ê³¼ íì•”ì€ RR 10-30ì…ë‹ˆë‹¤. 1.2ì˜ íš¨ê³¼ í¬ê¸°ëŠ” ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ì´ ì‰½ê²Œ ìƒì„±ë  ìˆ˜ ìˆëŠ” ë²”ìœ„ ë‚´ì— ìˆìŠµë‹ˆë‹¤. 'ë³´í†µ'ì´ ì•„ë‹ˆë¼ 'ë¶ˆí™•ì‹¤í•¨'ì…ë‹ˆë‹¤.",
              lesson: "In observational epidemiology, be skeptical of RR < 2. Such effects could be entirely confounded."
            },
            ignore_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Don't dismiss entirely",
              text: "RR 1.2 at a population level still matters. If millions eat high red meat, even small excess risks produce substantial burden. The effect may be real but confounded; it's worth investigating with different methods.",
              lesson: "Small effects can have large public health impact. Don't dismiss, but be appropriately uncertain."
            },
            consistent_overinterpret: {
              type: 'outcome',
              outcome: 'partial',
              title: "ì¼ê´€ì„±ì— ì£¼ì˜í•˜ì„¸ìš”!",
              text: "Consistency is reassuring, but cohort studies share SIMILAR biases: all have healthy user effects, similar measurement error, similar confounding structures. Consistency within one method doesn't rule out systematic bias in that method.",
              lesson: "ë°©ë²•(ì½”í˜¸íŠ¸, ì‚¬ë¡€ ëŒ€ì¡°, ë©˜ë¸ë¦¬ì•ˆ ë¬´ì‘ìœ„ ë°°ì •) ì „ë°˜ì˜ ì¼ê´€ì„±ì´ í•œ ê°€ì§€ ë°©ë²• ë‚´ì—ì„œì˜ ì¼ê´€ì„±ë³´ë‹¤ ë” ì•ˆì‹¬ì´ ë©ë‹ˆë‹¤."
            },
            shared_bias_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤. ë¶‰ì€ ê³ ê¸° ì†Œë¹„ì— ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ìœ ì „ì  ë³€ì´ë¥¼ ì‚¬ìš©í•˜ì—¬ ë©˜ë¸ì˜ ë¬´ì‘ìœ„ ë°°ì •(MR) ì—°êµ¬ê°€ ìˆ˜í–‰ëœë‹¤ë©´ ì–´ë–¨ê¹Œìš”? MRì´ ëŒ€ì¥ì•”ê³¼ ì•„ë¬´ëŸ° ê´€ë ¨ì´ ì—†ë‹¤ê³  ê°€ì •í•´ ë³´ê² ìŠµë‹ˆë‹¤.",
              question: "ì–´ë–¤ ê²°ë¡ ì„ ë‚´ë¦½ë‹ˆê¹Œ?",
              branches: [
                { text: "MRì´ í™•ì •ì ì…ë‹ˆë‹¤. ì½”í˜¸íŠ¸ ì—°êµ¬ì—ì„œëŠ” í˜¼ë€ì´ ë°œìƒí–ˆìŠµë‹ˆë‹¤.", nextNode: "mr_definitive_partial" },
                { text: "Triangulation: discordant results suggest confounding, but MR has limitations too", nextNode: "triangulation_correct" }
              ]
            },
            mr_definitive_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "MR isn't perfect either",
              text: "Mendelian randomization has limitations: genetic variants may affect multiple pathways (pleiotropy), instruments may be weak, genetic effects operate lifelong (not same as adult dietary change). Discordant MR suggests confounding in cohorts, but doesn't definitively prove null effect.",
              lesson: "í™•ì •ì ì¸ ë‹¨ì¼ ë°©ë²•ì€ ì—†ìŠµë‹ˆë‹¤. ì‚¼ê°ì¸¡ëŸ‰ì€ ê°ê° ì„œë¡œ ë‹¤ë¥¸ í•œê³„ê°€ ìˆëŠ” ì—¬ëŸ¬ ì ‘ê·¼ë²•ì˜ ì¦ê±°ë¥¼ ë¹„êµí•˜ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤."
            },
            triangulation_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Excellent triangulation!",
              text: "You've correctly identified: (1) small effect size â†’ possibly confounded; (2) consistency within method doesn't rule out shared bias; (3) discordant MR suggests confounding but isn't definitive. The appropriate conclusion is: 'Uncertain â€” possible small effect, possibly confounded.'",
              lesson: "This is the current scientific consensus on red meat and colorectal cancer: probably some effect, but magnitude uncertain due to potential confounding. Public health messaging should reflect this uncertainty."
            }
          }
        }
      },
      {
        type: 'quiz',
        content: {
          question: "ì–´ë–¤ ì‹œë‚˜ë¦¬ì˜¤ê°€ ì¸ê³¼ê´€ê³„ì— ëŒ€í•œ ê°€ì¥ ê°•ë ¥í•œ ê´€ì°° ì¦ê±°ë¥¼ ì œê³µí•©ë‹ˆê¹Œ?",
          options: [
            { id: 'a', text: "ëª¨ë‘ ìœ ì‚¬í•œ êµë€ êµ¬ì¡°ë¥¼ ê°–ëŠ” RR 1.3ì„ ë³´ì—¬ì£¼ëŠ” 20ê°œì˜ ì½”í˜¸íŠ¸ ì—°êµ¬", correct: false },
            { id: 'b', text: "ë‹¤ì–‘í•œ ë°©ë²•(ì½”í˜¸íŠ¸, ì‚¬ë¡€ ëŒ€ì¡°, MR, í˜•ì œ) ëª¨ë‘ RR ~3ì„ ë‚˜íƒ€ëƒ„", correct: true },
            { id: 'c', text: "RR 1.5ë¥¼ ë‚˜íƒ€ë‚´ëŠ” 100ë§Œ ëª…ì˜ ì°¸ê°€ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ 1ê°œì˜ ëŒ€ê·œëª¨ ì½”í˜¸íŠ¸ ì—°êµ¬", correct: false },
            { id: 'd', text: "A meta-analysis of 50 studies showing pooled RR 1.2 with IÂ² = 0%", correct: false }
          ],
          explanation: "Triangulation across different methods with different biases provides the strongest evidence. If cohort studies (confounding), case-control (recall bias), MR (pleiotropy), and sibling comparisons (genetic confounding) all converge on RR ~3, each method's biases are unlikely to produce the same false answer. Large N or many studies with the SAME bias doesn't help."
        }
      },
      {
        type: 'content',
        content: {
          title: "Mendelian Randomization: Nature's RCT",
          sections: [
            {
              heading: "The Brilliant Idea:",
              items: [
                "Genetic variants are assigned at conception (before any confounders)",
                "Like random assignment in an RCT",
                "Find a gene that affects exposure (e.g., alcohol metabolism)",
                "Compare outcomes in people with different gene variants",
                "Since genes are 'randomized,' confounding is eliminated"
              ]
            },
            {
              heading: "Example: Alcohol and Heart Disease",
              items: [
                "Observational: moderate drinkers have lower CVD than non-drinkers",
                "Confounding? Moderate drinkers may be healthier overall",
                "MR approach: Use ALDH2 gene (affects alcohol metabolism)",
                "People with 'slow metabolizer' variant drink less",
                "MR result: NO cardioprotection from moderate drinking",
                "ê´€ì°° ì—°ê´€ì„±ì´ í˜¼ë€ìŠ¤ëŸ¬ì› ìŠµë‹ˆë‹¤"
              ]
            },
            {
              heading: "Limitations (IMPORTANT):",
              items: [
                "PLEIOTROPY: Gene may affect outcome through other pathways",
                "WEAK INSTRUMENTS: Gene may explain tiny fraction of exposure",
                "POPULATION STRATIFICATION: Ancestry can confound",
                "DEVELOPMENTAL EFFECTS: Lifelong genetic effect â‰  adult intervention",
                "MRì€ ê°•ë ¥í•˜ì§€ë§Œ ì˜¤ë¥˜ê°€ ì—†ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ì‚¼ê°ì¸¡ëŸ‰"
              ]
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'mr-interpretation',
          title: "ì´ MR ì—°êµ¬ í•´ì„",
          situation: "Observational studies consistently show that higher vitamin D levels are associated with lower risk of multiple sclerosis (MS). RR = 0.60 (0.50-0.70) per 50 nmol/L higher vitamin D. An MR study uses genetic variants affecting vitamin D synthesis.",
          nodes: {
            start: {
              question: "MR ì—°êµ¬ì—ì„œëŠ” ë” ë†’ì€ ë¹„íƒ€ë¯¼ Dì— ëŒ€í•œ ìœ ì „ì  ì†Œì¸ì´ ë” ë‚®ì€ MS ìœ„í—˜(ìœ ì „ì ìœ¼ë¡œ ì˜ˆì¸¡ëœ â€‹â€‹50nmol/Lë‹¹ OR 0.70)ê³¼ ì—°ê´€ë˜ì–´ ìˆìŒì„ ë°œê²¬í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì‹œì‚¬í•˜ëŠ” ë°”ëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "Vitamin D supplementation will prevent MS", nextNode: "supplement_wrong" },
                { text: "ê´€ì°° ì—°ê´€ì„±ì€ ë‹¨ì§€ í˜¼ë™ëœ ê²ƒì´ ì•„ë‹ˆë¼ ì¸ê³¼ì ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.", nextNode: "causal_correct" },
                { text: "ê´€ì°° ì—°êµ¬ë¥¼ ê¸°ê°í•´ì•¼ í•©ë‹ˆë‹¤", nextNode: "dismiss_wrong" }
              ]
            },
            supplement_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Too far!",
              text: "MR supports causality of vitamin D LEVELS, but: (1) Lifelong genetically-determined levels â‰  adult supplementation; (2) The genetic effect operates from birth; (3) There may be critical windows in childhood. MR suggests vitamin D matters but doesn't prove SUPPLEMENTATION works.",
              lesson: "MRì€ ë…¸ì¶œì˜ ì¸ê³¼ íš¨ê³¼ë¥¼ í…ŒìŠ¤íŠ¸í•©ë‹ˆë‹¤. íŠ¹íˆ ì‹œê¸°/ìš©ëŸ‰/í˜•íƒœê°€ ë‹¤ë¥¸ ê²½ìš°ì—ëŠ” ì¤‘ì¬ê°€ íš¨ê³¼ê°€ ìˆëŠ”ì§€ ì•Œë ¤ì£¼ì§€ ì•ŠìŠµë‹ˆë‹¤."
            },
            causal_correct: {
              situation: "ì˜¬ë°”ë¥¸ í•´ì„ì…ë‹ˆë‹¤! MRì€ ì¸ê³¼ê´€ê³„ë¥¼ ì§€ì§€í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ í™•ì‹ ì„ ê°–ê¸° ì „ì— ë¬´ì—‡ì„ í™•ì¸í•´ì•¼ í• ê¹Œìš”?",
              question: "What's the key assumption to verify?",
              branches: [
                { text: "Sample size is adequate", nextNode: "sample_wrong" },
                { text: "The genetic variants don't affect MS through other pathways (pleiotropy)", nextNode: "pleiotropy_correct" }
              ]
            },
            dismiss_wrong: {
              type: 'outcome',
              outcome: 'partial',
              title: "Don't dismiss â€” triangulate!",
              text: "MR SUPPORTING observational findings is good news! When methods with different biases agree (observational: confounding; MR: pleiotropy), confidence increases. Consistency between methods is the goal of triangulation.",
              lesson: "ê´€ì°° ì—°êµ¬ì™€ MR ì—°êµ¬ ê°„ì˜ ì¼ì¹˜ëŠ” ì¸ê³¼ ê´€ê³„ì— ëŒ€í•œ ê·¼ê±°ë¥¼ ê°•í™”í•©ë‹ˆë‹¤. ì„œë¡œ ë‹¤ë¥¸ í¸í–¥ì´ ìˆìœ¼ë¯€ë¡œ ë‘˜ ë‹¤ ë™ì˜í•˜ë©´ ê´€ì°° ì—°êµ¬ì—ì„œ í˜¼ë™ë  ê°€ëŠ¥ì„±ì´ ì ìŠµë‹ˆë‹¤."
            },
            sample_wrong: {
              type: 'outcome',
              outcome: 'partial',
              title: "ì‚¬ì‹¤ì´ì§€ë§Œ ì£¼ìš” ê°€ì •ì€ ì•„ë‹™ë‹ˆë‹¤",
              text: "ì •í™•ë„ì— ìˆì–´ ì ì ˆí•œ í‘œë³¸ í¬ê¸°ê°€ ì¤‘ìš”í•˜ì§€ë§Œ MRì˜ ê¸°ë³¸ ê°€ì •ì€ ìœ ì „ì  ë³€ì´ê°€ ë…¸ì¶œì„ í†µí•´ì„œë§Œ ê²°ê³¼ì— ì˜í–¥ì„ ë¯¸ì¹œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¹„íƒ€ë¯¼ D ìœ ì „ìê°€ ë©´ì—­ ê¸°ëŠ¥(ë‹¤ë°œì„±)ì—ë„ ì§ì ‘ì ìœ¼ë¡œ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ê²½ìš° MRì€ í¸í–¥ë©ë‹ˆë‹¤.",
              lesson: "MR validity depends on: (1) Genes affect exposure, (2) Genes don't affect outcome except through exposure, (3) Genes aren't confounded (usually satisfied). Violation of #2 (pleiotropy) is the main threat."
            },
            pleiotropy_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Exactly right!",
              text: "ë‹¤ë°œì„±ì€ MRì˜ ì•„í‚¬ë ˆìŠ¤ê±´ì…ë‹ˆë‹¤. ë¹„íƒ€ë¯¼ D ìœ ì „ìê°€ ë©´ì—­ ê¸°ëŠ¥, íƒœì–‘ ë…¸ì¶œ í–‰ë™ ë˜ëŠ” ë‹¤ë°œì„± ê²½í™”ì¦ì— ëŒ€í•œ ê¸°íƒ€ ê²½ë¡œì—ë„ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ê²½ìš° MR ì¶”ì •ì¹˜ëŠ” í¸í–¥ë©ë‹ˆë‹¤. ë‹¤ë©´ë°œí˜„(MR-Egger, ê°€ì¤‘ ì¤‘ì•™ê°’)ì„ í…ŒìŠ¤íŠ¸/ì¡°ì •í•˜ëŠ” ë°©ë²•ì´ ì¡´ì¬í•˜ì§€ë§Œ ì—¬ì „íˆ ë¬¸ì œê°€ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤.",
              lesson: "When reading MR studies, always ask: 'Could these genes affect the outcome through OTHER pathways?' If yes, interpret cautiously. Use multiple genetic variants and sensitivity analyses."
            }
          }
        }
      },
      {
        type: 'story-deep',
        content: {
          label: "í•˜ìœ„ ê·¸ë£¹ í•¨ì •: ACCORD â€” í‰ê· ì´ í•´ë¥¼ ìˆ¨ê²¼ì„ ë•Œ",
          source: "NEJM 2008; ACCORD Study Group | Intensive glycemic control | Effect modification",
          timeline: [
            { year: "Hypothesis", text: "Lower blood sugar should prevent diabetic complications. Target HbA1c <6% (intensive) vs <7.5% (standard). Makes biological sense.", type: "normal" },
            { year: "2008", text: "ACCORDê°€ HARMì— ëŒ€í•´ ì¼ì° ì¤‘ë‹¨ë˜ì—ˆìŠµë‹ˆë‹¤. ì§‘ì¤‘ ì œì–´ë¡œ ì¸í•œ ì‚¬ë§ë¥  ì¦ê°€: HR 1.22(1.01-1.46). ì‚¬ë§ì 257ëª… ëŒ€ 203ëª…. ì˜ˆìƒê³¼ ì •ë°˜ëŒ€.", type: "crisis" },
            { year: "But Wait", text: "ADVANCE trial (similar design): NO mortality increase. VADT trial: NO mortality increase. Same intervention, different results. Why?", type: "crisis" },
            { year: "Subgroup Analysis", text: "ACCORD ì—°êµ¬ì—ì„œ ì´ì „ì— ì‹¬í˜ˆê´€ ì§ˆí™˜ì„ ì•“ì•˜ë˜ í™˜ìëŠ” ì§‘ì¤‘ í†µì œ ì‹œ ì‚¬ë§ë¥ ì´ ë” ë†’ì•˜ìŠµë‹ˆë‹¤. CVDê°€ ì—†ëŠ” í™˜ìì˜ ì‚¬ë§ë¥ ì€ ë” ë‚®ì•˜ìŠµë‹ˆë‹¤. AVERAGEëŠ” ë°˜ëŒ€ íš¨ê³¼ë¥¼ ëª¨í˜¸í•˜ê²Œ í–ˆìŠµë‹ˆë‹¤.", type: "revelation" },
            { year: "The Lesson", text: "íš¨ê³¼ ìˆ˜ì •: ê°œì…ì€ ì–´ë–¤ ì‚¬ëŒì—ê²ŒëŠ” ë„ì›€ì´ ë˜ê³  ë‹¤ë¥¸ ì‚¬ëŒì—ê²ŒëŠ” í•´ë¥¼ ë¼ì¹©ë‹ˆë‹¤. í•˜ìœ„ ê·¸ë£¹ ì „ì²´ì˜ í‰ê· í™”ëŠ” ì˜¤í•´ì˜ ì†Œì§€ê°€ ìˆëŠ” 'ë„' ë˜ëŠ” ì‘ì€ íš¨ê³¼ë¥¼ ì œê³µí•©ë‹ˆë‹¤. ë§ì¶¤í˜• ì˜ë£Œë¥¼ ìœ„í•´ì„œëŠ” WHOê°€ ì´ìµì„ ì–»ê³  WHOê°€ í”¼í•´ë¥¼ ì…ëŠ”ë‹¤ëŠ” ì´í•´ê°€ í•„ìš”í•©ë‹ˆë‹¤.", type: "revelation" },
            { year: "Clinical Impact", text: "ì´ì œ ì§€ì¹¨ì—ì„œëŠ” CVDê°€ ìˆëŠ” ë…¸ì¸ í™˜ìì˜ ê²½ìš° ê³µê²©ì ì¸ í˜ˆë‹¹ ëª©í‘œë¥¼ ë°˜ëŒ€í•˜ëŠ” ê²ƒì„ ê¶Œì¥í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ë” ì Šê³  ê±´ê°•í•œ ë‹¹ë‡¨ë³‘ í™˜ìì˜ ì§‘ì¤‘ì ì¸ ì¡°ì ˆì„ ìœ„í•´. í•˜ë‚˜ì˜ ëŒ€ë‹µì´ ëª¨ë“  ê²ƒì— ì í•©í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤.", type: "revelation" }
          ],
          realData: {
            endpoint: "All-cause mortality",
            drug: "Intensive glycemic control (HbA1c <6%)",
            placebo: "Standard control (HbA1c <7.5%)",
            rr: "Overall: HR 1.22 (1.01-1.46) | By CVD: OPPOSITE directions",
            ci: "Heterogeneity of treatment effect",
            nnh: "One-size-fits-all kills"
          },
          hook: "THE HOOK: ACCORDëŠ” ì™œ 'í‰ê· ì ì¸ ì¹˜ë£Œ íš¨ê³¼'ê°€ ìœ„í—˜í•  ìˆ˜ ìˆëŠ”ì§€ ë³´ì—¬ì¤ë‹ˆë‹¤. ëª¨ë“  í™˜ìì˜ í‰ê· ì€ ì‘ì€ í”¼í•´ì˜€ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì´ í‰ê· ì€ ì§‘ì¤‘ì ì¸ í†µì œê°€ ì–´ë–¤ ì‚¬ëŒì—ê²ŒëŠ” ë„ì›€ì´ ë˜ê³  ì–´ë–¤ ì‚¬ëŒì€ ì£½ì¸ë‹¤ëŠ” ì‚¬ì‹¤ì„ ìˆ¨ê²¼ìŠµë‹ˆë‹¤. ê´€ì°° ì—°êµ¬ë¥¼ í†µí•´ RCTê°€ ë†“ì¹œ íš¨ê³¼ ìˆ˜ì •ì„ íƒìƒ‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤."
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'effect-modification',
          title: "ì´ íš¨ê³¼ ìˆ˜ì • ë˜ëŠ” êµë€ì´ ìˆìŠµë‹ˆê¹Œ?",
          situation: "In your observational study, you find that a statin reduces cardiovascular events overall (HR 0.80). But when you stratify by age: <65 years HR 0.60; â‰¥65 years HR 0.95.",
          nodes: {
            start: {
              question: "What is happening here?",
              branches: [
                { text: "Confounding by age â€” need to adjust", nextNode: "confounding_wrong" },
                { text: "Effect modification â€” statin works better in younger patients", nextNode: "modification_correct" },
                { text: "Statistical artifact â€” subgroups are underpowered", nextNode: "artifact_partial" }
              ]
            },
            confounding_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì€ êµë€ì´ ì•„ë‹™ë‹ˆë‹¤!",
              text: "êµë€ì€ ì—°ë ¹ì´ ë…¸ì¶œ-ê²°ê³¼ ê´€ê³„ë¥¼ ì™œê³¡í•œë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤(ë‚˜ì´ê°€ ë§ì€ í™˜ìëŠ” ìŠ¤íƒ€í‹´ì„ ë³µìš©í•˜ê³  CVDì— ê±¸ë¦´ ê°€ëŠ¥ì„±ì´ ë” ë†’ìŒ). íš¨ê³¼ ìˆ˜ì •ì€ ìŠ¤íƒ€í‹´ì˜ íš¨ê³¼ê°€ ì—°ë ¹ì— ë”°ë¼ ë‹¤ë¥´ë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì´ë“¤ì€ ê·¼ë³¸ì ìœ¼ë¡œ ë‹¤ë¦…ë‹ˆë‹¤. ì´ë¯¸ ì—°ë ¹ë³„ë¡œ ê³„ì¸µí™”í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‹¤ì–‘í•œ íš¨ê³¼ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.",
              lesson: "í˜¼ë€ ìš”ì¸: í˜¼ë€ ìš”ì¸ì€ ê°€ì§œ ì—°ê´€ì„±ì„ ë§Œë“­ë‹ˆë‹¤. íš¨ê³¼ ìˆ˜ì •: íš¨ê³¼ëŠ” í•˜ìœ„ ê·¸ë£¹ì—ì„œ ì‹¤ì œë¡œ ë‹¤ë¦…ë‹ˆë‹¤. ê³„ì¸µí™”í•˜ë©´ íš¨ê³¼ ìˆ˜ì •ì´ ë“œëŸ¬ë‚©ë‹ˆë‹¤."
            },
            modification_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤! ì‹¤ì œë¡œ ë‚˜ì´ì— ë”°ë¼ íš¨ê³¼ê°€ ë‹¤ë¦…ë‹ˆë‹¤. ì´ì œ: ì „ì²´ HR 0.80ì„ ë³´ê³ í•´ì•¼ í•©ë‹ˆê¹Œ, ì•„ë‹ˆë©´ ê³„ì¸µí™”ëœ ê²°ê³¼ë¥¼ ë³´ê³ í•´ì•¼ í•©ë‹ˆê¹Œ?",
              question: "Best reporting:",
              branches: [
                { text: "ì „ì²´ HR 0.80ë§Œ ë³´ê³  â€” ê³„ì¸µí™”ëœ ê²°ê³¼ëŠ” ê°€ì„¤ ìƒì„±ì…ë‹ˆë‹¤.", nextNode: "overall_wrong" },
                { text: "ë‘ ê°€ì§€ ëª¨ë‘ ë³´ê³ í•˜ê³ , íš¨ê³¼ëŠ” ì—°ë ¹ ë° ì„ìƒì  ì˜ë¯¸ì— ë”°ë¼ ë‹¤ë¥´ë‹¤ëŠ” ì ì„ ê°•ì¡°í•©ë‹ˆë‹¤.", nextNode: "both_correct" }
              ]
            },
            artifact_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Worth checking, but pattern suggests real modification",
              text: "í•­ìƒ í•˜ìœ„ ê·¸ë£¹ ì°¨ì´ê°€ ìš°ì—°ì¼ ìˆ˜ ìˆëŠ”ì§€ í™•ì¸í•˜ì„¸ìš”. ê·¸ëŸ¬ë‚˜ HR 0.60ê³¼ HR 0.95ëŠ” í° ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤. ìƒí˜¸ ì‘ìš© í…ŒìŠ¤íŠ¸(ìƒí˜¸ ì‘ìš©ì˜ ê²½ìš° p) ì¤‘ìš”í•œ ê²½ìš° íš¨ê³¼ ìˆ˜ì •ì´ ì‹¤ì œì¼ ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤. ë¹„ë¡ ì¤‘ìš”í•˜ì§€ ì•Šë”ë¼ë„ ì„ìƒì ì¸ ì°¨ì´ê°€ ì¤‘ìš”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "Test for statistical interaction. But don't dismiss clinically important differences just because p>0.05 â€” subgroup analyses are often underpowered."
            },
            overall_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì€ ACCORD ì‹¤ìˆ˜ì…ë‹ˆë‹¤!",
              text: "ì „ë°˜ì ì¸ íš¨ê³¼ë§Œ ë³´ê³ í•˜ë©´ ìŠ¤íƒ€í‹´ì´ ì Šì€ í™˜ìì—ê²ŒëŠ” ë§¤ìš° ì˜ ì‘ìš©í•˜ê³  ë…¸ì¸ í™˜ìì—ì„œëŠ” ê±°ì˜ íš¨ê³¼ê°€ ì—†ë‹¤ëŠ” ì‚¬ì‹¤ì´ ìˆ¨ê²¨ì§‘ë‹ˆë‹¤. 65ì„¸ í™˜ìê°€ ìŠ¤íƒ€í‹´ ë³µìš©ì„ ê²°ì •í•˜ë©´ ì˜ëª»ëœ ì •ë³´ë¥¼ ì–»ê²Œ ë©ë‹ˆë‹¤. íš¨ê³¼ ìˆ˜ì •ì—ëŠ” ì„ìƒì  ì˜í–¥ì´ ìˆìŠµë‹ˆë‹¤.",
              lesson: "íš¨ê³¼ ìˆ˜ì •ì´ ìˆìœ¼ë©´ ì „ë°˜ì ì¸ íš¨ê³¼ê°€ ì˜¤í•´ë¥¼ ë¶ˆëŸ¬ì¼ìœ¼í‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê³„ì¸µí™”ëœ ê²°ê³¼ë¥¼ ë³´ê³ í•˜ê³  ëˆ„ê°€ ê°€ì¥ ë§ì€ í˜œíƒì„ ë°›ê³  ëˆ„ê°€ í˜œíƒì„ ë°›ì§€ ëª»í•  ìˆ˜ ìˆëŠ”ì§€ ë…¼ì˜í•©ë‹ˆë‹¤."
            },
            both_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "íˆ¬ëª…í•˜ê³  ì„ìƒì ìœ¼ë¡œ ìœ ìš©í•©ë‹ˆë‹¤!",
              text: "Reporting both allows clinicians to make better decisions. A 50-year-old might be more motivated to take statins (HR 0.60). An 80-year-old might reasonably decline (HR 0.95, with potential side effects). Personalized medicine requires understanding heterogeneity.",
              lesson: "íš¨ê³¼ ìˆ˜ì •ì€ ê·€ì°®ì€ ê²ƒì´ ì•„ë‹ˆë¼ ì •ë³´ì…ë‹ˆë‹¤. ì—¬ëŸ¬ í…ŒìŠ¤íŠ¸ì— ëŒ€í•´ ì ì ˆí•œ ì£¼ì˜ë¥¼ ê¸°ìš¸ì—¬ í•˜ìœ„ ê·¸ë£¹ íš¨ê³¼ë¥¼ íƒìƒ‰í•˜ê³  ë³´ê³ í•˜ë©´ ì„ìƒ ì¹˜ë£Œê°€ í–¥ìƒë©ë‹ˆë‹¤."
            }
          }
        }
      },
      {
        type: 'content',
        content: {
          title: "Beyond PS: Instrumental Variables & Natural Experiments",
          sections: [
            {
              heading: "When PS Methods Fail:",
              text: "Propensity scores require the 'no unmeasured confounding' assumption. When key confounders are unmeasured, we need different approaches: instrumental variables (IV) and natural experiments."
            },
            {
              heading: "Instrumental Variable Intuition:",
              items: [
                "ì¹˜ë£Œì— ì˜í–¥ì„ ì£¼ì§€ë§Œ ê²°ê³¼ì—ëŠ” ì˜í–¥ì„ ë¯¸ì¹˜ì§€ ì•ŠëŠ” ê²ƒì„ ì°¾ìŠµë‹ˆë‹¤(ì¹˜ë£Œë¥¼ í†µí•œ ê²½ìš°ëŠ” ì œì™¸)",
                "ì´ 'ê¸°ê¸°'ëŠ” í™˜ì í•˜ìœ„ ì§‘í•©ì— ëŒ€í•œ ë¬´ì‘ìœ„ ë°°ì •ì„ ëª¨ë°©í•©ë‹ˆë‹¤.",
                "Example: Distance to hospital affects treatment choice, not directly affecting outcome",
                "IV ì¶”ì •ì¹˜ëŠ” ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€ì´ ìˆì–´ë„ ìœ íš¨í•©ë‹ˆë‹¤. ê³„ì¸¡ê¸°ê°€ ìœ íš¨í•¨"
              ]
            },
            {
              heading: "Common Instruments in Healthcare:",
              items: [
                "Geographic variation (physician preference, facility availability)",
                "Calendar time (guideline changes, drug approvals)",
                "Mendelian randomization (genetic variants as instruments)",
                "Regression discontinuity (treatment thresholds based on arbitrary cutoffs)"
              ]
            },
            {
              heading: "Limitations:",
              items: [
                "Instruments often have weak correlation with treatment (low power)",
                "Exclusion restriction is untestable (must argue, can't prove)",
                "Estimates may be local (compliers only, not full population)",
                "Finding valid instruments is HARD â€” most proposed instruments fail scrutiny"
              ]
            },
            {
              heading: "Key Takeaway:",
              text: "IV ë°©ë²•ì€ ìœ íš¨í•œ ê³„ì¸¡ê¸°ê°€ ì¡´ì¬í•  ë•Œ ê°•ë ¥í•©ë‹ˆë‹¤. ë©˜ë¸ì˜ ë¬´ì‘ìœ„ ë°°ì •ì€ ìœ ì „ ê¸°ê¸°ë¥¼ ì‚¬ìš©í•œ IVì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ê°€ì •ì€ ê°•ë ¥í•˜ê³  ì¢…ì¢… ìœ„ë°˜ë©ë‹ˆë‹¤. IVë¥¼ ìœ ì¼í•œ ì¦ê±° ì†ŒìŠ¤ê°€ ì•„ë‹Œ ì‚¼ê°ì¸¡ëŸ‰ìœ¼ë¡œ ì‚¬ìš©í•˜ì„¸ìš”."
            }
          ]
        }
      },
      {
        type: 'principle',
        content: {
          text: "ğŸ¯ MASTERY CHECKPOINT: You've now learned the complete toolkit for observational evidence: bias identification, DAGs, study designs, ROBINS-I, propensity scores (matching, IPTW, overlap weights), target trial emulation, instrumental variables, Mendelian randomization, negative controls, Bradford Hill criteria, and triangulation. You can IDENTIFY when observational evidence is trustworthy and when it's not. This is the core competency of evidence-based medicine."
        }
      },
      {
        type: 'principle',
        content: {
          text: "âš ï¸ THE WARNING: Average effects can hide opposite effects in subgroups. 'No overall effect' might mean 'helps some, harms others.' Effect modification is not a statistical nuisance â€” it's clinical reality. When you find it, REPORT it. When you don't find it, you may have missed it."
        }
      }
    ]
  },
  // MODULE 11: THE CAPSTONE (Putting It All Together)
  {
    id: 11,
    title: "The Capstone",
    subtitle: "Putting It Together",
    principle: null,
    estimatedTime: "45 min",
    slides: [
      {
        type: 'title',
        content: {
          title: "The Capstone",
          subtitle: "ê´€ì°° ì—°êµ¬ ë¶„ì„",
          text: "í•™ìŠµí•œ ëª¨ë“  ë‚´ìš©ì„ ì ìš©í•˜ì—¬ ì‹¤ì œ ê´€ì°° ì—°êµ¬ë¥¼ ë¹„íŒì ìœ¼ë¡œ í‰ê°€í•˜ì„¸ìš”. í¸í–¥ì„ í‰ê°€í•˜ê³  ì„¤ê³„í•œ í›„ ê²°ë¡ ì„ ì‹ ë¢°í• ì§€ ê²°ì •í•˜ê²Œ ë©ë‹ˆë‹¤."
        }
      },
      {
        type: 'content',
        content: {
          title: "ìº¡ìŠ¤í†¤ ì—°ìŠµ: ì´ ì—°êµ¬ í‰ê°€",
          sections: [
            {
              heading: "The Study:",
              text: "ì½”í˜¸íŠ¸ ì—°êµ¬ì—ì„œëŠ” ìƒˆë¡œìš´ í˜ˆì••ì•½(ì•½ë¬¼ X)ì´ ê¸°ì¡´ ì•½ë¬¼(RR 0.60, 95% CI 0.52-0.70)ì— ë¹„í•´ ë‡Œì¡¸ì¤‘ ìœ„í—˜ì„ 40% ê°ì†Œì‹œí‚¤ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ì—ì„œëŠ” 50,000ëª…ì˜ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ê±´ê°• ë³´í—˜ ë°ì´í„°ë² ì´ìŠ¤ë¥¼ 3ë…„ê°„ ì¶”ì í–ˆìŠµë‹ˆë‹¤."
            },
            {
              heading: "Study Details:",
              items: [
                "Patients were classified as 'Drug X users' if they had â‰¥2 prescriptions",
                "Comparator was 'any other antihypertensive'",
                "ì—°ë ¹, ì„±ë³„, ë‹¹ë‡¨ë³‘ ë° ì´ì „ ì‹¬í˜ˆê´€ ì§ˆí™˜ì— ëŒ€í•´ ì¡°ì •ë˜ì—ˆìŠµë‹ˆë‹¤.",
                "Follow-up started from first Drug X prescription",
                "ì•½ë¬¼ XëŠ” ë” ìƒˆë¡­ê³  ë” ë¹„ìŒŒìœ¼ë©°, ë‹¤ë¥¸ ì•½í’ˆì´ ì‹¤íŒ¨í•œ í›„ì— ìì£¼ ì‚¬ìš©ë˜ì—ˆìŠµë‹ˆë‹¤."
              ]
            },
            {
              heading: "Your Task:",
              text: "ì´ ê³¼ì •ì˜ ì›ì¹™ì„ ì‚¬ìš©í•˜ì—¬ ì´ ì—°êµ¬ë¥¼ í‰ê°€í•©ë‹ˆë‹¤. í¸í–¥, êµë€, ì—°êµ¬ ì„¤ê³„ ë° ê²°ê³¼ê°€ ì„ìƒ ì‹¤ë¬´ë¥¼ ë³€ê²½í•´ì•¼ í•˜ëŠ”ì§€ ì—¬ë¶€ë¥¼ ê³ ë ¤í•˜ì‹­ì‹œì˜¤."
            }
          ]
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'capstone-assessment',
          title: "Capstone: Full Evaluation",
          situation: "ê·€ì‚¬ëŠ” Drug X ì—°êµ¬ë¥¼ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê° í¸ê²¬ì„ ì²´ê³„ì ìœ¼ë¡œ í•´ê²°í•˜ì„¸ìš”.",
          nodes: {
            start: {
              question: "STEP 1 - IMMORTAL TIME: Patients needed â‰¥2 prescriptions to be 'Drug X users.' Time from first to second prescription is...",
              branches: [
                { text: "Correctly classified as unexposed â€” no problem", nextNode: "immortal_wrong" },
                { text: "Likely immortal time â€” must survive to get 2 prescriptions", nextNode: "immortal_correct" }
              ]
            },
            immortal_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤! 2ë²ˆì˜ ì²˜ë°©ì´ í•„ìš”í•˜ë©´ ë¶ˆë©¸ì˜ ì‹œê°„ì´ ìƒê¸´ë‹¤. ì´ëŠ” ì•½ë¬¼ Xì˜ ì´ìµì„ í–¥í•œ í¸í–¥ì…ë‹ˆë‹¤.",
              question: "2ë‹¨ê³„ - í‘œì‹œì— ë”°ë¥¸ í˜¼ë™: ì•½ë¬¼ XëŠ” 'ë‹¤ë¥¸ ì•½ë¬¼ì´ ì‹¤íŒ¨í•œ í›„ì— ì‚¬ìš©ë˜ì—ˆìŠµë‹ˆë‹¤.' ì¦‰, ì•½ë¬¼ X ì‚¬ìš©ìëŠ”...",
              branches: [
                { text: "Sicker patients with harder-to-control BP â€” confounding AGAINST Drug X", nextNode: "indication_sicker_correct" },
                { text: "Healthier patients who can afford newer drugs â€” confounding FOR Drug X", nextNode: "indication_healthier_partial" }
              ]
            },
            immortal_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì€ ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ì…ë‹ˆë‹¤!",
              text: "í™˜ìê°€ ì²« ë²ˆì§¸ ì²˜ë°© í›„ ë‘ ë²ˆì§¸ ì²˜ë°© ì „ì— ì‚¬ë§í•œ ê²½ìš° 'ë¹„ ì•½ë¬¼ X ì‚¬ìš©ì'ë¡œ ë¶„ë¥˜ë˜ì§€ë§Œ ì‹¤ì œë¡œ ì•½ë¬¼ Xë¥¼ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤. ì²˜ë°©ì „ ì‚¬ì´ì˜ ì‹œê°„ì€ ë¶ˆë©¸ì´ë©° ì˜ëª» ë¶„ë¥˜ë©ë‹ˆë‹¤. ì´ëŠ” í•­ìƒ ìƒì¡´ì´ í•„ìš”í•œ ë…¸ì¶œì— ëŒ€í•œ ëª…ë°±í•œ ì´ìµ ìª½ìœ¼ë¡œ í¸í–¥ë©ë‹ˆë‹¤.",
              lesson: "Any exposure definition requiring multiple events (prescriptions, visits, tests) creates immortal time bias."
            },
            indication_sicker_correct: {
              situation: "ë§ìŠµë‹ˆë‹¤! ë” ì•„í”ˆ í™˜ìì—ê²Œ íˆ¬ì—¬ëœ ì•½ë¬¼ XëŠ” ì•½ë¬¼ì— ëŒ€í•´ í¸ê²¬ì„ ê°–ê²Œ ë©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì—°êµ¬ ê²°ê³¼ì— ë”°ë¥´ë©´ ì´ì ì´ ìˆìŠµë‹ˆë‹¤. ì ì‘ì¦ í¸í–¥ì´ ë°˜ëŒ€ì´ê³  ê²°ê³¼ê°€ ìœ ìµí•˜ë‹¤ëŠ” ê²ƒì€ ë¬´ì—‡ì„ ì˜ë¯¸í•©ë‹ˆê¹Œ?",
              question: "STEP 3 - DIRECTION OF BIAS: With immortal time (FOR) and confounding by indication (AGAINST), the NET bias is...",
              branches: [
                { text: "They cancel out â€” result is probably unbiased", nextNode: "cancel_wrong" },
                { text: "Unclear â€” depends on which bias is larger", nextNode: "direction_correct" }
              ]
            },
            indication_healthier_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Possible, but consider the full picture",
              text: "'ë‹¤ë¥¸ ì•½ë¬¼ì´ ì‹¤íŒ¨í•œ í›„ ì‚¬ìš©'ì€ ì¼ë°˜ì ìœ¼ë¡œ ê±´ê°•í•œ í™˜ìê°€ ì•„ë‹Œ í™˜ìë¥¼ ì¹˜ë£Œí•˜ê¸°ê°€ ë” ì–´ë µë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ê·¸ë“¤ì€ 1ì°¨ ì¹˜ë£Œì— ì‹¤íŒ¨í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•½ë¬¼ Xì— ëŒ€í•œ ì ì‘ì¦ìœ¼ë¡œ ì¸í•´ í˜¼ë€ì„ ì•¼ê¸°í•©ë‹ˆë‹¤. ì´ ì—°êµ¬ëŠ” ì‹¤ì œ ì´ì ì„ ê³¼ì†Œí‰ê°€í•©ë‹ˆë‹¤.",
              lesson: "Confounding by indication in drug studies usually makes new/expensive drugs look WORSE (given to sicker patients) â€” unless healthy user bias dominates."
            },
            cancel_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Biases don't just 'cancel out'!",
              text: "í¸í–¥ì´ ìƒì‡„ëœë‹¤ê³  ê°€ì •í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ì€ ì„¤ê³„ê°€ ì´ë¥¼ ìƒì„±í•  ë•Œ ê±°ì˜ í•­ìƒ ì¡´ì¬í•©ë‹ˆë‹¤. ì ì‘ì¦ì— ì˜í•œ í˜¼ë€ì€ ì²˜ë°© íŒ¨í„´ì— ë”°ë¼ ë‹¤ë¦…ë‹ˆë‹¤. ê° í¸í–¥ì˜ í¬ê¸°ë¥¼ ì¶”ì •í•´ì•¼ í•˜ë©° í¸í–¥ì´ ìƒì‡„ëœë‹¤ê³  ê°€ì •í•˜ì§€ ì•Šì•„ì•¼ í•©ë‹ˆë‹¤.",
              lesson: "Identifying bias direction is step 1. Estimating bias MAGNITUDE requires sensitivity analysis or design changes."
            },
            direction_correct: {
              situation: "Correct! Net bias is unclear. You need more information.",
              question: "STEP 4 - ROBINS-I ASSESSMENT: Given what you know, what is your overall risk of bias judgment?",
              branches: [
                { text: "Moderate â€” some concerns but usable", nextNode: "robins_moderate_wrong" },
                { text: "Serious â€” important problems that require caution", nextNode: "robins_serious_correct" },
                { text: "Critical â€” too flawed to be useful", nextNode: "robins_critical_partial" }
              ]
            },
            robins_moderate_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Too generous!",
              text: "ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ê³¼ ì¸¡ì •ë˜ì§€ ì•Šì€ êµë€(ê³ í˜ˆì••ì˜ ì¤‘ì¦ë„, ì´ì „ ì¹˜ë£Œ ì‹¤íŒ¨)ì´ ëª¨ë‘ ìˆëŠ” ì´ ì—°êµ¬ì—ëŠ” ì‹¬ê°í•œ ë°©ë²•ë¡ ì  ë¬¸ì œê°€ ìˆìŠµë‹ˆë‹¤. 'ì¤‘ë“±ë„'ëŠ” RCTë§Œí¼ ì¢‹ë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•˜ì§€ë§Œ ê·¸ë ‡ì§€ ì•ŠìŠµë‹ˆë‹¤.",
              lesson: "ROBINS-I is intentionally strict. Real-world drug studies rarely achieve 'low' or 'moderate' without careful design (new user, active comparator, etc.)."
            },
            robins_serious_correct: {
              situation: "Appropriate! The study has serious risk of bias. Final step:",
              question: "5ë‹¨ê³„ - ì„ìƒ ê²°ì •: ë™ë£ŒëŠ” ì´ ì—°êµ¬ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í™˜ìë¥¼ ì•½ë¬¼ Xë¡œ ì „í™˜í•˜ê¸°ë¥¼ ì›í•©ë‹ˆë‹¤. ë‹¹ì‹ ì€ ì¡°ì–¸í•©ë‹ˆë‹¤ ...",
              branches: [
                { text: "Switch â€” even with bias, 40% reduction is clinically meaningful", nextNode: "switch_wrong" },
                { text: "ì „í™˜í•˜ì§€ ë§ˆì‹­ì‹œì˜¤. ë” ë‚˜ì€ ì¦ê±°(RCT ë˜ëŠ” ë” ì˜ ì„¤ê³„ëœ ê´€ì°°)ë¥¼ ê¸°ë‹¤ë¦¬ì‹­ì‹œì˜¤.", nextNode: "wait_correct" }
              ]
            },
            robins_critical_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Possible, but justify carefully",
              text: "'ì¤‘ìš”'ëŠ” ì—°êµ¬ê°€ ë³¸ì§ˆì ìœ¼ë¡œ ìœ ìš©í•œ ì •ë³´ë¥¼ ì œê³µí•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì‹¬ê°í•œ ë¶ˆë©¸ì˜ ì‹œê°„ í¸í–¥ê³¼ í˜¼ë€ìœ¼ë¡œ ì¸í•´ ê²°ê³¼ëŠ” ì˜ì‹¬ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì•½ë¬¼ì˜ ì‹¤ì œ ì‚¬ìš©ì— ëŒ€í•œ ì¼ë¶€ ì •ë³´ëŠ” ì—¬ì „íˆ ì¡´ì¬í•©ë‹ˆë‹¤. ì£¼ìš” ê²½ê³ ê°€ í¬í•¨ëœ 'ì‹¬ê°í•¨'ì´ ë” ì ì ˆí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.",
              lesson: "Reserve 'critical' for truly fatal flaws: fabricated data, fundamental design impossibilities, or complete uninformativeness."
            },
            switch_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "ì´ê²ƒì´ ë°”ë¡œ HRT ì‹¤ìˆ˜ì…ë‹ˆë‹¤!",
              text: "A 40% reduction in an observational study with serious bias could easily be ENTIRELY artifactual. Remember: HRT showed 40-50% reduction in cohorts, but the truth was HARM. Immortal time alone can create 20-40% apparent benefit. Don't change practice based on seriously biased observational data.",
              lesson: "'í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•œ ê´€ì°° ê²°ê³¼'ë¥¼ 'ì‹¤ì œ íš¨ê³¼'ì™€ ë™ì¼ì‹œí•˜ì§€ ë§ˆì„¸ìš”. HRT, ë¹„íƒ€ë¯¼ D ë° ê¸°íƒ€ ì—­ì „ í˜„ìƒì€ ëª¨ë‘ ì„¤ë“ë ¥ ìˆëŠ” ê´€ì°° ì¦ê±°ë¡œ ì‹œì‘ë˜ì—ˆìŠµë‹ˆë‹¤."
            },
            wait_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Excellent clinical judgment!",
              text: "You've correctly identified that: (1) immortal time bias inflates benefit, (2) confounding direction is unclear, (3) ROBINS-I = serious risk, (4) a 40% reduction could be artifact. The appropriate response is to wait for better evidence while acknowledging uncertainty.",
              lesson: "This capstone synthesizes everything: bias identification, ROBINS-I assessment, and clinical decision-making under uncertainty. You've learned to see beyond the headline number."
            }
          }
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'capstone-screening',
          title: "ìº¡ìŠ¤í†¤ 2: ì„ ë³„ ë…¼ë€",
          situation: "ìƒˆë¡œìš´ í˜ˆì•¡ ê²€ì‚¬ì—ì„œëŠ” ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì´ˆê¸°ì— ë°œê²¬í•  ìˆ˜ ìˆë‹¤ê³  ì£¼ì¥í•©ë‹ˆë‹¤. ë§ˆì¼€íŒ…: 'ì¡°ê¸° ë°œê²¬ ì‹œ 5ë…„ ìƒì¡´ìœ¨ 80% ëŒ€ ë°œê²¬í•˜ì§€ ì•Šì„ ê²½ìš° 40%.' ê´€ì°° ì—°êµ¬ì— ë”°ë¥´ë©´ ì¡°ê¸° ì§„ë‹¨ì„ ë°›ì€ í™˜ìëŠ” 'ë” ì˜¤ë˜ ì‚°ë‹¤'ëŠ” ì‚¬ì‹¤ì´ ë°í˜€ì¡ŒìŠµë‹ˆë‹¤. ê·€í•˜ëŠ” ì¸êµ¬ ì„ ë³„ ê²€ì‚¬ë¥¼ ê¶Œì¥í• ì§€ ì—¬ë¶€ë¥¼ ê²°ì •í•˜ëŠ” ë³´ê±´ ì •ì±… ìœ„ì›íšŒì— ì°¸ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.",
          nodes: {
            start: {
              question: "ì²« ë²ˆì§¸: '80% ëŒ€ 40% ìƒì¡´' ì£¼ì¥ì— ëŒ€í•´ ë‹¹ì¥ ìš°ë ¤ë˜ëŠ” ë¶€ë¶„ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "The numbers sound too good â€” probably exaggerated", nextNode: "exaggerated_partial" },
                { text: "This is lead time bias â€” survival improves just by diagnosing earlier", nextNode: "lead_time_correct" },
                { text: "Sample sizes must have been small", nextNode: "sample_wrong" }
              ]
            },
            lead_time_correct: {
              situation: "Exactly! You demand MORTALITY data. They provide: 'Observational cohort shows 25% lower dementia-related mortality in screened patients (HR 0.75, 95% CI 0.65-0.87).'",
              question: "ì´ ì¸êµ¬ ì„ ë³„ ê²€ì‚¬ì— ëŒ€í•œ ì„¤ë“ë ¥ ìˆëŠ” ì¦ê±°ì…ë‹ˆê¹Œ?",
              branches: [
                { text: "ì˜ˆ â€” ì‚¬ë§ë¥ ì€ ì˜¬ë°”ë¥¸ ê²°ê³¼ì´ê³  HRì€ ì¤‘ìš”", nextNode: "mortality_wrong" },
                { text: "No â€” observational screening studies have healthy screener bias", nextNode: "screener_bias_correct" }
              ]
            },
            exaggerated_partial: {
              type: 'outcome',
              outcome: 'partial',
              title: "Skepticism is good, but identify the SPECIFIC bias",
              text: "ê·€í•˜ì˜ ì§ê°ì´ ë§ì§€ë§Œ êµ¬ì²´ì ì¸ ë©”ì»¤ë‹ˆì¦˜ì€ ë¦¬ë“œ íƒ€ì„ ë°”ì´ì–´ìŠ¤ì…ë‹ˆë‹¤. ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ ì„ ë³„ê²€ì‚¬ë¥¼ í†µí•´ 3ë…„ ì „ì— ë°œê²¬ë˜ì—ˆìœ¼ë‚˜ í™˜ìê°€ ì—¬ì „íˆ ê°™ì€ ë‚˜ì´ì— ì‚¬ë§í•˜ëŠ” ê²½ìš°, 5ë…„ ìƒì¡´ìœ¨ì€ 40%ì—ì„œ 80%ë¡œ ì¦ê°€í•˜ë©° ì‚¬ë§ë¥  í˜œíƒì€ 0ì…ë‹ˆë‹¤. ìƒì¡´ í†µê³„ëŠ” ìŠ¤í¬ë¦¬ë‹ì— ëŒ€í•´ ì²´ê³„ì ìœ¼ë¡œ ì˜¤í•´ë¥¼ ë¶ˆëŸ¬ì¼ìœ¼í‚µë‹ˆë‹¤.",
              lesson: "Always name the specific bias. 'Sounds too good' isn't actionable. 'Lead time bias inflates survival' is."
            },
            sample_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Sample size isn't the issue here!",
              text: "í™˜ìê°€ ë°±ë§Œ ëª…ì´ë¼ë„ ë¦¬ë“œ íƒ€ì„ í¸í–¥ìœ¼ë¡œ ì¸í•´ ìŠ¤í¬ë¦¬ë‹ì„ ìœ„í•œ ìƒì¡´ í†µê³„ëŠ” ì˜ë¯¸ê°€ ì—†ìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ëŠ” ì™„ë²½í•˜ê²Œ ì •í™•í•  ìˆ˜ ìˆì§€ë§Œ ê²€ì‚¬ê°€ ìƒëª…ì„ êµ¬í•˜ëŠ”ì§€ ì—¬ë¶€ì— ëŒ€í•´ì„œëŠ” ì•„ë¬´ ê²ƒë„ ì•Œë ¤ì£¼ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ëŠ” ë¬´ì‘ìœ„ ì˜¤ë¥˜ê°€ ì•„ë‹ˆë¼ ì²´ê³„ì  í¸í–¥ì…ë‹ˆë‹¤.",
              lesson: "Precision (large N) doesn't fix bias. A very precise estimate of the wrong thing is still wrong."
            },
            mortality_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "You forgot healthy screener bias!",
              text: "People who seek screening are systematically healthier: they exercise, eat well, have good healthcare access. They have lower mortality FROM EVERYTHING â€” including dementia â€” even if screening doesn't help. This is the same bias that fooled us with HRT, colonoscopy, and health checkups.",
              lesson: "Observational comparisons of screened vs unscreened populations are ALWAYS confounded by healthy screener bias. Only RCTs can eliminate it."
            },
            screener_bias_correct: {
              situation: "Perfect! You demand RCT evidence. They say: 'No RCT exists, but screening is harmless â€” it's just a blood test. Why not offer it while we wait for RCT results?'",
              question: "Your response:",
              branches: [
                { text: "Reasonable â€” a blood test has minimal harm", nextNode: "harmless_wrong" },
                { text: "ìŠ¤í¬ë¦¬ë‹ì€ ë¬´í•´í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. í•˜ìœ„ ìœ„í—˜ì´ ìˆìŠµë‹ˆë‹¤", nextNode: "harms_correct" }
              ]
            },
            harmless_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Screening cascade causes real harm!",
              text: "The blood test may be harmless, but what happens NEXT? False positives lead to: anxiety, depression, insurance discrimination, further invasive testing, treatments with side effects for disease that may never cause symptoms. For Alzheimer's with no disease-modifying treatment, early diagnosis may cause psychological harm without benefit.",
              lesson: "Screening harms: false positives â†’ anxiety + invasive follow-up; overdiagnosis â†’ treating indolent disease; psychological burden of 'patient' label. These are CERTAIN. Benefits are UNCERTAIN until RCT-proven."
            },
            harms_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Outstanding policy reasoning!",
              text: "You correctly identified: (1) survival claims = lead time bias; (2) mortality observational data = healthy screener bias; (3) screening has real downstream harms. Your recommendation: NO population screening until RCT demonstrates that mortality benefits outweigh harms of false positives, overdiagnosis, and psychological burden.",
              lesson: "This capstone integrates: lead time bias, healthy screener confounding, harm-benefit balance, and evidence standards. You've learned to think critically about screening claims."
            }
          }
        }
      },
      {
        type: 'decision-tree',
        content: {
          id: 'capstone-safety-signal',
          title: "ìº¡ìŠ¤í†¤ 3: ì•ˆì „ ì‹ í˜¸",
          situation: "A widely-used diabetes drug has been on the market for 8 years. Spontaneous reports suggest possible bladder cancer association. Observational studies show conflicting results: some OR 1.3, some OR 1.0. An industry-funded cohort shows no association. Patient advocacy groups demand withdrawal.",
          nodes: {
            start: {
              question: "ì²« ë²ˆì§¸ ë‹¨ê³„: ìƒì¶©ë˜ëŠ” ê´€ì°° ì¦ê±°ë¥¼ ì–´ë–»ê²Œ í‰ê°€í•©ë‹ˆê¹Œ?",
              branches: [
                { text: "ì—…ê³„ë¥¼ ì‹ ë¢°í•˜ì‹­ì‹œì˜¤. ì½”í˜¸íŠ¸ â€” ê°€ì¥ í¬ê³  ê°€ì¥ ì—„ê²©í•œ", nextNode: "industry_wrong" },
                { text: "Assess each study's risk of bias systematically using ROBINS-I", nextNode: "robins_correct" },
                { text: "ëª¨ë“  ì—°êµ¬ì˜ í‰ê·  â€” ì§„ì‹¤ì€ ì•„ë§ˆë„ ì¤‘ê°„ì— ìˆì„ ê²ƒì…ë‹ˆë‹¤", nextNode: "average_wrong" }
              ]
            },
            industry_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Funding bias is real!",
              text: "Industry-funded studies of their own drugs consistently show more favorable results than independent studies. This isn't necessarily fraud â€” it's design choices: shorter follow-up (bladder cancer takes years), healthier populations, favorable comparators. Evaluate the METHODS, not the sponsor.",
              lesson: "Assess risk of bias, not prestige. Large doesn't mean unbiased. Consider: follow-up duration, comparator choice, outcome ascertainment, time-related biases."
            },
            robins_correct: {
              situation: "ì¢‹ì€ ì ‘ê·¼ ë°©ì‹ì…ë‹ˆë‹¤! ROBINS-IëŠ” ë‹¤ìŒê³¼ ê°™ì´ ë°í˜”ìŠµë‹ˆë‹¤. OR 1.3ì„ ë³´ì—¬ì£¼ëŠ” ì—°êµ¬ëŠ” ë” ê¸´ ì¶”ì  ê¸°ê°„(5ë…„ ì´ìƒ)ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë¬´íš¨ë¥¼ ë‚˜íƒ€ë‚´ëŠ” ì—°êµ¬ëŠ” ì¶”ì  ê¸°ê°„ì´ ë” ì§§ìŠµë‹ˆë‹¤(2-3ë…„). ë°©ê´‘ì•”ì€ ì ë³µê¸°ê°€ ê¸¸ë‹¤. ì–´ë–¤ ê²°ë¡ ì„ ë‚´ë¦¬ì‹œë‚˜ìš”?",
              question: "Your interpretation:",
              branches: [
                { text: "ë¬´íš¨ ì—°êµ¬ëŠ” ì•„ë§ˆë„ ë§ì„ ê²ƒì…ë‹ˆë‹¤. ë” ë§ì€ ì—°êµ¬ì—ì„œ íš¨ê³¼ê°€ ì—†ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤.", nextNode: "null_wrong" },
                { text: "ì ì¬ ê²°ê³¼ì— ëŒ€í•œ ì¥ê¸° ì¶”ì  ì¡°ì‚¬ëŠ” ë°©ë²•ë¡ ì ìœ¼ë¡œ ì •í™•í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹ í˜¸ëŠ” ì‹¤ì œì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.", nextNode: "latency_correct" }
              ]
            },
            average_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Don't average biased with unbiased!",
              text: "ì¼ë¶€ ì—°êµ¬ì— ì„¤ê³„ ê²°í•¨(ì ì¬ ê²°ê³¼ì— ëŒ€í•œ ì§§ì€ ì¶”ì  ì¡°ì‚¬)ì´ ìˆëŠ” ê²½ìš° ë” ë‚˜ì€ ì—°êµ¬ë¡œ í‰ê· í™”í•˜ë©´ ê²°ê³¼ê°€ í¬ì„ë©ë‹ˆë‹¤. ì‹ í˜¸. ë‹¹ì‹ ì€ ì¢‹ì€ ì¦ê±°ì™€ ë‚˜ìœ ì¦ê±°ì˜ â€‹â€‹'í‰ê· 'ì„ ì›í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì™œ ê·¸ë“¤ì´ ë‹¤ë¥¸ì§€ ì´í•´í•˜ê³  ë°©ë²•ë¡ ì ìœ¼ë¡œ íƒ€ë‹¹í•œ ì¦ê±°ë¥¼ ì‹ ë¢°í•˜ê¸°ë¥¼ ì›í•©ë‹ˆë‹¤.",
              lesson: "ë©”íƒ€ ë¶„ì„ì€ í‰ê· ì´ ì•„ë‹™ë‹ˆë‹¤. í’ˆì§ˆ ê°€ì¤‘ì¹˜ë¥¼ ì ìš©í•œ í•©ì„±ì…ë‹ˆë‹¤. í’€ë§í•˜ê¸° ì „ì— ì´ì§ˆì„± ì†ŒìŠ¤ë¥¼ ì´í•´í•˜ì‹­ì‹œì˜¤."
            },
            null_wrong: {
              type: 'outcome',
              outcome: 'danger',
              title: "Count of studies doesn't matter â€” quality does!",
              text: "Three studies with 2-year follow-up can't detect a cancer that takes 5+ years to develop. They're methodologically incapable of finding the signal even if it exists. The two studies with adequate follow-up both show elevated risk. For latent outcomes, insufficient follow-up = unable to detect, not 'no effect.'",
              lesson: "For safety signals with latent outcomes: (1) Longer follow-up is REQUIRED; (2) Short-term null studies are uninformative; (3) Trust methodologically adequate studies, not study counts."
            },
            latency_correct: {
              situation: "Correct! Now: The drug helps millions with diabetes. Bladder cancer is rare. Even if OR=1.3 is real, absolute risk is small. How do you weigh benefits vs harms?",
              question: "Your recommendation:",
              branches: [
                { text: "Withdraw the drug â€” any cancer signal is unacceptable", nextNode: "withdraw_extreme" },
                { text: "í–¥ìƒëœ ëª¨ë‹ˆí„°ë§, í™˜ì/ì²˜ë°©ì êµìœ¡ ë° ì§€ì†ì ì¸ ì—°êµ¬", nextNode: "monitor_correct" }
              ]
            },
            withdraw_extreme: {
              type: 'outcome',
              outcome: 'partial',
              title: "ì´ìµ-ìœ„í•´ ê· í˜•ì„ ê³ ë ¤í•˜ì‹­ì‹œì˜¤!",
              text: "Diabetes causes heart attacks, strokes, amputations, blindness. If this drug provides substantial benefit and the cancer risk is small (NNH > 1000), withdrawal might cause NET HARM â€” more deaths from uncontrolled diabetes than prevented cancers. Regulatory decisions must weigh absolute risks.",
              lesson: "Drug safety isn't binary. Weigh: (1) magnitude of benefit, (2) magnitude of harm, (3) availability of alternatives, (4) population affected. Small relative risks in rare outcomes may be acceptable if benefits are large."
            },
            monitor_correct: {
              type: 'outcome',
              outcome: 'success',
              title: "Balanced regulatory thinking!",
              text: "Your recommendation acknowledges: (1) Signal is plausible given latency-appropriate evidence; (2) Absolute risk is small; (3) Benefits are substantial; (4) Uncertainty remains. Enhanced monitoring allows continued benefit while gathering more data. Consider contraindication in patients with prior bladder cancer or other high-risk features.",
              lesson: "This capstone integrates: signal evaluation, bias assessment, benefit-harm balance, and proportionate response. Real pharmacovigilance is nuanced, not reflexive withdrawal or dismissal."
            }
          }
        }
      },
      {
        type: 'content',
        content: {
          title: "ğŸ“ ê³¼ì • ì™„ë£Œ: ë°°ìš´ ë‚´ìš©",
          sections: [
            {
              heading: "You can now:",
              items: [
                "âœ“ Distinguish confounding, selection bias, and information bias",
                "âœ“ Draw and interpret DAGs (Directed Acyclic Graphs)",
                "âœ“ Identify immortal time bias and other time-related biases",
                "âœ“ Recognize lead time bias in screening studies",
                "âœ“ Conduct ROBINS-I risk of bias assessments",
                "âœ“ Understand propensity scores and their limitations",
                "âœ“ Use negative controls to detect unmeasured confounding",
                "âœ“ Apply the target trial framework",
                "âœ“ í•´ì„ Mendelian ë¬´ì‘ìœ„í™” ì—°êµ¬",
                "âœ“ Evaluate when to meta-analyze observational studies",
                "âœ“ ì¸ê³¼ ì¶”ë¡ ì„ ìœ„í•´ Bradford Hill ê¸°ì¤€ ë° ì‚¼ê°ì¸¡ëŸ‰ ì‚¬ìš©",
                "âœ“ Interpret pharmacovigilance signals appropriately",
                "âœ“ Understand effect modification and heterogeneity"
              ]
            },
            {
              heading: "The Seven Principles:",
              items: [
                "1. Association is not causation â€” confounding deceives",
                "2. Time flows one direction â€” temporality matters",
                "3. ë‹¹ì‹ ì€ ë‹¹ì‹ ì´ ì°¾ê³  ìˆëŠ” ê²ƒì„ ë´…ë‹ˆë‹¤. ì„ íƒ í¸í–¥ì€ ìˆ¨ê²¨ì ¸ ìˆìŠµë‹ˆë‹¤",
                "4. Measurement shapes reality â€” information bias distorts",
                "5. Adjustment is not magic â€” residual confounding remains",
                "6. The average can lie â€” heterogeneity matters",
                "7. Replication builds confidence â€” one study is never enough"
              ]
            }
          ]
        }
      },
      {
        type: 'content',
        content: {
          title: "Final Reflection",
          sections: [
            {
              heading: "Remember:",
              text: "ê´€ì°° ì¦ê±°ëŠ” RCT ì¦ê±°ë³´ë‹¤ ì—´ë“±í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ê²ƒì€ ë‹¤ë¦…ë‹ˆë‹¤. RCTê°€ ë¶ˆê°€ëŠ¥í•˜ê±°ë‚˜ ë¹„ìœ¤ë¦¬ì ì´ê±°ë‚˜ ë¶ˆì¶©ë¶„í•  ë•Œ ê´€ì°° ë°ì´í„°ëŠ” ìš°ë¦¬ê°€ ê°€ì§„ ìµœê³ ì˜ ì¦ê±°ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹ ì¤‘í•œ í•´ì„ì´ í•„ìš”í•©ë‹ˆë‹¤."
            },
            {
              heading: "The Thalidomide-HRT Paradox:",
              items: [
                "Thalidomide: Observational evidence SAVED lives (detected harm RCTs missed)",
                "HRT: Observational evidence COST lives (confounding created false benefit)",
                "ê´€ì°°ê³¼ ë¬´ì‘ìœ„í™”ê°€ ì°¨ì´ì ì´ ì•„ë‹ˆë¼ ì‹ ì¤‘í•¨ê³¼ ë¶€ì£¼ì˜í•œ ë¶„ì„ì´ì—ˆìŠµë‹ˆë‹¤."
              ]
            },
            {
              heading: "Your Responsibility:",
              text: "ì´ì œ ê´€ì°° ì¦ê±°ë¥¼ ì´í•´í•˜ëŠ” ì‚¬ëŒìœ¼ë¡œì„œ ë‹¹ì‹ ì€ ê·¸ê²ƒì´ ì‹ ë¢°í•  ìˆ˜ ìˆëŠ” ê²ƒì¸ì§€, ì˜¤í•´ì˜ ì†Œì§€ê°€ ìˆëŠ” ê²ƒì¸ì§€, ë” ë‚˜ì€ ë°ì´í„°ë¥¼ ìš”êµ¬í•´ì•¼ í•˜ëŠ” ê²ƒì¸ì§€ë¥¼ ì‹ë³„í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ëª¨ë“  ê´€ì°° ì—°êµ¬ë¥¼ ë°˜ì‚¬ì ìœ¼ë¡œ ë¬´ì‹œí•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ í™˜ìë¥¼ ë•ê¸° ìœ„í•´ ì´ ì§€ì‹ì„ ì‚¬ìš©í•˜ì‹­ì‹œì˜¤."
            },
            {
              heading: "The Straight Path:",
              text: "ê´€ì°° ê²°ê³¼ì— ëŒ€í•œ ë§¹ëª©ì ì¸ ì‹ ë¢°ì™€ ìë™ ë¬´ì‹œ ì‚¬ì´ì—ëŠ” ë¹„íŒì ì¸ í‰ê°€ê°€ ìˆìŠµë‹ˆë‹¤. ë‹¹ì‹ ì€ ê·¸ ê¸¸ì„ ê±·ëŠ” ë²•ì„ ë°°ì› ìŠµë‹ˆë‹¤. í˜„ëª…í•˜ê²Œ ì‚¬ìš©í•˜ì„¸ìš”."
            }
          ]
        }
      },
      {
        type: 'quiz',
        content: {
          question: "ê³¼ì •ì„ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤! ì§€ê¸ˆê¹Œì§€ ë°°ìš´ ëª¨ë“  ë‚´ìš©ì„ í† ëŒ€ë¡œ, ì˜í•™ì—ì„œ ê´€ì°° ì¦ê±°ì˜ ì—­í• ì„ ê°€ì¥ ì˜ í¬ì°©í•˜ëŠ” ì§„ìˆ ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ?",
          options: [
            { id: 'a', text: "ê´€ì°° ì¦ê±°ëŠ” ì„ìƒ ê²°ì •ì— ì ˆëŒ€ ì‚¬ìš©ë˜ì–´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. RCTë§Œ ê³„ì‚°ë©ë‹ˆë‹¤.", correct: false },
            { id: 'b', text: "ìƒ˜í”Œ í¬ê¸°ê°€ ì¶©ë¶„íˆ í´ ê²½ìš° ê´€ì°° ì¦ê±°ëŠ” RCT ì¦ê±°ë§Œí¼ ì‹ ë¢°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.", correct: false },
            { id: 'c', text: "ê´€ì°° ì¦ê±°ëŠ” í•„ìˆ˜ì ì´ì§€ë§Œ ì‹ ë¢° ì´ì „ì— í¸í–¥, êµë€ ë° ë³µì œì— ëŒ€í•œ ì‹ ì¤‘í•œ í‰ê°€ê°€ í•„ìš”í•©ë‹ˆë‹¤.", correct: true },
            { id: 'd', text: "ê´€ì°° ì¦ê±°ëŠ” ê°€ì„¤ì„ ìƒì„±í•˜ëŠ” ë°ì—ë§Œ ìœ ìš©í•˜ë©° í™•ì¸ì—ëŠ” ì „í˜€ ìœ ìš©í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.", correct: false }
          ],
          explanation: "Observational evidence is essential for rare harms, long-term outcomes, and questions that can't be randomized. But it requires rigorous bias assessment (ROBINS-I), understanding of confounding structures (DAGs), and triangulation across methods. The goal isn't to dismiss observational data â€” it's to know when it's trustworthy."
        }
      }
    ]
  }
];

// Render Functions
function renderModuleNav() {
  const nav = document.getElementById('module-nav');
  nav.innerHTML = modules.map((m, i) => `
    <button class="module-item ${i === currentModule ? 'active' : ''} ${gameState.modulesCompleted.includes(i) ? 'completed' : ''}"
            onclick="goToModule(${i})"
            aria-current="${i === currentModule ? 'true' : 'false'}">
      <div class="module-number">${gameState.modulesCompleted.includes(i) ? 'âœ“' : i}</div>
      <div class="module-info">
        <div class="module-title">${m.title}</div>
        <div class="module-subtitle">${m.subtitle}${m.estimatedTime ? ` Â· <span class="time-estimate">${m.estimatedTime}</span>` : ''}</div>
      </div>
    </button>
  `).join('');

  // Update total course time in header
  const totalMinutes = modules.reduce((sum, m) => {
    const mins = m.estimatedTime ? parseInt(m.estimatedTime) : 0;
    return sum + mins;
  }, 0);
  const hours = Math.floor(totalMinutes / 60);
  const mins = totalMinutes % 60;
  const timeDisplay = document.getElementById('total-time');
  if (timeDisplay) timeDisplay.textContent = `${hours}h ${mins}m total`;
}

// Badge checking and awarding
function checkBadges() {
  const newBadges = [];

  // Story Scholar - read all stories (complete modules with stories)
  if (gameState.modulesCompleted.length >= 10 && !gameState.earnedBadges.includes('story-scholar')) {
    newBadges.push('story-scholar');
  }

  // Decision Ace - complete significant decision trees
  const treesCompleted = Object.keys(gameState.decisionTrees).filter(k =>
    gameState.decisionTrees[k].history && gameState.decisionTrees[k].history.length > 0
  ).length;
  if (treesCompleted >= 15 && !gameState.earnedBadges.includes('decision-ace')) {
    newBadges.push('decision-ace');
  }

  // Methods Master - complete all modules
  if (gameState.modulesCompleted.length === 12 && !gameState.earnedBadges.includes('methods-master')) {
    newBadges.push('methods-master');
  }

  // Award new badges
  newBadges.forEach(badge => {
    gameState.earnedBadges.push(badge);
    showBadgeNotification(badge);
  });

  if (newBadges.length > 0) saveProgress();
}

function showBadgeNotification(badgeId) {
  const badge = BADGES[badgeId];
  if (!badge) return;

  const notification = document.createElement('div');
  notification.className = 'badge-notification';
  notification.innerHTML = `
    <div class="badge-icon" style="background: ${badge.color}">${badge.icon}</div>
    <div class="badge-info">
      <div class="badge-earned">Badge Earned!</div>
      <div class="badge-name">${badge.name}</div>
    </div>
  `;
  document.body.appendChild(notification);

  setTimeout(() => notification.classList.add('show'), 100);
  setTimeout(() => {
    notification.classList.remove('show');
    setTimeout(() => notification.remove(), 500);
  }, 3000);
}

function renderSlide() {
  const container = document.getElementById('slide-container');
  const module = modules[currentModule];
  const slide = module.slides[currentSlide];

  let html = '';

  switch(slide.type) {
    case 'title':
      html = `
        <div class="slide-title">
          <h1>${slide.content.title}</h1>
          <div class="subtitle">${slide.content.subtitle}</div>
          <p class="description">${slide.content.text}</p>
        </div>
      `;
      break;

    case 'principle-display':
      html = `
        <div class="principle-box">
          <div class="number">${module.principle !== null ? module.principle + 1 : ''}</div>
          <div class="text">"${slide.content.principle}"</div>
        </div>
      `;
      break;

    case 'principle':
      html = `
        <div class="principle-box" style="background: linear-gradient(135deg, rgba(212,175,55,0.15), rgba(30,39,97,0.1)); padding: 2rem;">
          <div class="text" style="font-size: 1.2rem; line-height: 1.6; white-space: pre-line;">${slide.content.text}</div>
        </div>
      `;
      break;

    case 'story-deep':
      html = renderStoryDeep(slide.content);
      break;

    case 'story-box':
      html = renderStoryBox(slide.content);
      break;

    case 'content':
      html = renderContent(slide.content);
      break;

    case 'method':
      html = renderMethod(slide.content);
      break;

    case 'tool':
      html = renderTool(slide.content);
      break;

    case 'decision-tree':
      html = renderDecisionTree(slide.content);
      break;

    case 'quiz':
      html = renderQuiz(slide.content);
      break;

    default:
      html = `<p>Unknown slide type: ${slide.type}</p>`;
  }

  container.innerHTML = html;
  updateProgress();
  updateNavButtons();

  // Announce slide change for screen readers
  const announcer = document.getElementById('slide-announce');
  if (announcer) {
    const module = modules[currentModule];
    announcer.textContent = `Slide ${currentSlide + 1} of ${module.slides.length}, Module: ${module.title}`;
  }
}

function renderStoryDeep(content) {
  return `
    <div class="story-deep">
      <div class="story-label">${content.label}</div>
      <div class="story-source">${content.source}</div>

      <div class="timeline">
        ${content.timeline.map(event => `
          <div class="timeline-event ${event.type}">
            <div class="timeline-year">${event.year}</div>
            <div class="timeline-text">${event.text}</div>
          </div>
        `).join('')}
      </div>

      <div class="real-data-card">
        <h4>The Data That Matters</h4>
        <div class="data-grid">
          <div class="data-item">
            <div class="data-value">${content.realData.endpoint}</div>
            <div class="data-label">Endpoint</div>
          </div>
          <div class="data-item">
            <div class="data-value">${content.realData.drug}</div>
            <div class="data-label">Exposed</div>
          </div>
          <div class="data-item">
            <div class="data-value">${content.realData.placebo}</div>
            <div class="data-label">Unexposed</div>
          </div>
          <div class="data-item">
            <div class="data-value">${content.realData.rr}</div>
            <div class="data-label">Effect</div>
          </div>
        </div>
      </div>

      <div class="story-hook">${content.hook}</div>
    </div>
  `;
}

function renderStoryBox(content) {
  return `
    <div class="story-box">
      <div class="story-box-header">
        <span class="story-box-icon">${content.icon || 'ğŸ“–'}</span>
        <span class="story-box-title">${content.title}</span>
      </div>
      ${content.source ? `<div class="story-box-source">${content.source}</div>` : ''}
      <div class="story-box-content">
        ${content.paragraphs.map(p => `<p>${p}</p>`).join('')}
      </div>
      <div class="story-box-lesson">
        <div class="story-box-lesson-label">The Lesson</div>
        <div class="story-box-lesson-text">${content.lesson}</div>
      </div>
    </div>
  `;
}

function renderContent(content) {
  return `
    <div class="content-box">
      <h3>${content.title}</h3>
      ${content.sections.map(section => `
        <div class="content-section">
          <h4>${section.heading}</h4>
          ${section.text ? `<p>${section.text}</p>` : ''}
          ${section.items ? `<ul>${section.items.map(item => `<li>${item}</li>`).join('')}</ul>` : ''}
        </div>
      `).join('')}
    </div>
  `;
}

function renderMethod(content) {
  return `
    <div class="method-box">
      <div class="method-label">${content.label}</div>
      <h3>${content.title}</h3>
      ${content.sections.map(section => `
        <div class="content-section">
          <h4>${section.heading}</h4>
          <p style="white-space: pre-line;">${section.text}</p>
        </div>
      `).join('')}
    </div>
  `;
}

function renderTool(content) {
  if (content.id === 'dag-builder') {
    return renderDAGBuilder(content);
  }
  return `
    <div class="tool-container">
      <h3>${content.title}</h3>
      <p class="tool-description">${content.description}</p>
      <p style="color: var(--light-text); font-style: italic;">Tool implementation coming soon...</p>
    </div>
  `;
}

function renderDAGBuilder(content) {
  return `
    <div class="tool-container">
      <h3>${content.title}</h3>
      <p class="tool-description">${content.description}</p>

      <div class="tool-inputs" style="grid-template-columns: 1fr 1fr;">
        <div class="input-group">
          <label>Exposure</label>
          <input type="text" id="dag-exposure" placeholder="e.g., HRT use" value="HRT use">
        </div>
        <div class="input-group">
          <label>Outcome</label>
          <input type="text" id="dag-outcome" placeholder="e.g., CHD" value="CHD">
        </div>
      </div>

      <div class="input-group">
        <label>Potential Confounders (one per line)</label>
        <textarea id="dag-confounders" rows="4" placeholder="e.g.,&#10;Socioeconomic status&#10;Exercise&#10;Education">Socioeconomic status
Exercise habits
Healthcare access
Education level</textarea>
      </div>

      <button class="tool-btn" onclick="generateDAG()">Generate DAG</button>

      <div class="tool-output" id="dag-output" style="display: none;">
        <div id="dag-plot" class="plot-area"></div>
        <div id="dag-interpretation"></div>
      </div>
    </div>
  `;
}

function escapeHTML(s) {
  const d = document.createElement('div');
  d.textContent = s;
  return d.innerHTML;
}

function generateDAG() {
  const exposureRaw = document.getElementById('dag-exposure').value || 'Exposure';
  const outcomeRaw = document.getElementById('dag-outcome').value || 'Outcome';
  const confoundersText = document.getElementById('dag-confounders').value;
  const confoundersRaw = confoundersText.split('\n').filter(c => c.trim());
  const exposure = escapeHTML(exposureRaw);
  const outcome = escapeHTML(outcomeRaw);
  const confounders = confoundersRaw.map(c => escapeHTML(c));

  const output = document.getElementById('dag-output');
  output.style.display = 'block';

  // Create nodes
  const nodes = [
    { id: 'exposure', label: exposure, x: 0, y: 0.5 },
    { id: 'outcome', label: outcome, x: 1, y: 0.5 }
  ];

  confounders.forEach((c, i) => {
    nodes.push({
      id: `conf${i}`,
      label: c.trim(),
      x: 0.5,
      y: 0.1 + (i * 0.2)
    });
  });

  // Create edges
  const edges = [];
  confounders.forEach((c, i) => {
    edges.push({ from: `conf${i}`, to: 'exposure' });
    edges.push({ from: `conf${i}`, to: 'outcome' });
  });
  edges.push({ from: 'exposure', to: 'outcome', style: 'dashed' });

  // Create Plotly visualization
  const nodeX = nodes.map(n => n.x);
  const nodeY = nodes.map(n => n.y);
  const nodeLabels = nodes.map(n => n.label);

  // Create edge traces
  const edgeTraces = edges.map(e => {
    const fromNode = nodes.find(n => n.id === e.from);
    const toNode = nodes.find(n => n.id === e.to);
    return {
      x: [fromNode.x, toNode.x],
      y: [fromNode.y, toNode.y],
      mode: 'lines',
      line: {
        color: e.style === 'dashed' ? '#D4AF37' : '#1e2761',
        width: 2,
        dash: e.style === 'dashed' ? 'dash' : 'solid'
      },
      hoverinfo: 'none'
    };
  });

  const nodeTrace = {
    x: nodeX,
    y: nodeY,
    mode: 'markers+text',
    marker: {
      size: 40,
      color: nodes.map(n => n.id === 'exposure' ? '#2D8B8B' : n.id === 'outcome' ? '#BF2D2D' : '#D4AF37')
    },
    text: nodeLabels,
    textposition: 'bottom center',
    hoverinfo: 'text'
  };

  const layout = {
    showlegend: false,
    xaxis: { showgrid: false, zeroline: false, showticklabels: false, range: [-0.2, 1.2] },
    yaxis: { showgrid: false, zeroline: false, showticklabels: false, range: [-0.1, 1.1] },
    margin: { t: 20, b: 40, l: 20, r: 20 },
    height: 350,
    paper_bgcolor: 'rgba(0,0,0,0)',
    plot_bgcolor: 'rgba(0,0,0,0)'
  };

  Plotly.newPlot('dag-plot', [...edgeTraces, nodeTrace], layout, { displayModeBar: false });

  // Interpretation
  document.getElementById('dag-interpretation').innerHTML = `
    <h4 style="color: var(--teal); margin-top: 1rem;">Interpretation</h4>
    <p><strong>Backdoor paths identified:</strong> ${confounders.length} potential confounders create backdoor paths from ${exposure} to ${outcome}.</p>
    <p><strong>To estimate the causal effect of ${exposure} on ${outcome}:</strong></p>
    <ul style="margin-left: 1rem;">
      <li>You must adjust for: ${confounders.join(', ') || 'No confounders identified'}</li>
      <li>The dashed arrow represents the causal effect of interest</li>
      <li>Solid arrows represent confounding paths that must be blocked</li>
    </ul>
    <p style="color: var(--red); margin-top: 0.5rem;"><strong>Warning:</strong> Unmeasured confounders may still exist!</p>
  `;

  addPoints(50);
  if (!gameState.toolsUsed.includes('dag-builder')) {
    gameState.toolsUsed.push('dag-builder');
  }
  saveProgress();
}

function renderDecisionTree(content) {
  const treeId = content.id;
  const treeState = gameState.decisionTrees[treeId] || { currentNode: 'start', history: [] };

  let node;
  if (content.nodes[treeState.currentNode]) {
    node = content.nodes[treeState.currentNode];
  } else {
    node = content.nodes.start;
    treeState.currentNode = 'start';
  }

  let html = `
    <div class="decision-tree">
      <h3>${content.title}</h3>
      <div class="decision-scenario">${content.situation}</div>
  `;

  // Show history
  if (treeState.history.length > 0) {
    html += `
      <div class="decision-history">
        ${treeState.history.map((h, i) => `<span class="history-step">${i + 1}. ${h}</span>`).join('')}
      </div>
      <button class="undo-btn" onclick="undoDecision('${treeId}')">â† Undo Last Choice</button>
    `;
  }

  // Current situation
  if (node.situation) {
    html += `<div class="decision-situation">${node.situation}</div>`;
  }

  // Check if it's an ending
  if (node.type === 'outcome' || node.isEnding) {
    html += `
      <div class="decision-outcome ${node.consequence || node.outcome}">
        <h4>${node.title || 'Outcome'}</h4>
        <p>${node.text || ''}</p>
        <div class="decision-lesson">${node.lesson || ''}</div>
      </div>
      <button class="tool-btn" style="margin-top: 1rem;" onclick="resetDecisionTree('${treeId}')">Try Again</button>
    `;
  } else {
    // Show question and branches
    html += `<div class="decision-question">${node.question}</div>`;
    html += `<div class="decision-branches">`;
    node.branches.forEach(branch => {
      html += `
        <button class="decision-branch" onclick="makeDecision('${treeId}', '${branch.nextNode}', '${branch.text.substring(0, 30).replace(/\\/g, '\\\\').replace(/'/g, "\\'")}...')">
          ${branch.text}
        </button>
      `;
    });
    html += `</div>`;
  }

  html += `</div>`;
  return html;
}

function makeDecision(treeId, nextNode, choiceText) {
  if (!gameState.decisionTrees[treeId]) {
    gameState.decisionTrees[treeId] = { currentNode: 'start', history: [] };
  }
  gameState.decisionTrees[treeId].history.push({ nextNode: nextNode, choiceText: choiceText });
  gameState.decisionTrees[treeId].currentNode = nextNode;
  addPoints(10);
  saveProgress();
  renderSlide();
}

function undoDecision(treeId) {
  const tree = gameState.decisionTrees[treeId];
  if (tree && tree.history.length > 0) {
    tree.history.pop();
    // Replay from start using stored nextNode values
    tree.currentNode = 'start';
    for (const entry of tree.history) {
      // Support both old string format and new object format
      const node = typeof entry === 'object' ? entry.nextNode : null;
      if (node) tree.currentNode = node;
    }
    saveProgress();
    renderSlide();
  }
}

function resetDecisionTree(treeId) {
  gameState.decisionTrees[treeId] = { currentNode: 'start', history: [] };
  saveProgress();
  renderSlide();
}

function renderQuiz(content) {
  const quizId = `quiz_${currentModule}_${currentSlide}`;

  return `
    <div class="quiz-container" role="group" aria-labelledby="quiz-question">
      <div class="quiz-question" id="quiz-question">${content.question}</div>
      <div class="quiz-options" role="radiogroup">
        ${content.options.map((opt, i) => `
          <button class="quiz-option"
                  role="radio"
                  aria-checked="false"
                  data-correct="${opt.correct}"
                  data-option-id="${opt.id}"
                  onclick="selectQuizOption(this, '${quizId}', ${opt.correct})">
            ${opt.text}
          </button>
        `).join('')}
      </div>
      <div class="quiz-feedback" id="feedback-${quizId}" role="alert" aria-live="polite">
        <p>${content.explanation}</p>
      </div>
    </div>
  `;
}

const _answeredQuizzes = new Set();

function selectQuizOption(element, quizId, isCorrect) {
  // Prevent re-answering after first answer
  if (_answeredQuizzes.has(quizId)) return;

  const container = element.closest('.quiz-container');
  const options = container.querySelectorAll('.quiz-option');
  const feedback = document.getElementById(`feedback-${quizId}`);

  // Clear previous selections
  options.forEach(opt => {
    opt.classList.remove('selected', 'correct', 'incorrect');
    opt.setAttribute('aria-checked', 'false');
  });

  // Mark selection
  element.classList.add('selected');
  element.setAttribute('aria-checked', 'true');

  // Show result
  if (isCorrect) {
    element.classList.add('correct');
    feedback.classList.add('show', 'correct');
    feedback.classList.remove('incorrect');
    addPoints(30);
  } else {
    element.classList.add('incorrect');
    feedback.classList.add('show', 'incorrect');
    feedback.classList.remove('correct');
    // Show correct answer
    options.forEach(opt => {
      if (opt.dataset.correct === 'true') {
        opt.classList.add('correct');
      }
    });
  }

  // Lock quiz after answering
  _answeredQuizzes.add(quizId);
  options.forEach(opt => {
    opt.style.pointerEvents = 'none';
    opt.setAttribute('aria-disabled', 'true');
  });

  saveProgress();
}

// Navigation
function nextSlide() {
  const module = modules[currentModule];
  if (currentSlide < module.slides.length - 1) {
    currentSlide++;
  } else if (currentModule < modules.length - 1) {
    if (!gameState.modulesCompleted.includes(currentModule)) {
      gameState.modulesCompleted.push(currentModule);
      addPoints(100);
      checkBadges();
    }
    currentModule++;
    currentSlide = 0;
  }
  saveProgress();
  renderSlide();
  renderModuleNav();
  window.scrollTo(0, 0);
}

function prevSlide() {
  if (currentSlide > 0) {
    currentSlide--;
  } else if (currentModule > 0) {
    currentModule--;
    currentSlide = modules[currentModule].slides.length - 1;
  }
  saveProgress();
  renderSlide();
  renderModuleNav();
  window.scrollTo(0, 0);
}

function goToModule(moduleIndex) {
  currentModule = moduleIndex;
  currentSlide = 0;
  saveProgress();
  renderSlide();
  renderModuleNav();
  closeSidebar();
  window.scrollTo(0, 0);
}

function updateNavButtons() {
  const prevBtn = document.getElementById('prev-btn');
  const nextBtn = document.getElementById('next-btn');

  prevBtn.disabled = currentModule === 0 && currentSlide === 0;

  const isLastSlide = currentModule === modules.length - 1 &&
                      currentSlide === modules[currentModule].slides.length - 1;
  nextBtn.textContent = isLastSlide ? 'Complete Course' : 'Next â†’';
}

function updateProgress() {
  let totalSlides = 0;
  let completedSlides = 0;

  modules.forEach((m, i) => {
    totalSlides += m.slides.length;
    if (i < currentModule) {
      completedSlides += m.slides.length;
    } else if (i === currentModule) {
      completedSlides += currentSlide;
    }
  });

  const percent = Math.round((completedSlides / totalSlides) * 100);
  document.getElementById('progress-fill').style.width = `${percent}%`;
  document.getElementById('progress-text').textContent = `${percent}% Complete`;
}

// Points System
function addPoints(points) {
  gameState.points += points;
  document.getElementById('points-display').textContent = gameState.points;
}

// Persistence
function saveProgress() {
  try {
    localStorage.setItem(STORAGE_KEY, JSON.stringify({
      currentModule,
      currentSlide,
      gameState
    }));
  } catch (e) {
    console.log('Could not save progress:', e);
  }
}

function loadProgress() {
  try {
    const saved = localStorage.getItem(STORAGE_KEY);
    if (saved) {
      const data = JSON.parse(saved);
      if (data.gameState) {
        gameState = {
          points: data.gameState.points || 0,
          earnedBadges: data.gameState.earnedBadges || [],
          toolsUsed: data.gameState.toolsUsed || [],
          modulesCompleted: data.gameState.modulesCompleted || [],
          scenariosCompleted: data.gameState.scenariosCompleted || {},
          decisionTrees: data.gameState.decisionTrees || {}
        };
      }
      if (typeof data.currentModule === 'number' && data.currentModule >= 0 && data.currentModule < modules.length) {
        currentModule = data.currentModule;
      }
      if (typeof data.currentSlide === 'number' && data.currentSlide >= 0) {
        currentSlide = Math.min(data.currentSlide, modules[currentModule].slides.length - 1);
      }
    }
  } catch (e) {
    console.log('Could not load progress:', e);
  }
}

// Mobile Menu
function toggleSidebar() {
  const sidebar = document.querySelector('.sidebar');
  const overlay = document.querySelector('.sidebar-overlay');
  const hamburger = document.querySelector('.hamburger');

  sidebar.classList.toggle('open');
  overlay.classList.toggle('show');
  hamburger.setAttribute('aria-expanded', sidebar.classList.contains('open'));
}

function closeSidebar() {
  const sidebar = document.querySelector('.sidebar');
  const overlay = document.querySelector('.sidebar-overlay');
  const hamburger = document.querySelector('.hamburger');

  sidebar.classList.remove('open');
  overlay.classList.remove('show');
  hamburger.setAttribute('aria-expanded', 'false');
}

// Modal utilities: close by ID, Escape key handler
function closeModalOverlay(id) {
  const el = document.getElementById(id);
  if (el) el.remove();
}

function _attachModalEscapeHandler(overlayId) {
  function handler(e) {
    if (e.key === 'Escape') {
      closeModalOverlay(overlayId);
      document.removeEventListener('keydown', handler);
    }
  }
  document.addEventListener('keydown', handler);
}

// Badges Modal
function openBadges() {
  const earnedCount = gameState.earnedBadges.length;
  const totalCount = Object.keys(BADGES).length;

  const html = `
    <div id="badges-modal-overlay" role="dialog" aria-modal="true" aria-label="Badges" style="position: fixed; inset: 0; background: rgba(0,0,0,0.5); z-index: 2000; display: flex; align-items: center; justify-content: center; padding: 1rem;">
      <div style="background: white; border-radius: 12px; max-width: 700px; max-height: 80vh; overflow-y: auto; padding: 2rem;">
        <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 1rem;">
          <h2 style="font-family: 'Cormorant Garamond', serif; color: var(--navy);">ğŸ† Badges (${earnedCount}/${totalCount})</h2>
          <button id="badges-modal-close" onclick="closeModalOverlay('badges-modal-overlay')" style="background: none; border: none; font-size: 1.5rem; cursor: pointer;" aria-label="Close badges">&times;</button>
        </div>
        <div class="badge-grid">
          ${Object.entries(BADGES).map(([id, badge]) => {
            const earned = gameState.earnedBadges.includes(id);
            return `
              <div class="badge-card ${earned ? 'earned' : 'locked'}">
                <div class="badge-icon" style="background: ${badge.color}">${badge.icon}</div>
                <div class="badge-name">${badge.name}</div>
                <div class="badge-requirement">${earned ? 'âœ“ Earned!' : badge.requirement}</div>
              </div>
            `;
          }).join('')}
        </div>
      </div>
    </div>
  `;

  document.body.insertAdjacentHTML('beforeend', html);
  const closeBtn = document.getElementById('badges-modal-close');
  if (closeBtn) closeBtn.focus();
  _attachModalEscapeHandler('badges-modal-overlay');
}

// Glossary
function openGlossary() {
  const terms = [
    { term: "Confounding", def: "ë…¸ì¶œê³¼ ê²°ê³¼ ëª¨ë‘ì™€ ì—°ê´€ë˜ì–´ ìˆì–´ ë‘˜ ì‚¬ì´ì˜ ëª…ë°±í•œ ê´€ê³„ë¥¼ ì™œê³¡í•˜ëŠ” ë³€ìˆ˜ì…ë‹ˆë‹¤." },
    { term: "Selection Bias", def: "ì°¸ê°€ìë¥¼ ì„ íƒí•˜ê±°ë‚˜ ìœ ì§€í•˜ëŠ” ë°©ì‹ì—ì„œ ë°œìƒí•˜ëŠ” ì²´ê³„ì ì¸ ì˜¤ë¥˜ ì—°êµ¬." },
    { term: "Information Bias", def: "Systematic error in measurement or classification of exposure or outcome." },
    { term: "DAG", def: "Directed Acyclic Graph - a visual representation of causal relationships between variables." },
    { term: "Cohort Study", def: "ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ëˆ„ê°€ ê²°ê³¼ë¥¼ ë‚´ëŠ”ì§€ ì•Œì•„ë³´ê¸° ìœ„í•´ ê·¸ë£¹ì„ ì¶”ì í•˜ëŠ” ê´€ì°° ì—°êµ¬" },
    { term: "Case-Control Study", def: "ë…¸ì¶œì„ ì‹ë³„í•˜ê¸° ìœ„í•´ ê²°ê³¼ê°€ ìˆëŠ” ì‚¬ëŒ(ì‚¬ë¡€)ê³¼ ê·¸ë ‡ì§€ ì•Šì€ ì‚¬ëŒ(ëŒ€ì¡°êµ°)ì„ ë¹„êµí•˜ëŠ” ì—°êµ¬." },
    { term: "Odds Ratio", def: "Ratio of odds of exposure in cases vs controls; approximates RR when outcome is rare." },
    { term: "Risk Ratio", def: "Ratio of risk in exposed vs unexposed; measures strength of association." },
    { term: "Healthy User Bias", def: "Confounding where people who seek treatment are systematically healthier." },
    { term: "Immortal Time Bias", def: "ë…¸ì¶œ ìƒíƒœê°€ ë°”ë€” ë•Œ ê°œì¸ ì‹œê°„ì„ ì˜ëª» ë¶„ë¥˜í•¨ìœ¼ë¡œì¨ ë°œìƒí•˜ëŠ” í¸í–¥" },
    { term: "ROBINS-I", def: "ë¹„ë¬´ì‘ìœ„ ì—°êµ¬ì˜ í¸í–¥ ìœ„í—˜ - í¸í–¥ í‰ê°€ë¥¼ ìœ„í•œ ì¤‘ì¬ ë„êµ¬" },
    { term: "Propensity Score", def: "Probability of receiving treatment given observed covariates; used for adjustment." },
    { term: "Target Trial", def: "ê´€ì°° ë¶„ì„ì´ ì—ë®¬ë ˆì´ì…˜í•˜ë ¤ê³  ì‹œë„í•˜ëŠ” ê°€ìƒ RCT." },
    { term: "Residual Confounding", def: "Confounding that remains after adjustment due to unmeasured or imperfectly measured confounders." },
    { term: "Effect Modification", def: "When the effect of exposure on outcome differs across levels of another variable." },
    { term: "IPTW", def: "Inverse Probability of Treatment Weighting - weights subjects by inverse of propensity score to balance confounders." },
    { term: "Overlap Weights", def: "Modern PS weighting targeting patients with clinical equipoise; weights by 1-PS for treated, PS for untreated." },
    { term: "Instrumental Variable", def: "A variable affecting treatment but not outcome except through treatment; enables causal inference despite unmeasured confounding." },
    { term: "Mendelian Randomization", def: "Using genetic variants as instrumental variables; leverages random inheritance to mimic randomization." },
    { term: "Bradford Hill Criteria", def: "Nine criteria for assessing causation from observational data: strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, analogy." },
    { term: "Triangulation", def: "Comparing evidence across multiple methods with different biases; concordance increases confidence in causal claims." },
    { term: "Negative Control", def: "An exposure-outcome pair with no expected causal relationship; association suggests unmeasured confounding." },
    { term: "Lead Time Bias", def: "Apparent survival improvement from earlier diagnosis without true mortality benefit; common in screening evaluation." },
    { term: "E-value", def: "Minimum strength of unmeasured confounding needed to explain away an observed association." },
    { term: "New User Design", def: "ìƒì¡´ì í¸í–¥ì„ í”¼í•˜ê³  ì¡°ê¸°ì— í¬ì°©í•˜ê¸° ìœ„í•´ ì¹˜ë£Œë¥¼ ì‹œì‘í•˜ëŠ” í™˜ì(ì¼ë°˜ì ì¸ ì‚¬ìš©ìê°€ ì•„ë‹˜)ë§Œ í¬í•¨ íš¨ê³¼." }
  ];

  const html = `
    <div id="glossary-modal-overlay" role="dialog" aria-modal="true" aria-label="Glossary" style="position: fixed; inset: 0; background: rgba(0,0,0,0.5); z-index: 2000; display: flex; align-items: center; justify-content: center; padding: 1rem;">
      <div style="background: white; border-radius: 12px; max-width: 600px; max-height: 80vh; overflow-y: auto; padding: 2rem;">
        <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 1rem;">
          <h2 style="font-family: 'Cormorant Garamond', serif; color: var(--navy);">Glossary</h2>
          <button id="glossary-modal-close" onclick="closeModalOverlay('glossary-modal-overlay')" style="background: none; border: none; font-size: 1.5rem; cursor: pointer;" aria-label="Close glossary">&times;</button>
        </div>
        ${terms.map(t => `
          <div style="margin-bottom: 1rem; padding-bottom: 1rem; border-bottom: 1px solid rgba(0,0,0,0.1);">
            <strong style="color: var(--teal);">${t.term}</strong>
            <p style="margin-top: 0.25rem; color: var(--navy);">${t.def}</p>
          </div>
        `).join('')}
      </div>
    </div>
  `;

  document.body.insertAdjacentHTML('beforeend', html);
  const closeBtn = document.getElementById('glossary-modal-close');
  if (closeBtn) closeBtn.focus();
  _attachModalEscapeHandler('glossary-modal-overlay');
}

function openToolLibrary() {
  alert('ë„êµ¬ ë¼ì´ë¸ŒëŸ¬ë¦¬ê°€ ê³§ ì¶œì‹œë©ë‹ˆë‹¤! ì´ ê³¼ì •ì—ì„œ ë‹¤ë£¨ëŠ” ë„êµ¬: â€¢ DAG ì‘ì„±ê¸° â€¢ í˜¼ë€ìŠ¤ëŸ¬ìš´ ì‹œê°í™” ë„êµ¬ â€¢ ROBINS-I í‰ê°€ â€¢ ì„±í–¥ ì ìˆ˜ ê³„ì‚°ê¸° â€¢ í‘œì  ì‹œí—˜ ì„¤ê³„ì');
}

// Initialize
document.addEventListener('DOMContentLoaded', () => {
  loadProgress();
  renderModuleNav();
  renderSlide();
  document.getElementById('points-display').textContent = gameState.points;

  // Mobile menu handlers
  document.querySelector('.hamburger').addEventListener('click', toggleSidebar);
  document.querySelector('.sidebar-overlay').addEventListener('click', closeSidebar);

  // Keyboard navigation
  document.addEventListener('keydown', (e) => {
    if (e.key === 'ArrowRight' && !e.target.matches('input, textarea, button, select, [role="button"]')) {
      nextSlide();
    } else if (e.key === 'ArrowLeft' && !e.target.matches('input, textarea, button, select, [role="button"]')) {
      prevSlide();
    }
  });
});
</script>
</body>
</html>
